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ABSTRACT 
 
Acyclovir (ACV) is an acyclic guanine nucleoside analogue used in the 
treatment of herpes simplex virus (HSV) and varicella zoster virus (VZV) 
infections. The human herpes virus-encoded thymidine kinase (HHV-TK) 
phosphorylates ACV generating ACV monophosphate, which is then converted 
to the active form ACV triphosphate by cellular kinases.  
The ProTide approach, causing the direct release of the monophosphate form 
into the cell, allows bypass of the first phosphorylation step of nucleoside 
analogues. In previous studies acyclovir ProTides were found to be active in 
vitro against human immunodeficiency virus (HIV), demonstrating a successful 
release of ACV monophosphate into the cell.  
 
In this work, an extensive study of structure-activity relationship was carried out 
varying the masking groups of the ACV ProTide. Subsequently, several 
substituents were considered on specific position of the guanine base and side 
chain of ACV resulting in the synthesis of the aryl phosphoramidate derivatives 
of ganciclovir, penciclovir, 6-O-alkyl acyclovir, 8-bromoacyclovir, and 8-
methylacyclovir.  
These derivatives were evaluated in vitro for their antiviral activity against HSV, 
VZV, human cytomegalovirus (HCMV), and HIV.  
Enzymatic and molecular modeling studies were carried out in order to 
investigate the bioactivaton of the phosphoramidate derivatives synthesised in 
this work and correlate these results with their biological activity. 
 
Finally, the ProTide approach was also applied to cidofovir resulting in the 
formation of the phosphonoamidate derivative of cyclic cidofovir. The in vitro 
antiviral activity of this compound against herpes viruses and poxviruses is 
reported, as well as investigation of the mechanism of activation, using 
enzymatic and molecular modeling studies.  
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Chapter 1. Introduction 
1.1 Viruses 
Viruses are submicroscopic agents that infect animals, plants, insects, as well as 
unicellular organisms, such as protozoa, bacteria, fungi, and yeasts. Despite their self-
replicating capacity, they are not considered living organisms. The essence of viruses 
consists in a small fragment of nucleic acid (DNA or RNA) enclosed in a protein shell. 
Lacking the machinery that synthesises the viral proteins, they need a host-cell to 
duplicate themselves. For this reason, they are obligate parasites.1  
1.1.1 Viruses Structure 
Virus structure has evolved in order to ensure the propagation of its genome. Despite 
several differences among virus families, some features are often present (fig.1.1):2 
• Genome and functional proteins such as enzymes 
• Capsid 
• Envelope  
• Receptors 
!
Figure 1.1. Generic virus structure  
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Genome 
The genome is a nucleic acid that contains the information needed for replication of 
viruses. Depending on the virus, the genome is either DNA or RNA. Its size does not 
allow viruses to encode for all the machinery required for their replication. For this 
reason, viruses have evolved as obligate parasites: they must use proteins of host cell to 
complete their life cycle1. The viral genome encodes for capsid subunits, receptors that 
protrude from the virus surface and are required to initiate the entry phase of viral 
infection, and enzymes that are involved either in viral genome transcription and 
replication or in the maturation of viral proteins.2  
Capsid 
The protein shell (capsid), which encloses the viral genome and proteins, is constituted 
of many identical subunits by self-assembly to produce a symmetrical structure. 
Considering the small size of viral nucleic acid and the limited number of proteins that 
can be encoded, this is an example of genetic efficiency developed by viruses. The 
purpose of the capsid is to protect its contents from the external environment and to 
release its contents inside the host cell.1 
Envelope 
Some viruses are surrounded by a phospholipid bilayer, containing transmembrane 
proteins, called the envelope. This additional coating is acquired by budding through 
cellular membranes of the host cell. Its presence or absence constitutes the distinction 
between enveloped and non-enveloped viruses. It greatly affects the initial phase of 
virus infection, the entry phase, and the release phase.2 
1.1.2 Virus lifecycle 
The lifecycle of a virus is commonly constituted by the following phases (fig. 1.2):1, 2  
1. Entry   
2. Uncoating  
3. Viral protein biosynthesis 
4. Replication of the viral genome 
Chapter 1 
! 3 
5. Assembly  
6. Maturation and release 
!
Figure 1.2. Generic virus life cycle: (1) entry; (2) uncoating; (3) viral protein biosynthesis; (4) 
replication of the viral genome; (5) assembly; (6) maturation and release 
!
Entry and uncoating 
The entry phase starts with the binding of virus-coded proteins on the surface of viral 
particle to specific proteins, carbohydrates, or lipid on the surface of the host cell.2 This 
event triggers the release of viruses into the host cell.2 The specificity of such 
interaction defines which type of cell is the target of virus infection. The pathway by 
which a virus passes through the plasma membrane differs from enveloped to non-
enveloped viruses. The enveloped viruses are released inside the host cell by fusion of 
the envelope with either the plasma membrane or the membrane of endosomes, in 
which the virus is enclosed after the receptor-mediated endocytosis.1 The non-
enveloped viruses can either release their genome directly inside the cell through the 
formation of a membrane pore or induce endocytosis of the whole viral particle.1  
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Once inside the cell, the following step is the uncoating, the removal of the capsid, 
through which the viral genome is made available to be transcribed and duplicated. 
Transcription, translation, and replication of the viral genome 
After the cell entry and uncoating, the virus life cycle differs from DNA to RNA 
viruses. 
DNA viruses are translocated into the nucleus, where the viral genome is transcribed 
into messanger RNA (mRNA) by host cell polymerase and duplicated by either cellular 
DNA polymerase (e.g. polyomaviruses) or virally encoded DNA polymerase (e.g 
herpes viruses).1 The viral mRNA is decoded by the ribosome of the host cell to 
produce the virus proteins.2  
In the case of RNA viruses, the genome either acts as mRNA and is translated 
immediately by the host ribosomes into proteins or requires a RNA-dependent RNA 
polymerase, which is carried into the host cell directly by the infecting virus, to 
produce the viral mRNA.2 The replication of the virus genome is carried out by a virus-
encoded RNA polymerase and generally does not require translocation into the cell 
nucleus.2  
Retroviruses are a particular kind of RNA viruses that use the virus-encoded reverse 
transcriptase enzyme to convert the viral genome into a DNA molecule which is 
integrated into the chromosomes of the host cell.2  
Assembly and maturation 
The following phase of virus infection is the assembly of viral particles. In this process 
viral nucleic acid and proteins, which are required to start a new cycle of viral 
infection, are packaged into the capsid.1 Once the viral particle has been assembled, the 
maturation of viruses is achieved by means of viral proteases, which cleave structural 
proteins in specific sites affording infectivity to the nascent viral particles.1  
Release 
The mature viral particles are released in the extracellular environment either by lysis 
of the host cell or exocytosis. In this phase enveloped viruses acquire their external 
phospholipid bilayer by budding through the cell membranes.1  
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1.2 Antiviral therapy 
Viral infections cause several diseases worldwide. In many cases the immune system of 
the host is able to defeat the viral infection by producing antibodies, but in other cases 
viruses can evade such defensive systems and cause an infection that can be either 
symptomatic or asymptomatic.3  
Vaccines have always been valid weapon in the prevention of viral infection by 
stimulating the immune system of a potential host to produce antibodies against a 
specific virus by means of the exposure to its antigens. However, their use in the 
antiviral therapy is prophylactic and their administration is generally ineffective when 
the virus has already infected the host.1  
 In order to keep viral infections under control, antiviral agents have been developed for 
those viruses that are able to overcome the natural defences of the host or when a 
vaccine is not available. In 1959, idoxouridine (IDU) was the first nucleoside analogue 
to be described as an antimetabolite that interferes with the polymerization of herpes 
viruses DNA.4 In the late 1970s, Acyclovir represented a significant breakthrough in 
antiviral drug development due to its high selectivity in inhibiting herpes viruses 
infections and low toxicity.4 After that, the research was further stimulated by the 
pandemic disease of acquired immunodeficiency syndrome (AIDS) and the need of new 
antiviral drugs against its etiological agent: the human immunodeficiency virus (HIV).4 
Nowadays, anti-HIV therapy has made a fatal disease like AIDS manageable.5 Despite 
these successes, there are still some viral diseases for which an appropriate antiviral 
therapy is missing. For example, the standard of care of Hepatitis C virus (HCV) is 
ribavirin with interferon but this therapy is successful in only half of the population 
worldwide.6 Moreover, the activity of antiviral agents is generally specific against one 
or few viruses.  
In general, an ideal target of the antiviral therapy is a virus-encoded protein. It should be 
essential for the viral replication or at least its inhibition should lead to the formation of 
non-infective viral particles. Moreover, the antiviral agent should exhibit a high affinity 
for the viral protein, but not for the cellular counterpart, in order to have low toxicity. 
The ratio between antiviral activity and toxicity define the selectivity index of an 
antiviral agent.6 
Chapter 1 
! 6 
 One of the main issues of the treatment of viral infections is their capacity to develop 
drug resistance. This is due to mutations of the genes that encode for the target protein, 
which is no longer recognised by the antiviral agent.1, 6 The exposure to an antiviral drug 
induces a selection pressure that allows the survival of only mutant strains that are drug 
resistant. Mutations occur naturally during genome replication. They are more frequent 
in the case of RNA viruses than in DNA viruses, because their polymerase is less 
accurate.1, 6 The higher the mutation rate, the more rapidly the resistance can develop. 
For this reason, the highly active antiretroviral therapy (HAART), which is currently 
applied for the treatment of HIV infection, is constituted by the combination of three or 
more different drugs in order to counteract the fast development of drug resistance.1, 5, 6 
Conversely, drug resistance is less likely to develop against antiviral agents that target 
host functions. In principle, a host protein could be an antiviral target if it is more 
important for the viral life cycle than for host functions.1 An example of this approach is 
given by the antiviral drug Maraviroc, which inhibits the entry phase of HIV by binding 
the co-receptor CCR5 on the surface of CD4+ T-Helper lymphocytes (target cells of 
HIV).5, 7 Obviously, targeting a host protein is inherently more likely to result in 
toxicity. 
Considering the virus lifecycle, the potential targets of the inhibition of virus replication 
are virus attachment and entry, virus uncoating, viral genome replication, virus 
maturation, and virus release.6 Most of the antiviral drugs on the market block the viral 
genome replication.8-10 Being the main focus of this thesis, this class of antiviral agents 
will be discussed more extensively. 
1.2.1 Inhibition of viral genome replication  
The viral genome replication is generally mediated by virus-encoded polymerases. 
These enzymes, similarly to cellular counterpart, mediate the polymerisation of nucleic 
acid by insertion of monophosphate nucleosides (nucleotides) in the growing chain.1 
The natural nucleosides in DNA are deoxyadenosine, deoxyguanosine, deoxycytidine, 
and thymidine (fig. 1.3); in RNA the same nucleobases are bound to ribose sugar 
affording adenosine, guanosine, and cytidine; the only exception is thymine that is 
replaced by uracil affording uridine.11  
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Figure 1.3. Structure of natural (deoxy)nucleosides 
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In the nucleic acid strand, nucleosides are bound together by a phosphodiester bond 
between the 3’-hydroxyl group of a residue and the 5’-hydroxyl group of the following 
one (fig. 1.4).11 
!
Figure 1.4. Phosphodiester bond of nucleic acid 
!
DNA consists of two nucleic acid strands, while RNA is constituted by only one strand. 
Figure 1.5 depicts the base pairing between the two strands of DNA: the hydrogen 
bonds lead adenine to interact with thymine and guanine with cytosine.11 According to 
this principle, knowing the sequence of nucleotides of one strand of DNA, we can 
deduce the complementary sequence on the other strand.!!
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Figure 1.5. Base pairing of DNA 
!
The elongation of the nucleic acid, is catalysed by the polymerase, DNA or RNA, in 5’-
3’ direction using one strand as a template and the mentioned principle of the base 
pairing. This means that the 3’-hydroxyl group of the terminal nucleotide residue in the 
growing nucleic acid strand attacks the phosphate in 5’ position of the incoming 
nucleoside triphosphate allowing its insertion with elimination of the pyrophosphate 
group (fig. 1.6). 11 
!
Figure 1.6. Polymerase-mediated insertion of nucleotides into the growing nucleid acid chain. 
!
The antiviral agents that mimic the natural nucleosides are defined as nucleoside 
analogues. They are inhibitors of viral polymerase and compete with the natural 
nucleoside triphosphates for insertion into the growing nucleic acid strand, often 
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resulting in the termination of its elongation. Due to their mechanism of action they 
must be phosphorylated to the triphosphate form in order to exert their activity, so a 
nucleoside analogue is a prodrug of nucleoside triphosphate. A high phosphorylation 
rate is essential in order to achieve good antiviral activity. Currently, the antiviral drugs 
belonging to this class have been approved for the treatment of herpes viruses, HIV, 
hepatitis B virus (HBV), and Hepatitis C virus (HCV).6, 8-10 
Non-nucleoside inhibitors of viral polymerase are another class of antiviral agents that 
exert their activity on the viral polymerase through a different mechanism of action in 
comparison to the antimetabolic nucleosides. At the moment foscarnet and the non-
nucleoside inhibitors of reverse transcriptase (NNRTI) are the only antiviral drugs 
belonging to this class that have been approved for the treatment of herpesviruses and 
HIV, respectively. 1, 6, 8-10 
1.2.1.1 Herpesvirus DNA polymerase inhibitors 
The Herpesviridae or herpes viruses are a family of DNA viruses. The members that 
have been identified as human pathogens are: herpes simplex virus type 1 (HSV-1), 
herpes simplex virus type 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus 
(EBV), cytomegalovirus (CMV), human herpes virus 6 (HHV-6), human herpes virus 
7 (HHV-7), and human herpes virus 8 known as Kaposi's sarcoma-associated herpes 
virus (HHV-8).1 The viral-encoded DNA polymerase carries out the replication of their 
genome. 
Vidarabine, idoxuridine, and trifluridine are anti-herpes viruses agents that have been 
superseded in late 1970s by acyclovir (ACV), due to its better profile in terms of 
potency and selectivity.12 Nowadays, ACV is still the first choice for the treatment of 
HSV and VZV infections.  Ganciclovir (GCV) and penciclovir (PCV) are analogues of 
ACV.12 Other drugs, which are currently approved for the treatment of herpes viruses, 
are the acyclic nucleoside phosphonate cidofovir (S-HPMPC) and the non-nucleoside 
foscarnet.13 Brividun (BVDU) is a deoxyuridine analogue that has not been approved 
in the UK and in the USA, but it has been commercialized in various countries in 
Europe and in Japan. 6,10,14 All these antiviral agents, illustrated in fig. 1.7, are 
inhibitors of the DNA polymerase encoded by herpes viruses.10  
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Figure 1.7. Structure of herpes viruses DNA polymerase inhibitors 
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Acyclovir (ACV) 
ACV is an acyclic guanine nucleoside analogue that lacks the 3’-hydroxyl on the side 
chain (fig. 1.8).15  
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Figure 1.8. Comparison of the structures of ACV and 2'-deoxyguanosine showing the lack of the 3’-
hydroxyl group 
!
In 1982 the FDA approved ACV for the treatment of herpes simplex virus type 1 (HSV-
1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV).  In order to 
improve its poor oral bioavailability (10-30%),6 the L-valinyl ester derivative 
valacyclovir (Valtrex®) was synthesised (fig. 1.9).16 This prodrug is completely 
metabolised to ACV by hydrolase enzymes during the first-pass intestinal and hepatic 
metabolism. The oral administration of valacyclovir increases the relative 
bioavailability of ACV by 3- to 5-fold. This is thought to result from the capacity of 
Valacyclovir to bind the intestinal and renal peptide transporters.17  
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Figure 1.9. Structure of valaciclovir 
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!
!In order to inhibit the herpes virus DNA polymerase, ACV must be phosphorylated to 
its triphosphate form.15 The first phosphorylation step is mediated by the human herpes 
virus-encoded thymidine kinase (HHV TK), which has 200 times greater affinity for 
ACV in comparison to the cellular kinase.15 Accordingly, the concentration of 
phosphorylated ACV is much higher (30 to 100 times) in HSV and VZV-infected cells 
than the concentration detected in uninfected cells. The monophosphate derivative 
(ACV-MP) is converted to ACV diphosphate (ACV-DP) and subsequently ACV 
triphosphate (ACV-TP) by cellular kinases (fig. 1.10).18, 19 The triphosphate form 
inhibits the viral polymerase 10-30 times more potently than the cellular  
counterpart.15, 20  
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Figure 1.10. Phosphorylation steps of ACV 
!
Acyclovir triphosphate is not only a competitive inhibitor of the viral polymerase, but it 
is also incorporated as a substrate into the nascent viral DNA chain (fig. 1.11).21, 22 
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Figure 1.11. Insertion of ACV-TP into the nascent viral DNA 
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Due to its lack of the 3’-hydroxyl group, ACV-TP acts as an obligate chain terminator 
preventing further elongation of the nucleic acid strand trapping the polymerase in a so 
called “dead-end-complex”, thus causing the inactivation of the replication machinery 
(fig. 1.12).  
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Figure 1.12. Termination of viral DNA elongation following ACV-TP incorporation 
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The selectivity for the virus-encoded TK and the viral polymerase account for the high 
therapeutic index of ACV.6 The treatment of herpes virus infections with ACV only 
rarely leads to development of resistance in immunocompetent patients. Several surveys 
revealed the low incidence of ACV-resistant strain of HSV (below 1%). This 
percentage increases in immunocompromised patients (5%) and particularly in patients 
receiving allogenic bone marrow transplant (30%).23 The mechanisms through which 
resistance to ACV develops are:24, 25  
• Total lack of the viral TK (TK deficient strains) 
• Impaired production or low activity of the viral TK (TK lower producer) 
• Modification of the viral TK with loss of binding affinity for ACV (TK altered) 
• Modification of the viral DNA polymerase with loss of binding affinity for  
ACV-TP 
Resistance to ACV involving the viral TK is more common than an alteration of the 
polymerase. This is related to the fact that the TK enzyme is not strictly necessary for 
the successful completion of viral replication, while the mutation of the viral 
polymerase results in highly attenuated strains.1     
Chapter 1 
! 13 
Ganciclovir (GCV) 
GCV is an analogue of ACV from which it differs due to the presence of an additional 
hydroxymethylene group on the acyclic side chain that mimics the  
3’-hydroxyl group of the sugar moiety of natural nucleosides (fig 1.13).  
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Figure 1.13 Structure of GCV showing the analogy with 2'-deoxyguanosine 
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GCV is active against HSV and HCMV;26 it has been approved for the treatment of 
HCMV infections in immunocompromised patients and the prevention of HCMV 
disease in transplant patients. Ganciclovir inhibits HSV and HCMV DNA polymerase; 
the active form is ganciclovir triphosphate. It shares a similar pathway of activation 
with ACV. The first phosphorylation step is mediated by the viral TK in HSV, while in 
HCMV this process is catalysed by a viral protein kinase (PK), which is encoded by the 
gene UL97.27 The lack of phosphorylation by this viral protein kinase is the reason for 
which ACV does not exert any activity against this member of herpes viruses 26. 
Phosphorylation of GCV to the diphosphate and triphosphate forms is mediated by 
cellular kinases.13 Similarly to ACV-TP, GCV triphosphate (GCV-TP) is a competitive 
inhibitor of deoxyguanosine triphosphate incorporation into the growing nucleic acid 
strand and also a substrate of viral DNA polymerase. However, it is not an obligate 
chain terminator: after GCV incorporation the insertion of an additional nucleotide is 
allowed before the termination of the DNA chain elongation.28 This is due to the 
presence of the hydroxymethylene group of GCV, which, as already mentioned, mimics 
the 3’-hydroxyl group.29 The main issue of this antiviral agent is its toxicity due to a 
lower selectivity for viral DNA polymerase in comparison to ACV: GCV-TP inhibits in 
some extent also cellular DNA polymerase. This is predictive of the bone marrow 
suppression (neutropaenia, anaemia, and thrombocytopaenia) that GCV induces.13  
Mechanisms of resistance involve modification of TK in HSV and PK in HCMV 
leading to lack of phosphorylation of GCV to the monophosphate form (GCV-MP). As 
already seen for ACV, the incidence of viral DNA polymerase alteration is far more 
likely.27 The oral bioavailability of Ganciclovir averages 6-9%.6 This percentage 
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increases up to 60% after adminstration of its valyl ester derivative valganciclovir (fig. 
1.14). The mechanism of metabolisation to Ganciclovir is the same of Valaciclovir.13    
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Figure 1.14. Structure of valganciclovir 
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Penciclovir (PCV) 
PCV is the carbo analogue of GCV, where a methylene group replaces the ether moiety 
on the side chain. Similarly to ACV, this compound is active against HSV and VZV.30 
Moreover, PCV has showed inhibitory activity of EBV and HBV replication.10 
As already seen for ACV and GCV, penciclovir triphosphate (PCV-TP) is an inhibitor 
of HSV and VZV DNA polymerase.31 HSV or VZV TK mediates the first 
phosphorylation step, and subsequent phosphorylation steps are mediated by cellular 
kinases. In particular, PCV-TP is less potent than ACV-TP as an inhibitor of viral DNA 
polymerase. However, due to a more efficient phosphorylation by both viral and cellular 
kinases, it reaches a higher concentration inside the host cell over that of ACV-TP.32 
The long intracellular half-life (t1/2= 17-20 h) of PCV-TP accounts for its prolonged 
antiviral activity.6 TK deficient strains, which are ACV-resistant, show cross-resistance 
to PCV.33 The low oral bioavailability (<5%) of PCV is considerably increased (ca 
75%) by its prodrug famciclovir (fig. 1.15) that consists in the diacetyl derivative of 6-
deoxypenciclovir.34 The bioactivation pathway of famciclovir to PCV involves the 
hydrolytic cleavage of one acetyl group in the intestine, followed by the cleavage of the 
second acetyl group in the liver.35 Finally, xantine oxidase or aldehyde oxidase  catalyze 
the oxidation of the 6-position.10, 36 Oral famciclovir, topical penciclovir, and 
intravenous PCV have been approved for the treatment of HSV and VZV infections.10 
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Figure 1.15. Structure of famciclovir 
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Cidofovir (S-HPMPC) 
Cidofovir is the S-enantiomer of 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine 
(S-HPMPC); the reference to its chirality is important, since the R-enantiomer is not as 
effective as the S-enantiomer.37, 38 Like adefovir and tenofovir, which are inhibitors of 
HIV reverse transcriptase and will be discussed in the following paragraphs,39  
S-HPMPC is an acyclic nucleoside phosphonate (ANP). This class of compounds bears 
a phosphonate group that mimics the phosphate moiety of normal nucleotides. For this 
reason, ANPs are able to deliver an isoster of the monophosphate form of nucleoside 
analogues directly into the cell.37 The replacement of the phosphoric ester bond with a 
methylene bridge in the phosphate moiety confers stability against the hydrolytic 
activity of phosphatase enzymes, which dephosphorylate normal nucleotides and 
prevent their use as antiviral agents.37 The antiviral spectrum of S-HPMPC is broad, 
including several DNA viruses, such as all eight human herpes viruses, papillomavirus, 
polyomavirus, poxviruses (vaccinia virus, cowpox virus, variola virus, etc.), and 
adenovirus.39 Intravenous cidofovir (Vistide®) has been approved for the treatment of 
CMV retinitis in HIV-infected patients.10 
Cidofovir exerts antiviral activity by means of its diphosphate metabolite  
(S-HPMPC-pp), which is competitive inhibitor of deoxycitydine triphosphate 
incorporation into the viral DNA chain, akin to triphosphate nucleoside analogues.37 
Both phosphorylation steps are mediated by cellular kinases (fig. 1.16).40  
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Figure 1.16. Bioactivation pathway of Cidofovir 
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In addition to the competitive inhibition of viral DNA polymerase, S-HPMPC-pp acts 
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also as a substrate. However, it is not an obligate chain terminator due to the presence of 
the hydroxymethylene group on the acyclic side chain, which mimics the 3’-hydroxyl 
group of natural nucleosides. Only the insertion of two consecutive molecules of S-
HPMPC into the growing nucleic acid strand leads to the termination of its 
polymerisation.41 The lack of involvement of virus-encoded proteins in the 
phosphorylation process explains the antiviral activity of S-HPMPC against thymidine 
kinase deficient-strains of HSV and VZV.37  
At physiological pH the phosphonate group is negatively charged and this accounts for 
the extreme low oral bioavailability of S-HPMPC that requires intravenous 
administration. However, the long intracellular half-life (t1/2= 87 h) of the phosphocoline 
metabolite, which slowly releases the antiviral agent as a sort of intracellular reservoir, 
allows the application of an infrequent dosing regimen.6 Differently from the others 
ANPs, no approved prodrugs of S-HPMPC possessing an increased oral biovailability 
are available. The alkoxyalkyl esters of Cidofovir are under preclinical investigation 
and will be discussed more extensively later. 
The main dose-limiting side effect of cidofovir is nephrotoxicity due to its accumulation 
in the renal proximal tubules.37, 39  
The internal cyclisation of the hydroxymethylene residue with the phosphonate group 
generates cyclic cidofovir (S-cHPMPC), which has been shown to be a prodrug of  
S-HPMPC (fig 1.17). It exhibits similar antiviral activity and lower nephrotoxicity, due 
to its reduced uptake in the renal proximal tubule cells.42, 43 The cellular cyclic cytosine 
monophosphate (cCMP) phosphodiesterase was found able to cleave the phosphodiester 
bond generating cidofovir.44  
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Figure 1.17. Structure of S-cHPMPC 
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Foscarnet and brivudin 
Foscarnet (phosphonoformic acid) is a non-nucleoside inhibitor of viral 
polymerase.45 It has been approved for the treatment of HCMV infections, 
particularly in immunocompromised patients, and acyclovir-resistant HSV infections. 
Moreover, foscarnet has shown inhibitory activity against HIV.14 Foscarnet structurally 
is a pyrophosphate analogue and its mechanism of action involves reversible binding to 
the pyrophosphate binding site of the viral polymerase. This event blocks the cleavage 
of the pyrophosphate group of the incoming deoxynucleoside triphosphate into the 
growing DNA chain by the viral polymerase during the viral genome replication.14 This 
results in termination of viral DNA polymerisation.  Due to this mechanism of action, 
foscarnet is active against HSV TK mutants and VZV UL97 mutants that show 
resistance to the antimetabolite nucleosides. The major dose-limiting side effect of 
foscarnet is nephrotoxicity. Due to its ionisation at physiological pH the oral 
bioavailability is poor and it requires intravenous administration.6  
Brivudin or (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU) is a 
nucleoside inhibitor of HSV and VZV DNA polymerase.46 Its 
triphosphate form is both a competitive inhibitor and substrate of viral 
DNA polymerase. The incorporation of BVDU in the viral genome 
destabilizes the DNA chain leading to termination of its 
polymerisation.47 Thymidine phosphorylase metabolises BVDU to (E)-5-(2-
bromovinyl)-2’-uracil (BVU) and 2-deoxyribose-1-phosphate. BVU is a potent inhibitor 
of the enzyme involved in pyrimidine metabolism. This enzyme is responsible for the 
metabolism of 5-fluorouracil and its inhibition increases the antiproliferative activity 
and toxicity of this anticancer agent, leading to fatalities in several cases.47   
1.2.1.2 Reverse transcriptase inhibitors 
Reverse transcriptase (RT) is a particular kind of polymerase that is able to produce 
copies of DNA using RNA as template. This enzyme mediates the replication of HIV 
and HBV genomes and differs consistently from the cellular counterpart, suggesting an 
ideal target of antiviral therapy. Most of the approved antiviral agents that inhibit the 
RT of HIV and HBV are nucleoside antimetabolites and are defined nucleoside reverse 
transcriptase inhibitors (NRTIs);8 some of them belong to the class of acyclic nucleoside 
phosphonates (adefovir and tenofovir) and are defined nucleotide reverse transcriptase 
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inhibitors (NtRTIs).8 As already mentioned, a group of non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) have been approved for the treatment of HIV.8 They 
exert their activity by binding to an allosteric pocket of RT that is distinct from the 
catalytic pocket where the NRTIs carry out the inhibition of viral genome replication.1 
NRTIs: anti-HIV agents 
In 1987, zidovudine (3’-azido-2’,3’-dideoxythymidine, AZT) was the first NRTI to be 
approved by the FDA for the treatment of HIV.48, 49 It is a 2’,3’-dideoxythymidine 
analogue where the hydroxyl group in 3’ position of the sugar moiety is replaced by an 
azido group (fig. 1.18). The resistance to AZT and its toxicity lead to the development 
of alternative anti-HIV drugs. The other NRTIs, which have been approved as anti-HIV 
agents, are (fig. 1.18): 2’,3’-didehydro-2’,3’-dideoxythymidine (Stavudine, d4T), 2’-
3‘dideoxyinosine (Didanosine, ddI),50 (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-
purin-9-yl]cyclopenten-1-methanol (Abacavir, ABC),51 (-)-!’-3’-thia-2’,3’-
dideoxycytidine (Lamivudine, 3TC),52 and (-)-!’-2’-3‘dideoxy-5-fluoro-3’-thiacytidine 
(Emtricitabine, FTC).53 
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Figure 1.18. Structures of NRTIs 
Also tenofovir, R-9-(2-phosphonylmethoxypropyl)adenine (R-PMPA), is an inhibitor of 
RT.37 It differs from the others nucleoside analogues in being a NtRTI that belongs to 
the class of ANPs (fig. 1.19). Differently from S-HPMPC, the R-enantiomer is more 
potent than the S-enantiomer.54 Its prodrug Tenofovir disoproxil fumarate, which will be 
further discussed later, has been approved for the treatment of HIV by the FDA under 
the name of Viread®.8,39,55 Tenofovir is also used in combination with either 
emtricitabine (Truvada®) or emtricitabine and efavirenz (Atripla®) for the treatment of 
HIV infections.8 
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Figure 1.19. Structure of tenofovir and its diisoproxil fumarate prodrug 
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Similarly to the inhibitors of herpesviruses DNA polymerase, the triphosphate of NRTIs 
and the diphosphate of tenofovir are the active forms that act as competitive inhibitors 
and substrates of RT.3,5 Since they lack the hydroxyl group in 3’ position, these 
compounds are obligate chain terminators. In contrast to herpesviruses, HIV does not 
encoded for enzymes that can phosphorylate nucleoside analogues. The formation of 
their active form is completely carried out by the cellular kinases. This lack of 
selectivity accounts for the accumulation of the active form in all dividing cells and not 
just in infected cells.1,6 A good affinity for the cellular kinases is essential in order to 
achieve an effective concentration of the nucleoside analogue triphosphate into the cell. 
In particular, the phosphorylation to the monophosphate form usually is the rate-
limiting step. The only well known exception is given by the bioactivation of AZT 
where the second phosphorylaton is a rate-limiting step.56 Similarly to S-HPMPC, R-
PMPA bypasses the first phosphorylation step by releasing the monophosphate 
nucleoside analogue directly into the cell.37 
Despite the good selectivity for RT, the inhibition of mitochondrial polymerase-! is the 
main reason of NRTIs toxicity.6 However, the development of 3TC and its analogue 
FTC has overcome this problem by means of an unusual sugar moiety: its L-
configuration, instead of the natural D-configuration, and the atom of sulphur in 
position 3 account for the great decrease of the inhibitory activity exerted on the cellular 
polymerase.1, 57 Although the efficacy against RT is lower in comparison to AZT, their 
therapeutic index is 100 times higher. Another important issue of these antiviral agents 
is the development of cross-resistance due to the error prone nature of RT.1, 6  
NRTIs: anti-HBV agents 
HBV reverse transcriptase is very similar to HIV reverse transcriptase.1 For this reason 
the anti-HIV drugs lamivudine and tenofovir are also active against HBV and they have 
been approved for the treatment of HBV infections, particularly in co-infected HIV 
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patients where they can exert their activity on both viruses.8,37,58 
Adefovir, 9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA), is an analogue of tenofovir 
and is active against HIV, HBV, and also herpesviruses (fig. 1.20).59 Its mechanism of 
action is analogous to that of tenofovir: its diphosphate form (akin to triphosphate 
nucleoside analogues) targets the viral polymerase inhibiting the elongation of the DNA 
chain.37 Its oral prodrug Adefovir dipivoxil (fig. 1.20), which will be further discussed 
later, has been approved for the treatment of HBV infections under the name of 
Hepsera®.6, 8, 60  
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Figure 1.20. Structure of adefovir and its produg adefovir dipivoxil 
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Entecavir and telbivudine are nucleoside analogues that selectively target the HBV 
reverse trascriptase and have been approved for the treatment of this infection (fig. 
1.21).61, 62 
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Figure 1.21. Structure of entecavir and telbivudine 
NNRTIs 
Nevirapine, efavirenz, delaviridine, etravirine, and rilpivirine are NNRTIs (fig. 1.22), 
which have been approved for the treatment of HIV infections by the FDA.8 These 
agents are non-competitive inhibitors of the HIV-RT.5 They bind to a hydrophobic 
pocket distinct from the active site and not essential for the function of RT. This 
interaction induces a conformational change in the enzymatic structure that greatly 
reduces the activity of RT.63 The binding site is virus strain specific, so NNRTIs are 
active only against HIV-1. For this same reason, their cytotoxicity is low, as they do not 
interact with human polymerases.63 The main issue of this class of antiviral agents, 
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particularly in the first generation (Nevirapine, Delaviridine, Efavirenz), is the rapid 
development of resistance due to a modification of the binding site.1, 6 For this reason, 
NNRTIs are never used in monotherapy, they are combined with others antiretroviral 
drugs in order to enhance efficacy and to avoid resistance.63, 64 
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Figure 1.22. Structure of NNRTIs 
1.2.1.3 HIV integrase inhibitors 
HIV integrase catalyses the integration of the viral genome into the host cell DNA.1 It is 
an essential and exclusive enzyme of HIV life cycle. Due to these features HIV 
integrase is an ideal target of antiviral therapy.3 However the only FDA-approved HIV 
integrase inhibitor is raltegravir (fig. 1.23). It is only used in combination with other 
anti-HIV drugs.65  
!
Figure 1.23. Structure of raltegravir 
1.2.1.4 Ribavirin 
Ribavirin (Virazole®) is a nucleoside analogue with antiviral activity that ranges in 
vitro and in vivo from DNA to RNA viruses.66 However, it has been approved only for 
the treatment of respiratory syncytial virus infection and, in combination with pegylated 
interferon-!, for hepatitis C virus infection; both of them are RNA viruses.9 
Structurally, ribavirin differs from the majority of nucleoside analogues in having a 
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normal sugar unit (D-Ribose) attached to a triazole group that mimics a natural purine 
nucleobase (fig. 1.24).  
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Figure 1.24. Structure of ribavirin 
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Its mechanism of action has not been fully clarified yet. Several studies showed that 
ribavirin has various sites where it can exert its antiviral activity. Host cell kinases 
mediate the phosphorylation of Ribavirin to the mono-, di-, and triphosphate forms.67 
The monophosphate derivative is a competitive inhibitor of inosine monophosphate 
dehydrogenase that is involved in de novo guanosine triphosphate (GTP)  
biosynthesis.68, 69 In principle, lowering the cellular GTP pools affects the viral genome 
replication and the activity of others viral GTP-dependent enzymes, which rely on the 
host cell’s source of GTP. Moreover, this effect may promote the incorporation of 
ribavirin triphosphate into the viral nucleic acid.70 This event induces the so called error 
‘catastrophe’, which is an accumulation of mutations over the edge of an error threshold 
that leads to the production of a non functional viral genome.71 In influenza virus 
infection, the triphosphate form of ribavirin shows inhibition of the RNA polymerase.72 
In Dengue virus infection, it inhibits the viral 2’-O-methyl transferase, while the 
monophosphate derivative inhibits the viral guanylyl transferase.73 Finally, ribavirin was 
found to exert an immunomodulatory activity in HCV and HBV patients.74, 75  
1.3 Pronucleotides 
The abundance of nucleoside analogues among the antiviral agents points at the 
relevance of viral polymerases as target of antiviral drug therapy.8-10!"#$!main features 
that make an ideal target of this enzyme are:1!
• The difference of structure with the cellular DNA polymerase, which is crucial 
in order to achieve selectivity. 
•  The importance of its function for the viral life cycle 
• Its druggability, due to the small molecular weight of its substrates 
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As already described in the paragraph on antiviral agents, nucleoside analogues need to 
be phosphorylated to the triphosphate form in order to exert their inhibitory activity on 
the viral polymerase; their success as antiviral agents depends not only on the affinity 
and selectivity for the viral polymerase but also on the rate of phosphorylation that 
provides the therapeutic concentration of the active form into host cells. On account of 
this, the release of the monophospate derivative of nucleoside analogues directly into 
infected cells has always been a target for antiviral drug development, because 
bypassing the first phosphorylation step has several advantages. First of all, this is the 
rate-limiting step of the metabolic activation for most nucleoside analogues, so 
nucleotides are supposed to show an improvement in activity in cases where parent 
nucleosides are inactive due to poor first intracellular phosphorylation step.6,76,77 In 
many cases, this is followed by an extension of antiviral spectrum, or an altered 
biological profile in some cases. For example, acyclovir triphosphate shows inhibitory 
activity against HIV and the pronucleotide of BVDU has proliferative activity against 
colon cancer.78,79 Therefore, nucleotides retain activity against certain mutant virus 
strains that develop resistance to the parent nucleosides (e.g TK- HSV and VZV).80  
Nevertheless, nucleotides themselves are not ideal drug candidates. There are some 
disadvantages that do not allow their administration as such. Due to the negative charge 
on the phosphate moiety at physiological pH, they have poor membrane permeability 
and bioavailability.76,80 Another disadvantage of nucleotides is their instability in 
biological media as they are rapidly dephosphorylated by phosphatase enzymes.80  
 
 As already discussed in the paragraphs regarding cidofovir, tenofovir, and adefovir, 
ANPs are resistant to the dephosphorylating activity of extracellular phosphatases. 
However, the therapeutic application of ANPs is limited by the negative charge of the 
phosphonate group that does not allow a significant cellular uptake or good 
bioavailability due to poor membrane permeability of these compounds.37, 38  
In order to overcome this issue, several pronucleotide approaches have been developed 
by masking the phosphate group with lipophilic moieties that allow the passive 
diffusion through cellular membranes.38, 76, 80-83 Once inside the cell, the pronucelotide is 
metabolised releasing the monophosphate form. Approaches that make use of this 
strategy are: 
• Bis(POM) and bis(POC) pronucleotides 
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• Bis(SDTE) and bis(SATE) pronucleotides 
• Cyclosal approach 
• Phospholipid conjugates 
• Peptide conjugates 
• Hepdirect approach  
• Phosphoramidate diester pronucleotides: the Wagner approach 
• Aryl Phosphoramidate triester pronucleotides: the ProTide approach 
• Phosphorodiamidate pronucleotides 
1.3.1 Bis(POM) and Bis(POC) pronucleotides 
The bis(POM) phosphoester derivatives of nucleoside analogues (1.1) mask the 
negative charge of the phosphate (X: O) or phosphonate moiety (X: CH2) by means of 
two pivaloyloxymethyl (POM) groups (figure 1.25).80, 84  
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Figure 1.25. Generic structure of Bis(POM) pronucleotides 
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The intracellular mechanism of bioactivation involves the esterase-mediated cleavage of 
both POM-groups in two steps (scheme 1.1).85 In the first step the carboxyesterase-
mediated cleavage of one of the two POM groups affords the hydroxymethyl 
phosphoester 1.2. This highly reactive intermediate spontaneously dissociates to give 
the phosphoester 1.3 by elimination of formaldehyde. The cleavage of the second POM 
group follows the same mechanism and results in the release of the 5’-monophosphate 
(X: O) or monophosphonate (X: CH2) form (1.4) of the nucleoside analogue.  
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Scheme 1.1. Bioactivation pathway of Bis(POM) pronucleotides 
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The bis(POM) prodrug of Adefovir (Adefovir dipivoxil) improves the poor oral 
bioavailability of the parent compound up to 30-60% and has been approved in 2002 for 
the treatment of HBV infections.6  
In the bis(POC) phosphotriester analogues the pivaloyl groups are replaced by 
isopropoxycarbonyl groups. Similarly to the bioactivation mechanism of bis(POM), the 
elimination of the masking group is catalysed by carboxyesterase enzymes and results 
in the release of the monophosphate form of the nucleoside analogue together with 
isopropanol, CO2 and formaldehyde. Although this approach avoids the formation of 
potentially toxic pivalic acid, it still generates formaldehyde. The application of the 
bis(POC) technology to tenofovir resulted in the synthesis of tenofovir disoproxyl 
fumarate that showed a 16- to 35- fold increase of the anti-HIV activity and no 
significant toxicity on account of the improvement of its cellular uptake.86  
1.3.2 Bis(SDTE) and Bis(SATE) pronucleotides  
The bis-[S-(2-hydroxyethylsulfidyl)-2-thioethyl] [bis(SDTE)] and bis-(S-acyl-2-
thioethyl) [bis(SATE)] phosphotriesters were first described by Imbach and Grosselin.87 
Similarly to bis(POM) and bis(POC) approaches, their mechanism of activation is 
mediated by enzymes (scheme 1.2).  
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Scheme 1.2. Bioactivation pathway of bis(SATE) and bis(SDTE) phosphotriesters 
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In the bioactivation of bis(SATE) phosphotriester derivatives (1.5), a carboxyesterases 
enzyme carries out the initial cleavage of the thioester bond of one of the two SATE  
groups with release of pivalic acid and the corresponding phosphothioester 1.6. Then, 
the spontaneous elimination of episulfide affords the intermediate phosphodiester 1.7. 
The elimination of the second S-acyl-2-thioethyl group follows the same pathway and 
leads to the release of the 5’-monophosphate of the nucleoside analogue (1.8). The 
bioactivation pathway of bis(SDTE) analogues (1.9) is slightly different.  The initial 
step is carried out by a reductase enzyme that cleaves the disulfide bond releasing 
thioethanol and the reactive intermediate thioethyltriester 1.10. The spontaneous 
elimination of episulfide affords the intermediate phosphodiester 1.11, which is 
metabolised to the 5’-monophosphate derivative 1.8 by a further reductase-mediated 
cleavage. Alternatively, phosphodiesterase enzyme can catalyse the hydrolysis of the 
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second masking group leading to the formation of the 5’-monophosphate product.80  
Examples of the application of these approaches are the bis(SATE) phosphotriester 
analogues of ACV,88 AZT,89 and d4T.90 All of them are successful in the intracellular 
release of the monophosphate of the parent nucleoside, and thus bypass the first 
phosphorylation step. In particular, the bis(SATE) pronucleotide of ACV extends the 
antiviral activity of ACV on HBV.  
1.3.3 The cyclosal approach 
The cyclosaligenyl phosphotriester derivatives of nucleoside analogues bear a salicyl 
alcohol molecule on the phosphate or phosphonate group. In contrast to other strategies, 
which mask the negative charge of the phosphate moiety by means of a biolabile group, 
the cyclosal approach involves chemical hydrolysis of the lipophilic masking unit 
(scheme 1.3).91  
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Scheme 1.3. Chemical hydrolysis of a generic Cyclosal pronucleotide 
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The release of the nucleoside 5’-monophosphate 1.14 from the phosphotriester 
derivative 1.12 proceeds in two consecutive steps. The first step is the selective 
hydrolysis of the phenolic ester bond, which is the most labile of the three P-O bonds 
due to the delocalisation of the negative charge of the phenoxide ion in the aromatic 
ring. Then, the spontaneous cleavage of the benzylic ester bond (1.13) results in the 
release of the nucleoside 5’-monophosphate 1.14. The cyclosal approach has been 
applied to many nucleoside analogues, such as ACV,92 BVDU,93 AZT,94 d4T,95 and the 
acyclic nucleoside phosphonate PMEA.96 This approach presents some limits that 
interfere with the efficacious release of nucleotide analogues in the intracellular 
compartment:80 
Chapter 1 
! 28 
• The efflux of the cyclosal derivatives through the membrane cell decreases their 
intracellular concentration 
• The masking group is cleaved also in the extracellular compartment due to its 
low hydrolytic stability   
In order to overcome these issues, second and third generations of cyclosal triesters 
bearing an esterase-cleavable function (lock-in cyclosal pronucleotides) were 
developed. In the second generation of cyclosal derivatives the cleavage of the ester 
group is mediated by cellular esterase and makes the metabolite more polar.97 Such an 
increase in polarity traps the phosphotriester derivative in the intracellular compartment, 
where it is bioactivated through the same mechanism of the first generation derivatives. 
This strategy was applied to the synthesis of various ester-functionalised derivatives of 
cycloSal-d4TMP (fig. 1.26).98 However, the chemical hydrolysis that affords d4TMP is 
very slow.  
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Figure 1.26. Lock-in cyclosal pronucleotide (2nd generation) 
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In the third generation, the esterase–cleavable function bears electron-donating or weak 
electron-withdrawing groups. Once inside the cell, the esterase-mediated cleavage of 
this substituent leads to a decrease in the hydrolysis stability of the cyclosal derivative 
that favors the elimination of the masking group on the phosphate moiety. The rational 
of this technology is to trigger selectively the release of the nucleotide analogue in the 
intracellular compartment: the idea of trapping the compound into the cell is applied at 
the nucleotide level. Following this strategy, diacyloxymethyl-cycloSal-d4TMPs and 5-
(1-acetoxyvinyl)-cycloSal-d4TMPs were synthesised (fig. 1.27).99, 100  
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Figure 1.27. Structure of cyclosal phosphotriester of nucleoside analogues (3rd generation) 
1.3.4 Phospholipid conjugates  
This technology has been developed by Hostetler and coworkers to improve the oral 
bioavailability and cellular uptake of acyclic nucleoside phosphonates.101 It consists of 
the esterification of the phosphonate group with an alkoxyalkyl chain that masks one of 
the two negative charges (1.15). The rational of this substitution is its resemblance to 
lysophosphatidylcholine (1.16), which easily crosses the cellular membrane and allows 
the cellular uptake of this lipophilic precursor (fig. 1.28).101 In particular the best results 
have been obtained using hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) 
esters. Inside the cell, the alkoxyalkyl chain of phospholipid moiety is selectively 
cleaved by the phospholipase C with release of the acyclic nucleoside phosphonate. The 
absence of this enzyme in plasma or pancreatic secretions avoids the metabolisation of 
these mimetic phospholipid derivatives during the oral absorption and prior to reach 
tissues.   
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Figure 1.28. Generic structure of alkoxyalkyl ester of acyclic nucleoside phosphonate (1.15) in 
comparison to lysophosphatidylcholine (1.16) 
!
The application of this approach to cidofovir afforded the alkoxyalkyl ester derivatives 
HDP-(S)-HPMPC and ODE-(S)-HPMPC,  which exhibited a striking increase in 
potency against several double stranded DNA viruses in comparison to the parent 
nucleoside (fig.1.29).101  
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Figure 1.29. Structures of hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) esters of  
S-HPMPC 
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The activity in vitro against HCMV and others herpes viruses has shown 2.5-to 4-log 
increases in potency (depending on the antiviral assay used).102 These compounds were 
also found to be more active than cidofovir against several poxviruses, such as 
smallpox, cowpox, monkeypox, and vaccinia viruses.103 The oral adminstration of such 
phospholipid conjugates was as effective as parental cidofovir in the treatment of CMV 
infections in murine models. They were also found to be effective in animal models of 
cowpox and vaccinia virus infections.104 Another important achievement of this 
approach is the lack of nephrotoxicity, which is the main dose limiting toxicity of 
intravenous cidofovir.6 The alkoxyalkyl ester derivative of cidofovir is not recognised 
by the transport mechanism that causes the accumulation of cidofovir in the kidney.105 
HDP-(S)-HPMPC, under the name of CMX001, completed Phase I clinical trials as oral 
drug for the treatment of HCMV and small pox infections. Phase II trials are currently 
in progress. This same approach has been applied to the cyclic derivative of cidofovir 
and several others acyclic nucleoside phosphonate including tenofovir and adefovir.101 
Recently, the hexadecyloxypropyl ester derivative of tenofovir (HDP-(R)-PMPA, fig. 
1.30) has entered in Phase I clinical trials as an oral drug, with the name CMX157, for 
the treatment of HIV infections. 
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Figure 1.30! Structure of the hexadecyloxypropyl ester of tenofovir  
Despite the striking improvement of antiviral activity afforded by this technology, the 
poor water solubility of these lipophilic precursors is still an issue of this approach. 
Recently, Kre!merová et al. tried to address this issue by synthesising ester derivatives 
of cidofovir and adefovir bearing hydroxyl groups or oxygen atoms on the aliphatic 
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chain.106 In general, these modifications resulted in a decrease or loss of activity due to 
inefficient cellular uptake or a lack of metabolism mediated by phospholipase C.  
1.3.5 Peptide conjugates 
In order to improve the oral bioavailability of acyclic nucleoside phosphonates, 
McKenna and co-workers have developed a technology that conjugates a dipeptide or a 
single amino acid with the phosphonate group.38 Similarly to valacyclovir, the rational 
of this approach is to improve the bioavailability of the parent drug by targeting the 
human peptide-specific intestinal transporter (hPEPT1), which is present in the 
gastrointestinal tract. The amino acidic moiety is cleaved during the first-pass 
metabolism. The L-Val-L-Ser-OMe dipeptide derivative of cyclic cidofovir (fig. 1.31) 
showed a 8-fold increase in the oral bioavailability of the parent drug.107  
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Figure 1.31. Structure of the L-Val-L-Ser-OMe dipeptide derivative of S-cHPMPC 
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However, further studies showed that such dipeptide conjugates are not transported, 
although they are recognised, by hEPT1.108 Steric hindrance or polarity of the amino 
acid moiety can be accounted for the lack of hEPT1-mediated transport of these peptidic 
conjugates, thus suggesting that a different transporter is involved in their absorption.  
1.3.6 HepDirect approach 
The cyclic 1-aryl-1,3-propanyl esters of phosphate or phosphonate nucleoside analogues 
are a class of pronucleotides developed by Metabasis and called HepDirect prodrugs. 
The aim of this approach is to treat the infections that affect the liver by delivering the 
drug specifically in this organ and thus decreasing the exposure to the other organs. This 
goal is achieved by coupling the parent drug with a masking group that is selectively 
recognized and cleaved by the cytocrome P450 (isoenzyme CYP3A4) expressed 
predominantly in the liver.109 Pradefovir (fig. 1.32) is the HepDirect prodrug of 
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Adefovir and it has been developed to treat HBV infections.110 The analogous prodrug 
of cytarabine monophosphate (MB07133, fig. 1.32) has been developed for the 
treatment of hepatocellular carcinoma.81  
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Figure 1.32. Hepedirect prodrugs 
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1.3.7 Phosphoramidate diester pronucleotides: the Wagner approach 
This approach has been developed by Wagner et al. to deliver the monophosphate form 
of nucleoside analogues into the cell. The cellular uptake is favored by masking one of 
the phosphate charges with an amino acid ester.80 This strategy is a variant of the 
ProTide approach, developed by McGuigan et al., that masks both negative charges of 
the phosphate group. The unmasked negative charge improves the water solubility and 
the stability in human blood of these compounds in comparison to the phosphotriester 
analogues.80 This class of pronucleotides differs from the other approaches with regard 
to the lack of chirality at the phosphorus. A phosphoramidase-type enzyme (Hint-1) 
mediates the cleavage of the amino acid moiety with release of the monophosphate 
derivative of the nucleoside analogue.80 The application of this approach afforded the 
phosphoramidate derivatives of AZT, 1-!-arabinofuranosylcytosine, and 5-fluoro-2’-
deoxyuridine (fig. 1.33).111, 112 Despite the improvement of antiviral activity in vitro, in 
vivo these derivatives have poor bioavailability and degrade to the parent nucleoside in 
the gastro intestinal tract. 
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Figure 1.33. Structures of phosphoramidate diesters of nucleoside analogues 
1.3.8 Aryl phosphoramidate triester pronucleotides: the ProTide approach 
This approach has been developed by McGuigan et al. with the aim of allowing the 
intracellular delivery of lipophilic precursors of nucleotide analogues by passive 
diffusion of the cellular membrane.82 As depicted in figure 1.34, the aryl 
phosporamidate triester of nucleoside analogues mask both negative charges of the 
phosphate group by means of aryl and amino acid moieties. 
Nuc
OP
O
O
NH
Ar
O
O
R''
R
R'
Nuc: nucleoside analogue
Ar: aryl moiety
R, R': aminoacid side chain
R'': ester moiety
!
Figure 1.34. Structural motifs of aryloxy phosphoramidate ProTide 
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In 1992 this technology was applied for the first time to the anti-HIV agent 
zidovudine.113 These derivatives exhibited anti-HIV activity in kinase deficient cell 
lines, proving the successful intracellular release of zidovudine monophosphate.114 Since 
then, the ProTide approach has been applied to several nucleoside analogues, such as 
2’,3’-dideoxyuridine,115 stavudine,116 abacavir,117 4’-azidouridine,118 brivudin,78 the 
anticancer agent 5-fluorouridine, 119 as well as the acyclic phosphonate nucleosides 
tenofovir and adefovir.120, 121 Recently, the aryl phosphoramidate pronucleotides 
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 INX-189, developed by Inhibitex/BMS, PSI-7977, developed by Pharmasset/Gilead, 
and the hybrid SATE/phosphoramidate IDX184, developed by Idenix, all entered 
clinical trials for the treatment of HCV infections (fig. 1.35).122-124 
N
NN
N
O
O
NH2
CH3
HO OH
CH3
O
P
HN
O O
O
O
CH3
INX-189
N
O
HO F
CH3
O
P
NH
O
O
O
HN
O
O
O CH3 NH
NN
N
O
O
NH2
HO OH
CH3
O
P
HN
O O
S
O
HO
PSI-7977 IDX-184 !
Figure 1.35. Structure of phosphoramidate pronucleotides in clinical trials as candidate for the 
treatment of HCV infection 
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The by-pass of the first phosphorylation step was achieved also in the case of 
acyclovir,125 providing the anti-HIV activity of acyclovir triphosphate.126 This topic will 
be discussed more extensively in the next chapter. The aryl phosphoramidate 
derivatives of N-acetylglucosamine were the first application of the ProTide approach 
on non-nucleoside agents.127 They were shown to have enhanced anti-osteoarthritic 
activity compared to their respective parent compounds. 
Proposed mechanism of activation of ProTides. 
The putative bioactivation mechanism of ProTides (1.17) is depicted in  
scheme 1.4.128-130 
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Scheme 1.4. Putative bioactivation pathway of aryloxy phosphoramidate pronucleotides 
Once inside the cell, the first activation step is the hydrolysis of the carboxylic ester 
moiety that affords the metabolite 1.18, a carboxyesterase enzyme is thought to mediate 
this cleavage.129 Recently, Gilead Science has performed mechanistic studies on the aryl 
phosphonamidate derivative of tenofovir GS-7340 showing that cathepsin A is the 
carboxypeptidase involved in this reaction.131 This cleavage is followed by an internal 
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nucleophilic attack of the carboxylate on the phosphorus atom with displacement of the 
aryl group and transient formation of a five-member cyclic intermediate 1.19. The 
instability of such intermediate does not allow its isolation. This cyclic anhydride is 
rapidly hydrolysed to the corresponding phosphoramidate derivative 1.20. The 
nucleophilic attack can take place either on the phosphorus centre (attack I) or on the 
carboxylate group (attack II). Recent in silico studies suggested that the former might be 
favored over the latter.132 The last step is cleavage of the P-N bond with delivery of the 
nucleoside monophosphate (1.21).129 Human Hint-1 (histidine triad nucleoside-binding 
protein), a phosphoramidase-type enzyme that belongs to the HIT (histidine triad) 
superfamily, is presumed to mediate this cleavage.78, 133  
Generic correlation structure – activity of ProTides 
An extensive study concerning the aryl, amino acid, and ester moieties was performed 
with the aim to identify the substituents that afford the optimal biological activity.82 
Figure 1.36 summarises the results of such investigation. 
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Figure 1.36. SAR of  aryloxy phosphoramidate pronucleotides 
Ester moiety 
The hydrolysis of the ester moiety is determinant for the bio-activation of the 
phosphoramidate. Even though the rate of the cleavage in the esterase studies does not 
correlate to the antiviral activity, the lability of the ester bond is necessary (but not 
sufficient alone) to achieve high biological activity. Different esters have been 
evaluated: linear (methyl, ethyl, n-propyl, pentyl), branched (tert-butyl, neopentyl, 2-
propyl), cyclic (cyclohexyl), and aromatic (benzyl, naphthyl). In particular, the t-butyl 
ester derivatives are often poorly active due to the lack of cleavage of the ester bond as 
its branched chain is too bulky to be processed by the carboxyesterase enzyme, while in 
many cases, the more lipophilic benzyl ester derivatives have exhibited the highest 
potency. Clearly, the more lipophilic the compound is, the better the cellular membrane 
diffusion will be, but the steric hindrance of these moieties must be taken into 
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consideration in terms of capacity of the enzymes to process the pronucleotide properly.   
Aryl moiety 
The elimination of the aryl group is not mediated by any enzyme, but it is the result of 
intramolecular cyclisation. For this reason the ability of this moiety to act as a good 
leaving group is essential for the successful metabolism of the ProTide. This is also the 
reason for which the development of the phosphoramidate technology has moved from 
the alkyl and haloakyl moieties to the aryl moiety (phenyl and 1-naphthol), which is a 
better leaving group due to its ability to delocalise the negative charge. Further studies 
performed on the aryl substitution of d4T phosphoramidates have shown that mild 
electron-withdrawing substituents (Cl, COOMe) lead to an increase of potency by 
enhancement of the leaving group ability of the aryl moiety in the formation of the 
aminoacyl intermediate, whilst strong electron-withdrawing groups (p-CN, p-NO2) 
cause a decrease of activity. 
Amino acid moiety 
The !-amino acid is essential for the successful bio-activation of phosphoramidates. 
Early studies have evaluated the replacement of the P-N bond by a P-O bond in lactyl 
and glycolyl analogues of AZT and d4T phosphoramidate showing a significant or 
complete loss of activity.82 Its replacement with n-alkylamine chains led to a complete 
loss of antiviral activity of AZT and d4T phosphoramidates. In general, the distance 
between the nitrogen and the carboxylic acid in the amino acid moiety is important for 
the activity: extending the chain length (e.g. "-amino acid) in d4T phosphoramidates 
resulted in poor activity.134 This study showed that in these derivatives the ester moiety 
is hydrolysed, but the intracellular cyclisation does not take place. A recent in silico 
study showed that the formation of the six-membered ring intermediate is not favored.132 
An extensive study that correlates the amino acid structure of d4T phosphoramidates 
with the antiviral activity was performed.135 From this study it was demonstrated that L-
alanine provides the best results. The one exception being phosphoramidates of N-
acetyl-glucosamine, where the L-Proline derivatives gave the best activity. 
Dimethylglycine derivatives retain the good antiviral activity exhibited by the L-alanine 
analogues. Surprisingly, the loss of the methyl group in the glycine phosphoramidate 
derivatives of d4T leads to a 60- 70- fold decrease of potency in comparison to the L-
alanine analogues. Bulky L-amino acids (e.g. L-valine, L-leucine, and L-isoleucine) are 
Chapter 1 
! 37 
not usually tolerated giving reduced activity. According to the study performed by 
Gilead Science on the hydrolysis rate of the ester moiety of nucleoside 
phosphonoamidate, Cathepsin A is not able to hydrolyse phosphoramidate with 
hindered side chains.131 Concerning the stereochemistry, unnatural D-amino acids are 
poorly active; this is probably due to the bad interaction with the enzymes involved in 
the bioactivation pathway. The D-alaninyl derivative of N-acetyl-glucosamine 
phosphoramidate is an exception to this trend. 
Phosphorus stereochemistry 
The unsymmetrical substitution introduces a chiral center in the phosphorus atom that, 
together with the other chiral centers of the molecule, causes the formation of a mixture 
of diastereomers. In some cases, one of the diastereomers has more potent biological 
activity than the other due to stereoselectivity of the enzymes involved in the 
bioactivation pathway. For example, the anti-HCV agent PSI-7977 (fig. 1.37) is the Sp 
diastereomer and exhibits a greater ability to produce higher intracellular concentration 
of triphosphate metabolite in comparison to the Rp diastereomer thus making it more 
active.123 The correlation between absolute configuration at the phosphorus centre and 
the relative potency of the antiviral agent has not been clarified yet.  
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Figure 1.37 Structure of PSI-7977 
1.3.9 Phosphorodiamidate pronucleotides 
The phoshorodiamidate pronucleotide approach makes it possible to overcome some 
limits of the ProTide approach: the release of phenol or naphthol, which might be toxic, 
and the formation of mixture of diasteroisomers that arises from the chirality of the 
phosphate centre. Such phosphate prodrug motifs were first applied to AZT by 
McGuigan et al.,82 but at that time their development was not further pursued due to the 
lack of improvement of the biological activity and the poor chemical yield. Since then, 
this approach has been applied by Gilead for the development of diamidate prodrugs of 
acyclic nucleoside phosphonates, such in the anticancer agent GS-9191  (fig. 1.38), 
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which is in Phase I clinical trial for the topical treatment of HPV lesions.81, 82, 136 
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Figure 1.38. Structure of the phosphonodiamidate derivative GS-9191 
!
More recently, phosphorodiamidates of 6-O-methy-2’-C-methyl guanosine (fig. 1.39) 
were described by McGuigan et al. as good candidates for clinical studies in the 
treatment of HCV infections.137  
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Figure 1.39. Phosphorodiamidates of 6-O-methyl-2’-C-methyl guanosinee 
!
The mechanism of bioactivation is analogous to the one already described for the aryl 
phosphoroamidate triester pronucleotides: the carboxyesterase-mediated cleavage of 
one or both the ester moieties leads to intracellular cyclization with elimination of the 
other amino acid moiety and subsequent formation of the phosphoramidate monoester, 
then the same pathway follows.137    
1.3.10 Summary of pronucleotide technologies 
Table 1 gives a summary of the strategies that allow the delivery of nucleotide 
analogues into the cell. 
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Table 1.1. Pronucleotide approaches 
Pronucleotide 
Approach 
Bioactivation 
Pathway 
In Clinical 
Trials/Approved 
Bis(POM)/Bis(POC) Esterase cleavage Yes 
Bis(SDTE)/Bis(SATE) Esterase/Reductase cleavage No 
Cyclosal Chemical hydrolys No 
Phosphoramidate diester Phosphoramidase cleavage No 
Phospholipid conjugate Phospholipase-C cleavage Yes 
Peptide conjugates Phosphatase cleavage No 
Hepdirect Cytochrome P450 Yes 
Arylphosphoramidate ProTide Esterase, phosphoramidase cleavage Yes 
Phosphorodiamidate Esterase, phosphoramidase cleavage Yes 
1.4 Aim of work 
The ProTide approach has proved to be effective in delivering the monophosphate form 
of acyclovir, thus bypassing the first phosphorylation step mediated by the human 
herpes virus-encoded thymidine kinase (HHV-TK) and achieving in vitro antiviral 
activity also against HIV.125, 126  
The aim of this work is:  
• to further investigate the application of the ProTide approach to acyclovir by 
modifying the aryl, amino acid, and ester moieties; 
• to extend this technology to other acyclic nucleosides by introducing different 
substituents at the guanine base and side chain of acyclovir. 
 
As summarised in figure 1.40, in the following chapters the synthesis and in vitro 
antiviral activity of novel aryl phosphoramidate derivatives of acyclovir and its 
derivatives 6-O-alkyl acyclovir, 8-bromoacyclovir, 8-methylacyclovir, penciclovir, and 
ganciclovir will be presented. Enzymatic and modelling studies are also presented in 
order to investigate the mechanism of activation of ProTides. 
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!
Figure 1.40. Outline of the thesis 
!
Furthermore, in this work the synthesis and in vitro biological activity of 
phosphonoamidate derivatives of cidofovir were evaluated (chapter 7).  
 
 
 
 
 
 
 
!
!
!
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Chapter 2. Synthetic route of ProTides 
2.1 Synthesis of aryl phosphoramidate derivatives of nucleoside 
analogues 
The synthesis of ProTides (2.3) can be achieved by the coupling reaction of the aryl 
amino acid ester phosphorochloridate 2.2 with the nucleoside analogue 2.1 through two 
different synthetic approaches (scheme 2.1A and B).  
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Scheme 2.1. General synthesis of ProTides: (A) Uchyiama approach, (B) van Boom approach. R, R1: 
amino acid side chain; R2: alkyl, aryl; R3: H, OH, O-protecting groups; R4: H, O-protecting group  
!
One method has been developed by Uchiyama et al. and is based on the deprotonation 
of the hydroxy group in the 5’ position of the nucleoside analogue 2.1 using tert-butyl 
magnesium chloride (tBuMgCl) as strong base (scheme 2.3A).1 The deprotonation 
affords the 5’-alkoxide group, which is more nucleophilic than the 5’-hydroxy group 
and this allows it to attack the phosphorus of the phosphorochloridate 2.2. Considering 
that the pKa of nucleoside hydroxyl groups are around 15 and the pKa of the conjugate 
acid of tBuMgCl is 45,2 both the secondary hydroxy groups in the 2’ and 3’ position and 
the primary hydroxy group in the 5’ position of the unprotected nucleoside analogue 
deprotonate in the presence of tBuMgCl. For this reason, the hydroxy groups in the 2’ 
and 3’ position must be protected in order to obtain exclusively the 5’-monophosphate 
analogue 2.3. 
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Another method that is applied in our lab for the synthesis of ProTides, has been 
developed by van Boom et al. and utilises N-methylimidazole (NMI) as reagent 
(scheme 2.3B).3 In this case, NMI (pKa ! 17) does not act as a base, because it is not 
strong enough to deprotonate the hydroxy group. However, NMI is presumably able to 
attack the phosphorochloridate 2.2 displacing the chloride.4 The corresponding 
intermediate delocalises a positive charge at the NMI moiety, which acts as a very good 
leaving group, thus increasing the reactivity towards nucleophiles. The phosphorylation 
of the unprotected nucleoside 2.1 occurs mainly at the primary hydroxy group in the 5’ 
position probably due to steric hindrance of the phosphorous provided by the 
imidazolium group.     
Starting from a diastereomeric mixture of aryl amino acid ester phosphorochloridate, 
both approaches generally afford the aryl phoshoramidate derivative of nucleoside 
analogue as mixture of diastereomers meaning that the coupling reaction is not 
stereospecific.5  
2.2 Synthesis of aryl amino acid ester phosphorochloridates 
The phosphorochloridate 2.2 is obtained by reaction of the appropriate amino acid ester 
salt 2.4 and the aryl phosphorodichloridate 2.5 in the presence of triethylamine (scheme 
2.2).6  
NH3
O
O
R2
R
R1
TsO
2.4
P
O Cl
Cl
O
2.5
R, R1: aminoacid side chain
R2: alkyl, aryl
P
O
O
NH
Ar
O
O
R2
R
R1
Cl
2.2
i
Reagents and conditions: (i) TEA, DCM, -78 ºC, then rt, 2 h
Ar
!
Scheme 2.2 General synthesis of aryl amino acid ester phosphorochloridates 
!
Table 2.1 summarises the aryl amino acid ester phosphorochloridates 2.2a-p 
synthesised in this work, including the 31P NMR chemical shifts (") in CDCl3, and the 
isolated yields.!!
!
!
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Table 2.1. Aryl amino acid phosphorochloridates 2.2a-p synthesised.  
(AA: amino acid moiety; R”: ester moiety; Ar: aryl moiety)  
Cpd AA R’’ Ar Yield 
31P NMR !  
(ppm) 
2.2a L-Alanine Bn Ph 86% 7.52, 8.05  
2.2b L-Alanine Bn 1-Naph 87% 7.52, 7.86 
2.2c L-Alanine tBu Ph 64% 7.81, 8.20 
2.2d L-Alanine CH2tBu Ph Quantitative 7.66, 8.19 
2.2e L-Alanine CH2tBu 1-Naph 63% 7.90, 8.21 
2.2f Glycine Bn Ph 90% 8.75 
2.2g 2,2-Dimethylglycine Bn Ph 90% 5.43 
2.2h 2,2-Dimethylglycine Bn 1-Naph Quantitative 5.83 
2.2i L-Valine Bn Ph 77% 8.89, 9.37 
2.2j L-Valine Bn 1-Naph Quantitative 9.26, 9.72 
2.2k L-Leucine Bn Ph 93% 8.10, 8.34 
2.2l L-Leucine Bn 1-Naph 65% 8.31, 8.56 
2.2m L-Isoleucine Bn Ph Quantitative 8.61, 9.01 
2.2n L-Isoleucine Bn 1-Naph 70% 8.98, 9.40 
2.2o L-Proline Bn Ph Quantitative 7.72, 7.78 
2.2p L-Phenylalanine Bn 1-Naph 60% 8.16, 8.29 
 
Chiral amino acids (e.g. L-alanine) afforded the relative phosphorochloridates as a 
mixture of two diastereomers (SSp and SRp) that displayed two peaks in the 31P NMR 
spectrum. The phosphorochloridates of achiral amino acid (e.g. glycine and 2,2-
dimethylglycine) were obtained as a mixture of enatiomers (Sp and Rp) and displayed 
only one peak in the 31P NMR spectrum. 
2.2.1 Synthesis of amino acid esters 
Some of the amino acid ester salts used in this work for the synthesis of the 
phosphorochloridates 2.2a-p are not commercially available, so their synthesis was 
required.  
The tosylate salt of 2,2-dimethylglycine benzyl ester (2.4a) and L-alanine neopentyl 
ester (2.4b) were prepared by reaction of the amino acid with the appropriate alcohol in 
toluene and in the presence of para-toluenesulphonic acid (TsOH) (scheme 2.3).6 A 
Dean-Stark apparatus was used in order to remove the water produced by the 
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condensation reaction. The desired products were obtained in high yield by ether-
induced crystallization from the crude of reaction.      
R2 OH
NH3
O
O
R2
R
R1
TsO
i
NH2
HO
O
R
R1
DMG R = R1: CH3
L-Ala R: CH3; R1: H
R2: Bn, CH2tBu
2.4a R = R1: CH3; R2: Bn
2.4b R: CH3; R1: H; R2: CH2tBu
Reagents and conditions: (i) TsOH, toluene, 110 ºC, 12 h !
Scheme 2.3. Synthesis of the tosylate salt of 2,2-dimethylglycine benzyl ester (2.4a) and L-alanine 
neopentyl ester (2.4b)  
2.2.2 Synthesis of aryl phosphorodichloridates 
The phenyl phosphorodichloridate (2.5a, fig. 2.1) is commercially available, while the 
naphthyl phosphorodichloridate (2.5b, fig. 2.1) is not.  
PO Cl
Cl
O
PO Cl
Cl
O
2.5a 2.5b !
Figure 2.1. Structures of phenyl phosphorodichloridate (2.5a) and naphthyl phosphorodichloridate 
(2.5b). 
!
The synthesis of 2.5b was carried out by treatment of naphthol with phosphorus 
oxychloride in the presence of triethylamine (TEA) (scheme 2.4).6 The crude of reaction 
was filtrated and used in the next step without any further purification. 
P
O Cl
Cl
O
P
Cl Cl
Cl
O
2.5b
i
OH
Reagents and conditions: (i) TEA, Et2O, -78 ºC, then rt, 2 h !
Scheme 2. 4 Synthesis of naphthyl phosphorodichloridate (2.5b) 
 
 
!
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Chapter 3. Aryl phosphoramidate derivatives of acyclovir 
3.1 Introduction to the application of the ProTide approach to 
acyclovir 
As already discussed in chapter 1, acyclovir (ACV) is an acyclic guanine nucleoside 
analogue (fig 3.1) that has been approved for the treatment of HSV and VZV 
infections.1 This antimetabolite nucleoside exerts inhibitory activity on the viral DNA 
polymerase by means of its triphosphate form (ACV-TP). The selectivity for the virus-
encoded TK, which is responsible for the formation of ACV monophosphate (ACV-
MP), and the viral polymerase accounts for the high therapeutic index of ACV.2 
NH
NN
N
O
NH2O
HO  
Figure 3.1. Structure of ACV 
 
The development of drug resistance to ACV mainly involves a partial or complete loss 
of the virus-encoded TK activity. Despite the fact that ACV has been used in the 
treatment of herpes virus infections for more than 30 years, the incidence of ACV-
resistant infections is not a risk among immunocompetent patients. However, this risk is 
a concern for immunocompromised patients and particularly in patients receiving 
allogenic bone marrow transplant.3 
The release of ACV-MP directly into the cell bypasses the HSV- and VZV-TK-
mediated phosphorylation of ACV affording activity also against TK-deficient strains of 
HSV and VZV. For this reason, in our group the ProTide approach was previously 
applied to the synthesis of aryl phosphoramidates of ACV, which were evaluated in 
vitro against ACV-sensitive and ACV-resistant strains of HSV and VZV.4 In particular, 
the L-alanine benzyl ester derivatives 3.1a and 3.1b (fig. 3.2) exhibited retention of 
activity against TK-deficient strains of HSV and VZV in the micromolar range, proving 
a successful bypass of the first phosphorylation step by releasing ACV-MP.  
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O
Bn CH3
3.1a Ar: Ph 
3.1b Ar: 1-Naph  
Figure 3.2 L-alanine benzyl ester derivatives 3.1a and 3.1b 
 
These compounds were also found significantly active against HIV in human T-
lymphocyte CEM and MT-4 cells (table 3.1).5 
Table 3.1. Anti-HIV and cytostatic activity of L-alanine benzyl ester derivatives 3.1a-b and ACV in 
CEM and MT-4 cell cultures (from ref. 5) 
 Antiviral Activity Cytotoxic/Cytostatic Activity 
 EC50 (µM)
 a IC50
 b(µM) CC50
 c(µM) 
Cps HIV-1 (CEM) HIV-2 (CEM) 
HIV-1 
(MT-4) 
 CEM MT-4 MT-4 
3.1a 16 ± 14 11 ± 4.9 5.7 ± 1.6 42 ± 11 33.8 ± 10.6 > 150 
3.1b 15 ± 14 8.9 ± 6.3 0.8 17 > 150 ND 
ACV > 250 > 250 > 250 > 250 > 250 > 250 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b 50% Inhibitory concentration, or compound concentration  required to inhibit 
cell proliferation by 50%; c 50% Cytotoxic  concentration, or compound concentration  that induces 
50% cell death in the cultures 
 
This result was not totally unexpected considering that early clinical trials pointed out 
the survival benefits of ACV treatment in HIV patients co-infected with HHV.6 At first 
the mechanism of action of ACV in inhibiting HIV was not clear. Recent trials, which 
showed reduction of HIV load in HSV-2 co-infected individuals following ACV 
treatment, argued that the suppression of the inflammation mediated by HSV-2 could be 
accountable for HIV load decrease.7, 8 However, studies in vitro proved that acyclovir 
triphosphate inhibits HIV-1 RT and HSV co-infection is necessary for the suppression 
of HIV-1 replication by ACV (EC50= 3.1 µM in tonsillar tissues co-infected ex-vivo 
with HSV-2).9, 10 The bioactivation mechanism of ACV accounts for the need of HSV-
TK activity in order to have inhibitory activity against HIV-1 RT. This finding is in 
agreement with results obtained in vitro with ACV ProTides.  
Compounds 3.1a and 3.1b are considered the lead compounds for ACV ProTide series 
and they will be reported as references for the antiviral activity of the novel aryl 
phosphoramidate derivatives of ACV discussed in the following paragraphs. 
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3.2 Design of novel aryl phosphoramidate derivatives of acyclovir: 
modification of aryl, amino acid, and ester moieties. 
In order to improve the antiviral activity of the L-Alanine benzyl ester derivatives 3.1a 
and 3.1b,
5
 novel aryl phosphoramidates of ACV were designed and synthesised varying 
the aryl, amino acid and ester moieties (3.2, fig. 3.3).  
NH
NN
N
O
NH2O
OP
O
O
NH
Ar
O
O
R''
R
R'
Ar: aryl moiety
R, R': amino acid (AA) side chain
R'': ester moiety
3.2
 
Figure 3.3. General structure of ACV ProTides 
 
As already discussed in chapter 1, the capacity of the masking groups to be good 
leaving groups or to adopt the right conformation in order to interact properly with the 
enzymes involved in the bioactivation pathway of ProTides is crucial for the successful 
release of the monophosphate form of nucleoside analogues.
11
 For this reason, the 
present work is focused on the study of the structure-activity relationships of the 
masking groups of ACV ProTides (tab. 3.2).  
In the first instance, the ACV ProTides 3.2a-f containing the phenyl group as aryl 
moiety, the benzyl group as ester moiety, and different amino acids were considered. 
Hydrophobic amino acids were selected considering to balance the liphophilicity and 
the steric hindrance of the amino acid side chain. The increase in the lipophilicity is 
meant to improve the cellular uptake of ProTides. However, it must be considered that 
bulky aliphatic side chains are more likely to cause loss of activity due to the lack of 
interaction with the enzymes involved in the bioactivation pathway of ProTides.
11
 The 
non-natural amino acid 2,2-dimethylglycine 3.2b was considered in order to evaluate 
the influence of the amino acid stereochemistry on the activity. Then, the replacement 
of the phenyl group with the naphthyl 3.2g-j was evaluated with the aim of improving 
the lipophilicity and leaving group ability of the aryl moiety. In addition, the biological 
evaluation of the elsewhere reported derivatives 3.2p and q, containing meta- and para-
ethyl-phenyl groups at the aryl moiety respectively, is included in this work due to the 
similar lipophilicity and lower steric hindrance of these substituents in comparison to 
the naphthyl group.12 Finally, in addition to the benzyl different esters such as neopentyl 
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and tert-butyl were also evaluated (3.2k and l). The biological evaluation of the 
previously reported L-valine methyl and ethyl ester derivatives 3.2n and o is included in 
this work.13 
Table 3.2. Aryl (Ar), amino acid (AA) and ester (R”) substituents of ACV ProTides 3.2 a-q 
Cps Ar AA R” 
3.2a Ph Gly Bn 
3.2b Ph DMG Bn 
3.2c Ph L-Val Bn 
3.2d Ph L-Leu Bn 
3.2e Ph L-Ile Bn 
3.2f Ph L-Pro Bn 
3.2g 1-Naph L-Val Bn 
3.2h 1-Naph L-Leu Bn 
3.2i 1-Naph L-Ile Bn 
3.2j 1-Naph L-Phe Bn 
3.2k Ph L-Ala tBu 
3.2l Ph L-Ala CH2-tBu 
3.2m 1-Naph L-Ala CH2-tBu 
3.2n13 1-Naph L-Val Me 
3.2o13 1-Naph L-Val Et 
3.2p12 3-Et-Ph L-Ala Bn 
3.2q12 4-Et-Ph L-Ala Bn 
 
3.3 Synthesis of ACV ProTides. 
Based on the previous experience in our group,14 ACV was protected at the amino group 
using N,N-dimethylformamide dimethyl acetal  in order to improve its poor solubility in 
THF (scheme 3.1),15 which is the solvent commonly used for the synthesis of ProTides.  
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i
Reagent and conditions: (i) N,N-dimethylformamide dimethyl acetal, DMF, rt, 24 h
ACV 3.3
 
Scheme 3.1. Protection of ACV 
 
For most of the ACV ProTides synthesised, coupling reaction of protected ACV (3.3) 
with the appropriate aryl amino acid ester phosphorochloridate (2.2) in anhydrous THF 
was carried out in the presence of tert-Butyl magnesium chloride (tBuMgCl), according 
to the Uchiyama approach described in chapter 2, and afforded the protected derivatives 
of ACV ProTide (3.4, scheme 3.2).16 However, in the case of glycine and proline 
derivatives this approach was not successful, so their synthesis was carried out in 
anhydrous THF/Pyridine mixture (3:2) in the presence of N-methylimidazole (NMI) 
according to the Van Boom procedure (scheme 3.2).17  
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i
3.4
Reagents and conditions: (i) anhydrous THF, tBuMgCl, rt, 12-14 h; 
or anhydrous THF/Pyr, NMI, rt, 12-14 h  
Scheme 3.2. Generic synthesis of ACV ProTides   
 
The DMF-protecting group was removed by refluxing 3.4 in isopropyl alcohol (iPrOH) 
obtaining the desired compounds 3.2 (scheme 3.3). 
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Reagents and conditions: (i) iPrOH, reflux, 48-62 h
3.4 3.2
 
Scheme 2.3. N2-DMF protecting group removal 
 
Table 3.3 summarises structures, 31P NMR chemical shifts (!) in deuterated methanol, 
and isolated yields of the ACV ProTides synthesised. All the ACV ProTides containing 
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chiral amino acid display two peaks at the 31P NMR spectra corresponding to the two 
diastereomeric configurations, except the L-Proline derivative, which was isolated as 
single diastereomer. This was likely due to the stereospecificity of the coupling 
reaction, giving only one peak at the 31P NMR spectrum.  
Table 3.3. ACV ProTides synthesised.  
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety)  
Protected 
Cps 
Ar AA R” 
Coupling 
Yield 
Final 
Cps 
31P NMR 
!  (ppm) 
Deprotection 
Yield  
3.4a Ph Gly Bn 81% 3.2a 4.77 2% 
3.4b Ph DMG Bn 93% 3.2b 2.13 14% 
3.4c Ph L-Val Bn 57% 3.2c 4.27, 4.51 8% 
3.4d Ph L-Leu Bn 65% 3.2d 3.60, 4.05 8% 
3.4e Ph L-Ile Bn 45% 3.2e 4.13, 4.42 3% 
3.4f Ph L-Pro Bn 16% 3.2f 1.68 4% 
3.4g 1-Naph L-Val Bn 60% 3.2g 4.79, 4.90 10% 
3.4h 1-Naph L-Leu Bn 65% 3.2h 4.04, 4.94 21% 
3.4i 1-Naph L-Ile Bn 47% 3.2i 4.63, 4.82 17% 
3.4j 1-Naph L-Phe Bn 50% 3.2j 3.77, 3.86 16% 
3.4k Ph L-Ala tBu 75% 3.2k 3.71, 3.81 22% 
3.4l Ph L-Ala CH2tBu 85% 3.2l 3.59, 3.80 14% 
3.4m 1-Naph L-Ala CH2tBu 53% 3.2m 4.09, 4.15 22% 
 
The yields of the coupling reactions may suggest that the phosphorylation of 3.3 with 
the phosphorochloridate 2.2 is negatively affected by the steric hindrance of the amino 
acid side chain. The instability of the P-N bond does not allow the removal of the DMF-
protecting group in basic conditions, but instead requires milder conditions, which 
afforded poor yields at the deprotection step. 
3.4 Biological evaluation of acyclovir ProTides 
The newly synthesised ACV ProTides 3.2a-m and the previously reported 3.2n-q were 
evaluated for their activity against HSV, VZV, HCMV in human embryonic lung (HEL) 
cell cultures. The antiviral activity of ACV ProTides was evaluated also against HIV in 
human T-lymphocyte cell cultures (CEM and MT-4 cells). In the case of the antiviral 
assays performed in HEL cell cultures against the herpes viruses, the minimum 
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concentration required to cause a microscopically visible alteration of cell morphology 
was measured and considered as a parameter of cytotoxicity. The cytostatic activity of 
these compounds on HEL and MT-4 cell cultures is also reported. In the case of the 
MT-4 cells, the compound concentration that induces 50% cell death in the cultures was 
evaluated too. The results of these assays will be presented in the next paragraphs. 
 
These derivatives were evaluated also against feline herpes virus, feline corona virus, 
influenza A and B viruses, para-influenza-3-virus, vescicular stomatitis, respiratory 
syncitial virus, punta toro virus, but no activity was detected. 
Also the protected intermediates of the ACV ProTides 3.4b, d, f, g, h, i, k, and m were 
evaluated for their activity against HSV, VZV, HCMV, and HIV. Most of them were 
found to be inactive. Only the 2,2-dimethylglycine and the L-proline benzyl ester 
derivatives 3.4b and 3.4f exhibited moderate to poor activity against HIV-1 in MT-4 
cells (EC50= 30-70 µM). These compounds resulted significantly less active in 
comparison to the unprotected ACV ProTides 3.2, indicating a detrimental effect of the 
N
2-DMF protecting group on their antiviral activity.  
3.4.1 Anti-HSV activity 
Three different strains of HSV were used to evaluate the anti-HSV activity of the ACV 
ProTides 3.2a-j in HEL cells: HSV-1 (KOS), HSV-2 (G), and thymidin kinase-deficient 
(TK-) HSV-1 (KOS). The minimum concentration required to cause a microscopically 
visible alteration of cell morphology (MCC) was found to be above 100 µM for all the 
compounds synthesised. 
Modification of the aryl and amino acid moieties  
Table 3.4 reports the anti-HSV activity of ACV ProTides 3.2a-j containing phenyl and 
naphthyl as aryl moieties, benzyl group as the ester, and different amino acids. The data 
include ACV and the lead compounds 3.1a and b as references.4  
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Table 3.4. Anti-HSV activity of ACV ProTides 3.2a-j in HEL cell cultures 
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety)  
    Antiviral Activity EC50 
a (µM) 
Cps Ar AA R” HSV-1 HSV-2 TK- HSV-1  
3.2a Ph Gly Bn 3 0.8 9 
3.2b Ph DMG Bn 1.4 ± 0.8 0.8 ± 0.1 5.5 ± 2.1 
3.2c Ph L-Val Bn 2 ± 0.1 0.9 ± 0.2 7.5 ± 6.4 
3.2d Ph L-Leu Bn 0.8 ± 0.1 0.7 ± 0.1 1.4 ± 0.8 
3.2e Ph L-Ile Bn 1.1 ± 0.4 1.1 ± 0.4 1.4 ± 0.8 
3.2f Ph L-Pro Bn >100 >100 >100 
3.2g 1-Naph L-Val Bn 0.7 3 2.5 
3.2h 1-Naph L-Leu Bn 1.2 1.1 1.3 
3.2i 1-Naph L-Ile Bn 1.2 1.5 3 
3.2j 1-Naph L-Phe Bn >20 >20 >20 
ACV - - - 0.4 0.2 50 
3.1a Ph L-Ala Bn 8 ± 5.7 4 ± 0 15 ± 7.1 
3.1b 1-Naph L-Ala Bn 2 ± 0 1.4 ± 0.8 10 ± 2.1 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
ACV exhibited activity against HSV-1 and HSV-2 in the sub-micromolar range (EC50= 
0.4 and 0.2 µM respectively) but markedly lost the activity against TK--HSV-1 (EC50= 
50 µM). Lead compounds 3.1a and 3.1b, did not improve the antiviral activity of ACV 
showing micromolar activity against HSV-1 and HSV-2. However, as already 
mentioned, they retained their activity against TK--HSV-1, demonstrating a successful 
by-pass of the first phosphorylation step.5  
The majority of the novel ACV ProTides 3.2a-j were found active against HSV-1 and 
HSV-2 (EC50: 0.7-3 µM) and showed retention of activity against TK-deficient HSV-1 
in contrast to ACV, demonstrating successful bypass of the first phosphorylation step. 
More specifically: 
• Glycine and 2,2-dimethylglycine derivatives 3.2a and b exhibited retention 
of activity when compared with the lead compounds 3.1a and b.  
• In disagreement with the common structure-activity relationship of the 
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ProTides, showing that the replacement of L-alanine with bulky amino acids leads 
to a significant loss of activity,11 ACV ProTides containing  L-valine (3.2c and 
3.2g), L-leucine (3.2d and 3.2h), and L-isoleucine (3.2e and 3.2i) as amino acid 
moiety displayed anti-HSV activity in the micromolar range. In particular, L-
leucine and L-isoleucine derivatives of the phenyl series (3.2d and 3.2e) showed 
slight improvement of activity against HSV-1 (EC50= 0.8-1.1 µM), HSV-2 (EC50= 
0.7-1.1 µM), and TK-deficient HSV-1 (EC50= 1.4 ± 0.8 µM) in comparison to the 
analogous lead compound 3.1a. 
• The L-proline and L-phenylalanine derivatives (3.2f and 3.2j) exhibited a 
complete loss of the anti-HSV activity. 
• The increase of lipophilicity, achieved through the replacement of the 
phenyl with the naphtyl group in the aryl moiety, did not improve the anti-HSV 
activity. 
Evaluation of meta- and para-ethyl-phenyl susbstituents 
Table 3.5 shows the anti-HSV activity of the elsewhere reported L-alanine benzyl ester 
derivatives of ACV ProTides bearing meta- or para-ethyl substituted phenyl group as 
aryl moiety (3.2p-q).12 As already mentioned, these substituents were considered due to 
their similar lipophilicity and lower steric hindrance when compared with the naphthyl 
group. ACV and the lead compounds 3.1a and b are reported as the reference 
compounds. 
Table 3.5. Anti-HSV activity of ACV ProTides 3.2p-q in HEL cell cultures  
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    Antiviral activity EC50 
a (µM) 
Cps Aryl AA R” HSV-1 HSV-2 TK- HSV-1 
3.2p12 4-Me-Ph L-Ala Bn 32.5 32.5 47.5 
3.2q12 4-Et-Ph L-Ala Bn 32.5 32.5 45 
ACV - - - 2 1 250 
3.1a Ph L-Ala Bn 8 ± 5.7 4 ± 0 15 ± 7.1 
3.1b 1-Naph L-Ala Bn 2 ± 0 1.4 ± 0.8 10 ± 2.1 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
Chapter 3 
 
 67 
The data show a marked decrease of potency of compounds 3.2p and q against HSV-1 
and HSV-2 in comparison to ACV and the analogous ProTides containing the 
unsubstituted phenyl (3.1a) or naphthyl group (3.1b) as aryl moiety. This antiviral 
activity was retained against TK--HSV-1, proving that this series of ACV ProTide is 
able to deliver the monophosphate form of ACV into the cell.  
Modification of the ester moiety  
Table 3.6 shows the anti-HSV activity of different ester derivatives of ACV ProTide 
such as the L-alanine tert-butyl and neopentyl ester derivatives 3.2k-m, as well as the 
previously reported L-valine methyl and ethyl ester derivatives 3.2n and o, which have 
been included in this work. The analogous benzyl ester derivatives 3.1a, 3.1b and 3.2g 
have been reported for comparison. 
Table 3.6. Anti-HSV activity of ACV ProTides 3.2k-o in HEL cell cultures  
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    Antiviral Activity EC50 
a (µM) 
Cps Ar AA R” HSV-1 HSV-2 TK- HSV-1  
3.2k Ph L-Ala tBu >100 >100 >100 
3.2l Ph L-Ala CH2tBu 3 12 2.5 
3.2m 1-Naph L-Ala CH2tBu 1.3 1.7 1.5 
3.2n13 1-Naph L-Val Me >100 >100 >100 
3.2o13 1-Naph L-Val Et 51 ± 9.2 32 ± 18 42 ± 3.5 
ACV - - - 0.4 0.2 50 
3.1a Ph L-Ala Bn 8 ± 5.7 4 ± 0 15 ± 7.1 
3.1b 1-Naph L-Ala Bn 2 ± 0 1.4 ± 0.8 10 ± 2.1 
3.2g 1-Naph L-Val Bn 0.7 3 2.5 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
The inactivity of the tert-butyl ester derivative 3.2k confirms the early study of 
structure-activity relationship conducted on aryl phosphoramidates of stavudine (d4T) 
showing that the tert-butyl ester derivative was the least potent of the series.11  
In contrast, the neopentyl ester analogues 3.2l and 3.2m showed antiviral activity in the 
micromolar range against HSV-1, HSV-2, and TK-deficient HSV-1. 
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Finally, the data show that in the case of L-valine derivatives the replacement of the 
benzyl (3.2g) with methyl (3.2n) and ethyl (3.2o) esters led to a significant loss of 
antiviral activity. This result is in agreement with the previous studies showing that L-
alanine methyl ester derivative of ACV ProTide was poorly active against HSV.4 As 
previously reported, the unsuccessful ester cleavage mediated by the cellular 
carboxyesterase may account for such a lack of activity.5 
3.4.2 Anti-VZV activity 
The antiviral activity of ACV protides 3.2a-d, 3.2f-g, 3.2k-l, and 3.2o-r against TK-
positive (TK+) and TK-deficient (TK-) strains of VZV in HEL cell cultures is reported 
in table 3.7. The data include ACV as reference compound. The lead compounds 3.1a 
and b are reported for comparison.4  
Table 3.7. Anti-VZV of ACV ProTides 3.2a-d, f-g, k-l, and o-r in HEL cell cultures 
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    Antiviral Activity EC50
a (µM) 
TK+ VZV strains TK- VZV strains 
Cps Ar AA R” 
YS  OKA  07-1  YS/R  
3.2a Ph Gly Bn 8.1 7.4 10.4 8.5 
3.2b Ph DMG Bn 5.8 5.9 3.7 1.6 
3.2c Ph L-Val Bn 2.6 6.8 7.8 0.3 
3.2d Ph L-Leu Bn N.D. b 1.6 5.3 2.6 
3.2f Ph L-Pro Bn N.D. >50 >50 N.D. b 
3.2g 1-Naph L-Val Bn 0.7 0.7 1.7 1.4 
3.2k Ph L-Ala tBu N.D. b 35 N.D. b >50 
3.2l Ph L-Ala CH2tBu 1.1 2.1 3.3 3 
3.2o 1-Naph L-Val Me N.D. b >50 >50 N.D. b 
3.2p 1-Naph L-Val Et N.D. b 26 23.7 N.D. b 
3.2q 3-Et-Ph L-Ala Bn 1.5 1 4 2.9 
3.2r 4-Et-Ph L-Ala Bn 1.5 1.4 3.2 2.7 
ACV - - - 1 4.17 73.6 94.3 
3.1a Ph L-Ala Bn 0.72 1.0 1.8 0.59 
3.1b 1-Naph L-Ala Bn 7.2 3.3 6.9 N.D 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; bnot determined  
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ACV was found active against TK+-VZV in the micromolar range; such activity was 
markedly decreased against the TK- strains. The lead compounds, 3.1a and b, exhibited 
good antiviral activity against both TK+ and TK- strains of VZV.4 In general, the newly 
synthesised ACV ProTides retained this activity, proving the successful release of ACV 
monophosphate inside the cell.  
In agreement with the major results obtained against HSV, L-valine and L-leucine 
benzyl ester derivatives (3.2c, 3.2d, 3.2g) were found active against VZV in the 
micromolar range retaining the antiviral activity of the lead compounds 3.1a and b. The 
L-Proline derivative 3.2f confirmed to be inactive, as already observed in the anti-HSV 
assay. The L-alanine neopentyl ester derivative 3.2l retained the anti-VZV activity in 
comparison to the benzyl ester analogue 3.1a. The L-valine methyl and ethyl ester 
derivatives 3.2o and 3.2p were found to be inactive or poorly active. 
In contrast to the results obtained against HSV, the meta and para-ethyl-phenyl 
derivatives 3.2q and 3.2-r did not show the same marked decrease of the anti-VZV 
activity in comparison to the L-alanine benzyl ester analogues 3.1a and 3.1b.  
The minimum concentration required to cause a microscopically visible alteration of 
HEL cell morphology (MCC) was found to be above 100 µM for all the compounds 
evaluated in the antiviral assay against VZV. 
3.4.3 Anti-HCMV activity 
Table 3.8 reports the antiviral activity of ACV ProTides 3.2a-d, 3.2f-g, 3.2k-l, and  
3.2o-r against HCMV in HEL cell cultures. GCV is included as reference compound. 
The L-alanine benzyl ester derivatives 3.1a and b are reported for comparison.18 The 
minimum concentration required to cause a microscopically visible alteration of HEL 
cell morphology (MCC) was above 100 µM for all the compounds tested against 
HCMV. 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
 70 
 
Table 3.8. Anti-HCMV activity of ACV ProTides 3.2a-d, f-g, k-l, and o-r in HEL cell cultures 
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    Antiviral Activity EC50
a (µM) 
Cps AR AA R” AD-169 strain Davis strain 
3.2a Ph Gly Bn 33.8 11.0 
3.2b Ph DMG Bn 11 4.3 
3.2c Ph L-Val Bn 4 2 
3.2d Ph L-Leu Bn 2.7 1 
3.2f Ph L-Pro Bn >50 >50 
3.2g 1-Naph L-Val Bn 2 0.9 
3.2k Ph L-Ala tBu >50 >50 
3.2l Ph L-Ala CH2-tBu 14.3 6.1 
3.2o 1-Naph L-Val Me 50 20 
3.2p 1-Naph L-Val Et 12.6 4.3 
3.2q 3-Et-Ph L-Ala Bn 9.3 6.7 
3.2r 4-Et-Ph L-Ala Bn 16.2 4.1 
GCV - - - 6.7 8.3 
3.1a Ph L-Ala Bn 12.6 2.9 
3.1b 1-Naph L-Ala Bn 2.1 1.8 
a 50% Effective concentration, or compound concentration required to inhibit virus-
induced cytopathicity by 50% 
 
All the ACV ProTides, except for the L-proline benzyl and L-alanine tert-butyl ester 
derivatives 3.2f and 3.2k, exhibited good to moderate anti-HCMV activity. Considering 
that ACV is not active against HCMV due to the lack of phosphorylation,19 this result 
confirms that the ProTide approach is effective in releasing the ACV monophosphate 
inside the cell. In particular, the 2,2-dimethylglycine, L-valine and L-leucine benzyl 
ester derivatives 3.2b, 3.2d and 3.2g showed activity against HCMV comparable to 
GCV and the lead compounds 3.1a and 3.1b. In contrast to the anti-HSV and anti-VZV 
assays, the L-valine ethyl ester derivative 3.2p displayed good anti-HCMV activity 
(EC50= 4.3-12.6 µM), while the L-valine methyl ester derivative 3.2o was poorly active 
(EC50= 20-50 µM).  
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3.4.4 Cytostatic activity of ACV ProTides in HEL cell cultures 
The cytostatic activity in HEL cell cultures of ACV protides 3.2a-d, 3.2f-g, 3.2k-l, and 
3.2o-r is reported in table 3.9.  
ACV is included as reference compound. The antiproliferative activity of L-alanine 
benzyl ester derivatives 3.1a and 3.1b on HEL cells is reported for comparison.4  
Table 3.9 Cytostatic activity of ACV ProTides 3.2a-d, f-g, k-l, and o-r on HEL cell cultures 
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    Cytostatic  Activity IC50
a (µM) 
Cps AR AA R” HEL 
3.2a Ph Gly Bn >100 
3.2b Ph DMG Bn >100 
3.2c Ph L-Val Bn 100 
3.2d Ph L-Leu Bn 100 
3.2f Ph L-Pro Bn >100 
3.2g 1-Naph L-Val Bn 74 
3.2k Ph L-Ala tBu >100 
3.2l Ph L-Ala CH2-tBu 43.3 
3.2o 1-Naph L-Val Me >100 
3.2p 1-Naph L-Val Et >100 
3.2q 3-Et-Ph L-Ala Bn 45.4 
3.2r 4-Et-Ph L-Ala Bn 47.3 
ACV - - - 559 
3.1a Ph L-Ala Bn >100 
3.1b 1-Naph L-Ala Bn 20 
a 50% Inhibitory concentration, or compound concentration  required to inhibit cell 
proliferation by 50% 
 
Most of the ACV ProTides did not exert antiproliferative activity on HEL cells below 
100 µM. Some of them showed moderate cytostatic activity (IC50: 43.3-74 µM). 
However, this result was not completely unexpected considering that the lead 
compound 3.1b exhibited similar effect (IC50: 20 µM), as previously reported in the 
literature.4 
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3.4.5 Anti-HIV activity 
The antiviral activity of ACV ProTides 3.2b, 3.2d, 3.2g-i, and 3.2k-m was evaluated 
against HIV-1 in CEM and MT-4 cell cultures and against HIV-2 in CEM cell cultures. 
Table 3.10 reports the anti-HIV-1 and cytostatic activity in MT-4 cell cultures of the 
selected ACV ProTides. The data include ACV as reference compound and the 
previously reported L-alanine benzyl ester derivatives 3.1a and 3.1b for comparison.5   
Table 3.10. Anti-HIV-1 and cytostatic activty of ACV ProTides in MT-4 cell cultures. 
(Ar: aryl moiety; AA: amino acid moiety; R”: ester moiety) 
    
Antiviral Activity 
EC50
a (µM) 
Cytostatic Activity 
IC50
b
 (µM) 
Cps Ar AA R” HIV-1 MT-4 
3.2b Ph DMG Bn 7 >150 
3.2d Ph L-Leu Bn 0.8 17 
3.2g 1-Naph L-Val Bn 10 48 
3.2h 1-Naph L-Leu Bn 2.5 21 
3.2i 1-Naph L-Ile Bn 4 21 
3.2k Ph L-Ala tBu >150 >150 
3.2l Ph L-Ala CH2tBu 4 >150 
3.2m 1-Naph L-Ala CH2tBu 0.7 70 
ACV - - - >250 >250 
3.1a Ph L-Ala Bn 5.7 ± 1.6 33.8 ± 10.6 
3.1b 1-Naph L-Ala Bn 0.8 > 150 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b 50% Inhibitory concentration, or compound concentration  required 
to inhibit cell proliferation by 50% 
 
As known, ACV does not exert any activity against HIV-1 and HIV-2 in the absence of 
herpes virus-encoded thymidine kinase.9  
The antiviral activity of the newly synthesised ACV ProTides against HIV-1 in MT-4 
cells suggests that the ACV monophosphate was released into the cell bypassing the 
first phosphoryation step of ACV. The 2,2-dimethylglycine benzyl ester derivative 3.2b 
was found active in the micromolar range (EC50= 7 µM) showing retention of activity in 
comparison to 3.1a and 3.1b. The ACV ProTides containing bulky amino acids such as 
L-Leucine (3.2d, 3.2h), L-Valine (3.2g) and L-isoleucine (3.2i) displayed good to 
moderate activity (EC50= 0.8-10 µM). However, these compounds showed also 
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moderate cytostatic activity (IC50= 21-48 µM). As observed against the herpes viruses, 
the L-alanine tert-butyl ester derivative 3.2k was inactive against HIV-1 in MT-4 cells. 
While, the L-alanine neopentyl ester derivatives 3.2l and 3.2m retained the activity 
diplayed by the lead compounds 3.1a and 3.1b.  
The concentration that induces 50% cell death in the cultures was above 150 µM for all 
the ACV ProTides tested against HIV-1 in MT-4 cells.  
Surprisingly, all these compounds were found to be totally inactive against HIV-1 and 
HIV-2 in CEM cell cultures, where the previously reported L-alanine benzyl ester 
derivatives 3.1a and 3.1b exhibited anti-HIV activity in the micromolar range (table 
3.1).  
3.4.6 Summary of the biological activity of ACV ProTides 
The biological evaluation of the ACV ProTides presented in this work strongly 
suggests that most of them successfully bypass the first phosphorylation of ACV, 
releasing the ACV monophosphate into the cell. This hypothesis is supported by the 
activity of these compounds against TK-deficient strains of HSV and VZV as well as 
against HCMV and HIV-1 in MT-4 cells.    
The glycine and 2,2-dimethylglycine benzyl ester derivatives 3.2a and 3.2b showed 
retention of activity against the herpes viruses when compared to the analogous L-
alanine benzyl ester derivatives 3.1a and 3.1b (tab. 3.4 and 3.7). Compound 3.2b 
showed similar result also against HIV-1 in MT-4 cell (tab 3.10). 
In disagreement with the common structure-activity relationships of ProTides, the aryl 
phosphoramidate derivatives of ACV 3.2c-e and 3.2g-l containing benzyl ester of bulky 
amino acids such as L-valine, L-leucine, and L-isoleucine exhibited good antiviral 
activity against both herpes viruses and HIV-1 in MT-4 cells with general retention of 
activity in comparison to the lead compounds 3.1a and 3.1b (tab. 3.4, 3.7, 3.8, 3.10). 
The flexibility of the acyclic chain of ACV may allow these derivatives to assume the 
right conformation in order to interact properly with the different enzymes involved in 
the activation pathway of the ProTides. 
The complete lack of activity of the L-proline derivative 3.2f has already been 
described in the application of the ProTide approach to the other nucleoside 
analogues.11 Whether the steric hinderance or the lack of the free NH are accountable 
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for the missed bioactivation of L-proline derivatives has not been clarified yet.5  
The inactivity of the L-phenylalanine derivative 3.2j is most probably correlated to the 
steric hindrance of the amino acid moiety that interferes with the carboxyesterase- or 
phosphoramidase-mediated cleavages.5  
The increase of lipophilicity afforded by the replacement of the phenyl group at the 
aryl moiety with the naphthyl did not improve the potency of the antiviral activity (tab. 
3.4). The introduction of meta- and para-ethyl-phenyl led to a marked decrease of the 
anti-HSV activity of 3.2p and 3.2q in comparison to 3.1a and 3.1b (tab 3.5). Similar 
decrease was not observed against VZV (tab 3.7). In a previous study, it was proved 
that the benzyl ester of 3.2p and 3.2q is successfully cleaved by the carboxypeptidase 
Y suggesting that these compounds can release ACV monophosphate into the cell 
according to the putative mechanism of activation of ProTides described in chapter 1.12 
The replacement of the benzyl ester of the L-alanine derivatives 3.1a and 3.1b with the 
tert-butyl group caused a complete loss of antiviral activity in all the biological assays 
presented in this work (tab 3.6-3.8 and 3.10). This result confirms previous studies 
showing that the tert-butyl ester derivatives are not successfully processed according to 
the putative mechanism of activation of ProTides.5, 11 Differently, the L-alanine 
neopentyl ester derivatives 3.2l and 3.2m were found active against both the herpes 
viruses and HIV-1 in MT-4 cells (tab. 3.6-3.9) showing a general retention of the 
antiviral activity when compared to the analogous benzyl ester derivatives 3.1a and 
3.1b. In comparison to the tert-butyl group, the additional methylene group of the 
neopentyl ester must be crucial in order to properly accommodate this moiety into the 
active site of the carboxyesterase.  
The previously reported L-valine methyl and ethyl ester derivatives 3.2n and 3.2o were 
found inactive or poorly active against HSV and VZV presumably due to the poor 
cleavage mediated by the carboxyesterase (tab. 3.6-3.7).5 However, compound 3.2o 
showed also good antiviral activity against HCMV (EC50= 4.3-12.6 µM, tab. 3.8).  
Some of the ACV ProTides presented in this work exerted moderate antiproliferative 
activity on Hel cell (IC50= 45.4-74 µM, tab 3.9) and MT-4 cell cultures (IC50= 17-70 
µM, tab. 3.10). These results may indicate that the application of the ProTide approach 
could induce the release of cytotoxic concentration of ACV triphosphate into the cell.   
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The lack of activity of the newly synthesised ACV ProTides against HIV-1 and HIV-2 
in CEM cell cultures is in contrast with all the biological results presented so far. 
However, it is in agreement with previous studies of the application of the ProTide 
approach to different nucleoside analogues showing that the replacement of the L-
alanine with other amino acids leads to the loss of the antiviral activity (10- to 100-
fold), particularly in the case of bulky amino acids.11 The inactivity of the  
2,2-dimethylglycine derivative is surprising, considering that this amino acid generally 
involves retention of the antiviral activity displayed by the L-alanine analogues. In 
comparison to the antiviral assays performed in HEL and MT-4 cell cultures, the lack of 
anti-HIV activity of the ACV ProTides in CEM cell cultures could be explained by a 
difference in terms of substrate affinity or intracellular levels of the enzymes involved 
in the intracellular bioactivation of ProTides.  
3.5 Enzymatic and modelling studies on ACV ProTides 
With the aim to understand the difference of antiviral activity among the novel ACV 
ProTides presented in the previous paragraphs, enzymatic and molecular modelling 
studies were performed. 
3.5.1 Study of the carboxyesterase activity 
According to the putative bioactivation mechanism of ProTides described in chapter 1, 
the cleavage of the ester moiety leads to the loss of the aryl moiety with formation of 
the phosphoramidate monoester intermediate, which is cleaved by a phosphoramidase-
type enzyme affording the monophosphate derivative of nucleoside analogues.11 As 
already mentioned, cathepsin A (catA, EC 3.4.16.5) has been indicated as the main 
intracellular enzyme responsible for the cleavage of the ester moiety of ProTides.20 
Unfortunately, human cathepsin A is not commercially available. However, it has been 
shown that this enzyme has a high degree of amino acid sequence homology with the 
yeast carboxypeptidase Y (CPY, EC 3.4.16.1), which is commercially available. The 
two enzymes have similar structure and similar substrate specificities.21,22 The formation 
of the phosphoramidate monoester as a product of the enzymatic ester hydrolysis has 
been extensively investigated in our group monitoring the reaction by 31P NMR.18 The 
phosphoramidate monoester was also synthesised by chemical hydrolysis of a ProTides 
in the presence of triethylamine confirming that the chemical shift of the phosphorus is 
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around 7-8 ppm in the 31P NMR spectrum.23  
In order to evaluate whether the ester group of the ACV ProTides presented in this work 
can be hydrolyzed according to the putative bioactivation mechanism of ProTides, 
enzymatic studies have been performed using CPY.    
In particular, compounds 3.2b, 3.2d, 3.2f, and 3.2j were selected with the aim to 
investigate the effect of the amino acid side chain hindrance on the carboxypeptidase Y 
activity and whether the difference of their antiviral activity can be correlated to the 
efficiency of the enzymatic reaction. Compounds 3.2k and 3.2l were chosen in order to 
study the enzymatic hydrolysis of the tert-butyl and neopentyl ester groups and 
correlate the activity of the CPY with their biological activity.  
General procedure  
Following the procedure developed in our lab to study the CPY-mediated hydrolysis of 
aryl phosphoramidate derivatives,18 ACV ProTide was dissolved in acetone-D6 and 
Trizma buffer (pH 7.6), then 31P NMR spectrum of the blank was recorded. The 
compound was incubated with CPY for 14h and the enzymatic reaction was monitored 
by 31P NMR analysis. 
The proposed pathway of the enzymatic reaction is depicted in figure 3.4. 
 
Figure 3.4.  Proposed mechanism of ester cleavage of ACV ProTides mediated by CPY 
 
Except for the 2,2-dimethylglycine and L-proline derivatives 3.2b and 3.2f, the starting 
material 3.2 shows two peaks around 4-5 ppm in the 31P NMR spectrum that correlate to 
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the two diastereomeric configurations. The hydrolysis of the ester affords compound 3.5 
(!"6 ppm) that leads through intracellular cyclisation to the formation of the unstable 
intermediate 3.6.  The nucleophilic attack of water, either on the phosphorus or on the 
carbonyl group, opens the ring affording the phosphoramidate monoester 3.7. As 
already reported, this species gives rise to only one peak around 7-8 ppm in the 31P 
NMR spectrum indicating the loss of chirality of the phosphorus.23 
Enzymatic study results-1: amino acid modification 
In the case of compound 3.2b (!P= 2.31 ppm, fig. 3.5A) and 3.2d (!P= 3.74, 3.91 ppm, 
fig. 3.5B), the hydrolysis of the ester moiety occurred in less than 6 min from exposure 
to CPY.  
 
Figure 3.5. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound (A) 3.2b and (B) 3.2d  
 
The formation of the intermediate resulting from the cleavage of the benzyl group of 
3.2b was not observed before the formation of the final product 3.7b (!P= 5.51 ppm, fig. 
3.5A). 
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In the case of 3.2d, the intermediate 3.5d (!P= 4.91, 5.29 ppm, fig. 3.5B) was converted 
to the corresponding phosphoramidate monoester 3.7d (!P= 7.30 ppm, fig. 3.5B) 
approximately by 50% after 13 min from exposure to CPY. The conversion of 3.2d was 
complete in less than 30 min. The fast cleavage of the benzyl ester of compound 3.2d 
proves that the hindrance of the L-leucine side chain is well tolerated by the 
carboxyesterase, confirming the biological activity seen with this compound. 
Similarly, the inactivity of compounds 3.2f (!P= 1.73 ppm, fig. 3.6A) and 3.2j (!P= 
3.77, 3.86 ppm, fig. 3.6B) has been confirmed by the incapacity of CPY to cleave the 
benzyl ester in presence of L-proline and L-phenylalanine amino acids, proving the 
detrimental effect of their hindrance on the bioactivation of these aryl phosphoramidate 
derivatives of ACV. 
 
Figure 3.6. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound (A) 3.2f and (B) 3.2j 
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Enzymatic study results-2: ester modification  
Figure 3.7 shows the 31P NMR spectra of compound 3.2k (!P= 3.77, 3.82 ppm) over the 
14 h incubation period with CPY. As expected from the previous studies and 
considering the inactivity of this compound in the antiviral assays, the enzyme was 
probably not able to cleave the tert-butyl ester group.  
 
Figure 3.7. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 3.2k 
 
In the case of compound 3.2l (!P= 3.81, 3.92 ppm, fig. 3.8), the enzymatic hydrolysis of 
the neopentyl ester afforded the intermediate 3.5l (!P= 4.75, 4.89 ppm, fig. 3.8), which 
then formed the phosphoramidate monoester 3.7l (!P= 7.19 ppm, fig 3.8) by loss of the 
phenyl group, as previously described in figure 3.4. After 90 min from the exposure to 
CPY, the diastereomer correlated to the upfield peak in the 31P NMR spectrum was 
almost completely processed, while 56% of the other diastereomer was still unreacted. 
After a 5 h period incubation, 3.2l was completely converted to 3.7l. This result, 
indicating that CPY is able to hydrolyse the neopentyl ester more efficiently than the 
tert-butyl ester, could justify the retention of antiviral activity against HSV, VZV, 
HCMV and HIV-1 in MT-4 cells found for this compound in comparison to L-alanine 
benzyl ester derivative 3.1a and 3.1b. 
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Figure 3.8. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 3.2l 
3.5.2 Molecular modelling studies  
Modelling studies were carried out in order to further investigate the ester hydrolysis of 
ACV ProTides by CPY and the processing of the correlated phosphoramidate 
monoester derivatives by human Hint-1. 
Docking of ACV ProTides within the active site of carboxypeptidase Y  
Using docking techniques, the interaction of ACV ProTides with the active site of the 
CPY was modelled on the crystal structure of the enzyme (protein data bank, 1YSC).24 
As depicted in figure 3.9, the mechanism of action of the ester cleavage within the 
catalytic site of this enzyme involves the coordination of the NH of the glycine 52 
(Gly52) and glycine 53 (Gly53) residues with the carbonyl group of the ester, which 
undergoes the nucleophilic attack of the serine residue 146 (Ser146).25 
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Figure 3.9. Mechanism of cleavage of the ester moiety of generic ACV ProTide 3.2 within the active 
site of CPY 
 
Compound 3.2d, 3.2f, and 3.2j were selected for this study in order to confirm the 
results obtained in the enzymatic experiments that suggest the poor interaction of the 
CPY with the ACV Protide containing L-proline and L-phenylalanine as amino acid 
moiety, while L-leucine is well tolerated. At the same time, the difference in terms of 
ester cleavage efficiency between the two diastereomers of the L-alanine neopentyl 
ester derivative 3.2l was investigated. 
CPY docking results-1: amino acid hindrance investigation 
The docking study of compound 3.2d within the catalytic site of CPY showed a positive 
interaction for both diastereomers. As depicted in figure 3.10 for the Rp diastereomer, 
the guanine base (in blue) is projected outside the pocket of the active site, the phenyl 
group (yellow) on the phosphate (purple) is on the right pocket, while the benzyl ester 
(red) is on the left pocket. 
Chapter 3 
 
 82 
 
Figure 3.10. Docking of 3.2d (Rp diasteromer) within the catalytic site of CPY. 
Guanine base (blue), phenyl group (yellow), phosphorus (purple), benzyl ester (red). 
 
The ester moiety is properly orientated to interact with the amino acid residues (Gly52, 
Gly53, and Ser146) involved in its cleavage (fig 3.11).   
 
Figure 3.11. Detail of the docking of 3.2d within the active site of CPY showing the orientation and 
the distance in angstroms of the carboxyl group toward the glycine and serine residues (Gly52, 
Gly53, and Ser146) responsible for its cleavage.  
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The same study was performed on compound 3.2f and 3.2j proving the detrimental 
effect of the L-proline and L-phenylalanine on this interaction. In particular, the 
restriction imposed by the pyrrolidine ring of L-proline forces the carbonyl group of the 
ester moiety to adopt an orientation that does not favour its coordination with Gly52 and 
Gly53 residues (figure 3.12, Sp diastereomer shown).  
 
 
Figure 3.12. Docking of 3.2f (Sp diastereomer) within the catalytic site of CPY. 
The pyrrolidine ring of L-Proline is shown in yellow. 
 
In the case of compound 3.2j, the hindrance of the phenylalanine side chain has a 
similar effect on the orientation of the carbonyl group of the ester moiety (fig. 3.13). 
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Figure 3.13. Docking of compound 3.2j (Rp diastereomer) within the catalytic site of CPY. 
 
CPY docking results-2: neopentyl ester investigation. 
Figure 3.14 shows the docking of both phosphate diastereomers (Rp and Sp) of 
compound 3.2j within the catalytic site of CPY.  
 
Figure 3.14 Docking of 3.2l within the catalytic site of CPY. The red arrows indicate the position of the 
carbonyl group.  
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In the Rp configuration, the carbonyl group of the neopentyl ester, indicated by the red 
arrow in figure 3.14, is orientated in opposite direction in comparison to the orientation 
adopted in the Sp configuration. As depicted in figure 3.15, this affects the interaction 
with Gly52, Gly53, and Ser146 residues. In particular, the carbonyl group of the Rp 
diastereomer appears to be properly orientated in order to be attacked by the residue of 
Ser146 and coordinated by the NH of the glycine residues, while the orientation in the 
Sp configuration is different and a positive interaction with these residues is less 
favoured.  
 
Figure 3.15. Detail of the docking of 3.2l (Rp and Sp diastereomers) within the active site of CPY 
showing the orientation and the distance in angstroms of the carboxyl group toward the glycine and 
serine residues (Gly52, Gly53, and Ser146) responsible for its cleavage.  
 
In conclusion, the result of this study suggests that the Sp may be the configuration of 
the diasteroisomer that is metabolised less efficiently by the CPY in the enzymatic 
experiment performed on 3.2l (fig. 3.8). This hypothesis also implies that the Sp 
diastereomer is correlated to the downfield signal in the 31P NMR spectrum, while the 
Rp diastereomer is correlated to the upfield signal.  
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Docking of the phosphoramidate monoester derivatives of ACV within the active site 
of human Hint-1 
According to the putative bioactivation mechanism of ProTides, the phosphoramidate 
monoester derivative of nucleoside analogue 3.7 is considered to be a substrate of 
human Hint-1 enzyme that may hydrolyse the phosphorus-nitrogen bond, releasing 
ACV monophosphate (ACV-MP).26, 27 As already described in chapter 1, human Hint-1 
is a phosphoramidase-type enzyme belonging to the HIT superfamily and its catalytic 
activity is based on three histidine residues. The proposed mechanism of action of this 
enzyme, depicted in figure 3.16, involves the nucleophilic attack of the hisitidine 112 
residue (shown in blue) to the phosphorus with the elimination of the amino acid 
moiety, which is favoured by the protonation mediated by a serine residue. Finally, the 
nucleophilic attack of a molecule of water to the phosphorus release ACV-MP and 
protonate the serine residue.28  
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Figure 3.16. Proposed mechanism of action of human Hint-1 (form ref. 26) 
 
In order to investigate the effect of the amino acid side chain hindrance on the human 
Hint-1 activity, docking studies of the metabolites 3.7b and 3.7d (fig. 3.17) were 
performed using a co-crystallised structure of the enzyme with adenosine 
monophosphate (AMP). 
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Figure 3.17. ACV phosphoramidates 3.7b and 3.7d   
 
Figure 3.18 shows that 3.7b binds in the catalytic site of human Hint-1. The guanine 
base and the side chain of acyclovir are well positioned in the enzymatic pocket. The 
phosphate moiety (purple) is slightly moved from the position adopted by the phosphate 
group of AMP (yellow), 
 
Figure 3.18. Superimposition of acyclovir phosphoramidate 3.7b with AMP (yellow) within the 
active site of huma Hint-1. The red arrow indicates the position of the phosphate group of AMP. 
 
However, figure 3.19 shows that the histidine and serine residues (His51, His112, 
His114, and Ser107) are in a suitable position to catalyse the cleavage of the P-N bond 
according to the mechanism of action previously described. This result is in agreement 
with the antiviral activity exhibited by the parent compound 3.2b and confirms the 
capacity of this compound to release ACV-MP inside the cell. 
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Figure 3.19. Detail of the docking of 3.7b within the active site of human Hint-1 showing the 
orientation and the distance in angstroms of the P-N bond (purple and blue) toward the histidine 
and the serine residues (His-51, His-112, His 114, and Ser107) responsible for its cleavage.  
 
Similarly, the modelling study performed on compound 3.7d (fig. 3.20) showed that this 
compound interact positively with the active site of the human Hint-1 confirming that 
the hindrance of L-leucine side chain is well tolerated by this enzyme, as suggested by 
the results of the antiviral assays. 
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Figure 3.20 A: superimposition of 3.7d with AMP (yellow) within the active site of human Hint-1 
enzyme. The red arrow indicates the position of the phosphate group of AMP. B: Detail of the 
docking of 3.7d within the active site of human Hint-1 showing the orientation and the distance in 
angstroms of the P-N bond (purple and blue) toward the histidine and the serine residues (His-51, 
His-112, His 114, and Ser107) responsible for its cleavage. 
3.6 Conclusions 
An extensive study of structure-activity relationship of ACV ProTide was conducted in 
this work by evaluating the effect of the modification of the aryl, amino acid, and ester 
moieties on the antiviral activity of compounds 3.2a-q against HSV, VZV, HCV, and 
HIV. The retention of antiviral activity of the L-valine, L-leucine, and L-isoeucine 
benzyl ester derivatives 3.2c-e and 3.2g-i against HSV, VZV, HCV, and HIV-1 in MT-4 
cells, in comparison to the L-alanine benzyl ester derivatives 3.1a and 3.1b, indicates 
that ACV monophosphate is released also in the presence of bulky masking groups. The 
L-alanine neopentyl ester derivatives 3.2l and 3.2m resulted to be as effective as the 
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analogous benzyl ester derivatives 3.1a and 3.1b. The increase of lipophilicity by 
replacement of the phenyl with the naphthyl group at the aryl moiety did not afford any 
improvement of activity. However, concern has arisen from the potential toxicity of 
some ACV ProTides due to their cytostatic effects observed on HEL and MT-4 cell 
cultures. 
The lack of activity of all the ACV ProTides synthesised in this work against HIV-1 and 
HIV-2 in CEM cell points at the L-alanine benzyl ester as the masking group of choice 
in the synthesis of the novel acyclic nucleoside ProTides, which will be discussed in the 
subsequent chapters. 
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Chapter 4. Aryl phosphoramidate derivatives of 6-O-alkyl 
acyclovir  
4.1 Introduction 
In this study alkoxy groups were introduced in the 6 position of ACV in order to 
investigate the effect of the nucleobase modification on the antiviral activity. Figure 4.1 
depicts the structure of 6-O-methyl ACV (4.1a) and 6-O-ethyl ACV (4.1b).  
N
NN
N
NH2O
HO
O R
4.1a R: CH3 
4.1b R: CH2CH3 !
Figure 4.1 Structure of 6-O-methyl ACV (4.1a) and 6-O-ethyl ACV (4.1b) 
!
The 6-O-alkyl-2-aminopurine nucleosides have already been described in the literature 
as prodrugs of guanosine analogues.1, 2 In particular, nelarabine (fig. 4.2) is the 6-
methoxy prodrug of the anti-proliferative agent 9-!-D-arabinofuranosylguanine (Ara-G, 
fig. 4.2).1 In 2005 nelarabine was approved for the treatment of T-cell lymphoblastic 
lymphoma and T-cell acute lymphoblastic leukemia. The endogenous adenosine 
deaminase (ADA) was identified as the enzyme responsible for the conversion of 
nelarabine to Ara-G in vivo (fig 4.2).1  
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!
Figure 4.2. Structures and metabolism of nelarabine and Ara-G  
!
 Recently, the ProTide approach has been applied to 6-O-methyl-2’-C-methyl guanosine 
affording the “double prodrug” INX-189 developed by the Inhibitex/BMS (fig. 4.3).2 As 
already mentioned in chapter 1, INX-189 is in phase 2 clinical trials for the treatment of 
HCV infections. 
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Figure 4.3. Structures of INX-189 and the parent nucleoside 6-O-methyl-2’-C-methyl guanosine 
!
In vitro, the anti-HCV activity of INX-189 was 500-fold greater, compared to the parent 
nucleoside.2 The improvement in antiviral activity of INX-189 has been observed also 
in comparison to ProTides of 2’-C-methyl guanosine, suggesting that the increase in 
compound lipophilicity, which is conferred by the 6-methoxy group, could account for 
the enhancement of cellular uptake of INX-189.2-4 The carboxypeptidase Y study 
indicates that INX-189 is successfully bioactivated according to the putative mechanism 
of activation of ProTides.2 It has been reported that in order to exert antiviral activity 
against HCV in vitro, INX-189 must be deaminated by most probably adenylate 
deaminase, which exerts the same activity as adenosine deaminase at the nucleotide 
level.4 Further studies in vitro were reported showing that INX-189 is converted to the 
monophosphate form before the 6-methoxy group is removed (fig. 4.4).5  
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Figure 4.4. Proposed metabolic pathway of INX-189 
!
Considering the successful application of the ProTide approach to 6-O-methyl-2’-C-
methyl guanosine, it appeared reasonable in this study to synthesise the 
phosphoramidate derivatives of 6-O-methyl ACV and 6-O-ethyl ACV in order to 
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evaluate the possibility of improving the antiviral activity of the ACV ProTides reported 
in chapter 3.  
4.2 Synthesis of 6-O-methyl ACV and 6-O-ethyl ACV 
The synthesis of compounds 4.1a and 4.1b was achieved following the procedure 
described in scheme 4.1. As previously described in the literature for the synthesis of 
penciclovir, ACV was acetylated using acetic anhydride (Ac2O) and  
4-dimethylaminopyridine (DMAP) as a catalyst to afford compound 4.2.6 The 
chlorination at the 6-position was carried out using phosphorus oxychloride (POCl3), 
benzyltriethylammonium chloride (BTEA) and N,N-dimethylaniline (DMA) to afford 
compound 4.3. According to the procedure reported in the literature for the synthesis of 
6-O-methyl-2’-C-methyl guanosine,4 the reaction of compound 4.3 with sodium 
methoxide (MeONa) in anhydrous methanol (MeOH) at room temperature led to the 
elimination of the acetyl group and the displacement of the 6-chloro affording 
compound 4.1a. Following the same strategy, the reaction of compound 4.3 with 
sodium ethoxide (EtONa) in anhydrous ethanol (EtOH) at 40 °C afforded compound 
4.1b.  
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(i) Ac2O, DMAP, DMF, 45 °C, 1.5h; (ii) POCl3, BTEA, DMA, ACN, 70 °C, 1h; 
(iii) MeONa, anhydrous MeOH, rt; (iv) EtONa, anhydrous EtOH, 40 ° C, 4 h
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Scheme 4.1. Synthesis of 6-O-methyl ACV and 6-O-ethyl ACV 
4.3 Design of 6-O-methyl and 6-O-ethyl ACV ProTides 
Considering the results obtained from the evaluation of the ACV ProTides as antiviral 
agents, phenyl and naphthyl L-alanine benzyl ester phosphoramidate derivatives 4.4a-d 
were synthesised  (fig. 4.5). The L-leucine benzyl ester derivative 4.4e was synthesised 
as well (fig.4.5). Considering that the analogous phosphoramidate of ACV (3.2d) is 
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effective in the release of its monophosphate form inside the cell, also in this case the 
hindrance of L-leucine side chain was expected to be well tolerated by enzymes 
involved in the bioactivation pathway of ProTides.  
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N
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O
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Ar
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Bn R'
O
R
4.4a R:  CH3; AR: Ph; R': CH3 
4.4b R:  CH3; AR: 1-Naph; R': CH3 
4.4c R:  CH2CH3 ; AR: Ph; R': CH3 
4.4d R: CH2CH3 ; AR: 1-Naph; R': CH3 
4.4e R:  CH3; AR: Ph; R': CH2CH(CH3)2 !
Figure 4.5 Structure of aryl phosphoramidate derivatives 4.4a-e  
4.3.1 Synthesis of 6-O-methyl and 6-O-ethyl ACV ProTides 
Following the procedure described in chapter 3 for the synthesis of ACV ProTides, the 
coupling of compounds 4.1a and 4.1b with the appropriate phosphochloridate 2.2 was 
performed in the presence of tBuMgCl and afforded compounds 4.4a-e (scheme 4.2).7 
All the compounds were obtained as mixtures of two diastereomers. 
 
2.2a AR: Ph; R': CH3 
2.2b AR: 1-Naph; R': CH3
2.2k AR: Ph; R': CH2CH(CH3)2
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Reagents and conditions: (i) Anhydrous THF, tBuMgCl, rt, 12-18h
i
R
4.1a R: CH3 
4.1b R: CH2CH3
4.4a R:  CH3; AR: Ph; R': CH3 
4.4b R:  CH3; AR: 1-Naph; R': CH3 
4.4c R:  CH2CH3 ; AR: Ph; R': CH3 
4.4d R: CH2CH3 ; AR: 1-Naph; R': CH3 
4.4e R:  CH3; AR: Ph; R': CH2CH(CH3)2
!
Scheme 4.2. Synthesis of aryl phosphoramidate derivatives 4.4a-e 
!
In the case of compound 4.4d, a transesterification reaction occurred during 
chromatographic purification, presumably due to a residue of the unreacted tBuMgCl 
and methanol that was used as solvent during the absorption of the sample on the silica. 
This reaction afforded compound 4.4f (scheme 4.3).   
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Reagents and conditions: (i) MeOH, tBuMgCl, rt !
Scheme 4.3 Transesterification reaction of compound 4.4d  
!
In order to prove that tBuMgCl was responsible of this novel transesterification reaction 
of the ProTides, neopentyl alcohol was added to a THF solution of compound 4.4a with 
a slight excess of tBuMgCl (1.1 eq). After 2 h, compound 4.4g was obtained in 70% 
yield (scheme 4.4). According to this result, the transesterifcation reaction of compound 
4.4a using n-butylamine was performed in the attempt to obtain compound 4.4h, but no 
detectable traces of product were obtained (scheme 4.4). 
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Reagents and conditions: (i) neopentyl alcohol, tBuMgCl, rt, 2h; 
(ii) n-butylamine, tBuMgCl, rt, 2h
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Scheme 4.4 Transesterification reaction of compound 4.4a  
!
In the case of the neopentyl alcohol, tBuMgCl (pKa = 45)
8 deprotonates the alcoholic 
group (pKa = 18)
8 affording the corresponding neopentyloxy anion that acts as a 
nucleophile in the replacement of the benzyl ester of compound 4.4a. The amino group 
of n-butylamine is a weak acid (pKa = 40)
8 and might not be strong enough in terms of 
nucleophilicity in order to displace the benzyl group of compound 4.4a. It must be 
pointed out that this study has been performed at room temperature and that an increase 
of temperature could overcome the lack of reactivity. Also further alcohols could be 
pursued to evaluate the extent of this reaction. 
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Table 4.1 summarises the aryl phosphoramidates of 6-O-methyl and 6-O-ethyl ACV 
synthesised. 
Table 4.1. 6-O-methyl and 6-O-ethyl ACV ProTides 4.4a-g 
(O6-R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group)!
Cps O6-R Ar AA R’’ 31P NMR Yield 
4.4a MeO Ph L-Ala Bn 3.76, 3.47 78% 
4.4b MeO 1-Naph L-Ala Bn 4.11, 3.93 60% 
4.4c EtO Ph L-Ala Bn 3.76, 3.47 53% 
4.4d EtO 1-Naph L-Ala Bn 4.11, 3.94 30% 
4.4e MeO Ph L-Leu Bn 4.03, 3.58 40% 
4.4f EtO 1-Naph L-Ala Me 4.05, 4.04 16%b 
4.4g MeO Ph L-Ala CH2tBu 3.76, 3.47 70%
b 
b Transesterification product 
The synthesis of the phosphoramidate derivatives 4.4a-e was carried out without 
protecting the 2-amino group of the parent nucleosides, as previously described for the 
synthesis of ACV ProTides, due to increased solubility in THF afforded by 6-alkoxy 
substituents. Not needing the deprotection step after the coupling reaction greatly 
improved the overall yield. As already described in the synthesis of the ACV ProTides, 
the hindrance of the L-leucine side chain negatively affects the coupling reaction. 
Formation of the transesterification side-product 4.4f accounts for the poor yield of 
compound 4.4d (scheme 4.3). 
4.3 Biological evaluation of 6-O-methyl ACV, 6-O-ethyl ACV and their 
phosphoramidate derivatives 
The 6-alkoxy derivatives of ACV 4.1a, 4.1b, and their phosphoramidate derivatives 
4.4a-g were evaluated for their antiviral activity against HSV, VZV, HCMV, and HIV. 
The antiproliferative activity of these compounds on several cell cultures was also 
evaluated.  
4.3.1 Anti-HSV activity  
Table 4.2 reports the antiviral activity of 4.1a, 4.1b and their phosphoramidates 
derivatives 4.1a-g against HSV-1, HSV-2, and thymidine kinase-deficient (TK-) HSV-1 
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in human embryonic lung (HEL) cells. The data include ACV and the L-alanine benzyl 
ester derivatives of ACV ProTide (3.1a and 3.1b)9 as reference compounds. 
Table 4.2. Anti-HSV activity of  4.1a, 4.1b and their phosphoramidate derivatives in HEL cells 
(R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group)!
 Antiviral Activity EC50
 a
 (µM)
 
Cps O6-R Ar AA R’’ HSV-1 HSV-2 TK- HSV-1  
4.1a MeO - - - 73 73 100 
4.4a MeO Ph L-Ala Bn 0.7 0.6 2.5 
4.4b MeO 1-Naph L-Ala Bn 0.4 0.4 2 
4.4e MeO Ph L-Leu Bn 15 6.5 65 
4.4g MeO Ph L-Ala CH2tBu 0.8 0.8 1.4 
4.1b EtO - - - >100 >100 >100 
4.4c EtO Ph L-Ala Bn 0.8 0.8 2 
4.4d EtO 1-Naph L-Ala Bn 0.4 0.4 2 
4.4f EtO 1-Naph L-Ala Me 1 1 1 
ACV - - - - 0.4 0.2 >250 
3.1a - - - - 8 ± 5.7 4 ± 0 15 ± 7.1 
3.1b - - - - 2 ± 0 1.4 ± 0.8 10 ± 2.1 
a 50%! Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%!
 
The antiviral activity observed for 4.1a and 4.1b show that the introduction of the 
alkoxy group in the 6 position of ACV nucleobase is detrimental for the anti-HSV 
activity. However, all the phosphoramidate derivatives of 4.1a and 4.1b showed good to 
moderate activity against HSV- 1 and HSV-2 (EC50= 0.4-15 µM). Most of them 
exhibited retention of this activity against TK- HSV-1. These results indicate that the 
bypass of the first phosphorylation step is crucial for the anti-HSV activity of the 6-O-
alkyl ACV ProTides. It is also suggested that into the cell compounds 4.1a and 4.1b are 
neither phosphorylated by the HSV-TK to afford the monophosphate form nor 
dealkylated by the cellular adenosine deaminase to afford ACV.  
The L-alanine derivatives 4.4a-d and 4.4g exhibited retention of the anti-HSV activity 
in comparison to the analogous derivatives of ACV ProTides 3.1a and 3.1b.9 In contrast 
to the results obtained in the case of the ACV Protides described in chapter 3, the 
replacement of L-alanine (4.4a) with L-Leucine (4.4b) in the amino acid moiety of 6-O-
alkyl ACV ProTides led to the partial loss of activity, particularly against TK- HSV-1 
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(EC50= 65 µM). This result suggests that the hindrance of the L-leucine side chain may 
not be well tolerated by enzymes involved in the bioactivation pathway. Moreover, the 
methyl ester derivative 4.4f showed good antiviral activity against HSV-1, HSV-2, TK--
HSV-1 (EC50= 1 µM), while the analogous ProTide of ACV were markedly less active 
(EC50= 10-16  µM against HSV-1 and HSV-2, EC50= 79 ± 29 µM against TK
- HSV-1).9  
Finally, the concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) was above 100 µM for all compounds synthesised. 
4.3.2 Anti-VZV activity  
Compounds 4.1a, 4.1b, and their phosphoramidate derivatives 4.4a-g were evaluated 
for their activity against TK-positive (TK+) and TK-deficient (TK-) strains of VZV in 
HEL cells (table 4.3). These data include ACV and the L-alanine benzyl ester 
derivatives of ACV ProTides (3.1a and 3.1b)10 as reference compounds. 
Table 4.3. Anti-VZV activity of 4.1a, 4.1b and their phosphoramidate derivatives in HEL cells 
(R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group)!
     Antiviral Activity EC50
 a
 (µM)
 
TK+ VZV strains TK- VZV strains 
Cps O6-R Ar AA R’’ 
YS OKA 07-1 YS/R 
4.1a MeO - - - - >50 >50 - 
4.4a MeO Ph L-Ala Bn 0.5 2.2 1.4 0.9 
4.4b MeO 1-Naph L-Ala Bn - 1.3 8.9 - 
4.4e MeO Ph L-Leu Bn 0.6 0.3 2.77 1.2 
4.4g MeO Ph L-Ala CH2tBu 0.1 0.2 0.2 0.3 
4.1b EtO - - - - >50 >50 - 
4.4c EtO Ph L-Ala Bn 0.3 0.4 2.6 2.2 
4.4d EtO 1-Naph L-Ala Bn 1.55 1.78 5.47 6.4 
4.4f EtO 1-Naph L-Ala Me 0.2 0.1 0.3 0.2 
ACV - - - - - 1.2 75 93 
3.1a - Ph L-Ala Bn 0.7 1.0 1.8 0.59 
3.1b - 1-Naph L-Ala Bn 7.2 3.3 6.9 N.D 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
When compared to ACV, compounds 4.1a and 4.1b exhibited a complete loss of 
activity against VZV, as already observed in the anti-HSV assay.  
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The phosphoramidate derivatives 4.4a-g were active against both TK+ and TK- strains of 
VZV in the micromolar and subicromolar range (EC50= 0.1-8.9 µM). These data show 
that the phosphoramidate derivatives 4.4a-g successfully bypassed the VZV-TK-
mediated phosphorylation, as proved by the activity against TK- VZV. Moreover, all 
these compounds exhibited retention of activity in comparison to ACV ProTides 3.1a 
and 3.1b. 
No cytotoxic effects were detected by microscopic analysis of HEL cells morfology 
(MCC > 100 µM) 
4.3.3 Anti-HCMV activity 
Table 4.4 reports the anti-HCMV activity in HEL cells of 4.1a, 4.1b and their 
phosphoramidates derivatives 4.4a, 4.4f, 4.4g. GCV is reported as reference compound. 
Table 4.4. Anti-HCMV activity of 4.1a, 4.1b and their derivatives 4.4a, 4.4f, 4.4g in HEL cells 
(R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group)!
     Antiviral Activity EC50 
a (µM) 
Cps O6-R Ar AA R’’ AD-169 strain Davis strain 
4.1a MeO - - - - >50 
4.1b EtO - - - - >50 
4.4a MeO Ph L-Ala Bn 17.5 11.3 
4.4f EtO 1-Naph L-Ala Me 4.2 2.4 
4.4g MeO Ph L-Ala CH2tBu 1.6 1.3 
GCV - - - - 8.3 3.1 
a 50% Effective concentration, or compound concentration required to inhibit virus-
induced cytopathicity by 50% 
 
The data regarding the nucleoside analogues 4.1a and 4.1b confirm their inactivity.  
The phosphoramidates derivatives 4.4a, 4.4f, and 4.4g showed anti-HCMV activity 
comparable to that of GCV.  
The concentration of these compounds required to cause a microscopically visible 
alteration of cell morphology (MCC) was above 100 µM. 
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4.3.4 Antiproliferative activity on HEL cell cultures of 6-O-methyl ACV, 6-O-ethyl 
ACV and their phosphoramidate derivatives  
The cytostatic activity on HEL cell cultures of compounds 4.1a, 4.1b, and their 
phosphoramidate derivatives 4.4a-g is reported in table 4.5.  
These data include ACV and the L-alanine benzyl ester derivatives of ACV ProTides 
(3.1a and 3.1b) as reference compounds.10 
Table 4.5. Cytostatic activity on HEL cell cultures of 4.1a, 4.1b and their phosphoramidate 
derivatives 4.4a-g. (R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group) 
     Cytostatic Activity IC50
 b (µM) 
Cps O6-R Ar AA R’’ HEL Cells 
4.1a MeO - - - >100 
4.4a MeO Ph L-Ala Bn 1.9 
4.4b MeO 1-Naph L-Ala Bn 0.7 
4.4e MeO Ph L-Leu Bn 0.9 
4.4g MeO Ph L-Ala CH2tBu 1.4 
4.1b EtO - - - >100 
4.4c EtO Ph L-Ala Bn 2.1 
4.4d EtO 1-Naph L-Ala Bn 1.3 
4.4f EtO 1-Naph L-Ala Me 4.2 
ACV - - - - 1770 
3.1a - Ph L-Ala Bn >100 
3.1b - 1-Naph L-Ala Bn 20 
a 50% inhibitory concentration, or compound concentration  required to inhibit cell 
proliferation by 50% 
 
Despite the fact that the concentration required to cause a microscopically visible 
alteration of cell morphology (MCC) was above 100 µM, the aryl phosphoramidate 
derivatives 4.4a-g exhibited marked antiproliferative activity on HEL cells (IC50= 0.7-
4.2 µM). It must be pointed out that this effect was not detected in the antiviral assays 
previously described, where confluent monolayers of HEL cells, which are not 
proliferating, were used. Indeed, the cytostatic activity on HEL cell was measured using 
non-confluent and highly proliferating cell cultures. This difference is indicative of a 
different cellular metabolism and must be taken into account when the results of the 
antiviral assays are compared with the cytostatic activity obtained in this assay. In 
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comparison to the ACV ProTides 3.1a and 3.1b, an increased cellular uptake of the 6-
O-alkyl ACV ProTides 4.4a-g may account for the formation of ACV triphosphate at 
concetrations that could exert inhibitory activity also on the DNA polymerase of HEL 
cells. Alternatively, it might be assumed that 6-O-alkyl ACV triphosphate could act 
itself as inhibitor of cellular DNA polymerase. However, no study has been reported in 
the literature that could support this hypothesis. 
4.3.5 Antiproliferative activity of 6-O-methyl ACV, 6-O-ethyl ACV and their 
phosphoramidate derivatives on murine leukemia, murine mammary carcinoma, 
human T-lymphocyte, and human cervix carcinoma cell cultures. 
Considering the cytostatic activity exerted on HEL cells, the inhibitory effect of the 
phosphoramidates derivatives 4.4a-f was evaluated on the proliferation of murine 
leukemia cells (L1210), murine mammary carcinoma cells (FM3A), human T-
lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa) (tab. 4.6). In 
addition the antiproliferative activity of the parent nucleosides 4.1a and 4.1b is reported. 
Table 4.6. Antiproliferative activity of compounds 4.1a, 4.1b and their phosphoramidate derivatives 
(R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group)!
     IC50 
a (µM) 
Cps O6-R Ar AA R’’ L1210 FM3A CEM HeLa 
4.1a Me - - - > 500 > 500 > 500 > 500 
4.4a Me Ph L-Ala Bn 0.88 ± 0.41 54 ± 14 17 ± 4 31 ± 3 
4.4b Me 1-Naph L-Ala Bn 1.9 ± 1.1 6.2 ± 4.0 11 ± 2 N.D. 
4.4e Me Ph L-Leu Bn 1.7 ± 1.0 26 ± 6 29 ± 11 16 ± 3 
4.1b Et - - - 349 ± 126 > 500 > 500 > 500 
4.4c Et Ph L-Ala Bn 2.8 ± 1.6 25 ± 3 31 ± 6 22 ± 1 
4.4d Et 1-Naph L-Ala Bn 5.6 ± 1.1 49 ± 4 16 ± 5 16 ± 1 
4.4f Et 1-Naph L-Ala Me 3.2 ± 0.9 172 ± 2 41 ± 9 23 ± 11 
a 50% inhibitory concentration, or compound concentration  required to inhibit cell proliferation 
by 50% 
 
Consistent with the previous results, compounds 4.1a and 4.1b did not show inhibitory 
activity on cell proliferation. As expected, the phosphoramidate derivatives 4.4a-f had 
antiproliferative effect. This activity was particularly marked in murine leukemia cells 
(L1210). The selectivity for this cell line was striking in the case of compound 4.4a. 
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These results confirm the cytotoxicity of the aryl phosphoramidate derivatives 4.4a-g 
and suggest it to be very cell dependent.  
4.3.6 Anti-HIV activity 
Table 4.6 reports the anti-HIV-1 and cytotoxic activity in MT-4 cell cultures of 4.1a, 
4.1b and their aryl phosphoramidate derivatives 4.4a-d and 4.4g. These data include 
ACV as reference. The previously reported L-alanine benzyl ester derivatives of ACV 
ProTide (3.1a and 3.1b)9 are reported for comparison.  The anti-HIV activity in CEM 
cell cultures of these compounds is currently under evaluation. 
Table 4.7 Anti-HIV-1, cytostatic and cytotoxic activity in MT-4 cells of 4.1a, 4.1b and their 
derivatives 4.4a-d and 4.4g. (R: O6-alkyl substituent; Ar: aryl group; AA: amino acid; R’’: ester group) 
     Antiviral Activity 
Cytostatic/Cytotoxic 
Activity 
EC50
a (µM) IC50
b
 (µM) CC50
c
 (µM)
 
Cps O6-R Ar AA R’’ 
HIV-1 MT-4 cells 
4.1a Me - - - >150 >150 >150 
4.4a Me Ph L-Ala Bn 0.4 2 20 
4.4b Me 1-Naph L-Ala Bn 0.6 6 >150 
4.4g Me Ph L-Ala CH2tBu 1.3 20 >150 
4.1b Et - - - >150 >150 >150 
4.4c Et Ph L-Ala Bn 1.2 6.2 50 
4.4d Et 1-Naph L-Ala Bn 0.7 2 4 
ACV - - - - >250 >250 >250 
3.1a - Ph L-Ala Bn 5.7 ± 1.6 33.8 ± 10.6 > 150 
3.1b - 1-Naph L-Ala Bn 0.8 N.D. d > 150 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b 50% Inhibitory concentration, or compound concentration  required to 
inhibit cell proliferation by 50%; c 50% Cytotoxic  concentration, or compound concentration 
that induces 50% cell death in the culture; d N.D.: not determined 
 
As expected compounds 4.1a and 4.1b did not exert any inhibitory activity against 
HIV-1.  
The phosphoramidates derivatives 4.4a-d and 4.4g showed antiviral activity in the 
micromolar and sub-micromolar range (EC50= 0.4-1.3 µM). As already described in the 
previous paragraphs, these compounds exerted antiproliferative activity on MT-4 cells 
(IC50= 2-20 µM) and, except 4.4b and 4.4g, induced 50% cell death in the culture at a 
concentration in the micromolar range (CC50= 4-50 µM). 
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4.3.7 Summary of the antiviral and antiproliferative activitiy of the 6-O-methyl 
and 6-O-ethyl acyclovir and their phosphoramidate derivatives. 
The biological results of 6-O-methyl ACV (4.1a) and 6-O-ethyl ACV (4.1b) showed a 
significant or complete loss of antiviral activity in comparison to ACV. Considering the 
biological activity exerted by the phosphoramidate derivatives 4.4a-g, these results 
suggest that the parent nucleosides 4.1a and 4.1b were neither phosphorylated to afford 
the monophosphate form nor dealkylated by the cellular adenosine deaminase to afford 
ACV.  
The antiviral activity of the phosphoramidate derivatives 4.4a-g shows that the 
application of the ProTide approach to the parent nucleosides 4.1a and 4.1b was 
successful in the bypass of the HHV-TK-mediated phosphorylation and suggests that 
the monophosphate form was released into the cell according to the putative mechanism 
of ProTide bioactivation. The studies reported in the literature on the phosphoramidates 
of 6-O-methyl-2’-C-methyl guanosine suggest that ProTides of 6-O-alkyl ACV may 
release ACV monophosphate.2,4 However, it has not been clarified yet whether the 
triphosphate form of 6-O-methyl and 6-O-ethyl ACV are inhibitors of DNA 
polymerase. An antiviral assay that combines the exposure to the phosphoramidate 
derivatives 4.4a-g with deoxycoformycin-5’-phosphate, inhibitor of adenilate 
deaminase and N6-methyl-AMP/dAMP aminohydrolase, may confirm whether or not 
the ProTides of 6-O-methyl and 6-O-ethyl ACV derivative are ‘double prodrugs’ of 
ACV triphosphate.4, 11-13  
Unfortunately, the phosphoramidate derivatives 4.4a-g exhibited marked cytostatic 
activity on HEL cell cultures and also on MT-4 cell cultures. Moreover, the 
antiproliferative activity of these compounds was observed also on L1210, FM3A, 
CEM, and HeLa cell cultures (tab 4.6). Inhibition of cellular DNA polymerase may 
account for this activity. No evidence has been reported in the literature that could 
account for the inhibitory activity of 6-O-alkyl ACV derivatives on cellular enzymes 
causing such cytotoxic effects.   
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4.4 Study of the adenosine deaminase activity on the 6-O-methyl and 6-
O-ethyl ACV  
Compounds 4.1a and 4.1b were incubated with adenosine deaminase (ADA) enzyme 
over a period of 20 h in order to prove whether the 6-alkoxy derivatives of ACV could 
be a prodrug of ACV triphosphate. The enzymatic reaction was monitored by recording 
UV spectra every 10 minutes (fig 4.6B). A UV spectrum of acyclovir was also recorded 
for comparison (fig 4.6A). As expected, the ADA assay performed on compound 4.1a 
showed no conversion within the incubation period of 20 h. Similar results were 
obtained for compound 4.1b.  
 
Figure 3.6. (A) UV spectrum of acyclovir; (B) Adenosine deaminase mediated deamination of 
compound 4.1a followed by UV spectroscopy 
!
The lack of conversion of compounds 4.1a and 4.1b to ACV could explain the 
inactivity of these compounds.   
Assuming that inside the cell the ProTides of 6-O-methyl and 6-O-ethyl ACV release 
acyclovir monophosphate, these results suggest that the adenylate deaminase may 
exhibit broader substrate specificity in comparison to ADA or that the conversion is 
catalysed by a different type of deaminase such as N6-methyl-AMP/dAMP 
aminohydrolase that has been proved to be involved in the deamination of several 6-O-
alkyl-2-aminopurine nucleotides.14  
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4.5 Study of the carboxyesterase activity 
In order to investigate the ester cleavage of the phosphoramidate derivative 4.4a and 
confirm the successful release of the monophosphate form according to the putative 
mechanism of activation of ProTides, an enzymatic study has been performed using 
CPY. The enzymatic assay was carried out following the procedure described for ACV 
ProTides in chapter 3. 
Figure 4.7 depicts the 31P NMR spectra of the enzymatic reaction over 14 h period of 
incubation.  
 
Figure 4.7. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 4.4a 
!
The hydrolysis of compound 4.4a (!P= 3.67, 3.72 ppm) occured in less than 6 min from 
the exposure to carboxypeptidase Y affording the intermediate 4.5 (!P= 4.78 and 4.88 
ppm). After 13 min from exposure to CPY, the intermediate 4.5 was converted to the 
corresponding phosphoramidate monoester 4.6 (!P= 6.81 ppm) by 50%. The conversion 
was complete in less than 34 min from the exposure to the enzyme. The fast cleavage of 
the benzyl ester of compound 4.4a proves that the hindrance of the 6-methoxy 
substituent is well tolerated by CPY, suggesting an efficient ester cleavage. 
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4.6 Docking study of the phosphoramidate derivatives of 6-O-methyl 
and 6-O-ethyl ACV within the active site of human Hint-1 enzyme  
As already mentioned, a study showed that INX-189, the ProTide of 6-O-methyl-2’-C-
methyl guanosine, is converted to the monophosphate form before that the 6-methoxy 
group is removed (fig. 4.4).5  
The modeling study of compounds 4.6 and 4.7 (fig. 4.8) within the active site of human 
Hint-1 co-crystallised with adenosine monophosphate (AMP) was performed using 
docking techniques in order to investigate whether the phosphoramidate monoester of 
6-O-methyl and 6-O-ethyl ACV could be successfully processed by this enzyme. 
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Figure 4.8. Phosphoramidate monoester derivatives of 6-O-methyl ACV (4.6) and 6-O-ethyl  
ACV (4.7) 
 
The docking study of compound 4.6 (fig. 4.9) shows that it binds in the enzymatic 
pocket of the human Hint-1 interacting in a similar way to AMP (green).  
  
 
Figure 4.9. Superimposition of compound 4.6 with AMP (green) within the active site of human 
Hint-1 enzyme.  
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Figure 4.10 shows that the histidine and serine residues (His51, His112, and His114, 
Ser107) are in a suitable position to catalyze the cleavage of the P-N bond according to 
the mechanism of action of the human Hint-1 described in chapter 3.15 This result 
suggests that 4.6 is successfully processed to the monophosphate in the cell. 
 
Figure 4.10. Detail of the docking of 4.6 within the active site of human Hint-1 showing the 
orientation and the distance in angstroms of the P-N bond (purple and blue) toward the histidine 
and the serine residues (His-51, His-112, His 114, and Ser_107) responsible for its cleavage (from 
ref 15)  
!
Figure 4.11 shows that compound 4.7 binds in the catalytic site of the human Hint-1. 
The guanine base and the side chain are well positioned in the enzymatic pocket.  
  Chapter 4    
 111 
 
Figure 4.11. Superimposition of compound 4.7 with AMP (green) within the active site of human 
Hint-1 enzyme. The red arrow indicates the position of the phosphate group of AMP 
!
Althought the phosphate moiety (purple) is slightly moved from the position adopted by 
the phosphate group of AMP (green), figure 4.12 shows that the histidine and serine 
residues (His51, His112, and His114, Ser107) are in a suitable position to catalyze the 
cleavage of the P-N bond.  
 
Figure 4.12. Detail of the docking of 4.7 within the active site of human Hint-1 showing the 
orientation and the distance in angstroms of the P-N bond (purple and blue) toward the histidine 
and the serine residues (His-51, His-112, His 114, and Ser_107) responsible for its cleavage  
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4.7 Conclusions 
The application of the ProTide approach to 6-O-methyl and 6-O-ethyl ACV was 
successful in the intracellular release of the monophosphate form inside the cell 
conferring biological activity to the parent nucleosides. The results of the enzymatic and 
modeling studies supported the hypothesis that the aryl phosphoramidate derivatives of 
6-O-methyl and 6-O-ethyl ACV were processed according to the putative mechanism of 
ProTide activation. However it has not been confirmed whether these compounds are 
dual prodrugs of ACV triphosphate. 
  
Unfortunately, the introduction of the alkoxy group in the 6 position of acyclovir led to 
the rise in cytotoxicity clearly indicating the unsuitability of this strategy as a way to 
improve the antiviral activity of ACV Protides. 
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Chapter 5. Aryl phosphoramidate derivatives of 8-bromo- and 
8-methylacyclovir 
5.1 Introduction 
As already described in chapter 1, the high therapeutic index of ACV as an antiviral 
agent is guaranteed by its high selectivity for the herpes virus DNA polymerase and by 
the fact that its active form, ACV triphosphate, is generated at effective concentrations 
in HSV and VZV infected cells, which contain the virally encoded TK required for the 
first phosphorylation step.1 The application of the ProTide approach to ACV, allowing 
the release of the monophosphate form directly into the cell, exposes also the uninfected 
cells to ACV triphosphate thus possibly decreasing its antiviral selectivity.2 Indeed, 
some of the ACV ProTides described in chapter 3 had moderate cytostatic activity. Also 
the 6-O-alkyl ACV ProTides, described in chapter 4, were found to be cytotoxic.  
Following these results, a modification of the structure of ACV was investigated in 
order to obtain phosphoramidate derivatives that could improve the antiviral activity of 
ACV without exerting cytotoxic effects. According to a previous study, the acyclic 
guanine nucleoside analogues such as 8-bromo-, 8-methyl-, and 8-iodoacyclovir (5.1-
5.3, fig 5.1) display good antiviral activity against HSV with an improved therapeutic 
index when compared to ACV.3  
N
N
N
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NH2
O
O
HO
H3C
N
N
N
NH
NH2
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O
HO
Br
5.1 5.2
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N
N
NH
NH2
O
O
HO
I
5.3  
Figure 5.1. Structures of 8-bromo-, 8-methyl-, and 8-iodoacyclovir derivatives  
Table 5.1 contains the antiviral and the antimetabolic activity, as well as the antiviral 
index, reported in the literature for ACV and compounds 5.1-5.3.3 The antimetabolic 
activity of the acyclic guanine nucleoside analogues has been evaluated by measuring 
the dose of compound required to inhibit the incorporation of 2’-deoxythymidine 
(dThd) or 2’-deoxyuridine (dUrd) into the DNA of primary rabbit kidney (PRK) cell 
cultures by 50% (ID50).
4, 5 The antiviral index is the ratio of the ID50 of the host cell 
DNA synthesis and the ID50 of the anti-HSV activity. All the three derivatives 5.1-5.3 
have a better antiviral index when compared to ACV, with 5.2 being the best 
compound.  
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Table 5.1 Antiviral activity, antimetabolic activity and antiviral index of 8-bromo-, 8-methyl-, and 
8-iodoacyclovir.  X: substituent in C-8 of ACV nucleobase 
  
Antiviral Activity in PRK 
Cell Cultures ID50
a
 (µg/ml) 
Antimetabolic Activity in PRK 
Cell Cultures ID50
b
  (µg/ml) 
 
Cps X 
HSV-1 
(KOS) 
HSV-2 !  
(G) 
dThd incorp dUrd incorp 
Antiviral 
Index c 
5.1 Br 0.5 0.5 340 225 450 
5.2 CH3 0.5 0.5 >400 >400 >800 
5.3 I 0.4 0.4 >350 >250 625 
ACV - 0.05 0.04 12 13 300 
a 50% Inhibitory dose or concentration required to reduce cytopathogenicity by 50% !; b 50% 
Inhibitory dose50 or concentration required to reduce [
3H-methyl]dThd or [3H-1’,2’]dUrd 
incorporation into cellular DNA by 50%; !c Ratio of ID50 for dThd or dUrd incorporation 
(whatever was lowest) to ID50 for HSV-1, HSV-2 ! (whatever was lowest) 
 
With the aim of identifying possible modifications of ACV that could improve the 
inhibitory activity and selectivity of the triphosphate form against HIV-RT, the 
introduction of a methyl or a halogen subsituent in the C-8 position of the guanine base 
of ACV was evaluated in an in silico study previously performed in our lab.6 For this 
purpose, virtual screening was carried out by applying the docking technique to HIV-
RT, adenylate kinase, guanylate kinase, and cellular DNA polymerase !. The docking 
study within the active site of HIV-RT showed that substitution at the 8 position of the 
guanine base of the acyclic guanine nucleoside analogues with a halogen atom or a 
methyl group is permitted. 
Considering these previous reports, it appeared reasonable to synthesise the 
phosphoramidate derivatives of 5.1 and 5.2. 
5.2 Synthesis of 8-bromo- and 8-methylacyclovir  
According to the procedure described in the literature,7 the bromination of ACV was 
achieved using N-bromosuccinamide (NBS) in acetic acid (CH3CO2H) affording 
compound 5.1 in 40% yield (procedure i, scheme 5.1). Alternatively, ACV was 
brominated on the C-8 position of the guanine base using a saturated solution of 
bromine in water (Br2/H2O). Compound 5.1 was obtained in 80% yield (procedure ii, 
scheme 5.1).3  
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N
NH
NH2
O
O
HO
ACV
i or ii
Reagents and conditions: 
(i) NBS, CH3CO2H, rt, 20 h (yield: 40%)
(ii) sature Br2/H2O, H2O, 0° C, 2h (yield: 80%)  
Scheme 5.1. Synthesis of 8-bromoacyclovir 
!
In the H-NMR spectrum of 5.1 (fig 5.2B) the absence of the peak at 7.82 ppm 
corresponding to the hydrogen on the C-8 of ACV (fig 5.2A) is one of the parameters 
that indicates the effective substitution at this position. 
 
Figure 5.2. H-NMR spectra (DMSO, 500 MHz) of (A) ACV and (B) 8-bromoacyclovir 
!
Furthermore the substitution of the hydrogen with bromine is also suggested in the 13C-
NMR spectrum, as the unsubstituted C-8 of ACV gives a negative signal (fig 5.3A), 
while its substitution with bromine results in a positive signal and in a characteristic 
upfield shift from 137 to 121 ppm due to the heavy halogen atom effect (fig. 5.3B).8  
Chapter 5 
! 118 
 
Figure 5.3. 13C-NMR spectra (DMSO, 125 MHz) of  (A) ACV and (B) 8-bromoacyclovir 
!
According to the procedure described in the literature,3, 9 the free-radical methylation of 
ACV with tert-butylhydroperoxide (tBuOOH) in the presence of ferrous sulfate (FeSO4) 
and sulfuric acid (H2SO4) afforded compound 5.2 in 53% yield (scheme 5.2).  
N
N
N
NH
NH2
O
O
HO
H3C
5.2
Yield: 53%
N
N
N
NH
NH2
O
O
HO
i
Reagents and conditions: (i) H2SO4 1M, FeSO4*7H2O, tBuOOH, 30-60 min, rt
ACV
 
Scheme 5.2. Free-radical methylation of ACV 
!
The introduction of the methyl group on the C-8 of ACV is evident in the H-NMR 
spectrum from the presence of a singlet integrating for 3 protons at 2.36 ppm, while the 
peak at 7.82 ppm, corresponding to the hydrogen on the C-8 of ACV is not visible (fig. 
5.4A). The presence of the methyl group on the C-8 is also recognised in the 13C-NMR 
spectrum where a peak at 13.34 ppm is present (fig 5.4B). Moreover, the signal of the 
C-8 changes from negative to positive due to the effect of the substitution and a 
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downfield shift of this signal is seen when the 13C-NMR spectra of ACV and 5.2 are 
compared (fig 5.4B). 
 
Figure 5.4! (A) H-NMR spectrum (DMSO, 500 MHz) and (B) 13C-NMR spectrum (DMSO, 125 
MHz) of 8-methylacyclovir 
!
In order to improve the yield of 5.2 a different synthetic approach was followed. In the 
literature the cross coupling reaction of 8-bromoadenosine with trimethylaluminum 
(AlMe3) has been reported to afford very good yield of 8-methyladenosine.
10 According 
to the procedure described in the literature,10 the protection of 5.1 with the trimethylsilyl 
group was performed in 1,4-dioxane using hexamethyldisiloxane (HMDS) in the 
presence of a catalytic amount of ammonium sulphate ((NH4)2SO4) under reflux 
conditions in argon atmosphere (i, scheme 5.3). The crude of the reaction, without any 
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purification, was redissolved in anhydorus THF and refluxed for 2 h in the presence of 
tetrakis (Pd(PPh3)4, 0.1 eq) and AlMe3 (2 eq) (ii, scheme 5.3). No formation of the 
desired product of the cross coupling reaction with AlMe3 was detected and the further 
desilylation was not carried out (iii, scheme 5.2).   
N
N
N
NH
NH2
O
O
HO
H3C
5.2
N
N
N
NH
NH2
O
O
HO
5.1
i, ii, iii
Reagents and conditions: (i) HMDS, (NH4)2SO4, 1-4 dioxane, 110 °C, 2-3 h; (ii) 
Pd(PPh3)4, AlMe3, anhydrous THF, 70 °C, 18 h; (iii) NH4Cl, MeOH, 65 °C, 2 h
Br
 
Scheme 5.3. Palladium-catalyzed cross coupling reaction of compound 8-bromoacyclovir with 
trimethylalluminium 
5.3 Design of 8-bromo- and 8-methylacyclovir ProTides 
In order to apply the ProTide approach to the acyclic guanosine analogues 5.1 and 5.2, 
compounds 5.4a-d and 5.5 were synthesised (fig 5.2). On the basis of the biological 
results of the ACV Protides described in chapter 3, the phosphoramidate derivatives 
5.4a-d and 5.5 were synthesized using L-Alanine benzyl ester as amino acid group and 
phenyl or naphthyl groups as aryl moiety. The phosphoramidate derivatives of ACV 
containing L-alanine as amino acid moiety were indeed the only ProTides active against 
HIV-1 and HIV-2 in CEM cell cultures with, in particular, the L-alanine benzyl ester 
derivatives exhibiting the best antiviral activity.2 Compound 5.4c was also synthesised 
in order to evaluate whether the 2,2-dimethylglycine benzyl ester derivative could retain 
the antiviral activity of the L-alanine benzyl ester phosphoramidate analogues 5.4a-b. 
Finally, the L-Valine benzyl ester derivative 5.4d was also prepared in order to evaluate 
whether the bulky side chain is well tolerated by the enzymes involved in the 
bioactivation of the ProTides. 
NH
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N
NH2
N
O
O
P
O
O
Ar
NH
O
O
Bn
O
X
5.4a X: Br; Ar: Ph; R: CH3; R': H 
5.4b X: Br; Ar: 1-Naph; R: CH3; R': H 
5.4c X: Br; Ar: 1-Naph; R: CH3; R': CH3
5.4d X: Br; Ar: 1-Naph; R: CH(CH3)2; R': H
5.5 X: CH3; Ar: Ph; R: CH3; R': H
R
R'
 
Figure 4.5. Structure of phosphoramidate derivatives 5.4a-d and 5.5 
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5.3.1 Synthesis of 8-bromo- and 8-methylacyclovir ProTides 
The synthesis of 8-bromoacyclovir ProTides 5.4a-d was performed following two 
different routes:  
• coupling reaction of 5.1 with the appropriate phosphorochloridate 2.2 affording 
compounds 5.4a-c; 
• bromination of ACV ProTide 3.2g affording compound 5.4d. 
 
According to the procedure described in chapter 3 for the synthesis of ACV ProTides, 
the coupling reactions of compounds 5.1 with the freshly prepared 
phosphorochloridates 2.2a, 2.2b and 2.2g were performed in the presence of tBuMgCl 
in anhydrous THF affording compounds 5.4a-c in 18-21% yield (scheme 5.4). 
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5.4a X: Br; Ar: Ph; R: CH3; R': H (Yield: 18%)
5.4b X: Br; Ar: 1-Naph; R: CH3; R': H (Yield: 21%) 
5.4c X: Br; Ar: 1-Naph; R: CH3; R': CH3 (Yield: 20%)
2.2a Ar: Ph; R: CH3; R': H 
2.2b Ar: 1-Naph; R: CH3; R': H
2.2g Ar: 1-Naph; R: CH3; R': CH3
Reagents and conditions: (i) anhydrous THF, tBuMgCl, rt, 12-18h
5.1
 
Scheme 5.4. Synthesis of the phosphoramidate derivatives 5.4a-c 
!
Alternatively, compound 5.4d was synthesised by bromination of the previously 
reported aryl phosphoramidate derivative of ACV 3.2g using NBS in THF (scheme 
5.5).7  
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Scheme 5.5. Synthesis of the phosphoramidate derivative 5.4d by bromination of the ACV ProTide 
3.2g 
!
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In the case of the synthesis of 8-methylacyclovir ProTide 5.5 the guanine base of 5.2 
was protected using N,N-dimethyl formamide dimethyl acetal with the aim to improve 
the solubility in THF and affording the N2-dimethylformamidine derivative 5.6 (scheme 
5.6).11 
NH
NN
N
O
NH2O
HO
NH
NN
N
O
N
OHO
N
CH3
CH3
i
5.2 5.6
H3C
H3C
Reagents and conditions: (i) N,N-dimethyl formamide dimethyl acetal , anhydrous DMF, rt, 24 h  
Scheme 5.6. Synthesis of the N2-dimethylformamidine derivative 5.6 
!
The coupling reaction of compound 5.6 with the phosphorochloridate 2.2a in anhydrous 
THF was performed in the presence of tBuMgCl and afforded compound 5.7 as mixture 
of two diastereomers in 27% yield (scheme 5.7). The dimethylformyl group was 
removed by refluxing 5.7 in 2-propanol (iPrOH) obtaining the desired compound 5.5 in 
21% yield (scheme 5.7).  
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Scheme 5.7. Synthesis of the phosphoramidate derivative 5.5 
 
Table 4.2 summarises the ProTides of 8-bromo- and 8-methylacyclovir synthesised. 
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Table 4.2. ProTides of 8-bromo- and 8-methylacyclovir 
(X: substituent in C-8; AA: amino acid) 
Cps X Aryl AA 31P NMR (ppm) Yield 
5.4a Br Ph L-Ala 3.72, 3.46 18% 
5.4b Br 1-Naph L-Ala 4.01, 3.92 21% 
5.4c Br 1-Naph DMG 2.52 20% 
5.4d Br 1-Naph L-Val 4.82, 4.74  36%a 
5.5 Me Ph L-Ala 3.77, 3.48 6%b 
a direct bromination of the ACV ProTide 3.4g; b overall yield of 2-steps synthesis 
 
The low overall yield of compound 5.5 (6%) is due to the additional deprotection step 
of the N2-dimethylformamidine derivative 5.7 required to obtain the final compound. In 
order to avoid the cleavage of the P-N bond, the removal of the N2-dimethylformamide 
group was performed under mild conditions, which are responsible for the incomplete 
deprotection of 5.7 and thus the low yield of the reaction (21%, scheme 4.6). 
Interestingly, the use of NBS as source of bromine in THF proved to be a suitable 
approach to introduce a bromine atom in the C-8 position of the guanine base of ACV 
ProTides.   
5.4 Biological evaluation of 8-bromoacyclovir, 8-methylacyclovir, and 
their phosphoramidate derivatives  
The acyclic guanine nucleoside analogues 5.1, 5.2, and their phosphoramidate 
derivatives 5.4a-d and 5.5 were evaluated for their antiviral activity against HSV, VZV, 
HCMV, and HIV. 
5.4.1 Anti-HSV activity  
Table 5.3 reports the antiviral activity of the phosphoramidate derivatives  
5.4a-d and 5.5 against HSV-1, HSV-2, and TK--HSV-1 in HEL cells. The anti-HSV 
activity of the parent nucleosides 5.1 and 5.2 was also evaluated and compared with the 
values reported in the literature (tab 5.1).3 ACV is included as a reference compound. 
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Table 5.3 Anti-HSV activity of 5.1, 5.2 and their phosphoramidate derivatives in HEL cell cultures 
(X: substituent in C-8; AA: amino acid) 
 Antiviral Activity EC50
a
 (µM)
 
Cps X Aryl AA HSV-1 HSV-2 TK- HSV-1  
5.1 Br - - 11 16 >100 
5.4a Br Ph L-Ala 79 48 >100 
5.4b Br 1-Naph L-Ala >100 >100 >100 
5.4c Br Ph DMG 60 50 >100 
5.4d Br 1-Naph L-Val >100 >100 >100 
5.2 Me - - 8 4 >100 
5.5 Me Ph L-Ala 46 42 >100 
ACV - - - 0.24 0.14 120 
a 50% Effective concentration, or compound concentration required to inhibit virus-
induced cytopathicity by 50% 
 
Compounds 5.1 and 5.2 exhibited activity against HSV-1 and HSV-2 in the micromolar 
range. The decrease of anti-HSV activity of compounds 5.1 and 5.2 in comparison to 
ACV (EC50= 0.14-0.24 µM) is consistent with the data reported in the literature (tab. 
4.1).3 Moreover 5.1 and 5.2, as well as ACV, did not retain activity against TK- HSV-1, 
showing that the 8-substituted derivatives of ACV require phosphorylation by HSV TK. 
The phosphoramidate derivatives 5.4a, 5.4c, and 5.5, bearing the phenyl group as aryl 
moiety, (EC50= 42-79 µM) showed a significant loss of activity against HSV-1 and 
HSV-2 in comparison to the parent nucleosides 5.1 and 5.2. The naphthyl derivatives 
5.4b and 5.4d were inactive against HSV-1 and HSV-2. None of the phosphoramidate 
derivatives 5.4a-d and 5.5 exerted antiviral activity against TK- HSV-1 below 100 µM.  
The concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) was found above 100 µM for all the compounds synthesised. 
5.4.2 Anti-VZV activity  
The antiviral activity of compounds 5.1, 5.2, and their phosphoramidate derivatives 
5.4a-d and 5.5 against TK-positive (TK+) and TK-deficient (TK-) strains of VZV in 
HEL cells are reported in table 5.4. ACV is included as reference compound. 
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Table 5.4. Anti-VZV activity of 5.1, 5.2 and their phosphoramidate derivatives in HEL cell cultures 
  (X: substituent in C-8; AA: amino acid) 
  Antiviral Activity EC50
a (µM) 
TK+ VZV strains TK- VZV strains 
Cps X Aryl AA YS OKA 07-1 YS/R 
5.1 Br - - - >50 >50 - 
5.4a Br Ph L-Ala - >50 >50 - 
5.4b Br 1-Naph L-Ala - >50 >50 - 
5.4c Br Ph DMG - >50 >50 - 
5.4d Br 1-Naph L-Val - >50 >50 - 
5.2 Me - - - 40.4 >100 - 
5.5 Me Ph L-Ala - 40.2 >100 - 
ACV - - - - 1.16 75 93 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%;   
 
Compound 5.1 was found inactive against TK+ strains of VZV (EC50> 50 µM), while 
compound 5.2 showed weak activity (EC50= 40.4 µM). As expected from data reported 
in the literature,12 ACV was active against TK+ VZV in the micromolar range (EC50= 
1.16 µM). These results could reflect a different substrate specificity of the VZV-TK 
compared with the HSV-TK. Indeed, the characterisation of the crystal structure of 
VZV-TK has highlighted some differences in the conformation of the active site 
between both enzymes that suggest different substrate selectivity.13 None of these 
compounds showed activity against TK- strains of VZV. 
Similarly to the parent nucleoside 5.1, the phosphoramidate derivatives 5.4a-d were 
inactive against TK+ and TK- VZV. The phosphoramidate derivative 5.5 retained the 
antiviral activity of the parent nucleoside 5.2 against TK+ VZV (EC50= 40.6 µM) and 
was inactive against TK- VZV. 
The concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) was above 100 µM for all the compounds synthesised. 
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5.4.3 Anti-HCMV activity 
Table 5.5 reports the antiviral activity of compounds 5.1, 5.2, and their 
phosphoramidate derivatives 5.4a-d and 5.5 against HCMV in HEL cells. Ganciclovir is 
reported as a reference compound. 
Table 5.5. Anti-HCMV activity of 5.1, 5.2, and their phosphoramidate derivatives in HEL cells 
(X: substituent in C-8; AA: amino acid) 
    Antiviral Activity EC50
a
  (µM)
 
Cps X Aryl AA AD-169 strain Davis strain 
5.1 Br - - >50 >50 
5.4a Br Ph L-Ala N.D b >50 
5.4b Br 1-Naph L-Ala N.D b >50 
5.4c Br Ph DMG N.D b >50 
5.4d Br 1-Naph L-Val N.D b >50 
5.2 Me - - >20 >100 
5.5 Me Ph L-Ala >100 >100 
GCV - - - 8.3 3.1 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b N.D.: not determined 
 
Compounds 5.1 and 5.2 were inactive against HCMV. This result is consistent with the 
lack of anti-HCMV activity of ACV as it is not phoshorylated by the virally encoded 
protein kinase, which instead is able to phosphorylate GCV.14, 15  
The phosphoramidate derivatives 5.4a-d and 5.5 were inactive against HCMV.  
The antiviral assay performed against HCMV has also shown that none of the 
compound synthesised altered cell morphology at concentrations below 100 µM.  
5.4.4 Cytostatic activity on HEL cell cultures of 8-bromoacyclovir, 8-
methylacyclovir and their phosphoramidate derivatives  
The acyclic guanine nucleoside analogues 5.1, 5.2, and their phosphoramidate 
derivatives 5.4a-d and 5.5 were evaluated for their antiproliferative activity on HEL 
cells. The concentration required to reduce cell growth by 50% was above 100 µM for 
all the compounds synthesised.  
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5.4.5 Anti-HIV activity 
Compounds 5.1, 5.2, and the L-alanine benzyl ester phoshoramidate derivatives  
5.4a-b and 5.5 were evaluated for their activity against HIV-1 in CEM cell and MT-4 
cell cultures and against HIV-2 in CEM cell cultures. 
Table 5.6 reports the anti-HIV-1 activity and cytostatic activity in MT-4 cell cultures of 
5.1, 5.2, and their phosphoramidate derivatives 5.4a-b and 5.5.  
ACV and the previously reported L-alanine benzyl ester derivatives of ACV ProTides 
(3.1a and 3.1b)2 are included as reference compounds.   
Table 5.6. Anti-HIV-1 and cytostatic activity in MT-4 cell cultures of compounds 5.1, 5.2, and their 
L-alanine benzyl ester derivatives 5.4a-b and 5.5. (X: substituent in C-8; AA: amino acid) 
    Antiviral Activity EC50
a (µM) Cytostatic Activity IC50
b
 (µM) 
Cps X Aryl AA HIV-1 MT-4 cells 
5.1 Br - - >150 >150 
5.4a Br Ph L-Ala >150 >150 
5.4b Br 1-Naph L-Ala >150 >150 
5.2 Me - - >150 >150 
5.5 Me Ph L-Ala >150 >150 
ACV - - - >250 >250 
3.1a - Ph L-Ala 5.7 ± 1.6 33.8 ± 10.6 
3.1b - 1-Naph L-Ala 0.8 N.D. c 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b 50% Inhibitory concentration, or compound concentration  required to 
inhibit cell proliferation by 50%; c N.D.: not determined 
Compounds 5.1 and 5.2 were inactive against HIV-1 in MT-4 cells. Since the in silico 
study previously performed in our lab on several derivatives of ACV as potential anti-
HIV agent suggested that 8-methyl- and 8-bromoacyclovir triphosphate may be 
inhibitors of HIV-RT,16 this result may indicate that the lack of anti-HIV activity of 
compounds 5.1 and 5.2, similarly to ACV,17 may be explained by the poor conversion 
of the 8-substituted ACV derivatives to the monophosphate form. However it must be 
pointed out that no in vitro studies have been reported in the literature regarding the 
inhibition of HIV-RT by 8-methylacyclovir triphosphate and 8-bromoacyclovir 
triphosphate.  
The phosphoramidate derivatives 5.4a-b and 5.5 were inactive against HIV-1 in MT-4 
cell cultures. 
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None of the compound synthesised exerted antiprioliferative activity against MT-4 cell. 
The results of the anti-HIV-1 and anti-HIV-2 assays performed in CEM cell culture 
confirm the lack of anti-HIV activity of compounds 5.1, 5.2 and their  
L-alanine benzyl ester phosphoramidate derivatives 5.4a-b and 5.5, which exhibited 
antiviral activity (EC50) above 250 µM. 
5.4.6 Summary of the biological activity of 8-bromo-, 8-methylacyclovir and their 
phosphoramidate derivatives 
The results of the antiviral assay performed on 8-bromo- and 8-methyacyclovir confirm 
the selective antiviral activity of these compounds against HSV-1 and HSV-2. The poor 
formation of the monophosphate derivative may account for the lack of activity against 
VZV, HCMV, and HIV. 
The lack of antiviral activity of the phosphoramidate derivatives 5.4a-d and 5.5 against 
TK--HSV-1 strongly suggests that the monophosphate form of 8-bromo- and 8-
methylacyclovir was not successfully released into the cell. Most probably, the antiviral 
activity displayed by the phenyl derivatives 5.4a, 5.4c, and 5.5 against HSV-1 and 
HSV-2 was due to the intracellular release of the parent nucleoside. The results of the 
antiviral assays performed against VZV, HCMV, and HIV confirm this hypothesis. 
5.5 Enzymatic and modeling studies 
Considering the putative mechanism of activation of ProTides described in chapter 1, 
enzymatic and molecular modelling studies were performed in order to further 
investigate the biological activity of the phosphoramidate derivatives  
5.4a-d and 5.5 and evaluate whether their inactivity could be attributed to poor 
conversion to the monophosphate form. 
5.5.1 Study of the carboxyesterase activity 
The enzymatic study of compounds 5.4a and 5.5 was performed using 
carboxypeoptidase Y (CPY) in order to investigate the first step in the bioactivation 
pathway of ProTides. The enzymatic assay was carried out following the procedure 
described in chapter 3. 31P NMR spectra were recorded at 30 minutes intervals in order 
to monitor the enzymatic reaction. 
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Figure 5.6 depicts the 31P NMR spectra of the enzymatic reaction performed on 
compound 5.4a over a 60 min period of incubation.  
The hydrolysis of compound 5.4a (!P= 3.75 and 3.91 ppm) occurred in less than 30 min 
after exposure to CPY, affording the intermediate 5.8 (!P= 4.71 and 4.86 ppm). After 
this period, the intermediate 5.8 was already converted to the phosphoramidate 
monoester 5.9 (!P= 7.27 ppm) by 70%. After a 60 min period of incubation, the 
conversion to 5.9 was complete.  
 
Figure 5.6 31P NMR spectra (acetone-D6, 202 MHz) of the enzymatic study performed on 
compound 5.4a 
The 31P NMR spectra of the enzymatic reaction performed on compound 5.5 over a 30 
min period of incubation is depicted in figure 5.7.  
 
Figure 5.7 31P NMR spectra (acetone-D6, 202 MHz) of the enzymatic study performed on 
compound 5.5 
!
The hydrolysis of compound 5.5 (!P= 3.67 and 3.80 ppm) occurred in less then 30 min 
from the exposure to the CPY (fig. 5.7). Due to rapid processing, the 31P NMR signal 
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corresponding to intermediate 5.10 was not detected and only the formation of the final 
product 5.11 (!P= 7.33 ppm) was observed. 
The enzymatic study performed on compounds 5.4a and 5.5 indicates that the benzyl 
ester is successfully cleaved by CPY, according to the putative mechanism of activation 
of ProTides.18 Thus the lack of antiviral activity probably cannot be correlated to a poor 
cleavage of the benzyl ester for these derivatives. 
5.5.2 Docking study of the phosphoramidate derivatives of 8-bromo- and 8-methyl-
acyclovir within the active site of human Hint-1 enzyme  
According to the putative mechanism of activation of ProTides previously described in 
chapter 1, human Hint-1 is considered to be responsible for the release of the free 
monophosphate form of nucleoside analogues by cleaving the P-N bond of 
phosphoramidate derivatives.19, 20  
In order to further investigate the bioactivation of the L-alanine benzyl ester 
phosphoramidate derivatives 5.4a and 5.5, the modeling study of compounds 5.9 and 
5.11 (fig. 5.8) within the active site of the human Hint-1 was performed using docking 
techniques. 
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Figure 5.8. Structures of the L-alanine phosphoramidate monoester derivatives 5.9 and 5.11 
!
Figure 5.9 shows the docking study of compound 5.9 within the active site of the human 
Hint-1 co-crystallised with AMP (shown in yellow).  
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Figure 5.9. Superimposition of compound 5.9 with AMP (yellow) within the active site of human 
Hint-1 enzyme. The red circle indicates the phosphate moiety of AMP. The red arrows indicate the 
position of the residues of serine 107 (Ser_107), hisitidine 112 (His_112), and histidine 114 
(His_114) involved in the cleavage of the P-N bond of compound 5.9 according to the mechanism of 
action of the human Hint-1 enzyme (from ref. 20) 
!
Despite a slight difference in comparison to the position adopted by AMP, the guanine 
base of compound 5.9 fits well into the enzymatic pocket. Instead, the orientation of the 
side chain of 8-bromoacyclovir places the phosphate moiety (shown in purple) in a 
totally different position when compared to the phosphate group of AMP (highlighted 
by the red circle). As result of the placement outside the enzymatic pocket, the P-N 
bond is not in a suitable position to interact with serine and histidine residues (indicated 
by the red arrows in fig. 5.9), which are responsible for its cleavage according to the 
mechanism of action of human Hint-1 ezyme.20  
The docking study of compound 5.11 (fig. 5.10) shows a similar result: the phosphate 
moiety (purple) is placed in a position that does not allow a proper interaction with the 
serine and histidine residues (red arrows in fig 4.6) involved in the cleavage of the P-N 
bond. 
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Figure 5.10. Superimposition of compound 5.11 with AMP (yellow) within the active site of human 
Hint-1 enzyme. The red circle highlights the phosphate moiety of AMP. The red arrows indicate the 
position of the residues of serine 107 (Ser_107), hisitidine 112 (His_112), and histidine 114 
(His_114) involved in the cleavage of the P-N bond of compound 5.11 according to the mechanism 
of action of the Hint enzyme (from ref. 20)  
!
In conclusion the modeling studies of compound 5.9 and 5.11 within the active site of 
the human Hint-1 enzyme strongly suggests that the inactivity of compounds 5.4a and 
5.5 may be due to the inefficacy of the phosphoramidase enzyme to cleave the P-N 
bond and release the monophosphate.  
5.6 Conclusions 
In order to overcome the decrease in selectivity induced by the application of the 
ProTide approach to ACV and the potential cytotoxic effect related to the inhibition of 
the cellular DNA replication, a series of phosphoramidate derivatives of 8-methyl- and 
8-bromoacyclovir were synthesised and evaluated for their activity against HSV, VZV, 
HCMV, and HIV. Unfortunately, the phosphoramidate derivatives 54a-d and 5.5 were 
found either poorly active or completely inactive. The enzymatic studies indicated that 
these compounds are successfully processed by carboxypeptidase Y. However modeling 
studies suggest that the metabolites of 8-methyl- and 8-bromoacyclovir ProTides may 
be poor substrates for human Hint-1, resulting in missed cleavage of the P-N bond.  
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Chapter 6. Aryl phosphoramidate derivatives of ganciclovir 
and penciclovir 
6.1 Introduction to the application of the ProTide approach to 
ganciclovir and penciclovir 
As described in chapter 1, ganciclovir (GCV) and penciclovir (PCV) are analogues of 
acyclovir (ACV), from which they differ for the presence of an additional 
hydroxymethylene group on the acyclic side chain that mimics the 3’ hydroxyl group of 
natural nucleosides (fig. 6.1).1 Moreover, PCV differs from GCV and ACV for the 
replacement of the oxygen on the side chain with a methylene group. These compounds 
are anti-herpes virus agents and share a similar mechanism of activation with ACV, 
leading to the formation of the triphosphate form that inhibits the viral DNA 
polymerase.1  
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Figure 6.1. Structures of GCV and PCV 
!
The application of the ProTide approach to GCV and PCV has been previously 
investigated in our group on the basis of the virtual screening carried out on several 
derivatives of ACV triphosphate as potential inhibitors of HIV-RT.2 In particular, the in 
silico study pointed out that GCV and PCV triphosphate could be good candidates as 
inhibitors of this enzyme. Following the procedure already described for the synthesis 
of ACV ProTides,3 several aryl phosphoramidate derivatives of GCV and PCV were 
previously prepared in our lab.4 When phenyl and naphthyl L-alanine benzyl ester 
phosphorochloridates were used, the bisphosphate prodrugs (bis-ProTide) 6.1a-d were 
exclusively obtained (fig. 6.2).4 Only in the case of the L-alanine isopropyl ester 
derivative of GCV it was possible to isolate the mono-ProTide 6.2, together with the 
bis-ProTide 6.3 (fig. 6.2).4  
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Figure 6.2. Structures of GCV and PCV ProTides 6.1a-d, 6.2, and 6.3 previously prepared in our 
lab (from ref. 4)  
The bis-ProTides derivatives of PCV 6.1a-b exhibited a significant loss of activity 
against TK-positive strains of VZV (EC50= 6.9-32.2 µM) in comparison to the parent 
nucleoside (EC50= 0.9-2.2 µM) and they were inactive against TK-deficient strains of 
VZV.5 This result may suggest that either the bisphosphate prodrugs are not 
successfully bioactivated or they release the parent nucleoside. 
The ProTides 6.1c-d, 6.2, and 6.3 were evaluated for their activity against HIV but 
found inactive.4 The inactivity of the mono-ProTide 6.2 may be due to the poor 
cleavage of the ester moiety in the bioactivation pathway, as suggested by the 
enzymatic study performed on this compound using carboxypeptidase Y.4  
In the same study also the application of the ProTide approach to the 6–methoxy 
derivative of PCV was described and the synthesis of ProTides 6.4a and 6.4b was 
reported (fig 6.3).4  
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Figure 6.3. Structure of the 6-methoxy-PCV ProTides 6.4a and 6.4b previously prepared in our lab 
(from ref. 4)  
!
 These compounds exhibited poor activity against TK-positive strains of HSV (EC50= 
38-58 µM against HSV-1 and 20-45 µM against HSV-2) and retention of this activity 
against TK-deficient strains of HSV-1 (EC50= 20-58 µM), while the parent nucleoside 
was completely inactive against both strains of HSV.  
6.2 Design of novel aryl phosphoramidate derivatives of GCV and 
PCV 
Considering the results obtained in the evaluation of ACV ProTides (chapter 3), 
compounds 6.5a-d (fig 6.4) were synthesised in order to investigate the antiviral activity 
of the phenyl and naphthyl 2,2-dimethylglycine benzyl ester phosphoramidate 
derivatives of GCV and PCV. The bisphosphate derivatives 6.6a-d were also obtained 
(fig 6.4). 
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Figure 6.4. Structure of phenyl and naphthyl 2,2-dimethylglycine benzyl ester phosphoramidate 
derivatives 6.5a-d (mono-ProTides) and 6.6a-d (bis-ProTides) 
 
Chapter 6!
! 138 
Phenyl and naphthyl L-alanine benzyl ester phosphoramidate derivatives 6.7a-d (fig 
6.5) were synthesised in order to evaluate the antiviral activity of the mono-ProTides of 
GCV and PCV and compare their activity with that of the analogous bis-ProTides 6.1a-
d previously prepared in our lab (fig. 6.2).  
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Figure 6.5. Structure of phenyl and naphthyl L-alanine benzyl ester phosphoramidate derivatives 
6.7a-d 
6.2.1 Synthesis of the 2,2-dimethylglycine benzyl ester derivatives of GCV and 
PCV ProTides 
The synthesis of the phenyl and naphthyl 2,2-dimethylglycine benzyl ester 
phosphoramidate derivatives of GCV and PCV was carried out following the same 
procedure described in chapter 3 for the synthesis of ACV ProTides. The protection of 
the guanine base with N,N-dimethyl formamide dimethyl acetal afforded the N2-
dimethylformamidine (N2-DMF) derivatives 6.8a and 6.8b  (scheme 6.1).6  
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Scheme 6.1 N2-dimethylformamidine derivatives of GCV and PCV 
!
The coupling reaction of compounds 6.8a and 6.8b with an excess of the appropriate 
phosphorochloridate 2.2 in THF was performed in the presence of tBuMgCl and 
afforded the monophosphate derivatives 6.9a-d in 30-56% yield along with the 
bisphosphate derivatives 6.10a-d in 33-40% yield (scheme 6.2).7 All these products 
were obtained as mixtures of diastereomers. 
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Scheme 6.2. Synthesis of the phenyl and naphthyl 2,2-dimethylglycine benzyl ester 
phosphoramidate derivatives 6.9a-d (mono-ProTides) and 6.10a-d (bis-ProTides) 
 
The yields of the coupling reactions reported in scheme 6.2 show that the 
monoProTides 6.9a-d and the bis-ProTides 6.10a-d are obtained in comparable 
amounts. These results are in contrast with the findings previously reported in our group 
showing that under the same conditions the synthesis of the L-alanine benzyl ester 
derivatives of GCV and PCV ProTides afforded only the bis-ProTide derivatives 6.1a-d 
(fig. 6.2).4  
The N2-DMF group was removed in 2-propanol (iPrOH) under reflux conditions 
obtaining the desired compounds 6.5a-d and 6.6-d in 2.7-6.5% yield (scheme 6.3). 
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Scheme 6.3. Deprotection of N2-DMF derivatives 6.9a-d and 6.10a-d 
6.2.2 Synthesis of the L-alanine benzyl ester derivatives of GCV and PCV mono-
ProTides 
In this work, different synthetic approaches were evaluated in order to obtain the L-
alanine benzyl ester derivatives of GCV and PCV mono-ProTides (6.7a-d, fig. 6.5).   
As described in the previous paragraph, the use of an excess of aryl amino acid ester 
phosphorochloridate (2-4 eq) and tBuMgCl (2 eq) can be the reason why both hydroxyl 
groups of GCV and PCV can be phosphorylated in the coupling reaction.  
In preliminary studies, the use of a lower amount (1.1 eq) of the freshly prepared phenyl 
and naphthyl L-alanine benzyl ester phosphorochloridates (2.2a and 2.2b) in the 
coupling reaction with the N2-DMF derivatives of GCV (6.8a) and PCV  (6.8b) was 
evaluated. Unfortunately, the reaction did not afford any product indicating that the 
excess of the phosphorochloridate is required to carry out the reaction in these 
conditions. The same reaction was repeated using 2 eq of phosphorochloridate and 
decreasing the amount of tBuMgCl from 2 to 1.1 eq in order to achieve the 
deprotonation of only one of the two hydroxyl groups of GCV and PCV and drive the 
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reaction toward the formation of the mono-ProTide. Also in this case no product was 
obtained.  
Following this unsuccessful result, pyridine was used as solvent to improve the 
solubility of the parent nucleoside. The phosphorylation of the N2-DMF derivatives 6.8a 
and 6.8b was performed in pyridine using 2-4 eq of the appropriate phosphorochloridate 
(2.2a and 2.2b) and in the presence of tBuMgCl (2 eq).  However, this approach was 
not successful. The same reaction was performed using unprotected PCV affording 
compound 6.7a in 5% yield as a mixture of diastereomers (scheme 6.4).  
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Scheme 6.4. Coupling reaction of PCV in pyridine 
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As alternative approach, the solubility of the parent nucleoside in THF was improved 
using a different protective group. For this purpose, the 2-amino group of PCV was 
protected using N,N-dibenzylformamide dimethylacetal affording compound 6.11 
(scheme 6.5), which showed higher solubility in THF in comparison to compound 6.8a.8  
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Scheme 6.5. Protection of PCV with the N,N-dibenzylformamide group 
!
The coupling reaction of 6.11 with the phosphorochloridate 2.2b (2 eq) was performed 
in THF and in the presence of tBuMgCl (2 eq) affording compound 6.12 in 30% yield 
as a mixture of diastereomers (scheme 6.6). No traces of the bis-ProTide analogue were 
detected. This result indicates that the solubility of the parent nucleoside is a crucial 
factor for the synthesis of the mono-ProTide derivative as the main product of the 
coupling reaction with aryl amino acid ester phosphorochloridates.  
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Scheme 6.6. Coupling reaction of N,N-dibenzyl-formamide-protected PCV with the 
phosphorochloridate 2.2b. 
!
According to the procedure described in the literature, trifluoroacetic acid aqueous 
(50% V/V) was used to remove the N,N-dibenzylformamide group from compound 
6.12.9 However, degradation of the starting material was observed indicating that under 
these conditions this approach is not suitable for the synthesis of ProTides. Milder 
conditions were applied to the elimination of the protective group. The reflux reaction 
in 2-propanol did not afford any product after 72 h.  
In order to improve the solubility in THF and make only one of the two hydroxyl 
groups on the side chain available for phosphorylation, the protection of GCV and PCV 
with the mono-methoxytrityl group (MMT) was evaluated. Following the procedure 
described in the literature, GCV and PCV were dissolved in DMF and reacted with 
mono-methoxytrityl chloride (MMT-Cl) in the presence of TEA and a catalytic amount 
of DMAP (scheme 6.7).10 The reaction yielded two different products for each parent 
compound: the more lipophilic (6.13a and 6.13b) bearing two protecting groups at the 
2-amino position and at one of the two hydroxyl group on the side chain; and the less 
lipophilic (6.14a and 6.14b) bearing the MTT group only at the 2-amino position.  
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Scheme 6.7. Protection of GCV and PCV with MMT-Cl 
The coupling reaction of compound 6.13a and 6.13b with the appropriate 
phosphorochloridate (2.2a and 2.2b) in THF was performed in the presence of tBuMgCl 
and afforded compounds 6.15a and 6.15b as mixtures of diastereomers in 40% and 38% 
yield, respectively (scheme 6.8).  
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Scheme 6.8. Coupling reaction of 6.13a and 6.13b with the phosphorochloridates 2.2a and 2.2b  
!
The removal of the MTT group was performed using para-toluensulfonic acid (TsOH) 
at room temperature and afforded the desired compounds 6.7b and 6.7c in 30% and 
28% yield, respectively (scheme 6.9). 
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Scheme 6.9 Detritylation reaction 
!
Finally, a diastereomeric mixture of the protected mono-ProTide 6.16 was obtained in 
35% yield by coupling reaction in THF of 6.14b with the phosphorochloridate 2.2b in 
the presence of tBuMgCl (scheme 6.10). This result shows that also compound 6.14b is 
suitable for the synthesis of the mono-ProTides confirming the important role of the 
solubility of the parent nucleoside in the coupling reaction. The detritylation of 6.16 
afforded the desired compound 6.7d in 25 % yield (scheme 6.10).  
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Scheme 6.10. Coupling reaction of compound 6.14b with the phosphorochloridate 2.2b and 
detritylation reaction. 
!
The coupling reaction of the phosphorochloridates 2.2a and 2.2b with the MMT-
protected derivatives of GCV and PCV represents the first successful route to the 
synthesis of the mono-ProTides derivatives containing L-alanine benzyl ester as a 
masking group.  
6.2.3 Summary of the GCV and PCV ProTides synthesised. 
Table 6.1 reports a summary of the L-alanine and 2,2-dimethylglycine benzyl ester 
derivatives of GCV and PCV ProTides 6.5a-d, 6.6a-d, and 6.7a-d, including the 
synthetic pathway, the yields of the coupling reaction (Coupl. Yield) and deprotection 
(Depr. Yield), the substitution pattern, and the 31P NMR chemical shift (!) of the final 
compounds in deuterated methanol. 
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Table 6.1. GCV and PCV ProTides synthesised 
 (Ar: aryl moiety; AA: amino acid moiety;)  
Starting 
material 
Coupl. 
Yield 
Depr. 
Yield 
Final 
Cps 
Ar AA 
Mono/Bis 
ProTide 
31P NMR !  
(ppm) 
N2-DMF 
PCV 
30% 5% 6.5a Ph DMG Mono 2.37, 2.35 
N2-DMF 
PCV 
48% 5% 6.5b 1-Naph DMG Mono 2.89, 2.85 
N2-DMF 
GCV 
40% 6.5% 6.5c Ph DMG Mono 2.26, 2.24 
N2-DMF 
GCV 
56% 2.7% 6.5d 1-Naph DMG Mono 2.65, 2.69 
N2-DMF 
PCV 
33% 5% 6.6a Ph DMG Bis 
2.23, 2.18, 
2.17 
N2-DMF 
PCV 
40% 5%` 6.6b 1-Naph DMG Bis 
2.76, 2.70, 
2.64, 2.57 
N2-DMF 
GCV 
38% 4.3% 6.6c Ph DMG Bis 
2.18, 2.16, 
2.11  
N2-DMF 
GCV 
35% 5.3% 6.6d 1-Naph DMG Bis 
2.63, 2.57, 
2.53, 2.52 
PCVb 5% - 6.7a Ph L-Ala Mono 
4.12, 4.05, 
3.61, 3.59  
N2,O-MMT 
PCV 
40% 30% 6.7b 1-Naph L-Ala Mono 
4.46, 4.44, 
4.16, 4.13 
N2,O-MMT 
GCV 
38% 28% 6.7c Ph L-Ala Mono 
3.92, 3.83, 
3.63, 3.61 
N2-MMT 
GCV 
35% 25% 6.7d 1-Naph L-Ala Mono 
4.29, 4.24, 
4.18, 4.09 
 
Not only the protection of GCV and PCV with the monomethoxytrityl group allowed to 
obtain the mono-ProTide derivatives, but it also represented an improvement in terms of 
yield of the deprotection step when compared to N2-DMF group. 
6.3 Diastereospecific synthesis of the mono-phosphoramidate 
derivatives of GCV and PCV  
Ganciclovir and penciclovir are prochiral molecules: the phosphorylation of one of the 
two hydroxyl groups generates a chiral center at the side chain affording the S and R 
enantiomers of GCV and PCV mono-phosphate (fig. 6.6). 
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Figure 6.6. S and R enantiomers of GCV and PCV monophosphate 
!
A Previous study pointed out the important role of stereochemistry in the intracellular 
activation of GCV showing that:  
• HSV-TK phosphorylates GCV affording exclusively the S enantiomer of the 
monophosphate derivative.11 
• The S enantiomers of GCV monophosphate reacts much faster than the R 
enantiomer in the phosphorylation step mediated by GMP kinase.11 
• While the S enantiomer of GCV triphosphate displays potent inhibitory activity 
against HSV-1 DNA polymerase, the R enantiomer is a poor inhibitor of this 
enzyme.11 
Considering these results, a pronucloetide approach that allows to release into the cell 
exclusively the S enatiomer of GCV monphosphate represents an improvement over the 
release of a mixture of the enatiomers.  
The synthetic route that has been described in previous paragraphs for the preparation of 
GCV and PCV ProTides is not stereoselective meaning that inside the cell their 
activation may lead to the release of both the enantiomers of the monophosphate. 
According to the procedure described in the literature for the enantioselective synthesis 
of ganciclovir cyanoethyl phospharamidite derivative, a route aimed to obtain the 
diastereoselective synthesis of GCV and PCV ProTides was developed.12  
Scheme 6.11 describes this route based on the enantioselective acetylation of the N2-
DMF derivatives of GCV and PCV (6.8a and 6.8b) in the presence of porcine 
pancreatic lipase (PPL). As previously reported in the literature for the acetylation of 
the analogous isobutyryl derivative of GCV, this reaction was expected to afford 
exclusively the S enantiomer of 6.17a and 6.17b.12 Thus, the coupling reaction of 6.17a 
and 6.17b with the phosphorochloridates 2.2a and 2.2b in the presence of tBuMgCl was 
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presumed to give rise to the formation of the diastereomers of 6.18a-d with only the S 
configuration at the chiral carbon of the side chain, which is the desired configuration 
according to the studies reported in the literature about the stereoselective bioactivation 
of GCV.11 The 31P NMR analysis of the ProTides synthesised through this route is 
expected to give only two peaks corresponding to the two diastereomers obtained (SSpS 
and SRpS) and has been considered as an easy tool to evaluate the diastereselectivity of 
the whole synthetic approach. However, no information can be obtained about the 
configuration of the stereocenters by this analysis.  
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Scheme 6.11. Diastereoselective route of GCV and PCV ProTides with S configuration at the chiral 
carbon of the side chain 
!
Following this route, the N2-DMF derivative of GCV 6.8b was reacted with vinyl 
acetate in the presence of PPL (scheme 6.12) affording the mono-acetylated derivative 
6.17b as main product (53%) along with a minor amount of the di-acetylated derivative 
6.20 (8%).  
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Scheme 6.12. PPL-mediated acetylation of N2-DMF derivative of GCV 
!
The coupling reaction of compound 6.17b with the freshly prepared 
phosphorochloridate 2.2a was performed in the presence of tBuMgCl and afforded 
compound 6.18c (scheme 6.13). The dimethylformamide group was removed in 2-
propanol (iPrOH) under reflux conditions affording compound 6.19c (scheme 6.13).  
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Scheme 6.13 Coupling reaction of the mono-acetylated derivative of GCV 6.17b with the 
phosphorchloridate 2.2a 
!
As depicted in figure 6.7, the 31P NMR spectrum of compound 6.19c in deuterated 
methanol showed 4 peaks corresponding to the 4 diastereomers with configuration 
SSpS, SRpS, SSpR, and SRpR at the stereocenters, demonstrating that the whole 
synthetic route was not diastereoselective as expected. This result may suggest that the 
PPL-mediated acetylation of compound 6.8b (scheme 6.12) lacked the expected 
enantioselectivity. The formation of the diacetate derivative 6.20, showed in scheme 
6.12, strongly supports this hypothesis.  
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Figure 6.7. 31P NMR spectrum (MeOD, 202 Mhz) and structures of the 4 diastereomers (S-Sp-S, S-
Rp-S, S-Sp-R, and S-Rp-R) of compound 6.19c  
!
Due to this unsuccessful result, an alternative approach was applied to the 
diastereoselective synthesis of PCV ProTides. As previously reported in the literature 
for the enantioselective synthesis of cyclopropavir monophosphate, PCV was protected 
at the 2-amino group of the guanine base with the isobutyryl group (i-Bu) affording 
compound 6.21, which was then converted to compound 6.22 by acetylation with acetic 
anhydride (Ac2O) (scheme 6.14).
13 Deacetylation was performed using pig liver esterase 
(PLE) and afforded the mono-acetyl derivative 6.23 in 60% yield (scheme 6.14). As 
described in the literature, this reaction was expected to be enantioselective.13   
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Scheme 6.14 Synthesis of the mono-acetyl derivative of N2-iBU-PCV (6.23)  
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Coupling reaction of compound 6.23 with the phosphorochloridate 2.2a was performed 
in the presence of tBuMgCl and afforded compound 6.24 (scheme 6.15).  
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Scheme 6.15. Coupling reaction of 6.23 with the phosphorochloridate 2.2a 
!
The 31P NMR spectrum of compound 6.24 (fig. 6.8) showed two peaks corresponding to 
two of the four possible diastereomeric configurations. This result suggests that the 
PLE-mediated deacetylation of compound 6.22 was enantioselective (scheme 6.15).  
 
Figure 6.8. 31P NMR spectrum (MeOD, 202 Mhz) of compound 6.24  
!
The removal of the N2-iBu group was attempted according to the procedure described in 
the literature (scheme 6.16).13 However, degradation of compound 6.24 occurred under 
these conditions and compound 6.25 was not obtained. 
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Scheme 6.16. N2-iBu group deprotection of compound 6.24 
!
In conclusion, the PPL-mediated acetylation of the N2-DMF derivatives of GCV did not 
achieve the expected selectivity (scheme 6.12), while the diastereoselective synthesis of 
PCV ProTide 6.24 was successfully obtained by means of the PLE-mediated 
deacetylation of compound 6.22 (scheme 6.14). However the isobutyryl group proved to 
be unsuitable for the synthesis of ProTides. These results suggest that the route 
involving the PLE-mediated deacetylation must be preferred over that where PPL-
mediated acetylation is used to achieve the diastereoselective synthesis of GCV and 
PCV ProTides.  
6.4 Biological evaluation of GCV and PCV ProTides  
The aryl phosphoramidate derivatives of GCV and PCV synthesised in this work were 
evaluated for their antiviral activity against HSV, VZV, HCMV, and HIV. The 
cytostatic activity on HEL and MT-4 cell cultures was also evaluated, as well as the 
concentration required to cause a microscopically visible alteration of HEL cell 
morphology and the concentration that induces 50% cell death in MT-4 cell cultures. 
6.4.1 Anti-HSV activity 
Table 6.2 reports the antiviral activity of compounds 6.5a-d, 6.6a-d, and 6.7a-d against 
HSV-1, HSV-2, and TK--HSV-1 in HEL cell cultures. The data include ACV and GCV 
as references. Moreover, the anti-HSV activity of the L-alanine benzyl ester derivatives 
of ACV ProTides (3.1a and 3.1b) are reported for comparison.3 
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Table 6.2. anti-HSV activity of GCV and PCV ProTides 6.5a-d, 6.6a-d, and 6.7a-d in HEL cells 
(Nuc: nucleoside; AA: amino acid moiety) 
 Antiviral Activity EC50
 a
 (µM)
 
Cps Nuc Aryl AA Mono/Bis HSV-1 HSV-2 TK- HSV-1  
6.5a PCV Ph DMG Mono 29 39 100 
6.5b PCV 1-Naph DMG Mono 75 51.5 100 
6.5c GCV Ph DMG Mono 0.1 0.3 0.1 
6.5d GCV 1-Naph DMG Mono 0.6 0.8 1.4 
6.6a PCV Ph DMG Bis >100 >100 >100 
6.6b PCV 1-Naph DMG Bis >20 >20 >20 
6.6c GCV Ph DMG Bis 1.45 2.5 1.5 
6.6d GCV 1-Naph DMG Bis 0.8 0.9 1.6 
6.7a PCV Ph L-Ala Mono 12 17.3 100 
6.7b PCV 1-Naph L-Ala Mono 72.5 79 100 
6.7c GCV Ph L-Ala Mono 0.55 3 3 
6.7d GCV 1-Naph L-Ala Mono 0.4 0.5 3 
ACV - - - - 0.1 0.2 112 
GCV - - - - 0.1 0.03 100 
3.1a ACV Ph L-Ala Mono 8 ± 5.7 4 15 ± 7.1 
3.1b ACV 1-Naph L-Ala Mono 2 1.4 ± 0.8 10 ± 2.1 
a 50% Effective concentration or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
Similarly to ACV, GCV exhibited activity against HSV-1 and HSV-2 in the 
submicromolar range (EC50= 0.1 and 0.03 µM respectively) and it lost activity against 
TK- strain of HSV-1 (EC50= 100  µM). 
All the novel derivatives of GCV ProTides (6.5c-d, 6.6c-d, and 6.7c-d) showed activity 
against HSV-1 and HSV-2 in the micromolar and sub-micromolar range (EC50= 0.1-3 
µM).  The retention of antiviral activity against TK- HSV-1 indicates the successful 
bypass of the HSV-TK-mediated phosphorylation step. The  
2,2-dimethylglycine benzyl ester derivatives of GCV ProTides 6.5c and 6.5d exhibited 
retention of anti-HSV activity when compared to the L-alanine benzyl ester analogues 
6.7c and 6.7d. The antiviral activity of 6.6c and 6.6d against TK- HSV-1 (EC50= 1.5-1.6 
µM) also suggests that the bis-ProTide derivatives of GCV successfully bypassed the 
first phosphorylation step mediated by the HSV-TK. This result is in contrast to the 
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study of the analogous L-alanine benzyl ester derivatives of GCV bis-ProTides 6.1c and 
6.1d previously reported in our group (fig 6.2).4  
In comparison to the previously reported L-alanine benzyl ester derivatives of ACV 
ProTides (3.1a and 3.1b),3 all the GCV ProTides presented in this work  (6.5c-d, 6.6c-d, 
and 6.7c-d) displayed retention of activity against HSV-1, HSV-2, and a slight 
improvement of potency against TK- HSV-1 (EC50= 0.15-3 µM).  
Surprisingly, the PCV ProTides 6.5a-b, 6.6a-b, and 6.7a-b showed a significant or 
complete loss of the anti-HSV activity in comparison to the analogous GCV derivatives. 
The antiviral activity of these compounds against HSV-1 and HSV-2 indicates that the 
phenyl derivatives 6.5a and 6.7a were more active than the naphthyl derivatives 6.5b 
and 6.7b. However, the significant decrease of potency against TK- HSV-1, which is 
comparable to that exhibited by ACV and GCV, strongly suggests that these derivatives 
of PCV ProTides did not release the phosphate form inside the cell and their anti-HSV 
activity was due to the release of the parent nucleoside instead. 
The concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) was above 100 µM for all the compounds synthesised, indicating 
low cytotoxicity. 
6.4.2 Anti-VZV activity 
Compounds 6.5a-c, 6.6b-d, and 6.7b-d were evaluated for their antiviral activity against 
TK-positive (TK+) and TK-deficient (TK-) strains of VZV in HEL cell cultures (table 
6.3). ACV and the previously reported L-alanine benzyl ester derivatives of ACV 
ProTides 3.1a and 3.1b are reported as reference compounds.14 
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Table 6.3. Anti-VZV activity of GCV and PCV ProTides 6.5a-c, 6.6b-d, and 6.7b-d in HEL cells 
(Nuc: nucleoside; AA: amino acid moiety) 
     Antiviral Activity EC50
a (µM) 
TK+ VZV strains TK- VZV strains 
Cps Nuc Aryl AA Mono/Bis 
YS OKA 07-1 YS/R 
6.5a PCV Ph DMG Mono >50 >50 
6.5b PCV 1-Naph DMG Mono 23.3 >50 
6.5c GCV Ph DMG Mono 6.40 7.3 3.3 2.4 
6.6b PCV 1-Naph DMG Bis >50 >50 >50 >50 
6.6c GCV Ph DMG Bis 8.8 21.7 8.3 12.5 
6.6d GCV 1-Naph DMG Bis 12.1 13.6 7.2 20 
6.7b PCV 1-Naph L-Ala Mono 16.2 9.3 >50 N.D. 
6.7c GCV Ph L-Ala Mono N.D. 2.7 4.8 N.D. 
6.7d GCV 1-Naph L-Ala Mono N.D. 9.5 8.2 N.D. 
ACV - - - - 1 4.2 73.6 94.3 
3.1a ACV Ph L-Ala - 0.7 1.0 1.8 0.59 
3.1b ACV 1-Naph L-Ala - 7.2 3.3 6.9 N.D 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
The phosphoramidate derivatives of GCV 6.5c, 6.6c-d, and 6.7c-d exhibited antiviral 
activity against TK+-VZV and TK—-VZV in the micromolar range, retaining the activity 
of the L-alanine benzyl ester derivatives of ACV ProTides 3.1a and 3.1b.14 These 
results show that the application of the ProTide approach to GCV allowed bypass of the 
first phosphorylation step mediated by the virus-encoded thymidine kinase also in the 
case of VZV. Moreover, the effective bioactivation of the bis-ProTide derivatives 6.6c 
and 6.6d, which was already observed in the anti-HSV assay, was confirmed also 
against VZV. 
PCV ProTides 6.5b and 6.7b were moderately active against TK+-VZV (EC50= 9.3-23.3 
µM), while compounds 6.5a and 6.6b were completely inactive (EC50> 50 µM). None 
of the PCV ProTides showed antiviral activity below 50 µM against TK--VZV. 
The concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) were above 100 µM for all the compounds synthesised confirming 
the lack of cytotoxicity, which was already observed in the anti-HSV assays.  
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6.4.3 Anti-HCMV activity 
Table 6.4 reports the antiviral activity of GCV and PCV ProTides 6.5a-d, 6.6a-d, and 
6.7a-d against HCMV in HEL cell cultures. Ganciclovir is included as reference 
compound. 
Table 5.4. Anti-HCMV activity of GCV and PCV ProTides 6.5a-d, 6.6a-d, and 6.7a-d in HEL cells!
(Nuc: nucleoside; AA: amino acid moiety) 
 Antiviral Activity EC50
 a
 (µM) 
Cps Nuc Aryl AA Mono/Bis AD-169 strain Davis strain 
6.5a PCV Ph DMG Mono >50 >50 
6.5b PCV 1-Naph DMG Mono >50 >50 
6.5c GCV Ph DMG Mono 38.5 15.7 
6.5d GCV 1-Naph DMG Mono 6.6 9.8 
6.6a PCV Ph DMG Bis >50 >50 
6.6b PCV 1-Naph DMG Bis >50 >50 
6.6c GCV Ph DMG Bis 50 23.5 
6.6d GCV 1-Naph DMG Bis 45 26 
6.7a PCV Ph L-Ala Mono >50 >50 
6.7b PCV 1-Naph L-Ala Mono >50 >50 
6.7c GCV Ph L-Ala Mono 6.84 4.0 
6.7d GCV 1-Naph L-Ala Mono 11.7 8.9 
GCV - - - - 9.2 9.4 
a 50% Effective concentratio n, or compound concentration required to inhibit virus-
induced cytopathicity by 50% 
 
GCV ProTides 6.5c-d, 6.6c-d, and 6.7c-d showed good to moderate activity against 
HCMV (EC50: 4-45 µM) in comparison to the parent nucleoside.  
The 2,2-dimethylgycine benzyl ester derivative 6.5d showed retention of activity in 
comparison to the analogous L-alanine benzyl ester derivative 6.7d, while compound 
6.5c exhibited a significant decrease of potency (EC50: 38.5-15.7 µM). Also the bis-
ProTide derivatives of GCV 6.6c and 6.6d exhibited a decrease in potency (EC50: 26-50 
µM) in comparison to the mono-ProTide analogues 6.5c and 6.5d. PCV ProTides 6.5a-
b, 6.6a-b, and 6.7a-b resulted completely inactive against HCMV. Also in this case 
none of the compounds evaluated resulted cytotoxic (MCC > 100 µM).    
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6.4.4 Cytostatic activity of GCV and PCV ProTides on HEL cell cultures 
All the phosphoramidate derivatives of GCV and PCV synthesised in this work were 
evaluated for their antiproliferative activity on HEL cell cultures. The concentration 
required to reduce cell growth by 50% was above 100 µM for all the compounds 
evaluated confirming the lack of cytotoxicity, as already indicated by the microscopy 
analysis of cell morphology performed during the antiviral assays previously described.  
6.4.5 Anti-HIV activity 
Table 6.5 reports the antiviral and cytostatic activity of the GCV and PCV ProTides 
6.5b-d, 6.6c-d, and 6.7a-d against HIV-1 in MT-4 cell cultures. ACV and the L-alanine 
derivatives of ACV ProTides 3.1a and 3.1d are included as reference compounds.3  
Table 6.5. Anti-HIV and cytostatic activity in MT-4 cell cultures of GCV and PCV ProTides!
(Nuc: nucleoside; AA: amino acid moiety) 
 
Antiviral Activity 
EC50
a (µM) 
Cytostatic Activity 
IC50
b
 (µM) 
Cps Nuc Aryl AA Mono/Bis HIV-1 MT-4 Cells 
6.5b PCV 1-Naph DMG Mono 95 100 
6.5c GCV Ph DMG Mono > 150 > 150 
6.5d GCV 1-Naph DMG Mono 10 26 
6.6c GCV Ph DMG Bis 10 13 
6.6d GCV 1-Naph DMG Bis > 150 > 150 
6.7a PCV Ph L-Ala Mono 10 > 150 
6.7b PCV 1-Naph L-Ala Mono 21 100 
6.7c GCV Ph L-Ala Mono 17 20 
6.7d GCV 1-Naph L-Ala Mono 8 100 
ACV - - - - >250 >250 
3.1a ACV Ph L-Ala - 5.7 ± 1.6 33.8 ± 10.6 
3.1b ACV 1-Naph L-Ala - 0.8 >150 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50%; b 50% Inhibitory concentration, or compound concentration  required to 
inhibit cell proliferation by 50%. 
 
The results of the anti-HIV assay performed in MT-4 cell cultures show that the L-
alanine benzyl ester derivatives of GCV ProTides 6.7c and 6.7d were active against 
HIV-1 in the micromolar range (EC50= 8-17 µM). Compound 6.7c exhibited 
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antiproliferative activity on the MT-4 cells (IC50= 20 µM). However, similar cytostatic 
activity was observed also in the case of the ACV ProTide 3.1a (IC50= 33.8 ± 10.6 
µM).3 Surprisingly, the 2,2-dimethylglycine benzyl ester derivative of GCV ProTides 
6.5c resulted inactive, while the analogous derivative bearing the naphthyl group as aryl 
moiety (6.5d) exerted moderate antiviral activity against HIV-1 (EC50= 10 µM), but also 
cytostatic activity (IC50= 26 µM). Similarly, the bis-ProTide derivative 6.6d was 
inactive, while compound 6.6c exhibited antiviral and cytostatic activity.  
PCV ProTides 6.7a and 6.7b showed antiviral activity against HIV-1 in MT-4 cell 
cultures comparable to that of the analogous derivatives of GCV ProTides 6.7c and 6.7d 
and weak or no inhibition of cell proliferation. These results suggests that compounds 
6.7a and 6.7b successfully released PCV monophosphate inside MT-4 cells. The lack of 
bioactivation of the dimethylglycine benzyl ester derivative of PCV ProTides 6.5b is 
indicated by the significant loss of anti-HIV-1 activity (EC50= 95 µM) in comparison to 
the analogous L-alanine benzyl ester derivative 6.7b (EC50= 21 µM). 
The concentration that induces 50% cell death in the MT-4 cell cultures was above 150 
µM for all the compounds synthesised.  
The anti-HIV activity in CEM cell cultures of GCV and PCV ProTides is currently 
under evaluation. 
6.4.6 Summary of the biological activity of the novel aryl phosphoramidate 
derivatives of GCV and PCV 
The results of the anti-HIV activity of the newly synthesised GCV and PCV ProTides 
6.5a-d, 6.6a-d, and 6.7a-d afford structure activity relationships significantly different 
from that implied by their antiviral activity against HSV, VZV, and HCMV. As claimed 
in the case of ACV ProTides, the differences in cell-type and cell cycle between the 
antiviral assays may affect the bioactivation pathway of ProTides. 
The data on anti-herpes virus activity, in particular against TK- strains of HSV and 
VZV, show that the application of the ProTide approach to GCV successfully achieved 
the bypass of the phosphorylation step mediated by the virus-encoded kinase. This 
result strongly suggests that the mono-ProTides 6.5c-d, 6.7c-d, and surprisingly also the 
bis-ProTides 6.6c-d may be converted inside the cell according to the putative 
mechanism of bioactivation of ProTides.15  
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In comparison to the GCV ProTides presented in this work, the loss of antiviral activity 
of the analogous derivatives of PCV 6.5a-b, 6.6a-b, and 6.7a-b against the herpes 
viruses suggests that the replacement of the ether group at the side chain of the 
nucleoside moiety with a methylene group may lead to the lack of bioactivation of these 
phosphoramidate derivatives.  
Also the 6-alkoxy derivatives of PCV ProTides 6.3a and 6.3b, which have been 
previously reported by our group (fig. 6.3),4 exhibited poor activity against HSV-1 
(EC50= 38-58 µM) and HSV-2 (EC50= 20-45 µM). However, they showed retention of 
activity against TK-deficient strains of HSV-1 (EC50= 20-58 µM), while the analogous 
PCV ProTides 6.7a and 6.7b presented in this work were completely inactive (EC50= 
100 µM). Assuming that the 6-alkoxy derivatives of PCV Protides are prodrugs of PCV 
triphosphate and are deaminated after the release of the monophosphate form, as 
reported for the 6-methoxy derivative of the 2’-C-methyl-guanosine ProTide,16 this 
result suggests that 6.3a and 6.3b may be bioactivated more efficiently than 6.7a and 
6.7b. 
The data of the anti-HIV-1 assay performed in MT-4 cell cultures suggest that the L-
alanine benzyl ester derivatives of both GCV and PCV ProTides 6.7a-d successfully 
bypass the first phosphorylation step by releasing their monophasphate form. This result 
confirms the findings of the in silico study previously performed in our group, which 
indicated PCV and GCV triphosphate as potential anti-HIV agents.2 However, in the 
case of the PCV ProTide 6.7a and 6.7b these results are in contrast to the data on the 
antiviral activity against HSV, VZV, and HCMV.  
The results of the anti-HIV activity of the 2,2-dimethylglycine benzyl ester derivatives 
of GCV ProTides 6.5c-d and 6.6c-d are in contrast with those obtained against the 
herpes viruses. Indeed, 6.5c, and 6.6d were inactive, while 6.5d and 6.6c exerted 
antiproliferative activity on MT-4 cells (IC50= 13-26 µM) comparable to their  
anti-HIV-1 activity (EC50= 10 µM). Thus, the correlation of the anti-HIV activity with 
the replacement of L-alanine with 2,2-dimethylglycine at the amino acid moiety is not 
clear. The poor antiviral activity of the 2,2-dimethylglycine benzyl ester derivative of 
PCV Protide 6.5b observed in the anti-herpes virus assays was confirmed also against 
HIV-1 in MT-4 cells (EC50= 95 µM). This result suggests that in MT-4 cell cultures the 
replacement of the L-alanine with 2,2-dimethylglycine at the amino acid moiety may 
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lead to a significant decrease of anti-HIV activity. These results further support the 
notion that the ProTide motif need to be tuned on a case-by-case basis.  
6.5 Enzymatic and modeling studies 
Enzymatic and molecular modelling studies were performed in order to investigate the 
difference of antiviral activity among the GCV and PCV ProTides presented in this 
work. 
6.5.1 Study of the carboxyesterase activity  
The enzymatic study of selected derivatives of GCV and PCV ProTides was performed 
using carboxypeoptidase Y (CPY) with the aim to evaluate whether the difference of 
their antiviral activity can be correlated to the activity of this enzyme. The enzymatic 
assay was carried out following the procedure described for the ACV ProTides (chapter 
3). The L-alanine benzyl ester phosphoramidate derivatives of PCV 6.7b and GCV 6.7c 
were chosen in order to study the effect of the nucleoside on the activity of CPY. The 
same assay was performed on the 2,2-dimethylglycine benzyl ester phosphoramidate of 
GCV 6.5c in order to evaluate the effect of the amino acid moiety replacement on the 
activity of CPY by comparison with the enzymatic study performed on compound 6.7c.    
The 31P NMR spectra of the enzymatic reaction performed on compound 6.7b over the 
14 h period of incubation is depicted in figure 6.9.  
According to the putative mechanism of ProTides activation, the hydrolysis of the 
benzyl ester of 6.7b (!P= 3.95, 4.00, and 4.16 ppm) afforded the intermediate 6.26 (!P= 
5.59 and 5.67 ppm), which was converted to the corresponding phosphoramidate 
monoester 6.27 (!P= 7.49 ppm). Compound 6.7b was hydrolyzed by 50% after a 40 min 
incubation period. The conversion of 6.7b to 6.27 was not complete after 14 h from 
exposure to the enzyme and 30% of the starting material was still unreacted after this 
period, indicating that compound 6.7b is slowly converted by CPY.  
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Figure 6.9. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 6.7b 
!
The 31P NMR spectra of the enzymatic reaction performed on compound 6.7c over the 
18 h period of incubation is depicted in figure 6.10. 
!
Figure 6.10. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 6.7c 
Due to the background noise the 31P NMR spectra showed in figure 6.10 are not very 
clear. For this reason the spectra have been deconvoluted (Lorentz-Gauss 
deconvolution, Bruker TOPSPIN 2.1). Deconvolution is a mathematical processing of 
the spectrum. It allows to show only the peaks that stands out significantly from the 
noise. The advantage of this procedure is that much cleaner spectra are obtained. 
However, some peaks may be mistaken for noise and not considered in the 
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deconvoluted spectrum. Figure 6.11 shows the deconvoluted 31P NMR spectra of the 
enzymatic reaction performed on compound 6.7c. In comparison to the original spectra 
(fig. 6.10) the appearance of the signal around 4.5 ppm after 15 min from the exposure 
to CPY is clearer  
 
Figure 6.11. Deconvoluted 31P NMR spectra (acetone-D6, 202 MHz) at different time of the 
enzymatic study performed on compound 6.7c 
!
According to the putative mechanism of ProTides activation, the benzyl ester cleavage 
of compound 6.7c (!P= 3.48-3.57 ppm,) afforded the intermediate 6.28 (!P= 4.61 ppm), 
which was converted to the corresponding phosphoramidate monoester 6.29  (!P= 7.28 
ppm) (fig 6.11). Also in this case the catalytic activity of CPY was slow, as 
demonstrated by the fact that the conversion of compound 6.7c to compound 6.29 was 
not complete after the 14 h incubation period resulting in 40% of 6.7c unreacted. This 
result is surprising considering that ACV ProTides with comparable antiviral activity 
were converted very quickly by CPY, as described in chapter 3. 
 
The 31P NMR spectra of the enzymatic reaction performed on compound 6.5c over a 14 
h period of incubation is showed in figure 6.12. 
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Figure 6.12. 31P NMR spectra (acetone-D6, 202 MHz) at different time of the enzymatic study 
performed on compound 6.5c 
!
The hydrolysis of compound 6.5c (!P= 2.19-2.29 ppm, broad signal) occurred in less 
then 15 minutes from the exposure to CPY (fig. 6.12). According to the putative 
mechanism of activation of ProTides, the formation of the intermediate 6.30 resulting 
from the cleavage of the benzyl group of 6.5c!was not observed before the formation of 
the final product 6.31 (!P= 5.61 ppm, broad signal). The fast conversion of compound 
6.5c is in agreement with the results of the enzymatic studies performed on the 
analogous ACV Protide 3.2b, which was hydrolysed by CPY in less than 6 minutes and 
exhibited similar antiviral activity against HSV, VZV, and HCMV, as described in 
chapter 3. The lack of antiviral activity of compound 6.5c against HIV-1 in MT-4 cell 
cultures suggest that a different substrate affinity could occur either at the level of the 
enzyme responsible for the ester cleavage or at the level of the phosphoramidase 
enzyme responsible for the P-N bond cleavage.  
6.5.2 Docking study of L-alanine derivatives of GCV and PCV ProTides  
The modeling study of the phosphoramidate monoesters 6.27 and 6.29 (fig. 6.13) into 
the active site of the human Hint-1 enzyme co-crystallised with adenosine 
monophosphate (AMP) was performed with the aim to further investigate the 
bioactivation of the L-alanine benzyl ester phosphoramidates of GCV and PCV 
according to the putative mechanism of activation of ProTides.15, 17 Both the 
diastereomers of 6.27 and 6.29 were evaluated for their ability to fit into the active site 
of the human Hint-1 enzyme. 
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Figure 6.13 Structure of the diastereomers of compound 6.27 and 6.29 
The docking study of compound 6.29 is shown in figure 6.14.  
 
Figure 6.14. Superimposition of the diastereomers (R and S) of compound 6.29 with AMP (yellow) 
within the active site of human Hint-1 enzyme. The red arrows indicate the position of the 
phosphate group of AMP. The phosphate group of 6.29 is shown in purple. The position in the 
catalytic pocket of histidine and serine residues (His_112, His_114, and Ser_107) responsible for the 
cleavage of the P-N bond is also shown 
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Both the diastereomers (R-6.29 and S-6.29) bind quite well in the active site of the 
human Hint-1 enzyme. The guanine base and the side chain are well positioned in the 
enzymatic pocket. However, the phosphate moiety (purple) is moved from the position 
adopted by the phosphate group of AMP (yellow), as shown by the red arrow in figure 
6.14. Nevertheless, the P-N bond is in a suitable position to be cleaved by interaction 
with the histidine and serine residues of the active site according to the proposed 
mechanism of action of the human Hint-1 described in chapter 3.17, 18 
This result is in agreement with the antiviral activity found for compounds 6.7c and 
6.7d suggesting that the L-alanine derivatives of GCV Protides are able to bypass the 
first phosphorylation step by releasing the monophosphate form of the parent 
nucleoside. 
 
Figure 6.15 shows the docking study of both the diastereomers of compound 6.27 (R-
6.27 and S-6.27). The guanine base and the side chain are well positioned in the 
enzymatic pocket, as shown by the superimposition with AMP (yellow). Similarly to 
compound 6.27, the phosphate moiety (purple) is moved from the position adopted by 
the phosphate group of AMP. However, in this case the amino acid moiety has an 
orientation that appears to favour the interaction of the serine residue 107 (red circle) 
with the phosphate group (purple) rather than the amino group (blue) of compound 
6.27. Considering that the serine residue 107 is supposed to protonate the amino group 
in order to favour the elimination of the amino acid moiety,17 this study suggests that 
6.27 does not interact properly with active site of the human Hint-1 enzyme resulting in 
the missed release of the monophosphate form. This result is strongly supported by the 
inactivity of compounds 6.7a and 6.7b against HSV, VZV, and HCMV. However, the 
anti-HIV activity exhibited by these compound in MT-4 cell cultures is in contrast to 
this hypothesis. This may suggest that in MT-4 cells a different substrate affinity of the 
phosphoramidase enzyme responsible for the cleavage of the P-N bond could be 
accountable for the anti-HIV activity exerted by the L-alanine benzyl ester derivatives 
of PCV ProTides 6.7a and 6.7b. 
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Figure 6.15. Superimposition of the diastereomers (R and S) of compound 6.27 with AMP (yellow) 
within the active site of human Hint-1 enzyme. The red circles indicate the serine residue 107. The 
phosphate group of 6.27 is shown in purple. 
6.6 Conclusions 
Novel L-alanine and 2,2-dimethylglycine benzyl ester derivatives of GCV and PCV 
Protides were synthesised in this work. In particular, a synthetic route was developed in 
order to achieve the phosphorylation of only one of the two primary hydroxyl groups of 
PCV and GCV side chain. The application of this route resulted in the synthesis of the 
L-alanine benzyl ester derivatives 6.7a-d. Moreover the use of the monomethoxytrityl 
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group for the protection of GCV and PCV improved the yield at the deprotection step 
(25-30%) in comparison to that usually achieved with the N2-DMF group (4-6%). 
According to the results of the antiviral assays performed against the herpes viruses, the 
aryl phosphoramidate derivatives of GCV 6.5c-d, 6.6c-d, and 6.7c-d were successfully 
bioactivated in the cell exerting antiviral activity against HSV, VZV, and HCMV. By 
contrast, the application of the ProTide approach to PCV did not succeed in bypassing 
the first phosphorylation step. This result is confirmed by the modelling study of the L-
alanine phosphoramidate monoester derivatives of PCV and GCV 6.27 and 6.29 within 
the active site of the human Hint-1 enzyme, showing that in the case of the PCV 
derivative 6.27 the P-N bond is not in a suitable position for the cleavage.  
The anti-HIV-1 assay performed in MT-4 cell cultures afforded contrasting results. The 
L-alanine benyl ester derivatives of GCV and PCV ProTides 6.7a-d showed activity 
against HIV-1 (EC50: 8-17 µM). This result confirms the findings of the virtual 
screening previously performed in our group on the derivatives of ACV showing that 
GCV and PCV triphosphate are good candidates as inhibitors of the HIV-1 RT. This 
result also suggests that a different substrate affinity of the enzymes involved in the 
bioactivation of ProTides may occur in the MT-4 cells.    
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Chapter 7. Phosphonoamidate prodrugs of cidofovir 
7.1 Introduction 
Cidofovir (S-HPMPC), tenofovir (R-PMPA), and adefovir (PMEA) are acyclic 
nucleoside phosphonates (ANPs) that exert broad antiviral activity (fig. 7.1).1-3  
O P
O
OH
OH
CH3
N
N N
N
NH2
R-PMPA
O P
O
OH
OH
N
N N
N
NH2
PMEA
N
N
NH2
O
O P
O
OH
OH
OH
S-HPMPC  
Figure 7.1. Structures of the ANPs cidofovir, tenofovir, and adefovir 
 
In particular, cidofovir is active against a wide variety of DNA viruses including all the 
herpes viruses, poxviruses, polyomavirus, papillomavirus, and adenovirus.2 Adefovir is 
active against herpes viruses, retroviruses, and hepadnaviruses displaying the broadest 
antiviral spectrum among the series of ANPs.2 The antiviral spectrum of tenofovir is 
limited to retroviruses and hepadnaviruses.2  
This class of nucleotide analogues are characterised by the replacement of the sugar 
moiety with an acyclic chain and by the presence of a phosphonate group that mimics 
the 5’-phosphate of natural nucleotides and confers resistance against extracellular 
phosphatases.3 Inside the cell the ANPs are phosphorylated by cellular kinases to the 
diphosphate form, which in similarity to the triphosphate form of the antiviral 
nucleoside analogues inhibits the replication of the viral genome.3  
As mentioned in chapter 1, in order to overcome the poor membrane permeability of the 
ANPs, due to the negative charge of the phosphonate group, several oral prodrugs of 
this class of compounds were synthesised.4-7  
In particular, the ProTide approach was applied to tenofovir and adefovir in a previous 
study carried out in our group by Ballatore resulting in the formation of the phenyl L-
alanine methyl ester phosphonoamidate derivatives 7.1 and 7.2 (fig. 7.2) that exhibited 
improved anti-HIV activity in vitro in comparison to the parent ANPs.8  
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Figure 7.2. Structure of the phenyl L-alanine methyl ester phosphonamidate derivatives 7.1 and 7.2 
 
Also Gilead-Science investigated the aryl phosphonoamidate derivatives of ANPs 
extensively resulting in the synthesis of the prodrug of tenofovir GS-7340 (fig 7.3), 
which proved to be 500 to 1000-fold more potent than tenofovir against HIV in vitro. 
GS-7340 completed phase 1 clinical trials for the treatment of HIV infections.9  
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Figure 7.3. Structure of the phosphonoamidate prodrug GS-7340 
 
Moreover, Gilead-Science has also applied similar approach to the synthesis of 
phosphonoamidate derivatives of cyclic cidofovir (S-cHPMPC) obtaining the 
L-alanine ethyl (GS-7357 diastereomer I, GS7358 diastereomer II), phenylethyl (GS-
7356), and butyl (GS-8262) ester derivatives  (fig 7.4), which were evaluated for their 
activity against vaccinia virus (VV) and cowpox virus (CPXV).10 The two diastereomers 
of the L-alanine ethyl ester derivative (GS-7357 and GS7358) showed retention of the 
anti-poxvirus activity when compared to S-HPMPC, meanwhile compounds GS-7356 
and GS-8262 were found to be 5- to 7-fold more potent than S-HPMPC.  
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Figure 7.4. Structures of cyclic cidofovir and the L-alanine phosphonoamidate derivatives 
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As already mentioned in chapter 1, S-cHPMPC was proved to exert antiviral activity as 
prodrug of S-HPMPC.11, 12 A study reported in the literature indicated that the cellular 
cyclic cytidine monophosphate (cCMP) phosphodiesterase is the intracellular enzyme 
responsible for the release of S-HPMPC by cleavage of the phosphodiester bond of  
S-cHPMPC.13 However, no studies regarding the metabolism of the phosphonoamidate 
derivatives of S-cHPMPC were reported. 
More recently, the phosphonodiamidate pronucleotide approach, which shares a similar 
mechanism of activation with ProTides,14 have been applied to the antiproliferative 
agent 9-(2-phosphonomethoxyethyl)-N6-cyclopropyl-2,6,diaminopurine (cPrPMEDAP) 
by Gilead-Science, resulting in the synthesis of the phosphonodiamidate derivative GS-
9191 (fig 7.5), now in phase 1 clinical trials for the topical treatment of human 
papillomavirus-induced lesions.15  
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Figure 7.5. Structure of the phosphonodiamidate derivative GS-9191 
 
These studies show that the amidate derivatives of ANPs succesfully overcome the poor 
membrane permeability of the parent drugs. For this reason, the purpose of this study is 
the synthesis of the amidate derivatives of S-HPMPC and  
S-cHPMPC and the evaluation of their biological activity. 
7.2 Design of amidate derivatives cidofovir and cyclic cidofovir  
As a first example of the synthesis of diamidate prodrugs of S-HPMPC the L-alanine 
benzyl ester phosphonodiamidate 7.3 was planned (fig 7.6). L-alanine was chosen as 
masking group on the basis of the results obtained in our lab on the anti-HIV activity of 
adefovir and tenofovir ProTides.8 The benzyl ester was selected on the basis of studies 
reported in chapter 3 on acyclovir ProTides.   
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Figure 7.6. Structure of the phosphonodiamidate 7.3 
 
The phosphonoamidates GS-7356 and GS-8262 (fig. 7.4) were proved to be more 
effective against VV and CPXV than S-HPMPC also suggesting that the amidate 
derivatives of S-cHPMPC successfully improve the cellular uptake of cidofovir.10 The 
synthesis of the phosphonoamidate derivative of S-cHPMPC 7.4 was thus also 
considered (fig. 7.7). 
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Figure 7.7. Structure of the phosphonoamidate 7.4. 
7.2.1 Synthesis of the diamidate derivatives of cidofovir  
The synthesis of adefovir and tenofovir ProTides was previously developed in our lab.8 
It is based on the replacement of the hydroxyl groups at the phosphonate moiety with 
chlorine atoms, which then act as leaving groups in the nucleophilic substitutions of the 
phosphorochloridate intermediates 7.5-7.8 with the aryloxy and the amino acid ester, 
affording the aryl phosphonamidate derivatives 7.1 and 7.2 (scheme 7.1). However, this 
methodology afforded the ProTides in extremely low yield (5%). 
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Scheme 7.1. Synthetic route of amidate derivatives of tenofovir and adefovir described by Ballatore 
et al. (from ref. 8) 
 
An alternative synthetic route has been reported for the synthesis of the aryl 
phosphonoamidate and phosphonodiamidate derivatives of the cyclic nucleoside 
phosphonate GS-9148 and the antiproliferative agent cPrPMEDAP by Gilead-
Science.16, 17 The synthesis of a generic diamidate derivative of cPrPMEDAP, performed 
according to this strategy, is depicted in scheme 7.2. The free phosphonic acid is 
activated toward the nucleophilic attack of the amino derivative (NH2R) by oxidation-
reduction condensation with 2,2’-dithiophyridine ((PyS)2) and triphenylphosphine 
(PPh3) affording the S,S-di-2-pyridyl-dithiophosphonate intermediate 7.9,  where the 
pyridylthio group is replaced by the nucleophilic species leading to the product 7.10.18  
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Scheme 7.2. Synthetic route of the diamidate derivatives of cPrPMEDAP (7.10) 
 
The yields of the reaction are variable (11-74%) and may depend on the nature of the 
amino acid,19 but in general they were higher than the yields achieved through the 
Ballatore procedure. For this reason, we decide to apply this methodology also to the 
synthesis of 7.3. However, using S-HPMPC as starting material the desired product was 
not obtained under these conditions. 
In a study previously reported, the synthesis of the morpholide derivative of  
S-HPMPC (7.11) was investigated as intermediate for the preparation of the 
diphosphoryl derivative (7.12).20 Indeed, the standard procedure for the synthesis of 
triphosphate nucleoside analogues consists in conversion of the monophosphate 
derivative into its activate intermediate morpholide or imidazolide in the presence of 
1,3-dicyclohexylcarbodiimide (DCC) as coupling regent followed by the reaction of the 
residue with inorganic diphosphate.21,22 However, the synthesis of the morpholide 
derivative of S-HPMPC (7.12) was not succesful under these conditions and the internal 
cyclisation of the hydroxymethylene group with the phosphorus occurred affording 
instead the cyclic derivative of S-HPMPC (scheme 7.3).20  
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Scheme 7.3. Attempted synthesis of the diphosphoryl derivative of cidofovir (7.12) through the 
morpholide intermediate 7.11 resulting in the formation of cyclic cidofovir (from ref. 20) 
 
The synthesis of the morpholide intermediate (7.14) and thus the diphosphate derivative 
7.12 was accomplished by protecting the primary hydroxyl group of  
S-HPMPC with the dimethoxytrityl group (DMTr) (7.13) (scheme 7.4).20 
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Reagents and conditions: (i) TBA, methanol, rt; (ii) DMMTr-Cl, DMSO, rt, 3 h; (iii) morpholine, 
DCC, 2-methylpropan-2-ol, reflux; (iv) (Bu3NH)2H2P2O7, DMSO; (v) HCl  
Scheme 7.4. Synthesis of the diphosphoryl derivative of cidofovir by means of hydroxymethylene 
tritylation (from ref. 20) 
 
Moreover, during the synthesis of the phenyl ester derivative of S-cHPMPC (7.16) the 
phosphorochloridate 7.15 was obtained starting from cidofovir under the conditions of 
the Vilsmeier reaction (scheme 7.5).23 This result confirms that the activation of the 
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phosphonic acid, by introduction of a good leaving group, induces intramolecular 
cyclisation with the hydroxymethylene group.  
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7.5. Synthesis of salicylate and aryl ester derivatives 198a-l (from ref. 23)  
 
Considering these studies, it appeared necessary first to protect the hydroxymethylene 
group of the side chain of S-HPMPC in order to prepare the diamidate derivative 7.3.  
Following a literature procedure,20  the tritylation of the tributylammonium salt of S-
HPMPC (7.17) afforded compound 7.18 in 32% yield as a free acid (scheme 7.6).  
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Scheme 7.6. Tritylation of the primary hydroxyl group of S-HPMPC 
 
The phosphonate 7.18 was treated with an excess of L-alanine benzyl ester (6 eq) in the 
presence of triethylamine (12 eq) in anhydrous pyridine at 60 °C under argon 
atmosphere. Addition of a solution of 2,2’-dithiopyridine (7 eq) and triphenylphosphine 
(7 eq) in pyridine at 60 °C afforded compound 7.19 in 20% yield (scheme 7.7). 
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Scheme 7.7 Synthesis of the diamidate derivative of S-HPMPC (7.19) 
 
The detritylation of compound 7.19 was attempted using 5 equivalents of p-
toluensulfonic acid (TsOH) in a mixture of dichloromethane and methanol at room 
temperature, as previously described for GCV and PCV (scheme 7.8). Unfortunately, 
the desired product 7.4 was not obtained. After 1 h the starting material had not reacted. 
An additional 2.5 equivalents of TsOH led to the degradation of 7.19.  
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Scheme 7.8. Detritylation of compound 7.19 
 
More recently, the improvement in the synthesis of diamidate prodrugs of ANPs was 
reported in the literature.19 According to this strategy, the dialkyl phosphonate ester 
derivative of ANPs (7.20) was silylated with trimethylsilyl bromide (TMS-Br) affording 
the intermediate 7.21 (scheme 7.9), which was used in the next step without any 
purification. The reaction of the bis(trimethylsilyl) ester derivative 7.21 with 2,2'-
dithiopyridine and triphenylphosphine in the presence of an excess of the amino acid 
ester (NH2R) yielded the diamidate derivative of ANPs 7.22 (scheme 7.9) with 
improved yield (83-98%) when compared with those obtained with the same procedure 
starting from the free phosphonic acid (50-70%).  
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Scheme 7.9. General synthetic route of diamidate prodrugs of ANPs starting from the dialkyl ester 
derivative 
 
The application of this approach to the synthesis of the diamidate derivative of 
S-HPMPC 7.24 required (S)-N
1
-[(3-triphenylmethoxy-2-diethylphosphonylmethoxy)-
propyl)]cytosine (7.23) as starting material (scheme 7.10).  
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Reagents and conditions: (i) TMSBr, 2,6-lutidine, anhydrous ACN; (ii) L-ala-O-Bn, 
TEA, anhydrous Pyr, 60°C, 20 min; (iii) (PyS)2, PPh3, anhydrous Pyr, 60°C, 16 h  
Scheme 7.10. General synthetic route of the diamidate derivative of S-HPMPC (7.24) starting from 
(S)-N1-[(3-triphenylmethoxy-2-diethylphosphonylmethoxy)-propyl)]-cytosine (7.23) 
 
For this purpose, the synthesis of compound 7.23 was performed. Following the 
procedure described in the literature,24, 25 (R)-glycidol (7.25) was protected using trityl 
chloride (TrCl) in the presence of TEA under argon atmosphere (i, scheme 7.11). The 
epoxy ring of the trityl derivative 7.26 was opened by reaction with cytosine (Cyt) and 
K2CO3 in DMF at 105 °C affording compound 7.27 in 71% yield (ii, scheme 7.11). The 
N
4-benzoyl derivative 7.28 was obtained in 83% yield protecting 7.27 with benzoic 
anhydride at 100 °C (iii, scheme 7.11).  
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Scheme 7.11. Synthesis of the intermediate 7.28 
 
The tosylation of the diethyl(hydroxymethyl)phosphonate 7.29 was performed using p-
toluensulfonyl chloride (TosCl) in the presence of DMAP and TEA and affording 
compound 7.30 in 61% yield (scheme 7.12). 
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Scheme 7.12. Tosylation of diethyl-(hydroxymethyl)-phosphonate (7.29) 
 
The coupling reaction of the tosyl derivative 7.30 with compound 7.28 in the presence 
of NaH at 5° C under argon atmosphere yielded the fully protected derivative of 
cidofovir 7.31 (i, scheme 7.13). Debenzoylation of 7.31 was performed using 
methanolic ammonia and afforded compound 7.23 in 95% yield (ii, scheme 7.13).  
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Scheme 7.13 Synthesis of N1-[(3-triphenylmethoxy-2-diethylphosphonylmethoxy)-propyl)]-cytosine 
(7.23) 
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According to the strategy previously described,19, 26 the diethyl ester derivative 7.23 was 
silylated using trimethylsilyl bromide (TMSBr) in the presence of 2,6-lutidine under 
argon atmosphere (i, scheme 6.14). The crude of the reaction, without further 
purification, was treated with an excess of L-alanine benzyl ester (L-Ala-O-Bn) in 
anhydrous pyridine at 60 °C (ii, scheme 7.14), then a solution of 2,2'-dithiopyridine and 
triphenylphosphine in anhydrous pyridine was added (iii, scheme 7.14). Unfortunately 
the desired product (7.24) was not detected by mass spectrometry analysis of the crude 
of reaction.  
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Scheme 7.14. Synthesis of the diamidate derivative of S-HPMPC through silylation of the diethyl 
ester derivative 7.23 
 
In conclusion, the synthesis of the phosphonodiamidate 7.3 was not achieved perhaps 
due to the interference of the hydroxymethylene group of S-HPMPC and the 
unsuitability of its protection with the trityl group.  
7.2.2 Synthesis of the amidate derivatives of cyclic cidofovir  
Finally, the synthesis of the amidate derivative of S-cHPMPC (7.4) was performed. 
Following the procedure described in the literature,27 the treatment of S-HPMPC with 
N,N-dicyclohexyl-4-morpholinecarboxamidine (DCMC) and 1,3-
dicyclohexylcarbodiimide (DCC) afforded S-cHPMPC as dicyclohexyl-
morpholinocarboxamidine salt in 50% yield (scheme 7.15). The reaction of  
S-cHPMPC with an excess of L-alanine benzyl ester in presence of 2,2'-dithiopyridine 
and triphenylphosphine in anhydrous pyridine at 60 °C afforded compound 7.4 in 30% 
yield as a mixture of two diastereomers (scheme 7.15). 
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Scheme 7.15 Synthesis of the phosphonoamidate derivative 7.4 
7.3 Biological evaluation of the amidate derivative of cyclic cidofovir 
The amidate derivative of cyclic cidofovir 7.4 was evaluated for its activity against 
HSV, VZV, HCMV, and poxviruses such as vaccinia virus (VV), cowpox virus 
(CPXV), and camelpox virus (CMLV). The antirpoliferative activity of this compound 
on HEL cell cultures was also evaluated.  
7.3.1 Anti-HSV activity  
Table 7.1 reports the antiviral activity of 7.4 against HSV-1, HSV-2, and thymidine 
kinase-deficient (TK-) HSV-1 in HEL cells. The anti-HSV activity of the parent 
compound, cyclic cidofovir (S-cHPMPC), was also evaluated. Cidofovir (S-HPMPC) 
and acyclovir (ACV) are included as reference compounds. 
Table 7.1 Anti-HSV activity of S-cHPMPC and its phosphonamidate derivative 7.4 in HEL cells 
 Antiviral Activity EC50
a (µM) 
Cps HSV-1 HSV-2 TK- HSV-1  
7.4 0.3 0.4 0.2 
S-cHPMPC 0.8 1.2 0.5 
S-HPMPC 0.8 N.D. 0.6 
ACV 0.5 0.4 >222 
a 50% Effective concentration, or compound concentration required to 
inhibit virus-induced cytopathicity by 50% 
 
ACV, S-HPMPC and S-cHPMPC showed antiviral activity against HSV-1 and HSV-2 
confirming the results reported in the literature.3, 11, 28 As already described in chapter 1, 
inside the cell S-cHPMPC is converted to S-HPMPC by the cCMP phosphodiesterase-
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mediated cleavage of its phosphodiester bond,11 thus the antiviral activity of S-cHPMPC 
is due to the release of the diphosphate derivative of S-HPMPC as the active form.11 
Due to the presence of the phosphonate group, S-HPMPC and its prodrug S-cHPMPC, 
akin to monophosphate nucleoside analogues, do not require the HSV-TK-mediated 
phosphorylation to be bioactivated thus retaining activity also against TK—HSV-1 
(EC50= 0.20-0.65 µM), while ACV is completely inactive.  
The phosphonoamidate derivative 7.4 exhibited anti-HSV activity in the submicromolar 
range (EC50= 0.20-0.40 µM) retaining the activity of the parent compound S-cHPMPC. 
The concentration required to cause a microscopically visible alteration of cell 
morphology (MCC) was found above 100 µM for 7.4, as well as S-cHPMPC and S-
HPMPC. 
7.3.2 Anti-VZV activity  
The antiviral activity of compounds 7.4 and its parent compound S-cHPMPC against 
TK-positive (TK+) and TK-deficient (TK-) strains of VZV are reported in table 7.2. 
ACV is included as a reference compound. 
Table 7.2. Anti-VZV activity of S-cHPMPC and its phosphonamidate derivative 7.4 in HEL cells 
 Antiviral Activity EC50
a (µM) 
 TK+ VZV strains TK- VZV strains 
Cps YS OKA 07-1 YS/R 
7.4 N.D.c 0.14 0.16 0.16 
S-cHPMPC N.D.c 0.25 0.49 0.28 
ACV N.D.c 2.55 182 N.D.c 
a 50% Effective concentration, or compound concentration required to reduce virus 
plaque formation by 50% 
 
S-cHPMPC exhibited antiviral activity in the submicromolar range against both TK+ 
and TK- strains of VZV (EC50= 0.25-0.49 µM), while ACV lost its activity against TK
- 
VZV (EC50= 182 µM) due to the lack of virus-encoded TK required for phosphorylation 
to its monophosphate form.  
The phosphonoamidate derivative 7.4 retained the anti-VZV activity of the parent 
compound (S-cHPMPC) against both TK+ and TK- strains (EC50= 0.14-0.16 µM).  
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The minimum concentration of 7.4 required to cause a microscopically visible alteration 
of cell morphology was found to be above 100 µM  
7.3.3 Anti-HCMV activity  
Table 7.3 reports the antiviral activity of S-cHPMPC and its phosphonoamidate 
derivative 7.4 against AD-169 and Davis strains of HCMV in HEL cell cultures. GCV 
and S-HPMPC are included as reference compounds. 
Table 7.3. Anti-HCMV activity of S-cHPMPC and its phosphonamidate derivative 7.4 in HEL cells 
 Antiviral Activity EC50
 a
 (µM)
 
Cps AD-169 strain Davis strain 
7.4 0.42 0.22 
S-cHPMPC 1.1 0.61 
S-HPMPC 0.97 0.69 
GCV 11.38 4.45 
a 50% Effective concentration, or compound concentration required to reduce 
virus plaque formation by 50% 
 
In agreement with the studies reported in the literature,3, 29 S-HPMPC and S-cHPMPC 
were active against HCMV displaying similar potency.  
Compound 7.4 exerted anti-HCMV activity in the submicromolar range (EC50= 0.22-
0.42 µM) showing retention of activity in comparison to S-HPMPC and S-cHPMPC.  
Also in this antiviral assay, microscopy analysis of the cell culture revealed that the 
minimum concentration of 7.4 required to cause alteration of cell morphology was 
above 100 µM.  
7.3.4 Anti-poxvirus activity  
The phosphonoamidate 7.4 and its parent compound S-cHPMPC were evaluated for 
their antiviral activity against Lederle and Western Reserve strains of vaccinia virus 
(VV), Brighton strain of cowpox virus (CPXV), and CMLV-1 strain of camelpox virusv 
(CMLV) in HEL cell cultures (table 7.4). Also S-HPMPC was evaluated for its anti-
poxvirus activity and these results were compared with data reported in the literature.30  
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Table 7.4. Anti-poxvirus activity of S-cHPMPC and phosphonamidate derivative 7.4 in HEL cells 
 Antiviral Activity EC50
 a
 (µM)
 
 VV  CPXV CMLV 
Cps 
Lederle  
strain  
Western 
Reserve strain 
Brighton 
strain 
CMLV-1 
strain 
7.4 0.94 2.0 2.38 2.15 
S-cHPMPC 2.57 10.10 4.52 4.10 
S-HPMPC 3.48 9.17 7.48 8.20 
a 50% Effective concentration, or compound concentration required to inhibit virus-induced 
cytopathicity by 50% 
 
S-HPMPC exhibited anti-poxvirus activity in the micromolar range confirming the 
results reported in the literature,30 S-cHPMPC retained the antiviral activity of  
S-HPMPC against VV, CPXV, and CMLV. 
As already observed in antiviral assays against the herpes viruses, the 
phosphonoamidate derivative 7.4 exhibited retention of activity in comparison to S-
HPMPC and S-cHPMPC.  
7.3.5 Cytostatic activity of the amidate derivative of cyclic cidofovir on HEL cell 
cultures 
The cytostatic activity on HEL cell cultures of 7.4 and its parent compound S-cHPMPC 
is reported in table 7.5.  
These data include S-HPMPC, ACV, and GCV as reference compounds. 
Table 7.5. Cytostatic activity of S-cHPMPC and its phosphonamidate derivative 7.4 
 Cytostatic Activity IC50
 a (µM)  
Cps HEL Cells 
7.4 53 
S-cHPMPC 240 
S-HPMPC 330 
ACV >1778 
GCV 520 
a 50% Inhibitory concentration or compound concentration 
required to reduce cell proliferation by 50% 
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S-HPMPC, S-cHPMPC, ACV, and GCV exerted cytostatic activity only at high 
concentrations. 
The amidate derivative of S-cHPMPC 7.4 exhibited moderate antiproliferative activity 
on HEL cell cultures (IC50= 53 µM). As already described for the 6-alkoxy derivatives 
of ACV ProTide (chapter 4), it must be pointed out that the inhibition of cell growth 
was evaluated in non-confluent and highly proliferating HEL cells, while the antiviral 
assays previously described were performed on confluent resting HEL cells. It could be 
assumed that the higher metabolism of proliferating HEL cell may affect positively the 
bioactivation of 7.4. Improvement in the bioactivation and cellular uptake, due to the 
masking of the negative charge of the phosphonate group, could account for the 
cytostatic activity of 7.4 detected in this assay.  
7.3.6 Summary of the biological activity of the phosphonoamidate derivative of 
cyclic cidofovir 
The results of the antiviral assays against herpes viruses (HSV, VZV, and HCMV) and 
poxivruses (VV, CPXV, CMLV) indicate that the phosphonoamidate derivative 7.4 
released cyclic cidofovir, which was then converted inside the cell to cidofovir and its 
active form cidofovir diphosphate according to the metabolic pathway already described 
in the literature.2,3,11,13 No significant improvement in the antiviral activity was observed 
compared to cidofovir and cyclic cidofovir. However, it must be pointed out that the 
improvement of the antiviral activity against poxvirus of analogous derivatives of cyclic 
cidofovir previously reported in the literature was observed in human foreskin fibroblast 
cell cultures, while the antiviral activity of 7.4 was evaluated in non-proliferating HEL 
cells.10 The uptake, activation and conversion steps of this class of prodrugs may be 
dependent on the nature of the cell line and its metabolism, as also suggested by the 
cytostatic activity exerted by 7.4 on highly proliferating HEL cells (IC50= 53 µM).  
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7.4 Enzymatic and modeling studies 
Enzymatic and molecular modelling studies were performed in order to investigate the 
mechanism of activation of 7.4.  
7.4.1 Study of the carboxyesterase activity 
In order to evaluate whether 7.4 could be processed following the same mechanism of 
bioactivation of phosphonoamidate prodrugs of ANPs,9, 31 an enzymatic study was 
performed using carboxypeptidase Y (CPY) according to the procedure described in 
chapter 3. 
Figure 7.8 depicts the 31P NMR spectra and the proposed metabolic pathway of the 
enzymatic reaction performed on compound 7.4 over a 20 h period of incubation. The 
31P NMR spectra of compound 7.4 in deuterated acetone (acetone-d6) and phosphate 
buffer (pH= 7.6) showed two peaks at 17.80 and 18.98 ppm (blank, fig. 7.8A) 
corresponding to the two diastereomers (Sp and Rp). The mixture of diastereomers was 
not separated, so it was not possible to correlate the absolute configuration at the 
phosphorus center with the 31P NMR signals. Normalisation of the integrals to the total 
sum of the spectrum was carried out on the data and used as an indicator for the relative 
abundance of the two diastereomers. The relative abundance in the blank of the 
diastereomers of 7.4 was 54% (!P = 17.80 ppm) and 46% (!P = 18.98 ppm) (fig. 7.8A). 
The 31P NMR spectra at different time of the enzymatic study showed that:  
• After 15 min from the exposure to the CPY, two peaks appeared at 18.39 ppm 
and 19.47 ppm. They may be tentatively correlated to the hydrolysis of the 
benzyl ester of compound 7.4 affording the intermediate 7.34 (fig. 7.8B).  
• After 180 min from exposure to CPY, normalisation of the integrals to the total 
sum of the spectrum showed that the relative abundance of the two 
diastereomers of 7.4 was 17% (!P = 17.80 ppm) and 30% (!P = 18.98 ppm). 
Comparing this data with the relative abundance of the two diastereomers in the 
blank, the diastereomer corresponding to the signal at 17.80 ppm was found to 
be processed faster than the diastereomer corresponding to the signal at 18.98 
ppm. 
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• After the 20 h period of incubation, the diastereomers of compound 7.4 with 
chemical shift at 17.80 ppm was completely processed, while 20% of the initial 
amount of the other (!P= 18.98 ppm) was still unreacted (fig. 7.8A).  
The enzymatic reaction afforded two metabolites that displayed 31P NMR signals at 
17.17 ppm and 8.22 ppm, respectively (fig. 7.8A).  
 
Figure 7.8. 31P NMR spectra (acetone-D6, 202 MHz) and (B) proposed methabolic pathway of the 
enzymatic study performed on compound 7.4 
 
After this period, the solution of the enzymatic reaction was treated with methanol, 
causing denaturation of the enzyme, and centrifuged.32 The mass analysis performed on 
the supernatant liquid strongly suggests that one of the metabolites was S-cHPMPC (fig. 
7.9). From the 31P NMR experiment performed on S-cHPMPC in deuterated methanol, 
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this metabolite can be correlated to the signal at 8.22 ppm (fig. 7.8A). The mass 
analysis revealed also that the other metabolite with 31P NMR signal at 17.17 ppm (fig. 
7.8A) was the L-alanine conjugate of cidofovir (7.35), while the 31P NMR signal at 
18.98 (fig. 7.8A) is correlated to the unreacted diastereomer of 7.4 (fig. 7.9).  
 
Figure 7.9. Mass analysis in positive mode (A) and negative mode (B) performed on the supernatant 
liquid of the enzymatic reaction after CPY denaturation with methanol and centrifugation 
These results are in agreement to some extent with the metabolic study of the 
phosphonamidate prodrug GS-7340 reported in the literature showing that the 
cathepsin-A-mediated cleavage of the ester moiety, which affords the intermediate 7.36, 
leads to formation of the metabolite 7.37 according to the putative mechanism of 
activation depicted in scheme 7.16.9, 31, 33  
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Scheme 7.16 Proposed mechanism of activation of GS-7340 mediated by cathepsin A (from ref.10, 
32, 34)  
It may be tentatively assumed that similar mechanism of reaction also occurs in the case 
of 7.4 in the presence of CPY leading to the formation of the metabolite 7.34 (scheme 
7.17).  
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Scheme 7.17 Proposed mechanism of reaction of 7.4 mediated by CPY 
The faster metabolism observed for one diastereomer over the other points out the role 
of the phosphorus stereochemistry in the bioactivation process. In analogy with this 
result, the half life of the Rp diastereomer of phenyl L-alanine isopropyl ester derivative 
of tenofovir (GS-7339) in MT-2 cell cultures (t1/2>1000 min.) has been reported to be 
longer in comparison to the Sp diastereomer GS-7340 (t1/2= 28.3 ± 7.4 min.) indicating a 
slower conversion to tenofovir as suggested by the 12-fold higher anti-HIV-1 activity of 
GS-7340 compared to that of GS-7339.9 However, it must be taken into consideration 
that the stability study of the two diastereomers of salicylate phosphoester prodrugs of 
S-cHPMPC (7.36) in buffer solution at pH 7.4 and 37 °C, previously reported in the 
literature, showed that exocyclic and endocyclic hydrolysis of the P-O bond occur 
resulting in the formation of S-cHPMPC and the monoester derivative of S-HPMPC 
7.37, respectively (scheme 7.18).23 Therefore, the chemical hydrolysis of the endocyclic 
P-O bond of compound 7.4 cannot be ruled out. This could also explain the formation 
of cyclic cidofovir detected during the enzymatic assay of 7.4 performed in the presence 
of CPY (fig 7.8). 
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Scheme 7.18.  Chemical hydrolysis of the salicylate phosphoester derivatives of cyclic cidofovir 
(7.36) at pH 7.4 and 37 ºC. 
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7.4.2 Docking of the L-alanine benzyl ester derivative of cyclic cidofovir within the 
active site of carboxypetidase Y. 
A modeling study of 7.4 was performed using a crystal structure of CPY in order to 
investigate the interaction of the benzyl ester group with the residues of the catalytic site 
responsible for the carboxylester cleavage. Moreover this study meant to detect any 
difference of orientation of the ester moiety in an attempt to explain the lower reactivity 
of one diastereomer over the other in the enzymatic assay previously described (fig. 
7.8).  
The conformational study performed on salicylate and aryl phosphoester derivatives of 
S-cHPMPC previously described in the literature has shown that the 6-membered 
phosphonate ring of cyclic cidofovir adopts a chair conformation with the cytosine 
preferentially in an equatorial position.23 However, it was also proved that in same cases 
the nucleobase of analogous compounds can be crystallised in axial position, and that in 
solution there could be an equilibrium between two different chair conformations where 
the nucleobase alternates between axial and equatorial position.34  
The separation of the mixture of diastereomers was not achieved during the purification 
process of 7.4. For this reason, it was not possible to carry out the studies of the crystal 
structure and NMR coupling constants required to assign the relative conformation of 
the phosphonate ring of each diastereomer. Thus, we assumed that the 6-membered 
phosphonate ring of 7.4 adopts a chair conformation with the cytosine in equatorial 
position placing the amino acid moiety at the phosphonate group in axial position in the 
case of the Rp diastereomer (7.4ax) and in the equatorial position in the case of the Sp 
diastereomer (7.4eq) (fig. 7.10), based on previous studies led on the salicylate and aryl 
phosphoester derivatives of S-cHPMPC.23  
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Figure 7.10 Chair conformations of Rp and Sp diastereomers of  7.4 
 
Figure 7.11 shows the docking of both phosphate diastereomers (Rp and Sp) of 7.4 
within the active site of the CPY enzyme. 
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Figure 7.11 Docking of (A) Rp and (B) Sp diastereomers of 7.4 within the active site of CPY. The 
red arrows indicate the position of the carboxylester group 
 
The carboxyl group of the Rp diastereomer, indicated by the red arrow in figure 7.11A, 
is oriented in the opposite direction compared to the carboxyl group of Sp diastereomer 
(fig. 7.11B) affecting the interaction with the glycine  (Gly52 and Gly53) and serine 
(Ser146) residues, which are responsible for the benzyl ester cleavage, as already 
describe in chapter 3.35 Indeed, in the case of the Rp diastereomer the carboxyl group 
points toward the glycine and serine residues resulting in a suitable position for them to 
interact properly (fig 7.12A). By contrast, in the case of the Sp diastereomer the 
orientation of the carboxyl group does not favour a positive interaction with these 
residues (fig 7.12B).  
 
Figure 7.12 Detail of the docking of (A) Rp and (B) Sp diastereomers of 7.4 within the active site of 
the CPY enzyme showing the orientation and the distance in angstroms of the carboxyl group 
toward the glycine and the serine residues (Gly_52, Gly_53, and Ser_146) responsible for the benzyl 
ester cleavage. 
Assuming that 7.4 is converted to 7.35 by carboxypeptidase Y according to the 
mechanism proposed in scheme 7.17, these results are in agreement with the enzymatic 
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study previously described (fig. 7.8) showing that one of the two diastereomers of 7.4 is 
processed faster than the other. Moreover this study suggests that the Rp diastereomer 
may be processed faster than the Sp diastereomer.  
7.4.3 Docking of the L-alanine conjugate of cidofovir within the active site of  
Hint-1 enzyme 
According to the putative mechanism of activation of ProTides, the hydrolysis of the 
ester moiety of the aryl phosphoramidate derivatives, which leads to the elimination of 
the aryl group, is followed by the cleavage of the P—N bond.36 In the case of 
phosphonoamidate and phosphonodiamidate derivatives of ANPs, this last step was 
investigated affording two possible mechanisms of reaction:37  
• Chemical hydrolysis at acidic pH 
• Enzymatic hydrolysis mediated by a phosphoramidase-type enzyme such as the 
human Hint-1  
In particular, it was proved that the L-alanine conjugate of tenofovir 7.37 (matabolite of 
the phosphonoamidate derivative GS-7340 in the presence of cathepsin A) was 
converted to R-PMPA with a half life of 49 min at pH 4.5, while it was stable in the 
presence of human Hint-1 at pH 7.2 (scheme 7.19). Instead, the analogous L-alanine 
conjugate of cPrPMEDAP 7.38 was successfully converted by both chemical hydrolysis 
at acidic pH and human Hint-1-mediated cleavage of the P-N bond affording 
cPrPMEDAP as product and suggesting that both mechanisms of action could be 
involved in the conversion of the prodrug (scheme 7.19).37  
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Scheme 7.19 Half-lives (t1/2) of nucleotide-amino acid conjugates 7.38 and 7.39 at pH 4.5 and in the 
presence of Hint-1 (from ref. 37)  
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The modelling study of the L-alanine conjugate of S-HPMPC (7.35) was performed 
within the active site of human Hint-1 enzyme co-crystallised with adenosine 
monophosphate (AMP) using docking techniques in order to evaluate whether this 
phosphoramidase-type enyme may be involved in the bioactivation of the 
phosphonoamidate of S-cHPMPC (fig 7.13).  
 
Figure 7.13 Superimposition of compound 7.35 with AMP (yellow) within the active site of human 
Hint-1 enzyme. The red circle highlights the phosphate moiety of AMP. The red arrows indicate the 
position of the residues of serine 107 (Ser_107), hisitidine 112 (His_112), and histidine 114 
(His_114) involved in the cleavage of the P-N bond of compound 7.35 according to the mechanism 
of action of the Hint enzyme.38  
 
The superimposition of 7.35 with AMP (shown in yellow in fig 7.13) within the 
enzymatic pocket of Hint-1 shows that the phosphorus of 7.35 (shown in purple in fig 
7.13) is placed in a completely different position in comparison to the phosphate group 
of AMP (highlighted by the red circle in fig 7.13). As a result, the P-N bond of 7.35 is 
not in a suitable position to interact with the serine and histidine residues (indicated by 
the red arrows in fig. 7.13), which are responsible for its cleavage according to the 
mechanism of action of human Hint-1 enzyme.38 The result of this study strongly 
suggests that 7.35 is a poor substrate for human Hint-1 and could be converted to 
cidofovir by chemical hydrolysis of the P-N bond at acidic pH, typical of lysosomes, as 
previously reported in the case of GS-7340.37 In order to validate the modelling study, 
the docking of L-alanine conjugates of R-PMPA (7.37) and cPrPMEDAP (7.38) within 
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the active site of Hint-1 enzyme co-crystallised with AMP was carried out confirming 
the results previously reported in the literature (scheme 7.19).37 In particular, the 
docking of the L-alanine conjugate of cPrPMEDAP (7.38) within the active site of 
human Hint-1 (fig. 7.14) shows that the nucleobase fits quite well into the enzymatic 
pocket adopting a position similar to that of AMP (shown in yellow), while the 
phosphonate moiety of 7.38 (purple) is moved from the position adopted by the 
phosphate group of AMP (highlighted by the red circle).  
 
Figure 7.14 Superimposition of compound 7.38 with AMP (yellow) within the active site of human 
Hint-1 enzyme. The red circle highlights the phosphate moiety of AMP. The red arrows indicate the 
position of the residues of serine 107 (Ser_107), hisitidine 112 (His_112), and histidine 114 
(His_114) involved in the cleavage of the P-N bond of compound 7.39 according to the mechanism 
of action of the Hint enzyme.38  
 
Nevertheless, the P-N bond is in a suitable position to interact with serine and histidine 
residues, which are responsible for its cleavage, as also indicated more specifically in 
figure 7.15. 
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Figure 7.15. Detail of the docking of 7.38 within the active site of Hint-1 showing the orientation 
and the distance in angstroms of the P-N bond (purple and blue) toward the histidine and the serine 
residues (His-51, His-112, His 114, and Ser_107) responsible for its cleavage.  
 
To the contrary, the phosphonate group of 7.37, like in the case of 7.35, is placed in a 
totally different position within the active site of human Hint-1 in comparison to AMP 
resulting in an unsuitable position to interact with the serine residue 107 and histidine 
residues 112 and 114 (fig. 7.16).  
 
Figure 7.16. Superimposition of compound 7.37 with AMP (yellow) within the active site of human 
Hint-1 enzyme. The red circle highlights the phosphate moiety of AMP. The red arrows indicate the 
position of the residues of serine 107 (Ser_107), hisitidine 112 (His_112), and histidine 114 
(His_114) involved in the cleavage of the P-N bond according to the mechanism of action of the 
Hint enzyme.38  
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7.5 Conclusion 
The phosphonoamidate prodrugs of cidofovir were considered as a possible strategy to 
overcome the poor membrane permeability of the parent compound. The L-alanine 
benzyl ester derivative of cyclic cidofovir (7.4) was synthesised. Unfortunately the 
synthesis of the analogous phosphonodiamidate derivative of cidofovir (7.3) was not 
achieved. This result suggests that a different protective group of the hydroxymethylene 
side chain of cidofovir should be used in order to obtain the phosphonodiamidate 
derivatives of cidofovir. 
The biological results show retention of antiviral activity of 7.4 against herpes viruses 
and poxviruses indicating the release of cidofovir inside the cell. No cytotoxic effects 
were observed during the antiviral assays by microscopy analysis of cell morphology. 
However, a moderate cytostatic activity was observed in proliferating HEL cells. This 
effect may be explained by improvement of cellular uptake of 7.4 in comparison to S-
cHPMPC and S-HPMPC. 
Enzymatic study of 7.4 was performed using carboxypeptidase Y and afforded the L-
alanine conjugate of cidofovir (7.35) as main metabolite of the reaction. However, it is 
not clear whether the endocyclic cleavage occurs through the mechanism of reaction 
already described for the phosphoramidate and phosphonoamidate derivatives of 
nucleoside analogues or by chemical hydrolysis of the phosphoester bond, as previously 
described in the case of salicylate and aryl ester prodrugs of cyclic cidofovir. 23, 31, 33, 36, 37 
The enzymatic study also showed also that one of the two diastereomers is converted 
faster than the other. The docking of 7.4 within the active site of CPY suggests that the 
diastereomer Rp may interact better with the amino acid residues of the catalytic site 
than the diastereomer Sp. The modelling study of 7.35 within the active site of human 
Hint-1 suggests that this metabolite is not converted to cidofovir by enzymatic 
hydrolysis of the P-N bond but by chemical hydrolysis at acidic pH as previously 
reported in the case of the aryl phosphonoamidate prodrug GS-7340.37          
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Chapter 8. Main conclusions 
The application of the ProTide approach to several acyclic nucleosides was evaluated in 
this work starting from acyclovir and varying the aryl, amino acid, and ester moieties, as 
well as specific positions of the side chain and guanine base.   
 
ProTides bearing L-alanine have historically shown good results. For this reason, new 
projects have usually started from a family of L-alanine-derived ProTides. Indeed, the 
first ProTides of acyclovir reported in the literature were L-alanine derivatives.  
Very importantly, the study of structure-activity relationship initially performed in this 
work on ACV ProTides showed that bulky amino acids such as L-valine, L-leucine, and 
L-isoleucne were well tolerated by the enzymes involved in their bioactivation pathway, 
as demonstrated by their antiviral activity against TK- HSV and TK- VZV, as well as 
HCMV and HIV-1 in MT-4 cells. These results further support the notion that the 
ProTide motif needs to be tuned on a case-by-case basis when applying this technology 
to a novel nucleoside. However, the lack of activity against HIV-1 and HIV-2 in CEM 
cells cultures of the aryl phosphoramidate derivatives of ACV synthesised in this work 
suggests that their activation!might be dependent on the nature of the cell line.  
 
The biological evaluation of 6-O-alkyl ACV ProTides as potential double prodrugs of 
ACV monophosphate showed that these derivatives were cytotoxic, perhaps the 
increase of their cellular uptake may account for these toxic effects. 
 The study of the aryl phosphoramidate derivatives of 8-bromoacyclovir, 8-
methylacyclovir, ganciclovir and penciclovir showed that even small structural changes 
on the nucleoside moiety of ProTides can affect the processing of the phosphoramidate 
moiety, and thus the antiviral activity of these compounds. In particular, introduction of 
methyl group or bromine atom at the C-8 of the guanine base of ACV ProTides caused 
a significant loss of antiviral activity. The additional hydroxymethylene group on the 
side chain was well tolerated in the case of ganciclovir ProTides. The replacement of 
the oxygen on the side chain of ganciclovir with the methylene group of PCV affected 
negatively the antiviral activity of the ProTides derivatives against herpes viruses. 
However, PCV ProTides showed anti-HIV-1 activty in MT-4 cells comparable to that 
of GCV ProTides supporting the hypothesis that different substrate affinities of the 
enzymes involved in the bioactivation of PCV ProTides may occur in the MT-4 cells.  
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Collectively these results points out the necessity of evaluating the potential of each 
nucleoside and not relying on structural similarities for prediction of ProTides 
bioactivation. 
 
Finally, the application of the phosphoramidate approach to cidofovir resulted in the 
synthesis of the L-alanine benzyl ester derivative of cyclic cidofovir, which showed 
retention of antiviral activity in comparison to the parent compound.  
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Chapter 9. EXPERIMENTAL PROCEDURES 
9.1 General Experimental Details 
Solvents and Reagents  
All solvents and reagents commercially available were used without any further 
purification. The following solvents were purchased as anhydrous: chloroform 
(CHCl3), dichloromethane (DCM), diethyl ether (Et2O), N,N-dimethylformamide 
(DMF), pyridine, tetrahydrofyran (THF).All glassware was dried in the oven at 130°C 
for several hours and allowed to cool down. 
Thin Layer Chromatography 
The reactions were analysed by Thin Layer Chromatography (TLC) on commercially 
available Merck Kieselgel plates. Separated components were visualized using ultra 
violet light (245 and 366 nm). Preparative TLC plates (20x20 cm, 500-2000 µm) were 
purchased from Merck. 
 Column Chromatography (CC) 
Column chromatography was performed using Silica gel (Fisher, 60A, 35-70µm) as 
stationery phase. Glass columns were packed in the appropriate eluent under gravity. 
Samples were applied as a concentrated solution in the same eluent, or pre absorbed 
onto silica gel. The fractions containing the product were analyzed by TLC then 
combined together and the solvent removed under vacuum. 
NMR Spectroscopy 
1H, 13C, 31P were recorded on a Brucker Avance 500 spectrometer (500, 125, 202 MHz 
respectively) at 25 °C.  Spectra were calibrated to the residual signal of the deuterated 
solvent used. Chemical shift are given in parts per million (ppm) and coupling costant 
(J) in Hertz. The following abbreviations are used in the NMR signals assignment: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br s (broad singlet), JC-P 
(coupling between carbon and phosphorus), Jgem (geminal coupling).  
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High Performance Liquid Chromatography (HPLC) 
Analytical and semi-preparative experiments were ran on a Varian ProStar equipment 
(LC Work Station, Varian ProStar 335LC detector, Varian fraction collector model 701, 
ProStar 201 delivery system) using Varian Pursuit XRs 5C18 (150 x 4.6mm) as an 
analytical column and Varian Puruit XRs 5C18 (150 x 21.2 mm) as semi-preparative 
column. Used software was Galaxie Chromatography Data System.  
Mass Spetroscopy (MS) 
High and low resolution mass spectroscopy was performed as a service by 
CardiffUniversity, using electrospray (ES). 
Elemental Analysis (CHN)  
CHN microanalysis was performed as a service by MEDAC Ltd., Surrey. 
UV Spectroscopy (UV) 
UV experiments were conducted using a Varian 50 Bio UV-Visisble 
spectrophotometer. 
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9.2. Experimental procedures for chapter 2: synthesis of aryl amino 
acid ester phosphorochloridates  
Standard procedure A  
To a stirred solution of the appropriate amino acid ester salt 2.4 (1 eq) and the 
appropriate aryl dichlorophosphate 2.5 (1 eq.) in anhydrous DCM was added dropwise 
at -78 °C anhydrous TEA (2 eq). Following the addition, the reaction mixture was 
stirred at -78 °C for 30 min, then at room temperature for 1 h. Formation of desired 
compound was monitored by 31P NMR. After this period the solvent was removed under 
reduced pressure to give an oil. Most of the aryl phosphorochloridates synthesized were 
purified by flash column chromatography (eluting with ethyl acetate/petroleum ether= 
70/30). 
Synthesis of 2,2-Dimethylglycine benzyl ester tosylate [2.4a] 
 Chemical Formula: C19H25NO5S 
Molecular Weight: 379.4705 
2,2-Dimethylglycine (1.02 g, 9.89 mmol), benzyl alcohol (15 mL) and 
p-toluenesulphonic acid (2.06 g, 10.83 mmol) were refluxed in toluene 
(13 mL) overnight using a Dean-Stark apparatus. After cooling to room temperature 
toluene was evaporated under reduced pressure. Upon standing (1 h) a solid formed 
from the crude oil and Et2O was added to give the product as a white precipitate. The 
mixture was filtered and the white solid washed with Et2O and dried under vacuum. 
(Yield: 80%, 2.90 g) 
1H NMR (500 MHz, CDCl3): ! 7.74 (2H, d, J = 8.1 Hz, Ts), 7.44-7.35 (5H, m, CH2Ph), 
7.10 (2H, d, J = 8.1 Hz, Ts), 5.12 (2H, s, OCH2), 2.32 (3H, s, CH3 (Ts)), 1.54 (6H, s, 2 x 
CH3). 
Synthesis of L-alanine neopentyl ester tosylate [2.4b] 
Chemical Formula: C15H25NO5S 
Molecular Weight: 331.4277 
 
L-alanine (4 g, 44.89 mmol), neopentyl alcohol (25 mL) and p-
toluenesulphonic acid (9.48 g, 49.84 mmol) were refluxed in toluene (60 mL) overnight 
using a Dean-Stark apparatus. After cooling to room temperature toluene was 
evaporated under reduced pressure. Upon standing (1 h) a solid formed from the crude 
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oil and Et2O was added to give the product as a white precipitate. The mixture was 
filtered and the white solid washed with Et2O and dried under vacuum. (Yield: 80%, 
12g) 
1H NMR (500 MHz, MeOD): ! 7.73 (2H, d, J = 8.1, Ts), 7.26 (2H, d, J = 8.1, Ts), 4.16 
(1H, q, J = 7.2 Hz, CHCH3), 4.03 (1H, d, Jgem = 10.5 Hz, COOCH2(CH3)3), 3.92 (1H, 
d, Jgem = 10.5 Hz, COOCH2(CH3)3), 2.39 (3H, s, CH3 (Ts)), 1.58 (3H, d, J = 7.2 Hz, 
CHCH3), 1.00 (9H, s, COOCH2(CH3)3). 
Synthesis of 1-naphthyl dichlorophosphate [2.5b] 
Chemical Formula: C10H7Cl2O2P 
Molecular Weight: 331.4277 
 
Phosphorus oxychloride (2.59 mL, 27.74 mmol) and 1-naphthol (4.00 
g, 27.74 mmol) were stirred in anhydrous Et2O under an argon atmosphere. Anhydrous 
TEA was added (3.87 mL, 27.74 mmol) at -78 oC and after 30 minutes, the solution was 
allowed to warm to room temperature. After 31P NMR, the solvent was removed under 
reduced pressure and the residue was triturated with anhydrous Et2O to give the crude 
product as yellowish oil. (Crude yield 95%, 6.91 g).  
31P-NMR (CDCl3, 202 MHz): ! 3.72. 
1H-NMR (CDCl3, 500 MHz): ! 8.02-8.00 (1H, m, 
H-8), 7.81-7.80 (1H, m, H-5), 7.72-7.70 (1H, m, H-4), 7.54-7.45 (4H, m, H-2, H-3, H-6, 
H-7). 
Synthesis of phenyl-(benzyloxy-L-alaninyl) phosphorochloridate [2.2a] 
Chemical Formula: C16H17ClNO4P 
Molecular Weight: 353.7372 
Prepared according to standard procedure A, using phenyl 
dichlorophosphate (1.27 mL, 8.50 mmol), L-alanine benzyl ester 
tosylate  (3 g, 8.5 mmol), anhydrous TEA (2.36 mL, 17 mmol) in 
anhydrous DCM (70 mL). The reaction mixture was stirred at -78 oC for 30 min., then 
at room temperature for 2 h. The crude was purified by column chromatography eluting 
with ethyl acetate/petroleum ether = 70/30 to give an oil (86%, 2.57 g).  
31P-NMR (CDCl3, 202 MHz): ! 8.05, 7.52. 
1H-NMR (CDCl3, 500 MHz): ! 7.44-7.25 
(10H, m, PhO, OCH2Ph), 5.24-5.22 (2H, m, OCH2Ph), 4.30-4.21 (2H, m, CHNH, 
CHNH), 1.56-1.54 (3H, m, CHCH3). 
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Synthesis of 1-naphthyl-(benzyloxy-L-alaninyl) phosphorochloridate [2.2b] 
Chemical Formula: C20H19ClNO4P 
Molecular Weight: 403.7959 
Prepared according to standard procedure A, using naphthyl 
dichlorophosphate (0.30 mL, 2 mmol), L-alanine benzyl ester 
hydrochloride (0.43 g, 2 mmol), anhydrous TEA (0.56 mL, 4 mmol) 
in anhydrous DCM (15 mL). The reaction mixture was stirred at -78 oC for 1 h, then at 
room temperature for 3.5 h. The crude was obtained as an oil (87%, 0.62 g).  
31P-NMR (CDCl3, 202 MHz): ! 7.86, 7.52. 
1H-NMR (CDCl3, 500 MHz): ! 7.33-7.28 
(10H, m, NaphO, OCH2Ph), 5.15-5.13 (2H, m, OCH2Ph), 4.18-4.13 (1H, m, CHNH), 
1.46-1.44 (3H, m, CHCH3). 
Synthesis of phenyl-(tert-butoxy-L-alaninyl) phosphorochloridate [2.2c] 
Chemical Formula: C13H19ClNO4P 
Molecular Weight: 319.721 
Prepared according to standard procedure A, phenyl dichlorophosphate 
(3.95 mL, 26.54 mmol), L-alanine tert-butyl ester tosylate (4.8 g, 
26.42 mmol), anhydrous TEA (7.36 mL, 52.84 mmol) in anhydrous 
DCM (80 mL). The reaction mixture was stirred at -78 oC for 30 min, then at room 
temperature for 30 min. The crude was purified by column chromatography eluting with 
ethyl acetate/hexane = 70/30 to give an oil (64%, 5.4 g).  
31P-NMR (CDCl3, 202 MHz): ! 8.20, 7.81. 
1H-NMR (CDCl3, 500 MHz): ! 7.41-7.38 
(2H, m, PhO), 7.30-7.24 (3H, m, PhO), 4.35-4.24 (1H, m, NH), 4.14-4.01 (1H, m, 
CHCH3), 1.52-1.49 (12H, m, C(CH3)3, CHCH3). 
Synthesis of phenyl-(neopentyloxy-L-alaninyl) phosphorochloridate [2.2d] 
Chemical Formula: C14H21ClNO4P 
Molecular Weight: 333.7476 
Prepared according to standard procedure A, from phenyl-
dichlorophosphate (1.13 mL, 7.54 mmol), L-alanine neopentyl ester 
tosylate (2.5 g, 7.54 mmol), anhydrous TEA (2.10 mL, 15.08 
mmol) and anhydrous DCM (45 mL). The reaction mixture was stirred at -78 oC for 30 
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min, then at room temperature for 2 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil 
(quantitative yield , 2.48 g).  
31P-NMR (CDCl3, 202 MHz): ! 7.66, 8.19. 
1H-NMR (CDCl3, 500 MHz): ! 7.44-7.26 
(5H, m, PhO), 4.42-4.37 (1H, m, NH), 4.34-4.21 (1H, m, CHCH3), 3.97-3.93 (1H, m, 
COOCH2(CH3)3 of one diasteroisomer), 3.90-3.86 (1H, m, COOCH2(CH3)3 of one 
diasteroisomer), 1.58-1.55 (3H, m, CHCH3), 0.99 (4.5H, s, COOCH2(CH3)3 of one 
diastereomer), 0.98 (4.5H, s, COOCH2(CH3)3 of one diastereomer. 
Synthesis of phenyl-(neopentyloxy-L-alaninyl) phosphorochloridate [2.2e]. 
Chemical Formula: C18H23ClNO4P 
Molecular Weight: 383.8063 
Prepared according to standard procedure A, from naphthyl 
dichlorophosphate (1.97 g, 7.54 mmol), L-alanine neopentyl ester 
tosylate (2.5 g, 7.54 mmol), anhydrous TEA (2.10 mL, 15.08 mmol) 
and anhydrous DCM (45 mL). The reaction mixture was stirred at -78 oC for 30 min, 
then at room temperature for 2 h. The crude was purified by column chromatography 
eluting with ethyl acetate/petroleum ether = 70/30 to give an oil (63%, 1.8 g). 
31P-NMR (CDCl3, 202 MHz): ! 8.21, 7.90. 
1H-NMR (CDCl3, 500 MHz): ! 8.11-7.45 
(7H, m, NaphO), 4.48-4.44 (1H, m, NH), 4.38-4.35 (1H, m, CHCH3), 3.99-3.84 (2H, m, 
COOCH2(CH3)3), 1.62-1.58 (3H, m, CHCH3), 0.99 (4.5H, s, COOCH2(CH3)3 of one 
diastereomer), 0.98 (4.5H, s, COOCH2(CH3)3 of one diastereomer. 
Synthesis of phenyl-(benzyloxy-glicinyl) phosphorochloridate [2.2f]. 
 Chemical Formula: C15H15ClN4OP 
 Molecular Weight: 339.7107 
Prepared according to standard procedure A, from phenyl 
dichlorophosphate (2.21 mL, 14.81 mmol), glycine benzyl ester tosylate  
(5.00 g, 14.81 mmol), anhydrous TEA (4.20 mL, 30.00 mmol) and 
anhydrous DCM (100 mL). The reaction mixture was stirred at -78 ºC for 30 min, then 
at room temperature for 1 h. The crude was purified by column chromatography eluting 
with ethyl acetate/petroleum ether = 70/30 to give an oil (90%, 4.50 g). 
31P NMR (CDCl3, 202 MHz): ! 8.75. 
1H NMR (CDCl3, 500 MHz): ! 7.45-7.24 (10H, m, 
PhO, OCH2Ph), 5.26 (2H, s, OCH2Ph), 4.27-4.26 (1H, bs, NH), 4.04-3.91 (2H, m, 
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NHCH2). 
Synthesis of phenyl-(benzyloxy-dimethylglycinyl) phosphorochloridate [2.2g]. 
Chemical Formula: C17H19ClNO4P 
Molecular Weight: 367.7638 
Prepared according to the standard procedure A, from phenyl 
dichlorophosphate (2.45 mL, 16.40 mmol) and 2,2-dimethylglycine 
benzyl ester tosylate (6.00 g, 16.4 mmol), anhydrous TEA (4.58 mL, 
33.00 mmol) and anhydrous DCM (150 mL). The reaction mixture was stirred at -78 oC 
for 30 min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil (90%, 
5.50 g).  
31P NMR (CDCl3, 202 MHz): ! 5.43. 
1H NMR (CDCl3, 500 MHz): ! 7.41-7.23 (10H, m, 
PhO, OCH2Ph), 5.24 (2H, s, OCH2Ph), 4.70-4.68  (1H, bs, NH), 1.74, 1.72 (6H, 2s, 
C(CH3)2). 
Synthesis of 1-naphthyl-(benzyloxy-dimethylglycinyl) phosphorochloridate [2.2h] 
Chemical Formula: C21H21ClNO4P 
Molecular Weight: 417.8225 
Prepared according to the standard procedure A, from naphthyl 
dichlorophosphate (1.53 g, 5.88 mmol) and 2,2-dimethylglycine 
benzyl ester tosylate (2.15 g, 5.88 mmol), anhydrous TEA (4.59 mL, 
32.94 mmol) and anhydrous DCM (50 mL). The reaction mixture was stirred at -78 oC 
for 30 min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil 
(quantitative yield, 2.7 g). 
31P-NMR (CDCl3, 202 MHz): ! 5.83. 
1H-NMR (CDCl3, 500 MHz): ! 8.13-7.33 (12H, 
m, Naph, OCH2Ph), 5.25 (2H, s, OCH2Ph), 1.80, 1.76 (6H, 2s, C(CH3)2). 
Synthesis of phenyl-(benzyloxy-L-valinyl) phosphorochloridate [2.2i] 
Chemical Formula: C18H21ClNO4P 
Molecular Weight: 381.7904  
Prepared according to standard procedure A, from phenyl-
dichlorophosphate (0.91 mL, 6.13 mmol), L-valine benzyl ester 
tosylate (2.33 g, 6.13 mmol), anhydrous TEA (1.71 mL, 12.26 
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mmol) and anhydrous DCM (50 mL). The reaction mixture was stirred at -78 oC for 30 
min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil (77%, 
1.80 g). 
31P NMR (CDCl3, 202 MHz): ! 9.37, 8.89. 
1H NMR (CDCl3, 500 MHz): ! 7.42-7.23 
(10H, m, PhO, OCH2Ph), 5.24-5.23 (2H, m, OCH2Ph), 4.08-3.96 (1H, m, NHCH), 2.24-
2.17 (1H, m, CH(CH3)2), 1.05-1.01 (3H, m, CH(CH3)2), 0.94-0.91 (3H, m, CH(CH3)2).  
Synthesis of 1-naphthyl-(benzyloxy-L-valinyl) phosphorochloridate [2.2j] 
Chemical Formula: C22H23ClNO4P 
Molecular Weight: 431.8491 
Prepared according to standard procedure A, from naphthyl 
dichlorophosphate (1.72 g, 6.58 mmol), L-valine benzyl ester 
tosylate (2.5 g, 6.58 mmol), anhydrous TEA (1.83 mL, 13.16 
mmol) and anhydrous DCM (50 mL). The reaction mixture was stirred at -78 oC for 30 
min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil 
(quantitative yield %, 2.8 g). 
31P NMR (CDCl3, 202 MHz): ! 9.72, 9.26. 
1H NMR (CDCl3, 500 MHz): ! 8.09-7.31 
(12H, m, Naph, OCH2Ph), 5.24-5.16 (2H, m, OCH2Ph), 4.29-4.20 (1H, m, NHCH), 
2.26-2.18 (1H, m, CH(CH3)2), 1.05-1.02 (3H, m, CH(CH3)2), 0.96-0.92 (3H, m, 
CH(CH3)2)  
Synthesis of phenyl-(benzyloxy-L-leucinyl) phosphorochloridate [2.2k]. 
Chemical Formula: C19H23ClNO4P 
Molecular Weight: 395.8170 
 
Prepared according to standard procedure A, from phenyl-
dichlorophosphate (0.91 mL, 6.13 mmol), L-leucine benzyl ester 
tosylate (2.41 g, 6.13 mmol), anhydrous TEA (1.71 mL, 12.26 mmol) and anhydrous 
DCM (50 mL). The reaction mixture was stirred at -78 ºC for 30 min, then at room 
temperature for 1 h. The crude was purified by column chromatography eluting with 
ethyl acetate/petroleum ether = 70/30 to give an oil (93%, 2.25 g). 
31P NMR (CDCl3, 202 MHz): ! 8.34, 8.10. 
1H NMR (CDCl3, 500 MHz): ! 7.43-7.22 
(10H, m, PhO, OCH2Ph), 5.27-5.09 (2H, m, OCH2Ph), 4.21-4.11 (1H, m, NHCH), 1.90-
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1.75 (1H, m, CH2CH(CH3)2), 1.71-1.59 (2H, m, CH2CH(CH3)2), 0.98-0.95 (6H, m, 
CH3).  
 
Synthesis of Naphthyl-(benzyloxy-L-leucinyl) phosphorochloridate [2.2l]. 
Chemical Formula: C23H25ClNO4P 
Molecular Weight: 445.8757 
 
Prepared according to standard procedure procedure A, from 
naphthyl dichlorophosphate (1.6 g, 6.13 mmol), L-leucine benzyl 
ester tosylate (2.41 g, 6.13 mmol), anhydrous TEA (1.71 mL, 12.26 mmol) and 
anhydrous DCM (50 mL). The reaction mixture was stirred at -78 ºC for 30 min, then at 
room temperature for 1 h. The crude was purified by column chromatography eluting 
with ethyl acetate/petroleum ether = 70/30 to give an oil (65%, 1.76 g). 
31P NMR (CDCl3, 202 MHz): ! 8.56, 8.31. 
1H NMR (CDCl3, 500 MHz): ! 8.03-7.28 
(12H, m, Naph, OCH2Ph), 5.27-5.09 (2H, m, OCH2Ph), 4.21-4.11 (1H, m, NHCH), 
1.90-1.75 (1H, m, CH2CH(CH3)2), 1.71-1.59 (2H, m, CH2CH(CH3)2), 0.98-0.95 (6H, m, 
CH3). 
Synthesis of phenyl-(benzyloxy-L-isoleucinyl) phosphorochloridate [2.2m]. 
Chemical Formula: C19H23ClNO4P 
Molecular Weight: 395.8170 
 
Prepared according to standard procedure procedure A, from 
phenyl dichlorophosphate (0.91 mL, 6.13 mmol), L-isoleucine 
benzyl ester tosylate  (2.41 g, 6.13 mmol), anhydrous TEA (1.71 
mL, 12.26 mmol) and anhydrous DCM (50 mL). The reaction mixture was stirred at -78 
ºC for 30 min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil 
(quantitative yield, 2.41 g). 
31P NMR (CDCl3, 202 MHz): ! 9.01, 8.61. 
1H NMR (CDCl3, 500 MHz): ! 7.45-7.22 
(10H, m, PhO, OCH2Ph), 5.27-5.19 (2H, m, OCH2Ph), 4.11-4.00 (1H, m, NHCH), 1.52-
1.40 (1H, m, NHCHCH, 1.25-1.16 (2H, m, CH(CH3)CH2CH3), 0.94-0.75 (6H, m, CH3). 
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Synthesis of Naphthyl-(benzyloxy-L-isoleucinyl) phosphorochloridate [2.2n]. 
Chemical Formula: C23H25ClNO4P 
Molecular Weight: 445.8757 
 
Prepared according to standard procedure A, from naphthyl 
dichlorophosphate (1.85 g, 7.1 mmol), L-isoleucine benzyl ester 
tosylate (2.8 g, 7.1 mmol), anhydrous TEA (1.97 mL, 14.2 mmol) and anhydrous DCM 
(50 mL). The reaction mixture was stirred at -78 ºC for 30 min, then at room 
temperature for 1 h. The crude was purified by column chromatography eluting with 
ethyl acetate/petroleum ether = 70/30 to give an oil (70%, 2.26 g). 
31P NMR (CDCl3, 202 MHz): ! 9.40, 8.98. 
1H NMR (CDCl3, 500 MHz): ! 8.09-7.29 
(12H, m, Naph, OCH2Ph), 5.25-5.23 (2H, m, OCH2Ph), 4.20-4.17 (1H, m, NHCH), 
1.54-1.42 (1H, m, NHCHCH), 1.26-1.14 (2H, m, CHCH(CH3)CH2CH3), 1.00 (1.5 H, d, 
J = 6.8 Hz, CHCH3 of one diasteroisomer), 0.97 (1.5H, d, J = 6.8 Hz, CHCH3 of one 
diasteroisomer), 0.91 (3H, t, J = 7.4 Hz, CH2CH3). 
Synthesis of phenyl-(benzyloxy-L-prolinyl) phosphorochloridate [2.2o]. 
Chemical Formula: C18H19ClNO4P 
Molecular Weight: 379.7745 
Prepared according to standard procedure A, from phenyl 
dichlorophosphate (3.09 mL, 20.68 mmol), L-proline benzyl ester 
tosyltate  (5.00 g, 20.68 mmol), anhydrous TEA (5.76 mL, 41.36 mmol) and anhydrous 
DCM (100 mL). The reaction mixture was stirred at -78 ºC for 30 min, then at room 
temperature for 1 h. The crude product was obtained as an oil (quantitative, 7.85 g).  
31P NMR (CDCl3, 202 MHz): ! 7.78, 7.72. 
1H NMR (CDCl3, 500 MHz): ! 7.40-7.19 
(10H, m, PhO, OCH2Ph), 5.25-5.15 (2H, m, OCH2Ph), 4.58-4.55 (0.5H, m, NCH of one 
diastereoisomer), 4.49-4.45 (0.5H, m, NCH, of one diastereoisomer), 3.64-3.45 (2H, m, 
NCH2), 2.31-2.21 (1H, m, NCHCH2), 2.18-2.10 (1H, m, NCHCH2), 2.09-1.92 (2H, m, 
NCHCH2CH2). 
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Synthesis of Naphthyl-(benzyloxy-L-phenylalaninyl) phosphorochloridate [2.2p]. 
Chemical Formula: C26H23ClNO4P 
Molecular Weight: 479.8919 
Prepared according to standard procedure A, from naphthyl 
dichlorophosphate (2.7 g, 10.28 mmol), L-Phenylalanine benzyl 
ester tosylate (3 g, 10.28 mmol), anhydrous TEA (2.86 mL, 20.56 
mmol) and anhydrous DCM (60 mL). The reaction mixture was stirred at -78 ºC for 30 
min, then at room temperature for 1 h. The crude was purified by column 
chromatography eluting with ethyl acetate/petroleum ether = 70/30 to give an oil (60%, 
3 g). 
31P NMR (CDCl3, 202 MHz): 8.29, 8.16. 
1H-NMR (CDCl3, 500 MHz): ! 8.05-6.80 
(17H, m, NaphO, CHCH2Ph, OCH2Ph), 5.19-4.97 (2H, m, OCH2Ph), 4.64-4.52 (1H, m, 
CHNH), 3.22-3.10 (2H, m, CHCH2Ph). 
9.3. Experimental procedures for chapter 3: synthesis of acyclovir 
ProTides 
Figure 9.1 reports the numbering assigned to different positions of ACV structure. In 
particular the side chain positions have been assigned in analogy to the structure of 2’-
deoxyguanosine.  
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Standard procedure B: Grignard (tButMgCl) method 
To a stirring suspension of N2-DMF ACV 3.3 (1 eq.) in anhydrous THF was added 
dropwise, under argon atmosphere tButMgCl, (2 eq.). The reaction mixture was stirred 
at room temperature for 30 min. Then, a solution of the appropriate aryl amino acid 
ester phosphorochloridate 2.2 (2 to 4 eq.) in anhydrous THF was added dropwise and 
the reaction mixture was stirred at room temperature overnight. The solvent was 
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removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH in different proportions.  
Standard procedure C: N-methylimidazole (NMI) method 
To a stirring suspension of 3.3 (1 eq.) and the appropriate aryl amino acid ester 
phosphorochloridate 2.2 (3 to 4 eq.) in anhydrous THF/pyridine mixture (3/2) was 
added dropwise under an argon atmosphere NMI (5-10 eq.). The reaction mixture was 
stirred at room temperature overnight. The solvent was removed under reduced 
pressure. The residue was dissolved in DCM, washed with water (twice) and 0.5 N HCl 
(twice). The organic phase was dried over MgSO4, filtered, reduced to dryness and the 
crude purified by column chromatography eluting with DCM/MeOH in different 
proportions.  
Synthesis of N2-DMF-acyclovir: 
N2-(N,N-dimethylformamidine)-9-[(2-hydroxyethoxy)methyl]guanine [3.3] 
Chemical Formula: C11H16N6O3 
Molecular Weight: 280.2831 
 
To a suspension of ACV in anhydrous DMF (70 ml) 
was added N,N-dimethylformamide dimethyl acetale (11.75 ml, 88.8 mmol) and the 
reaction mixture was stirred at room temperetature for 24 h. After this period the 
suspension was filtered, and the solid was washed with diethyl ether to give a white 
solid (92%, 4.55g). 
1H NMR (DMSO, 500 MHz): ! 11.30 (1H, s, NH), 8.58 (1H, s, CHN(CH3)2), 7.94 (1H, 
s, H-8), 5.45 (2H, s, H-1’), 4.65 (1H, br s, OH), 3.53-3.49 (4H, m, H-4’, H-5’), 3.18-
3.04 (6H, 2s, N(CH3)2). 
Synthesis of N2-DMF-acyclovir-[phenyl(benzyloxyglicinyl)] phosphate [3.4a]. 
Chemical Formula: C26H30N7O7P 
Molecular Weight: 583.5329 
Prepared according to standard procedure C 
using 3.3 (1.00 g, 3.57 mmol) in a 3/2 mixture of 
THF/pyridine (50 mL), 2.2f (3.64 g, 10.70 
mmol) dissolved in anhydrous THF (10 mL) and 
NMI (0.85 ml, 10.70 mmol). The reaction mixture was stirred at room temperature 
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overnight. The solvent was removed under reduced pressure. The residue was purified 
by column chromatography, gradient elution of DCM/MeOH (98/2, then 97/3, then 
96/4, then 95/5) to give a white solid (81%, 1.69 g).  
31P NMR (MeOD, 202 MHz): ! 4.78 
1H NMR (MeOD, 500 MHz): ! 8.70 (1H, s, 
NCHN(CH3)2), 7.92 (1H, s, H-8), 7.39-7.28 (7H, m, PhO, OCH2Ph), 7.20-7.15 (3H, m, 
PhO, OCH2Ph), 5.53 (2H, s, H-1’), 5.16 (2H, s, OCH2Ph), 4.29-4.17 (2H, m, H-5’), 
3.80-3.74 (4H, m, H-4’, NHCH2), 3.17, 3.11 (6H, 2s, N(CH3)2). 
Synthesis of acyclovir-[phenyl(benzyloxyglicinyl)] phosphate [3.2a]. 
Chemical Formula: C23H25N6O7P 
Molecular Weight: 528.4544 
A solution of 3,4a (1.69 g, 2.89 mmol) in isopropanol 
(60 mL) was stirred under reflux for 48 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. The product was purified 
by preparative reverse phase HPLC (gradient elution of H20/MetOH from 100/0 to 
20/80 in 5 min, isocratic 20/80 for 10 min, from 20/80 to 0/100 in 10 min, isocratic 
0/100 for 5 min) to give a white solid (2%, 0.031 g).  
31P NMR (MeOD, 202 MHz): ! 4.77. 
1H NMR (MeOD, 500 MHz): ! 7.81 (1H, s, H-8), 
7.37-7.31 (7H, m, PhO, OCH2Ph), 7.18-7.16 (3H, m, PhO, OCH2Ph), 5.44 (2H, s, H-
1’), 5.17 (2H, s, OCH2Ph), 4.26-4.16 (2H, m, H-5’), 3.80 (1H, s, NHCH2), 3.77-3.76 
(3H, m, H-4’, NHCH2). 
13C NMR (MeOD, 126 MHz): ! 43.91 (NHCH2), 67.11 (d, JC–P 
= 5.40 Hz, C-5’), 67.95 (OCH2Ph), 69.37 (d, JC–P = 7.40 Hz, C-4’), 73.66 (C-1’), 
117.57, 121.43, 121.47, 126.10, 129.37, 129.43, 129.58, 130.73 (C-5, PhO, OCH2Ph), 
137.23 (‘ipso’ OCH2Ph), 139.74 (C-8), 152.31 (d, JC–P = 6.00 Hz, ipsoPhO), 153.23 (C-
4), 155.67 (C-2), 159.39 (C-6), 172.31 (d, JC–P = 4.90 Hz, COOCH2Ph). EI MS= 
529.1617 (M+H). Elemental analysis calculated for C23H25N6O7P"H2O: C, 50.55; H, 
4.98; N, 15.38. Found: C, 50.97; H, 4.73; N, 15.31. 
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Synthesis of N2-DMF-acyclovir-[phenyl-(benzyloxydimethylglicinyl)] phosphate 
[3.4b]. 
Chemical Formula: C28H34N7O7P 
Molecular Weight: 611.5860 
Prepared according to standard procedure B, 
from 3.3 (0.50 g, 1.78 mmol) in anhydrous THF 
(20 mL), tButMgCl (1.0 M THF solution, 3.70 
mL, 3.70 mmol), 2.2g (2.01 g, 5.34 mmol) in 
anhydrous THF (10 mL). The reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure and the residue was 
purified by column chromatography, gradient elution of DCM/MeOH = 98/2, then 96/4 
to give a white solid (93%, 1.02 g). 
 
31P NMR (MeOD, 202 MHz): ! 2.17. 
1H NMR (MeOD, 500 MHz): ! 8.69 (1H, s, 
NCHN(CH3)2), 7.91 (1H, s, H-8), 7.40-7.25 (7H, m, PhO, OCH2Ph), 7.17-7.15 (3H, m, 
PhO, OCH2Ph), 5.53 (2H, s, H-1’), 5.19-5.06 (2H, m, OCH2Ph), 4.18-4.12 (2H, m, H-
5’), 3.77-370 (2H, m, H-4’), 3.18 (3H, s, N(CH3)2), 3.12 (3H, s, N(CH3)2), 1.48, 1.47 
(6H, 2s, C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.42 (d, JC–P = 6.60 Hz, CH3), 27.58 
(d, JC–P = 6.60 Hz, CH3), 35.38 (NCHN(CH3)2), 41.51 (NCHN(CH3)2), 57.98 (C(CH3)2), 
67.02 (d, JC–P = 5.60 Hz, C-5’), 68.20 (OCH2Ph), 69.43 (d, JC–P = 7.40 Hz, C-4’), 73.69 
(C-1’), 120.35, 121.47, 121.51, 125.99, 129.31, 129.58, 130.68 (C-5, PhO, OCH2Ph), 
137.36 (‘ipso’ OCH2Ph), 140.62 (C-8), 152.28, 152.33 (ipsoPhO, C-4), 159.37 (C-2), 
159.90 (NCHN(CH3)2), 176.51 (d, JC–P = 3.70 Hz, COOCH2Ph). EI MS= 612.2316 
(M+H). Anal. Calcd for C28H34N7O7P·0.5H2O: C, 54.19; H, 5.68; N, 15.80. Found: C, 
54.16; H, 5.61; N, 15.70. 
Synthesis of acyclovir [phenyl(benzyloxy-dimethylglicinyl)] phosphate [3.2b]. 
Chemical Formula: C25H29N6O7P 
Molecular Weight: 556.5075 
A solution of 3.4b (1.02 g, 1.65 mmol) in isopropanol 
(50 mL) was stirred under reflux for 48 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography, 
gradient elution of DCM/MeOH (98/2, then 96/4, then 94/6). The residue was then 
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triturated with ether, filtered and washed with water to give a white solid (14%, 0.13 g). 
31P NMR (MeOD, 202 MHz): ! 2.13. 
1H NMR (MeOD, 500 MHz): ! 7.81 (1H, s, H-8), 
7.39-7.29 (7H, m, PhO, OCH2Ph), 7.25-7.14 (3H, m, PhO, OCH2Ph), 5.43 (2H, s, H-
1’), 5.17-5.09 (2H, m, OCH2Ph), 4.15-4.12 (2H, m, H-5’), 3.74-3.69 (2H, m, H-4’), 
1.50, 1.49 (6H, 2s, C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.37 (d, JC–P = 4.80 Hz, 
C(CH3)2), 27.57 (d, JC–P = 6.60 Hz, C(CH3)2), 57.99 (C(CH3)2), 67.01 (d, JC–P = 5.70 Hz, 
C-5’), 68.22 (OCH2Ph), 69.46 (d, JC–P = 7.50 Hz, C-4’), 73.61 (C-1’), 117.52, 121.34, 
121.38, 121.47, 121.51, 125.96, 129.06, 129.14, 129.29, 129.34, 129.52, 129.56, 
130.06, 130.66 (C-5, PhO, OCH2Ph), 137.36 (‘ipso’ OCH2Ph), 139.74 (C-8), 152.31 (d, 
JC–P = 7.30, ipsoPhO), 153.45 (C-4), 155.68 (C-2), 176.54 (d, JC–P = 3.80, COOCH2Ph). 
EI MS= 557.1891 (M+H). HPLC = H2O/ACN from 100/0 to 0/100 in 30 min = 
retention time 16.37 min; H2O/MeOH 100/0 to 20/80 in 5 min, 20/80 isocratic 10 min, 
then to 0/100 in 10 min = retention time 18.19 min. 
Synthesis of N2-DMF-acyclovir-[phenyl(benzyloxy-L-valinyl)] phosphate [3.4c]. 
Chemical Formula: C29H36N7O7P 
Molecular Weight: 625.6126 
Prepared according to Standard Procedure C, 
from 3.3 (0.40 g, 1.43 mmol) in anhydrous THF 
(20 mL), tBuMgCl (1.0 M THF solution, 2.86 
mL, 2.86 mmol), 2.2i (1.63 g, 4.29 mmol) in anhydrous THF (10 mL). The reaction 
mixture was stirred at room temperature overnight. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6, to give a 
white solid (57%, 0.51 g).  
31P NMR (MeOD, 202 MHz): ! 4.52, 4.18. 
1H NMR (MeOD, 500 MHz): ! 8.68 (1H, s, 
NCHN(CH3)2), 8.03, 7.97 (1H, 2s, H-8), 7.38-7.11 (10H, m, PhO, OCH2Ph), 5.52, 5.50 
(2H, 2s, H-1’), 5.10, 5.03 (2H, 2s, OCH2Ph), 4.16 (2H, s, H-5’), 3.76-3.64 (3H, m, 
NHCH, H-4’), 3.15, 3.10 (6H, 2s, N(CH3)2), 2.03-1.99 (0.5H, m, CH(CH3)2 of one 
diastereoisomer), 1.93-1.91 (0.5H, m, CH(CH3)2 of one diastereoisomer), 0.86-0.84 
(6H, m, CH(CH3)2). 
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Synthesis of acyclovir-[phenyl(benzyloxy-L-valinyl)] phosphate [3.2c]. 
Chemical Formula: C26H31N6O7P 
Molecular Weight: 570.5341 
A solution of 3.4c (0.51 g, 0.81 mmol) in isopropanol 
(20 mL) was stirred under reflux for 48 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography, 
gradient elution of DCM/MeOH (98/2 then 96/4 then 94/6) to give a white solid which 
was further purified by preparative reverse phase HPLC (gradient elution of 
H20/CH3CN from 100/0 to 0/100 in 30 min) to give a white solid (8%, 0.037 g). 
31P NMR (MeOD, 202 MHz): ! 4.51, 4.27. 
1H NMR (MeOD, 500 MHz): ! 7.82-7.80 
(1H, 2s, H-8), 7.37-7.30 (7H, m, PhO, OCH2Ph), 7.19-7.14 (3H, m, PhO, OCH2Ph), 
5.45-5.43 (2H, 2s, H-1’), 5.14-5.13 (2H, m, OCH2Ph), 4.16-4.14 (2H, m, H-5’), 3.74-
3.66 (3H, m, H-4’, NHCH), 2.05-2.01 (1H, m, NHCHCH), 0.91-0.85 (6H, m, 
CH(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 18.15, 18.31 (2s, CH(CH3)2), 19.47, 19.51 
(2s, CH(CH3)2), 33.07 (d, JC–P = 7.20 Hz, CH(CH3)2) 33.25 (d, JC–P = 7.20 Hz, 
CH(CH3)2), 61.93, 61.97 (2s, NHCH), 67.05 (d, JC–P = 5.80 Hz, C-5’), 67.13 (d, JC–P = 
5.80 Hz, C-5’), 67.82 (OCH2Ph), 69.36 (d, JC–P = 4.70 Hz, C-4’), 69.42 (d, JC–P = 4.70 
Hz, C-4’), 73.63 (s, C-1’), 117.56, 121.34, 121.38, 121.48, 121.51, 126.00, 126.07, 
129.39, 129.41, 129.56, 129.57, 129.62, 130.69 (C-5, PhO, OCH2Ph), 137.23 (‘ipso’ 
OCH2Ph), 139.71 (C-8), 152.22 (d, JC–P = 4.70 Hz, ipsoPhO), 152.28 (d, JC–P = 4.70 Hz, 
ipsoPhO), 153.39 (C-4) 155.68 (C-2), 159.41 (C-6), 173.95 (d, JC–P = 3.50, 
COOCH2Ph), 174.08 (d, JC–P = 3.50, COOCH2Ph). EI MS= 593.1895 (M+Na). HPLC = 
H2O/ACN from 100/0 to 0/100 in 30 min = retention time 17.29 min; H2O/MeOH 100/0 
to 20/80 in 5 min, 20/80 isocratic 10 min, then to 0/100 in 10 min = retention time 
20.09, 20.47 min. 
Synthesis of N2-DMF-acyclovir-[phenyl(benzyloxy-L-leucinyl)] phosphate [3.4d]. 
Chemical Formula: C30H38N7O7P 
Molecular Weight: 639.6392 
 
Prepared according to Standard Procedure C, 
from 3.3 (0.40 g, 1.43 mmol) in anhydrous THF 
(20 mL), tBuMgCl (1.0 M THF solution, 2.86 
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mL, 2.86 mmol), 2.2k (2.25 g, 5.68 mmol) in anhydrous THF (10 mL). The reaction 
mixture was stirred at room temperature overnight. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 then 95/5, to give a 
white solid (65%, 0.59 g).  
31P NMR (MeOD, 202 MHz): ! 4.10, 3.57. 
1H NMR (MeOD, 500 MHz): ! 8.69 (1H, s, 
NCHN(CH3)2), 7.95, 7.93 (1H, 2s, H-8), 7.44-6.98 (10H, m, PhO, OCH2Ph), 5.56-5.49 
(2H, m, H-1’), 5.12-5.11 (2H, m, OCH2Ph), 4.21-4.07 (2H, m, H-5’), 3.99-3.83 (1H, m, 
NHCH), 3.76-3.74 (2H, m, H-4’), 3.16 (3H, s, N(CH3)2), 3.11 (3H, s, N(CH3)2), 1.70-
1.61 (1H, m, CH2CH(CH3)2), 1.54-1.40 (2H, m, CH2CH(CH3)2), 0.91-0.76 (6H, m, 
CH2CH(CH3)2). 
Synthesis of acyclovir-[phenyl(benzyloxy-L-leucinyl)] phosphate [3.2d]. 
Chemical Formula: C27H33N6O7P 
Molecular Weight: 584.5607 
 
A solution of 3.4d (0.59 g, 0.93 mmol) in isopropanol 
(20 mL) was stirred under reflux for 48 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6. The product was purified 
by preparative reverse phase HPLC (gradient elution of H20/CH3CN from 100/0 to 
0/100 in 30 min) to give a white solid (8%, 0.042 g). 
31P NMR (MeOD, 202 MHz): ! 4.05, 3.60. 
1H NMR (MeOD, 500 MHz): ! 7.82, 7.79 
(1H, 2s, H-8), 7.38-7.37 (7H, m, PhO, OCH2Ph), 7.19-7.15 (3H, m, PhO, OCH2Ph), 
5.45, 5.42 (2H, 2s, H-1’), 5.12, 5.13 (2H, 2s, OCH2Ph), 4.16-4.07 (2H, m, H-5’), 3.95-
3.88 (1H, m, NHCH) 3.74-3.71 (2H, m, H-4’), 1.73-1.66 (0.5H, m, CH2CH(CH3)2 of 
one diastereoisomer), 1.62-1.46 (2.5H, m, CH2CH(CH3)2 of one diastereoisomer, 
CH2CH(CH3)2), 0.91-0.80 (6H, m, CH2CH(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 
21.75, 22.01, 23.12, 23.20 (4s, CH2CH(CH3)2), 25.40, 25.55 (2s, CH(CH3)2), 43.84 (d, 
JC–P = 7.40 Hz, CH2CH(CH3)2), 44.05 (d, JC–P = 7.40 Hz, CH2CH(CH3)2), 54.48, 54.70 
(2s, NHCH), 67.03 (d, JC–P = 1.80 Hz, C-5’), 67.07 (d, JC–P = 1.80 Hz, C-5’), 67.87, 
67.89 (2s, OCH2Ph), 69.35 (d, JC–P = 2.40 Hz, C-4’), 69.41 (d, JC–P = 2.40 Hz, C-4’), 
73.64 (s, C-1’), 117.54, 121.26, 121.30, 121.51, 121.54, 125.99, 126.09, 129.36, 129.38, 
129.47, 129.57, 129.59, 130.69, 130.71 (C-5, PhO, OCH2Ph), 137.27 (‘ipso’ OCH2Ph), 
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139.70, 139.74 (2s, C-8), 152.22 (d, JC–P = 2.10 Hz, ipsoPhO), 152.27 (d, JC–P = 2.10 Hz, 
ipsoPhO), 153.56 (C-4), 155.66 (C-2), 159.37, 159.38 (2s, C-6), 174.85 (d, JC–P = 2.80 
Hz, COOCH2Ph), 175.09 (d, JC–P = 2.80 Hz, COOCH2Ph). EI MS= 607.2051 (M+Na). 
Anal. Calcd for C27H33N6O7P!H2O: C, 53.82; H, 5.85; N, 13.95. Found: C, 54.16; H, 
5.62; N, 13.67.  
 
Synthesis of N2-DMF-Acyclovir-[phenyl(benzyloxy-L-isoleucinyl)] phosphate 
[3.4e]. 
Chemical Formula: C30H38N7O7P 
Molecular Weight: 639.6392 
 
Prepared according to Standard Procedure C, 
from 3.3 (0.49 g, 1.75 mmol) in anhydrous THF 
(20 mL), tBuMgCl (1.0 M THF solution, 2.86 
mL, 2.86 mmol), 2.2m (2.41 g, 6.09 mmol) in anhydrous THF (10 mL). The reaction 
mixture was stirred at room temperature overnight. After this period tBuMgCl (1.0 M 
THF solution, 2. mL, 2 mmol) was added and the reaction mixture was stirred at room 
temperature for 6 h. The residue was purified by column chromatography gradient 
elution of DCM/MeOH = 98/2 then 96/4 then 95/5, to give a white solid (45%, 0.50 g).  
31P NMR (MeOD, 202 MHz): ! 4.44, 4.05. 
1H NMR (MeOD, 500 MHz): ! 8.69 (1H, s, 
NCHN(CH3)2), 7.98-7.97 (1H, m, H-8), 7.33-7.16 (10H, m, PhO, OCH2Ph), 5.53-5.52 
(2H, 2s, H-1’), 5.14-5.06 (2H, m, OCH2Ph), 4.20-4.11 (2H, m, H-5’), 3.83-3.65 (3H, m, 
NHCH, H-4’), 3.15-3.10 (6H, 2s, N(CH3)2), 1.78-1.71 (1H, m, CH(CH3)CH2CH3), 1.52-
1.36 (1H, m, CH(CH3)CH2CH3), 1.16-1.07 (1H, m, CH(CH3)CH2CH3), 0.86-0.80 (6H, 
m, CH(CH3)CH2CH3). 
Synthesis of acyclovir-[phenyl(benzyloxy-L-isoleucinyl)] phosphate [3.2e]. 
Chemical Formula: C27H33N6O7P 
Molecular Weight: 584.5607 
 
A solution of 3.4e (0.50 g, 0.78 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography, 
gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. The product was purified 
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by preparative reverse phase HPLC (gradient elution of H20/CH3CN from 100/0 to 
0/100 in 30 min) to give a white solid (3%, 0.015 g).  
31P NMR (MeOD, 202 MHz): ! 4.42, 4.13. 
1H NMR (MeOD, 500 MHz): ! 7.82-7.80 
(1H, 2s, H-8), 7.39-7.30 (7H, m, PhO, OCH2Ph), 7.19-7.14 (3H, m, PhO, OCH2Ph), 
5.45-5.44 (2H, 2s, H-1’), 5.16-5.09 (2H, m, OCH2Ph), 4.17-4.12 (2H, m, H-5’), 3.79-
3.77 (1H, m, NHCH), 3.75-3.73 (2H, m, H-4’), 1.78-1.72 (1H, m, NHCHCH), 1.49-
1.39 (1H, m, CHCH2CH3), 1.19-1.08 (1H, m, CHCH2CH3), 0.88-0.80 (6H, m, 
CH(CH3)CH2CH3). 
13C NMR (MeOD, 126 MHz): ! 11.52, 11.55, 15.84, 15.88 (4s, 
CH(CH3)CH2CH3), 25.80, 25.90 (2s, CH(CH3)CH2CH3), 39.86 (d, JC–P = 6.90 Hz, 
CH(CH3)CH2CH3), 40.01 (d, JC–P = 6.90 Hz, CH(CH3)CH2(CH3), 60.72, 60.86 (2s, 
NHCH), 67.05 (d, JC–P = 5.00 Hz, C-5’), 67.10 (d, JC–P = 5.00 Hz, C-5’), 67.81 
(OCH2Ph), 69.36 (d, JC–P = 5.50 Hz, C-4’), 69.42 (d, JC–P = 5.50 Hz, C-4’), 73.63, 73.65 
(2s, C-1’), 117.54, 121.32, 121.36, 121.50, 121.54, 126.00, 126.08, 129.40, 129.41, 
129.55, 129.57, 129.65, 129.66, 130.68, 130.69 (C-5, PhO, OCH2Ph), 137.21 (‘ipso’ 
OCH2Ph), 139.72 (C-8), 152.22 (d, JC–P = 1.60 Hz, ipsoPhO), 152.27 (d, JC–P = 1.60 Hz, 
ipsoPhO), 153.21 (C-4), 155.67 (C-2), 159.38 (C-6), 173.91 (d, JC–P = 3.00 Hz, 
COOCH2Ph), 174.07 (d, JC–P = 3.00 Hz, COOCH2Ph). EI MS= 607.2044 (M+Na). 
HPLC: H2O/ACN from 100/0 to 0/100 in 20 min = retention time 15.00 min. 
Synthesis of N2-DMF-acyclovir-[phenyl(benzyloxy-L-prolinyl)] phosphate [3.4f]. 
Chemical Formula: C29H34N7O7P 
Molecular Weight: 623.5967 
 
Prepared according to standard procedure C 
using 3.3 (1.00 g, 3.57 mmol) in a 3/2 
mixture of THF/pyridine (50 mL), 2.2o (4.07 
g, 10.71 mmol) in anhydrous THF (10 mL) and NMI (0.85 mL, 10.70 mmol). The 
reaction mixture was stirred at room temperature overnight. The solvent was removed 
under reduced pressure. The residue was purified by column chromatography, gradient 
elution of DCM/MeOH = 98/2, then 97/3, then 96/4, to give a white solid (16%, 0.35 g). 
31P NMR (MeOD, 202 MHz): ! 1.73. 
1H NMR (MeOD, 500 MHz): ! 8.68 (1H, s, 
NCHN(CH3)2), 7.94 (1H, s, H-8), 7.38-7.26 (7H, m, PhO, OCH2Ph), 7.19-7.13 (3H, m, 
PhO, OCH2Ph), 5.60-5.50 (2H, m, H-1’), 5.16-5.08 (2H, m, OCH2Ph), 4.31-4.22 (2H, 
m, H-5’, NCH), 4.19-4.14 (1H, m, H-5’), 3.79-3.78 (2H, m, H-4’), 3.27-3.19 (2H, m, 
NCH2), 3.17 (3H, s, N(CH3)2), 3.10 (3H, s, N(CH3)2) 2.15-2.07  (1H, m, NCHCH2), 
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1.98-1.91 (1H, m, NCHCH2), 1.89-1.73 (2H, m, NCHCH2CH2). 
13C NMR (MeOD, 126 
MHz): ! 26.18 (d, JC–P = 8.90 Hz, NCHCH2CH2CH2), 32.19 (d, JC–P = 8.90 Hz, 
NCHCH2), 35.36, 41.49 (2s, NCHN(CH3)2), 48.09 (d, JC–P = 4.50 Hz, NCH2), 62.17 (d, 
JC–P = 7.00 Hz, NCH), 67.08 (d, JC–P = 5.00 Hz, C-5’), 67.99 (OCH2Ph), 69.49 (d, JC–P = 
7.20 Hz, C-4’), 73.73 (C-1’), 120.38, 121.17, 121.21, 126.18, 129.34, 129.60, 130.87 
(C-5, PhO, OCH2Ph), 137.26 (‘ipso’ OCH2Ph), 140.68 (C-8), 152.03 (d, JC–P = 6.50 Hz, 
ipsoPhO), 154.54 (C-4), 159.41 (C-2), 159.55 (NCHN(CH3)2), 160.23 (C-6), 174.84 
(COOCH2Ph).  EI MS= 624.2338 (M+H). Elemental analysis Calculated for 
C29H34N7O7P·H2O: C, 54.29; H, 5.66, N, 15.28. Found: C, 54.63; H, 5.44; N, 15.23 
Synthesis of acyclovir-[phenyl(benzyloxy-L-prolinyl)] phosphate [3.2f]. 
Chemical Formula: C26H29N6O7P 
Molecular Weight: 568.5182 
A solution of 3.4f (0.35 g, 0.56 mmol) in isopropanol 
(20 mL) was stirred under reflux for 48 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography gradient elution of DCM/MeOH (98/2, 
then 96/4, then 94/6). The product was purified by preparative reverse phase HPLC 
(gradient eluition of H20/MeOH from 100/0 to 20/80 in 5 min, isocratic 20/80 for 10 
min, from 20/80 to 0/100 in 10 min, isocratic 0/100 for 5 min) to give a white solid as a 
pure diastereoisomer (4%, 0.020 g). 
31P NMR (MeOD, 202 MHz): ! 1.68. 
1H NMR (MeOD, 500 MHz): ! 7.84 (1H, m H-8), 
7.38-7.27 (7H, m, PhO, OCH2Ph), 7.22-7.12 (3H, m, PhO, OCH2Ph), 5.49-5.44 (2H, m, 
H-1’), 5.17-5.11  (2H, m, OCH2Ph), 4.32-4.21 (2H, m, NCH, H-5’), 4.18-4.10 (1H, m, 
H-5’), 3.80-3.71 (2H, m, H-4’), 3.31-3.22 (2H, m, CHNCH2), 2.15-2.11 (1H, m, 
CH2NCHCH2CH2), 1.99-197 (1H, m, CH2NCHCH2CH2), 1.91-1.76 (2H, m, 
CH2NCHCH2CH2). 
13C NMR (MeOD, 126 MHz): ! 26.18 (d, JC–P = 8.90 Hz, 
NCHCH2CH2), 32.20 (d, JC–P = 4.60 Hz, NCHCH2), 48.12 (d, JC–P = 4.60 Hz, CHNCH2), 
62.17 (d, JC–P = 7.00 Hz, NCH), 67.08 (d, JC–P = 5.00 Hz, C-5’), 68.03 (OCH2Ph), 69.46 
(d, JC–P = 7.40 Hz, C-4’), 73.66 (C-1’), 117.60, 121.18, 121.22, 126.16, 129.36, 129.40, 
129.59, 130.85 (C-5, PhO, OCH2Ph), 137.25 (‘ipso’ OCH2Ph), 139.75 (C-8), 152.05 (d, 
JC–P = 6.70 Hz, ipsoPhO), 153.34 (C-4), 155.74 (C-2), 159.50 (C-6), 174.84 
(COOCH2Ph). EI MS= 569.1917 (M+H). HPLC = H2O/ACN from 100/0 to 0/100 in 30 
min = retention time 16.57 min; H2O/MeOH 100/0 to 20/80 in 5 min, 20/80 isocratic 10 
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min, then to 0/100 in 10 min = retention time 19.07 min. 
Synthesis of N2-DMF-acyclovir-[1-naphthyl(benzyloxy-L-valinyl)] phosphate 
[3.4g]. 
Chemical Formula: C33H38N7O7P 
Molecular Weight: 675.6713 
Prepared according to Standard Procedure B, 
from 3.3 (0.70 g, 2.5 mmol) in anhydrous THF 
(35 mL), tBuMgCl (1.0 M THF solution, 5 mL, 
5 mmol), 2.2j (2.16 g, 5 mmol) in anhydrous THF (15 mL). The reaction mixture was 
stirred at room temperature overnight. After this period the solvent was removed under 
reduced pressure. The residue was purified by column chromatography gradient elution 
of DCM/MeOH = 98/2 then 96/4 then 94/6, to give a white solid (60%, 1 g). 
31P NMR (MeOD, 202 MHz): ! 4.96, 4.73. 
1H NMR (MeOD, 500 MHz): ! 8.50 (1H, s, 
NCHN(CH3)2), 8.13-8.10 (1H, m, H-8 Naph), 7.97-7.82 (2H, m, H-8, H-6 Naph), 7.64-
7.63 (1H, m, H-2 Naph), 7.5-7.42 (2H, m, H-5 Naph, H-7 Naph), 7.35-7.22 (7H, m, 
Naph, OCH2Ph), 5.44 (2H, 1s, H-1’), 5.02 (2H, 1s, OCH2Ph), 4.25-4.20 (2H, m, H-5’), 
3.74-3.70 (3H, m, NHCH, H-4’), 3.03-2.99 (6H, m, N(CH3)2), 2.02-1.95 (1H, m, 
CH(CH3)2), 0.84-0.81 (6H, m, CH(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 18.38, 18.27 
(2s, CH(CH3)2), 19.55, 19.60 (2s, CH(CH3)2), 33.07 (d, JC–P = 7.20 Hz, CH(CH3)2) 33.23 
(d, JC–P = 7.20 Hz, CH(CH3)2), 35.34, 41.48 (2s, N(CH3)2), 62.03, 62.07 (2s, NHCH), 
67.24 (d, JC–P = 5.54 Hz, C-5’), 67.38 (d, JC–P = 5.54 Hz, C-5’), 67.80 (s, OCH2Ph), 
69.40, 69.46 (2s, C-4’), 73.72 (s, C-1’), 116.13, 116.15, 116.33, 116.36, 120.35, 122.74, 
122.86, 125.87, 125.92, 126.53, 127.42, 127.45, 127.78, 127.87, 128.84, 128.88, 
129.35, 129.40, 129.53, 129.54, 129.57 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 
Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.21 (‘ipso’ OCH2Ph), 137.11, 
137.14 (2s, C-8a Naph) 140.55 (s, C-8), 148.03 (d, JC–P = 7.50 Hz, ‘ipso’ ONaph), 
148.05 (d, JC–P = 7.50 Hz, ‘ipso’ ONaph) 152.36 (s, C-4), 159.24 (s, C-2), 159.77 (s, 
N(CH3)2), 160.18, (s, C-6), 173.86 (d, JC–P = 2.52 Hz, COOCH2Ph), 174.09 (d, JC–P = 
2.52 Hz, COOCH2Ph). EI MS= 676.26 (M+H
+). HPLC = H2O/ACN from 90/10 to 
0/100 in 20 min = retention time 15.23 min; H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 
isocratic 10 min, then to 0/100 in 5 min = retention time 12.45, 12.84 min. 
 
NH
NN
N
O
N
O
OP
O
O
NH
O
O
Bn
CH N
CH3
CH3
CH3
CH3
Chapter 9 
 224 
Synthesis of acyclovir-[1-naphthyl(benzyloxy-L-valinyl)] phosphate [3.2g]. 
Chemical Formula: C30H33N6O7P 
Molecular Weight: 620.5928 
A solution of 3.4g (0.9 g, 1.33 mmol) in isopropanol (60 
mL) was stirred under reflux for 62 h. The solvent was 
then removed under reduced pressure and the residue 
was purified by column chromatography, gradient elution of DCM/MeOH (98/2 then 
96/4 then 94/6) to give a white solid which was further purified by preparative reverse 
phase HPLC (gradient elution of H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 
10 min, then to 0/100 in 5 min) to give a white solid (10%, 0.08 g). 
31P NMR (MeOD, 202 MHz): ! 4.79, 4.90. 
1H NMR (MeOD, 500 MHz): ! 8.13-8.10 
(1H, m, H-8 Naph), 7.89-7.87 (1H, m, H-6 Naph), 7.77 (1H, s, H-8), 7.71-7.68 (1H, m, 
H-2 Naph), 7.55-7.51 (2H, m, H-5 Naph, H-7 Naph), 7.45-7.25 (7H, m, Naph, 
OCH2Ph), 5.39 (2H, 1s, H-1’), 5.05 (2H, 1s, OCH2Ph), 4.24-4.19 (2H, m, H-5’), 3.78-
3.73 (3H, m, NHCH, H-4’), 2.03-2.01 (1H, m, CH(CH3)2), 0.89-0.84 (6H, m, 
CH(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 18.23, 18.32 (2s, CH(CH3)2), 19.48, 19.52 
(2s, CH(CH3)2), 33.07 (d, JC–P = 7.30 Hz, CH(CH3)2) 33.27 (d, JC–P = 7.30 Hz, 
CH(CH3)2), 62.05, 62.09 (2s, NHCH), 67.26 (d, JC–P = 5.54 Hz, C-5’), 67.37 (d, JC–P = 
5.54 Hz, C-5’), 67.83 (s, OCH2Ph), 69.36 (d, JC–P = 7.18 Hz, C-4’), 69.45 (d, JC–P = 7.18 
Hz, C-4’), 73.68, 73.64 (2s, C-1’), 116.19, 116.22, 116.35, 116.38, 117.54, 117.59, 
122.75, 122.87, 125.87, 125.91, 126.51, 126.52, 127.40, 127.43, 127.74, 128.79, 
128.83, 129.33, 129.37, 129.49, 129.54, 129.57 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, 
C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.26 (‘ipso’ OCH2Ph), 137.13 
(s, C-8a Naph) 139.69 (s, C-8), 148.03 (d, JC–P = 7.56 Hz, ‘ipso’ ONaph), 148.06 (d, JC–P 
= 7.56 Hz, ‘ipso’ ONaph) 153.36 (s, C-4), 155.56 (s, C-2), 159.37 (s, C-6), 173.96 (d, 
JC–P = 2.52 Hz, COOCH2Ph), 174.10 (d, JC–P = 2.52 Hz, COOCH2Ph). EI MS= 621.2204 
(M+H+). HPLC = H2O/ACN from 90/10 to 0/100 in 20 min = retention time 14.19 min; 
H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 10 min, then to 0/100 in 5 min = 
retention time 11.59, 11.89 min. 
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Synthesis of N2-DMF-acyclovir-[1-naphthyl(benzyloxy-L-leucinyl)] phosphate 
[3.4h]. 
Chemical Formula: C34H40N7O7P 
Molecular Weight: 689.6979 
Prepared according to Standard Procedure B, 
from 3.3 (0.45 g, 1.60 mmol) in anhydrous 
THF (20 mL), tBuMgCl (1.0 M THF solution, 
3.21 mL, 3.21 mmol), 2.2l (1.43 g, 3.21 mmol) in anhydrous THF (5 mL) and the 
reaction mixture was stirred at room temperature overnight. The residue was purified by 
column chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 to give a 
white solid (65%, 0.73 g). 
31P NMR (MeOD, 202 MHz): ! 4.39, 3.87. 
1H NMR (MeOD, 500 MHz): ! 8.51, 8.49 
(1H, 2s, NCHN(CH3)2), 8.29, 8.28 (1H, 2s, H-8 Naph), 8.14, 8.11 (1H, m,
 H-6 Naph), 
7.91, 7.89 (1H, 2s, H-8), 7.85-7.84 (1H, m, H-2 Naph), 7.78-7.77 (1H, m, H-5 Naph), 
7.66, 7.64 (1H, m, H-7 Naph), 7.50-7.19 (7H, m, Naph, OCH2Ph), 5.44, 5.41 (2H, 2s, 
H-1’), 5.06, 5.04 (2H, m, OCH2Ph), 4.25-4.13 (2H, m, H-5’), 3.99-3.92 (1H, m, 
NHCH), 3.74-3.71 (2H, m, H-4’), 3.03, 3.02, 3.00, 2.99 (6H, 4s, N(CH3)2) 1.64-1.57 
(0.5H, m, CH2CH(CH3)2 of one diastereoisomer), 1.51-1.30 (2.5H, m,  CH2CH(CH3)2 of 
one diastereoisomer, CH2CH(CH3)2), 0.80-0.66 (6H, m, CH2CH(CH3)2). 
13C NMR 
(MeOD, 126 MHz): ! 22.74, 22.93, 23.08, 23.22 (4s, CH2CH(CH3)2), 25.42, 25.60 (2s, 
CH(CH3)2), 35.39, 41.51 (2s, N(CH3)2), 43.81 (d, JC–P = 7.68 Hz, CH2CH(CH3)2), 44.03 
(d, JC–P = 7.68 Hz, CH2CH(CH3)2), 54.74, 54.85 (2s, NHCH), 67.28 (d, JC–P = 5.42 Hz, 
C-5’), 67.53 (OCH2Ph ), 67.88 (d, JC–P = 5.42 Hz, C-5’), 69.43 (d, JC–P = 3.49 Hz, C-4’), 
69.49 (d, JC–P = 3.49 Hz, C-4’), 73.76 (s, C-1’), 115.07, 116.06, 116.09, 116.43, 116.46, 
122.72, 122.87, 123.32, 123.79, 125.89, 125.99, 126.39, 126.53, 126.88, 127.12, 
127.49, 127.79, 127.81, 128.53, 128.88, 128.92, 129.19, 129.26, 129.39, 129.42, 
129.47, 129.56, 129.60 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-
7 Naph, C-8 Naph, OCH2Ph), 136.17, 136.26 (2s, ‘ipso’ OCH2Ph), 137.17 137.20 (2s, 
C-8a Naph), 138.37 (C-8), 148.02 (d, JC–P = 7.50, ‘ipso’ ONaph), 150.50 (d, JC–P = 7.50, 
‘ipso’ ONaph), 152.26, 152.58 (2s, C-4), 159.27 (s, C-2), 159.84 (s, N(CH3)2), 174.70 
(d, JC–P = 2.71 Hz, COOCH2Ph), 175.10 (d, JC–P = 2.71 Hz, COOCH2Ph). EI MS= 
712.26 (M+Na+). HPLC = H2O/ACN from 90/10 to 0/100 in 30 min, then 0/100 
isocratic for 5 min = retention time 19.00 min; H2O/MeOH 90/10 to 0/100 in 30 min, 
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then 0/100 isocratic for 5 min = retention time 26.85, 27.01 min. 
Synthesis of acyclovir-[1-naphthyl(benzyloxy-L-leucinyl)] phosphate [3.2h] 
Chemical Formula: C34H40N7O7P 
Molecular Weight: 689.6979 
A solution of 3.4h (0.73 g, 1.06 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography gradient elution of DCM/MeOH = 
98/2 then 96/4 then 94/6. The product was purified by preparative reverse phase HPLC 
(gradient elution of H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 10 min, then to 
0/100 in 5 min) to give a white solid (21%, 0.14g). 
31P NMR (MeOD, 202 MHz): 4.49, 4.04. 
1H NMR (MeOD, 500 MHz): ! 8.29, 8.28 (1H, 
2s, H-8 Naph), 8.15, 8.11 (1H, m, H-6 Naph), 7.86, 7.85 (1H, 2s, H-8), 7.85-7.84 (1H, 
m, H-2 Naph), 7.79-7.78 (1H, m, H-5 Naph), 7.69-7.66 (1H, m, H-7 Naph), 7.62-7.20 
(7H, m, Naph, OCH2Ph), 5.36, 5.33 (2H, 2s, H-1’), 5.06, 5.05 (2H, m, OCH2Ph), 4.23-
4.13 (2H, m, H-5’), 3.99-3.94 (1H, m, NHCH), 3.72-3.68 (2H, m, H-4’), 1.67-1.60 
(0.5H, m, CH2CH(CH3)2 of one diastereoisomer), 1.55-1.30 (2.5H, m,  CH2CH(CH3)2 of 
one diastereoisomer, CH2CH(CH3)2), 0.82-0.67 (6H, m, CH2CH(CH3)2). 
13C NMR 
(MeOD, 126 MHz): ! 22.74, 22.95, 23.08, 23.22 (4s, CH2CH(CH3)2), 25.42, 25.63 (2s, 
CH(CH3)2), 43.82  (d, JC–P = 7.86, Hz CH2CH(CH3)2), 44.08 (d, JC–P = 7.86 Hz, 
CH2CH(CH3)2), 54.75, 54.85 (2s, NHCH), 67.30 (d, JC–P = 5.47 Hz, C-5’), 67.54 
(OCH2Ph), 67.92 (d, JC–P = 5.47 Hz, C-5’), 69.42 (d, JC–P = 7.44 Hz, C-4’), 69.48 (d, JC–P 
= 7.44 Hz, C-4’), 73.73 (s, C-1’), 115.10, 115.12, 116.12, 116.15, 116.48, 116.50, 
122.73, 122.88, 123.37, 123.79, 125.90, 125.99, 126.40, 126.56, 126.88, 127.12, 
127.46, 127.49, 127.79, 128.52, 128.85, 128.89, 129.18, 129.26, 129.39, 129.40, 
129.43, 129.45, 129.55, 129.59 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 
Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.18, 136.26 (2s, ‘ipso’ OCH2Ph), 137.17 
137.23 (2s, C-8a Naph), 139.88 (C-8), 148.00 (d, JC–P = 7.39 Hz, ‘ipso’ ONaph), 150.50 
(d, JC–P = 7.39 Hz, ‘ipso’ ONaph), 155.64 (C-4), 159.50 (s, C-2), 174.90 (d, JC–P = 2.50, 
COOCH2Ph), 175.10 (d, JC–P = 2.50, COOCH2Ph). EI MS= 657.22 (M+Na
+). HPLC = 
H2O/ACN from 100/0 to 0/100 in 20 min, then 0/100 isocratic for 5 min = retention 
time min 15.00; H2O/MeOH 90/10 to 0/100 in 25 min, then 0/100 isocratic for 5 min = 
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retention time 22.91 min. 
Synthesis of N2-DMF-acyclovir-[1-naphthyl(benzyloxy-L-isoleucinyl)] phosphate 
[3.4i]. 
Chemical Formula: C34H40N7O7P 
Molecular Weight: 689.6979 
Prepared according to Standard Procedure B, 
from 3.3 (0.40 g, 1.43 mmol) in anhydrous 
THF (20 mL), tBuMgCl (1.0 M THF 
solution, 2.85 mL, 2.85 mmol), and 2.2n 
(1.27 g, 2.85 mmol) in anhydrous THF (5 mL). The reaction mixture was stirred at 
room temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4 to give a white solid (47%, 0.47 g). 
31P NMR (MeOD, 202 MHz): ! 4.87, 4.56. 
1H NMR (MeOD, 500 MHz): ! 8.55 (1H, bs, 
NCHN(CH3)2), 8.13, 8.11 (1H, 2s, H-8 Naph), 7.88-7.85 (2H, m, H-6 Naph, H-8), 7.67-
7.65 (1H, m, H-2 Naph), 7.52-7.46 (2H, m, H-5 Naph, H-7 Naph), 7.43-7.24 (7H, m, 
Naph, OCH2Ph), 5.46 (2H, bs, H-1’), 5.08-4.96 (2H, m, OCH2Ph), 4.29-4.16 (2H, m, H-
5’), 3.83-3.74 (3H, m, H-4’, NHCH), 3.06, 3.04 (3H, 2s, N(CH3)2), 3.03 (3H, bs, 
N(CH3)2) 1.74-1.69 (1H, m, CH(CH3)CH2CH3), 1.44-1.35 (1H, m, CH(CH3)CH2CH3), 
1.12-1.03 (1H, m, CH(CH3)CH2CH3), 0.81 (3H, m, CH(CH3)CH2CH3), 0.76-0.73 (3H, 
m, CH(CH3)CH2CH3). 
13C NMR (MeOD, 126 MHz): ! 11.55, 11.64 (2s, 
CH(CH3)CH2CH3), 15.84, 15.94 (2s, CH(CH3)CH2CH3), 25.89, 25.95 (2s, 
CH(CH3)CH2CH3), 35.35 (N(CH3)2), 39.91 (d, JC–P = 7.08 Hz, CH(CH3)CH2CH3), 39.99 
(d, JC–P = 7.08 Hz, CH(CH3)CH2(CH3), 41.49 (N(CH3)2), 60.84, 60.96 (2s, NHCH), 
67.26 (d, JC–P = 5.44 Hz, C-5’), 67.37 (d, JC–P = 5.44 Hz, C-5’), 67.80 (OCH2Ph), 69.42, 
69.48 (2s, C-4’), 73.73 (2s, C-1’), 116.11, 116.14, 116.39, 116.41, 120.36, 122.75, 
122.88, 125.88, 125.95, 126.50, 126.53, 127.43, 127.46, 127.78, 127.79, 128.85, 
128.88, 129.37, 129.42, 129.53, 129.58, 129.62 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, 
C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.23 (‘ipso’ 
OCH2Ph), 137.11 137.14 (2s, C-8a Naph), 140.56 (C-8), 148.00 (d, JC–P = 7.26 Hz, 
‘ipso’ ONaph), 148.04 (d, JC–P = 7.26 Hz, ‘ipso’ ONaph), 152.39 (C-4), 159.27 (C-2), 
159.80 (N(CH3)2), 160.19 (C-6), 173.80 (d, JC–P = 2.75 Hz, COOCH2Ph), 174.00 (d, JC–P 
= 2.75 Hz, COOCH2Ph). EI MS= 712.267 (M+Na
+). HPLC = H2O/ACN from 90/10 to 
0/100 in 30 min, then 0/100 isocratic for 5 min = retention time 19.00 min; H2O/MeOH 
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90/10 to 0/100 in 30 min, then 0/100 isocratic for 5 min = retention time 24.24, 24.61 
min. 
Synthesis of acyclovir-[1-naphthyl(benzyloxy-L-isoleucinyl)] phosphate [3.2i]. 
Chemical Formula: C34H40N7O7P 
Molecular Weight: 689.6979 
A solution of 3.4i (0.44 g, 0.64 mmol) in 
isopropanol (20 mL) was stirred under reflux for 62 
h. The solvent was then removed under reduced 
pressure and the residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. The 
product was purified by preparative reverse phase HPLC (gradient elution of 
H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 10 min, then to 0/100 in 5 min) to 
give a white solid (17%, 0.07g). 
31P NMR (MeOD, 202 MHz): ! 4.82, 4.63. 
1H NMR (MeOD, 500 MHz): ! 8.16-8.11 
(1H, m, H-8 Naph), 7.88-7.87 (1H, 2s, H-6 Naph), 7.77 (bs, H-8), 7.70-7.68 (1H, m, H-
2 Naph), 7.54-7.50 (2H, m, H-5 Naph, H-7 Naph), 7.43-7.20 (7H, m, Naph, OCH2Ph), 
5.38 (2H, bs, H-1’), 5.09-4.98 (2H, m, OCH2Ph), 4.24-4.19 (2H, m, H-5’), 3.84-3.81 
(1H, m, NHCH), 3.75-3.73 (2H, m, H-4’), 1.77-1.70 (1H, m, CH(CH3)CH2CH3), 1.47-
1.37 (1H, m, CH(CH3)CH2CH3), 1.14-1.05 (1H, m, CH(CH3)CH2CH3), 0.87-0.85 (3H, 
m, CH(CH3)CH2CH3), 0.79-0.74 (3H, m, CH(CH3)CH2CH3). 
13C NMR (MeOD, 126 
MHz): ! 11.50, 11.59 (2s, CH(CH3)CH2CH3), 15.79, 15.87 (2s, CH(CH3)CH2CH3), 
25.90, 25.97 (2s, CH(CH3)CH2CH3), 39.92 (d, JC–P = 7.12 Hz, CH(CH3)CH2CH3), 40.06 
(d, JC–P = 7.12 Hz, CH(CH3)CH2(CH3), 60.84, 60.98 (2s, NHCH), 67.27 (d, JC–P = 5.46 
Hz, C-5’), 67.36 (d, JC–P = 5.46 Hz, C-5’), 67.83 (OCH2Ph), 69.38 (d, JC–P = 7.24 Hz, C-
4’), 69.47 (d, JC–P = 7.24 Hz, C-4’), 73.66, 73.70 (2s, C-1’), 116.17, 116.19, 116.40, 
116.42, 117.53, 117.57, 122.75, 122.88, 123.10, 123.85, 125.88, 125.94, 126.26, 
126.52, 126.87, 127.00, 127.42, 127.44, 127.76, 128.81, 128.84, 129.36, 129.39, 
129.43, 129.51, 129.52, 129.62 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 
Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.28 (‘ipso’ OCH2Ph), 137.11 137.12 (2s, C-
8a Naph), 139.71 (C-8), 148.00 (d, JC–P = 8.03 Hz, ‘ipso’ ONaph), 153.38 (C-4), 155.64, 
155.65 (2s, C-2), 159.38 (C-6), 173.90 (d, JC–P = 3.48 Hz, COOCH2Ph), 174.10 (d, JC–P 
= 3.48 Hz, COOCH2Ph). EI MS= 657.22 (M+Na
+). HPLC = H2O/ACN from 100/0 to 
0/100 in 20 min, then 0/100 isocratic for 5 min = retention time min 14.92; H2O/MeOH 
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90/10 to 0/100 in 25 min, then 0/100 isocratic for 5 min = retention time 22.77, 23.00 
min. 
Synthesis of N2-DMF-acyclovir-[phenyl(benzyloxy-L-phenylalaninyl)] phosphate 
[3.4j]  
Chemical Formula: C37H38N7O7P 
Molecular Weight: 723.7141 
Prepared according to Standard Procedure B, 
from 3.3 (0.7 g, 2.5 mmol) in anhydrous THF 
(30 mL), tBuMgCl (1.0 M THF solution, 5 mL, 
5 mmol), and 2.2p (2.4 g, 5 mmol) in anhydrous THF (3 mL). The reaction mixture was 
stirred at room temperature overnight. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4, then 94/6 to give to 
give a white solid (50%, 0.72 g).  
31P-NMR (MeOD, 202 MHz): ! 3.85, 3.73. 1H-NMR (MeOD, 500 MHz): ! 8.41, 8.39 
(1H, 2s, NCHN(CH3)2), 8.26, 8.24 (1H, 2s, H-8 Naph), 8.04, 8.01 (1H, m,
 H-6 Naph), 
7.87, 7.85 (1H, 2s, H-8), 7.71-7.70 (1H, m, H-2 Naph), 7.57-7.56 (1H, m, H-5 Naph), 
7.45, 6.82 (13H, m, Naph, OCH2Ph, CHCH2Ph), 5.34, 5.33 (2H, 2s, H-1’), 4.99-4.93 
(2H, m, COOCH2Ph), 4.23-4.14 (1H, m, CHCH2Ph), 4.07-3.95 (2H, m, H-5’), 3.61-3.57 
(2H, m, H-4’), 3.02-2.99 (6H, m, N(CH3)2), 2.92-2.69 (2H, m, CHCH2Ph). 
Synthesis of acyclovir-[phenyl(benzyloxy-L-phenylalaninyl)] phosphate [3.2j]. 
Chemical Formula: C34H33N6O7P 
Molecular Weight: 668.6356 
A solution of 3.4j (0.34 g, 0.47 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by flash column chromatography, gradient elution of DCM/MeOH 
(98/2 then 96/4 then 94/6), to give a white solid which was further purified by 
preparative reverse phase HPLC (gradient elution of H20/CH3CN from 90/10 to 0/100 in 
25 min) to give a white solid (16%, 0.05 g).  
31P-NMR (MeOD, 202 MHz): ! 3.86, 3.77. 1H-NMR (MeOD, 500 MHz): ! 8.05, 8.00 
(1H, 2s, H-8 Naph), 7.85, 7.84 (1H, m, H-6 Naph), 7.73 (1H, bs, H-8), 7.66-7.64 (1H, 
m, H-2 Naph), 7.52-7.45 (2H, m, H-5 Naph, H-7 Naph), 7.34, 7.08 (12H, m, Naph, 
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OCH2Ph, CHCH2Ph), 5.31, 5.30 (2H, 2s, H-1’), 5.05-4.98 (2H, m, COOCH2Ph), 4.25-
4.18 (1H, m, CHCH2Ph), 4.00-3.75 (2H, m, H-5’ of one diastereoisomer), 3.59 (2H, br 
s, H-4’), 3.08-3.01 (1H, m, CHCH2Ph of one diastereoisomer), 2.89-2.81 (1H, m, 
CHCH2Ph of one diastereoisomer). 
13C-NMR (MeOD, 125 MHz): ! 40.91 (d, JC–P = 
8.14 Hz, CHCH2Ph), 40.98 (d, JC–P = 8.14 Hz, CHCH2Ph), 57.89, 58.08 (2s, CHCH2Ph), 
67.01 (d, JC–P = 5.53 Hz, C-5’), 67.08 (d, JC–P = 5.53 Hz, C-5’), 68.01, 68.06 (2s, 
COOCH2Ph), 69.28, 69.33 (2s, C-4’), 73.64 (C-1’), 116.15, 116.18, 116.21, 122.80, 
122.83, 125.88, 126.54, 127.42, 127.44, 127.73, 127.91, 127.94, 128.78, 128.81, 
129.32, 129.47, 129.50, 129.52, 129.54, 130.55, 130.66 (C-5, NaphO, OCH2Ph, 
CHCH2Ph), 136.21, 136.23(2s, ‘ipso’ CHCH2Ph), 136.93, 136.98 (2s, ‘ipso’ OCH2Ph), 
137.95 138.09 (2s, C-8a Naph), 139.69 (C-8), 147.90 (d, JC–P = 7.25 Hz, ‘ipso’ ONaph), 
148.00 (d, JC–P = 7.25 Hz, ‘ipso’ ONaph), 153.32 (C-4), 155.62 (C-2), 159.38 (C-6), 
173.86 (d, JC–P = 3.53 Hz, COOCH2Ph), 173.94 (d, JC–P = 3.53 Hz, COOCH2Ph). EI 
MS= 691.21 (M+Na+), 707.18 (M+K+). HPLC = H2O/ACN from 100/0 to 30/70 in 10 
min, then 30/70 isocratic for 10 min, from 30/70 to 0/100 in 5 min, then 0/100 isocratic 
for 5 min = retention time min 15.35; H2O/MeOH 90/10 to 0/100 in 25 min, then 0/100 
isocratic for 5 min = retention time 22.77, 23.00 min. 
Synthesis of N2-DMF-acyclovir-[1-phenyl(tert-butoxy-L-alaninyl)] phosphate 
[3.4k]. 
Chemical Formula: C24H34N7O7P 
Molecular Weight: 563.5432 
 
Prepared according to Standard Procedure B, 
from 3.3 (0.40 g, 1.43 mmol) in anhydrous THF 
(15 mL), tBuMgCl (1.0 M THF solution, 2.86 mL, 2.86 mmol), 2.2c (1.37 g, 4.32 
mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at room 
temperature overnight. The residue was purified by flash column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4, to give a white solid (75%, 0.60 g).  
31P-NMR (MeOD, 202 MHz): ! 3.91, 3.73. 1H-NMR (MeOD, 500 MHz): ! 8.63 (1H, s, 
NCHN(CH3)2), 7.95, 7.93 (1H, 2s, H-8), 7.34-7.31 (2H, m, PhO), 7.20-7.15 (3H, m, 
PhO), 5.56, 5.55 (2H, 2s, H-1’), 4.28-4.20 (2H, m, H-5’), 3.85-3.76 (3H, m, H-4’, 
CHCH3), 3.17, 3.08 (3H, 2s, N(CH3)2), 3.07, 3.06 (3H, 2s, N(CH3)2), 1.43-1.42 (9H, m, 
C(CH3)3), 1.31-1.26 (3H, m, CHCH3). 
13C-NMR (MeOD, 125 MHz): ! 20.63 (d, JC–P = 
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7.03 Hz, CHCH3), 20.74 (d, JC–P = 7.03 Hz, CHCH3), 28.31 (C(CH3)3), 35.46, 41.63 (2s, 
N(CH3)2), 52.14, 52.26 (2s, CHCH3), 67.07 (d, JC–P = 6.12 Hz, C-5’), 67.12 (d, JC–P = 
6.12 Hz, C-5’), 69.49 (d, JC–P = 3.74 Hz, C-4’), 69.55 (d, JC–P = 3.74 Hz, C-4’), 73.81 
(C-1’), 82.63, 82.66 (2s, C(CH3)3), 120.29, 121.43, 121.47, 121.49, 121.53, 126.11, 
130.78 (C-5, PhO), 140.67 (C-8), 152.22 (d, JC–P = 5.30 Hz, ‘ipso’PhO), 152.27 (d, JC–P 
= 5.30 Hz, ‘ipso’PhO), 153.85 (C-4), 159.33 (C-2), 159.92 (CHN(CH3)2), 160.19 (C-6), 
174.21 (d, JC–P = 5.90 Hz, COOC(CH3)3), 174.40 (d, JC–P = 5.90 Hz, COOC(CH3)3). EI 
MS = 564.23 (M+H), 586.22 (M+Na).  
Synthesis of acyclovir-[phenyl(tert-butoxy-L-alaninyl)] phosphate [3.2k].  
Chemical Formula: C21H29N6O7P 
Molecular Weight: 508.4647 
A solution of 3.4k (0.50 g, 0.89 mmol) in isopropanol 
(25 mL) was stirred under reflux for 50 h. After this 
period the solvent was removed under reduced pressure 
and the residue was purified by flash column 
chromatography, gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8. 
The product was purified by preparative TLC (gradient elution of DCM/MeOH = 98/2 
then 96/4 then 92/8) to give a white solid (22%, 0.10 g).  
31P-NMR (MeOD, 202 MHz): ! 3.81, 3.71. 1H-NMR (MeOD, 500 MHz): ! 7.87, 7.86 
(1H, 2s, H-8), 7.34-7.31 (2H, m, PhO), 7.26-7.14 (3H, m, PhO), 5.48, 5.46 (2H, 2s, H-
1’), 4.26-4.21 (2H, m, H-5’), 3.83-3.80 (3H, m, H-4’, CHCH3), 1.44-1.42 (9H, m, 
C(CH3)3), 1.33-1.29 (3H, m, CHCH3). 
13C-NMR (MeOD, 125 MHz): ! 20.61 (d, JC–P = 
6.70 Hz, CHCH3), 20.73 (d, JC–P = 6.70 Hz, CHCH3), 28.29 (C(CH3)3), 52.18, 52.28 (2s, 
CHCH3), 67.08 (d, JC–P = 5.50 Hz, C-5’), 67.14 (d, JC–P = 5.50 Hz, C-5’), 69.45 (d, JC–P = 
6.63 Hz, C-4’), 69.51 (d, JC–P = 6.63 Hz, C-4’), 73.79 (C-1’), 82.81, 82.87 (2s, C(CH3)3), 
117.44, 121.37, 121.41, 121.15, 121.49, 121.62, 121.66, 124.02, 124.62, 124.92, 
126.16, 130.12, 130.20, 130.22, 130.30, 130.34, 130.80,  (C-5, PhO), 139.98 (C-8), 
152.14, 152.20 (2s, C-4), 153.44 (‘ipso’PhO), 155.70 (C-2), 159.55 (C-6), 174.44 (d, JC–
P = 5.30 Hz, COOC(CH3)3), 174.55 (d, JC–P = 5.30 Hz, COOC(CH3)3). EI MS = 509.19 
(M+H). HPLC = H2O/MeOH from 100/0 to 30/70 in 5 min, then 30/70 isocratic for 10 
min, from 30/70 to 0/100 in 5 min, then 0/100 isocratic for 5 min = retention time 12.64 
min. 
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Synthesis of N2-DMF-acyclovir-[phenyl(neopentoxy-L-alaninyl)] phosphate [3.4l]. 
Chemical Formula: C25H36N7O7P 
Molecular Weight: 577.5698 
Prepared according to Standard Procedure B, 
from 3.3 (0.50 g, 1.78 mmol) in anhydrous 
THF (25 mL), tBuMgCl (1.0 M THF 
solution, 3.56 mL, 3.56 mmol), 2.2d (1.19 g, 3.56 mmol) in anhydrous THF (5 mL). 
The reaction mixture was stirred at room temperature overnight. After this period the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6, to give a 
white solid (85%, 0.88 g).  
31P-NMR (MeOD, 202 MHz): ! 3.87, 3.59. 1H-NMR (MeOD, 500 MHz): ! 8.65, 8.60 
(1H, 2s, NCHN(CH3)2), 7.92 (1H, bs, H-8), 7.32 (2H, bs, PhO), 7.17 (3H, m, PhO), 
5.54, 5.51 (2H, 2s, H-1’), 4.25-4.21 (2H, m, H-5’), 3.95 (1H, bs, CHCH3), 3.82-3.75 
(4H, m, H-4’, COOCH2(CH3)3), 3.22-3.14 (3H, m, N(CH3)2), 3.08-3.04 (3H, m, 
N(CH3)2) 1.34-1.33 (3H, m, CHCH3), 0.92-0.90 (9H, m, COOCH2(CH3)3). 
Synthesis of acyclovir-[phenyl(neopentoxy-L-alaninyl)] phosphate [3.2l]. 
Chemical Formula: C22H31N6O7P 
Molecular Weight: 522.4913 
A solution of 3.4l (0.88 g, 1.52 mmol) in isopropanol 
(30 mL) was stirred under reflux for 62 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography, gradient elution of DCM/MeOH (98/2 
then 96/4 then 94/6) to give a white solid which was further purified by preparative 
reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 
isocratic 10 min, then to 0/100 in 5 min) to give a white solid (14%, 0.11 g). 
31P-NMR (MeOD, 202 MHz): ! 3.80, 3.59. 1H-NMR (MeOD, 500 MHz): ! 7.90, 7.88 
(1H, 2s, H-8), 7.36-7.33 (2H, m, PhO), 7.21-7.17 (3H, m, PhO), 5.56, 5.50 (2H, 2s, H-
1’), 4.24-4.19 (2H, m, H-5’), 4.01-3.95 (1H, m, CHCH3), 3.87-3.77 (4H, m, H-4’, 
COOCH2(CH3)3), 1.39 (1.5H, d, J= 2.52, CHCH3 of one diasteroisomer), 1.35 (1.5H, d, 
J= 2.52, CHCH3 of one diasteroisomer), 0.96-0.95 (9H, m, COOCH2(CH3)3). 
13C NMR (MeOD, 126 MHz): ! 20.56 (d, JC–P = 6.90 Hz, CHCH3) 20.70 (d, JC–P = 6.90 
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Hz, CHCH3), 26.73, 26.84 (2s, COOCH2(CH3)3), 51.63, 51.73 (2s, CHCH3), 67.03 (d, 
JC–P = 5.63 Hz, C-5’), 67.12 (d, JC–P = 5.63 Hz, C-5’), 69.41 (d, JC–P = 7.17 Hz, C-4’), 
69.49 (d, JC–P = 7.17 Hz, C-4’), 73.75 (C-1’), 75.40, 75.42 (2s, COOCH2(CH3)3), 117.27, 
121.40, 121.43, 121.47, 121.50, 122.23, 126.06, 126.10, 127.08, 127.77, 130.14, 
130.43, 130.72, 130.88 (C-5, PhO), 139.73 (C-8), 152.20 (d, JC–P = 2.80 Hz, ‘ipso’PhO), 
152.25 (d, JC–P = 2.80 Hz, ‘ipso’PhO), 153.73 (s, C-4), 155.73 (C-2), 159.23 (s, C-6), 
175.01 (d, JC–P = 5.64 Hz. COOCH2(CH3)3), 175.16 (d, JC–P = 5.64 Hz, COOCH2(CH3)3). 
EI MS= 523.2061 (M+H+). HPLC = H2O/ACN from 90/10 to 0/100 in 20 min = 
retention time 11.87 min; H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, 
then to 0/100 in 5 min = retention time 11.40 min. 
Synthesis of N2-DMF-acyclovir-[1-naphthyl(neopentoxy-L-alaninyl)] phosphate 
[3.4m]. 
Chemical Formula: C29H38N7O7P 
Molecular Weight: 627.6285 
 
Prepared according to Standard Procedure B, 
from 3.3 (0.45 g, 1.61 mmol) in anhydrous THF 
(20 mL), tBuMgCl (1.0 M THF solution, 3.21 
mL, 3.21 mmol), 2.2e (1.20 g, 3.21 mmol) in anhydrous THF (5 mL). The reaction 
mixture was stirred at room temperature overnight. After this period the solvent was 
removed under reduced pressure. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6, to give a white solid (53%, 
0.54 g).  
31P-NMR (MeOD, 202 MHz): ! 4.21, 4.05. 1H-NMR (MeOD, 500 MHz): ! 8.56, 8.60 
(1H, 2s, NCHN(CH3)2), 8.16-8.12 (1H, m, H-8 Naph), 7.92-7.89 (1H, m, H-6 Naph), 
7.82, 7.80 (1H, 2s, H-8), 7.70-7.68 (1H, m, H-2 Naph), 7.54-7.52 (2H, m, H-5 Naph, H-
7 Naph), 7.47, 7.37 (2H, m, H-3 Naph, H-4 Naph), 5.53, 5.51 (2H, 2s, H-1’), 4.34-4.26 
(2H, m, H-5’), 4.08-4.01 (1H, m, CHCH3), 3.86-3.84 (2H, m, H-4’), 3.80-3.70 (2H, m, 
COOCH2(CH3)3), 3.12, 3.11 (3H, 2s, N(CH3)2), 3.08-3.07 (3H, 2s, N(CH3)2), 1.35, 1.33 
(3H, 2d, J= 7.11 Hz, CHCH3), 0.92-0.91 (9H, m, COOCH2(CH3)3). 
13C NMR (MeOD, 
126 MHz): ! 20.71 (d, JC–P = 7.00 Hz, CHCH3) 20.83 (d, JC–P = 7.00 Hz, CHCH3), 
26.80, 26.82 (2s, COOCH2C(CH3)3), 32.34, 32.37 (2s, COOCH2C(CH3)3), 35.40, 41.56 
(2s, N(CH3)2), 51.77, 51.82 (2s, CHCH3), 67.32 (d, JC–P = 5.80 Hz, C-5’), 67.36 (d, JC–P 
= 5.80 Hz, C-5’), 69.47 (d, JC–P = 6.76 Hz, C-4’), 69.52 (d, JC–P = 6.76 Hz, C-4’), 73.74 
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(C-1’), 75.39, 75.42 (2s, COOCH2C(CH3)3), 116.24, 116.26, 116.32, 116.34, 120.36, 
122.73, 122.81, 125.95, 126.56, 127.45, 127.47, 127.80, 128.88, 128.91 (C-5, C-2 
Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph), 136.23 (C-8a 
Naph), 140.57 (C-8), 148.00 (d, JC–P = 1.51 Hz, ‘ipso’ ONaph), 148.10 (d, JC–P = 1.63 
Hz, ‘ipso’ ONaph) 152.38 (C-4), 159.23 (s, C-2), 159.79 (CHN(CH3)2), 160.17 (C6) 
174.90 (d, JC–P = 5.33 Hz, COOCH2C(CH3)3), 175.10 (d, JC–P = 5.33 Hz, 
COOCH2C(CH3)3). EI MS= 650.252 (M+Na
+). HPLC = H2O/ACN from 90/10 to 0/100 
in 30 min, then 0/100 isocratic for 5 min = retention time 17.21 min; H2O/MeOH 90/10 
to 0/100 in 30 min, then 0/100 isocratic for 5 min = retention time 25.05 min.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
Synthesis of acyclovir-[1-naphthyl(neopentoxy-L-alaninyl)] phosphate [3.2m] 
Chemical Formula: C26H33N6O7P 
Molecular Weight: 572.5500 
A solution of 3.4m (0.54 g, 0.86 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. The solvent 
was then removed under reduced pressure and the 
residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. The product was purified 
by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 20/80 in 5 
min, 20/80 isocratic 10 min, then to 0/100 in 5 min) to give a white solid (22%, 0.11g). 
31P-NMR (MeOD, 202 MHz): ! 4.15, 4.09. 1H-NMR (MeOD, 500 MHz): ! 8.14-8.12 
(1H, 2s, H-8 Naph), 7.87-7.85 (1H, m, H-6 Naph), 7.81, 7.79 (1H, 2s, H-8), 7.69-7.68 
(1H, 2s, H-2 Naph), 7.58-7.50 (2H, m, H-5 Naph, H-7 Naph), 7.46-7.35 (2H, m, H-3 
Naph, H-4 Naph), 5.42, 5.40 (2H, 2s, H-1’), 4.32-4.29 (1H, m, H-5’), 4.28-4.24 (1H, m, 
H-5’), 4.11-4.03 (1H, m, CHCH3), 3.83-3.70 (4H, m, H-4’, COOCH2(CH3)3), 1.35, 1.38 
(3H, 2d, J= 7.10 Hz,   CHCH3), 0.92-0.90 (9H, m, COOCH2(CH3)3). 
13C NMR (MeOD, 
126 MHz): ! 20.71 (d, JC–P = 7.00 Hz CHCH3) 20.86 (d, JC–P = 7.00 Hz, CHCH3), 26.77, 
26.79 (2s, COOCH2C(CH3)3), 32.31, 32.35 (2s, COOCH2C(CH3)3), 51.80, 51.84 (2s, 
CHCH3), 67.31 (d, JC–P = 6.12 Hz, C-5’), 67.37 (d, JC–P = 6.12 Hz, C-5’), 69.40 (d, JC–P = 
6.97 Hz, C-4’), 69.50 (d, JC–P = 6.97 Hz, C-4’), 73.77 (C-1’), 75.41, 75.46 (2s, 
COOCH2(CH3)3), 116.28, 116.30, 116.36, 116.38, 117.47, 117.50, 122.71, 122.79, 
125.96, 126.56, 127.46, 127.77, 128.50, 128.86 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, 
C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph), 136.23 (C-4a Naph), 139.77 
(C-8), 147.99, 148.00 (‘ipso’ ONaph), 153.37 (C-4), 155.64 (s, C-2), 159.57 (C6) 
175.10 (d, JC–P = 5.47 Hz, COOCH2C(CH3)3), 175.20 (d, JC–P = 5.47 Hz, 
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COOCH2C(CH3)3). EI MS= 595.211 (M+Na
+). HPLC = H2O/ACN from 100/0 to 0/100 
in 20 min, then 0/100 isocratic for 5 min = retention time 13.77 min; H2O/MeOH 90/10 
to 0/100 in 25 min, then 0/100 isocratic for 5 min = retention time 21.29, 21.41 min. 
9.4. Experimental procedures for chapter 4: synthesis of 6-O-methyl 
and 6-O-ethyl acyclovir ProTides  
Standard procedure D 
To a stirring solution of 6-O-alkyl acyclovir 4.1a and 4.1b (1 eq.) in anhydrous THF 
was added dropwise under argon atmosphere tButMgCl (2 eq.). The reaction mixture 
was stirred at room temperature for 30 min. Then, a solution of the appropriate aryl 
amino acid ester phosphorochloridate 2.2 (2 to 4 eq.) in anhydrous THF was added 
dropwise and the reaction mixture was stirred at room temperature overnight. The 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH in different proportions. 
Synthesis of 9-[(2-Acetoxy-ethoxy)methyl]guanine [4.2] 
Chemical Formula: C10H13N5O4 
Molecular Weight: 267.2413 
Acetic anhydride (4.20 mL, 44.40 mmol) was added dropwise 
to a suspension of ACV (4 g, 17.76 mmol), TEA (5 mL, 35.87 mmol), and DMAP (0.22 
g, 1.77mmol) in ACN (250 mL). The reaction was stirred at room temperature for 4 h. 
Methanol was added to quench the reaction and the mixture was filtered. The resulting 
solid was washed with Et2O and dried (4.35 g, 92%). 
1H NMR (DMSO, 500 MHz): ! 10.63 (1H, s, NH), 7.82 (1H, s, H-8), 6.50 (2H, bs, 
NH2), 5.36 (2H, s, H-1’), 4.09-4.07 (2H, m, H-5’), 3.68-3.66 (2H, m, H-4’), 1.97 (3H, s, 
CH3). 
Synthesis of 9-[(2-Acetoxy-ethoxy)methyl]-2-amino-6-chloropurine [4.3] 
Chemical Formula: C10H12ClN5O3 
Molecular Weight: 285.6870 
 
A mixture of 4.2 (2g, 7.48 mmol) and 
bennzyltriethylammonium chloride (3.42 g, 14.96 mmol) in ACN (24 mL) was cooled 
to 0° C and added to a mixture of N,N-dimethylaniline (1.04 mL, 8.22 mmol) and 
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POCl3 (3.44 mL, 37.4 mmol). The reaction mixture was stirred in a preheated oil bath at 
85 °C for 20 min. The solvent was removed. The yellow foam was dissolved in CHCl3 
and vigorously stirred with crushed ice for 30 min. The layers were separated and the 
aqueous phase was extracted with CHCl3. Crushed ice was added to the combined 
organic phase, which was washed (ice/H2O 3 times, 5% Na2CO3/H2O once) and dried 
over Na2SO4 and concentrated. The residue was purified by column chromathography, 
gradient elution of DCM/MeOH (98/2, then 96/4, then 95/5) to give a white solid (47%, 
0.5 g). 
1H NMR (CHCl3, 500 MHz): ! 7.88 (1H, s, H-8), 5.47 (2H, s, H-1’), 4.14-4.11 (2H, m, 
H-5’), 3.71-3.68 (2H, m, H-4’), 1.96 (3H, s, CH3). 
13C NMR (CDCl3, 126 MHz): ! 
20.73 (CH3), 62.78 (C-4’), 67.59 (C-5’), 72.67 (C-1’), 124.70 (C-5), 142.17 (H-8), 
151.36 (C-6), 154.09 (C-4), 159.66 (C-2), 170.79 (COOCH3). EI MS= 286.07 (M+H). 
Synthesis of 6-O-methyl acyclovir: 9-[(2-hydroxyethoxy)methyl]-2-amino-6-
methoxypurine [4.1a] 
Chemical Formula: C9H13N5O3 
Molecular Weight: 239.2312 
To a stirring suspension of 4.3 (1.5 g; 5.25 mmol) in anhydrous 
MeOH (18 mL) was added at 0 °C NaOMe (1.48 g, 27 mmol) in anhydrous MeOH 
(25% P/P). The mixture was stirred at room temperature for 24 h then quenched by 
addition of Amberlite (H+). The mixture was then filtered and methanol was removed 
under reduced pressure. The residue was purified by column chromatography gradient 
elution DCM/MeOH (98/2, then 96/4, then 94/6, then 92/8) to give a white solid (0.8 g, 
68%).  
1H NMR (MeOH, 500 MHz): ! 7.98 (1H, s, H-8), 5.56 (2H, s, H-1’), 4.08 (3H, s, 
OCH3), 3.66-3.63 (4H, m, H-4’, H-5’). 
13C NMR (MeOH, 126 MHz): ! 54.26 (OCH3), 
61.94 (C-4’), 71.96 (C-5’), 73.94 (C-1’), 115.08 (C-5), 141.27 (C-8), 155.25 (C-4), 
162.18 (C-2), 162.80 (C-6). EI MS= 239.09 (M+H). HPLC = H2O/ACN from 100/0 to 
0/100 in 20 min = retention time 6.60 min; H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 
isocratic 10 min, then to 0/100 in 5 min = retention time 5.91 min. 
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Synthesis of 6-O-ethyl acyclovir: 9-[2-hydroxyethoxy)methyl[-2-amino-6-
ethoxypurine [4.1b] 
Chemical Formula: C10H15N5O3 
Molecular Weight: 253.2578     
     
To a stirring suspension of 4.3 (1.7 g; 5.95 mmol) in anhydrous 
methanol (20 mL) was added at 0 °C NaOEt (1.82 g, 26.78 mmol) in anhydrous 
methanol (25% P/P). The mixture was stirred at 40 °C for 4 h then quenched by 
addition of Amberlite (H+). The mixture was then filtered and methanol was removed 
under reduced pressure. The residue was purified by column chromatography gradient 
elution DCM/Methanol (98/2, then 96/4, then 94/6, then 92/8) to give a white solid 
(0.55 g, 36%). 
1H NMR (MeOH, 500 MHz): ! 7.98 (1H, s, H-8), 5.56 (2H, s, H-1’), 4.56 (2H, q, J= 
7.09 Hz, OCH2CH3), 3.66-3.63 (4H, m, H-4’, H-5’), 1.46 (3H, t, J= 7.09 Hz, 
OCH2CH3). 
13C NMR (MeOH, 126 MHz): ! 14.82 (OCH2CH3), 61.95 (OCH2CH3), 
63.59 (C-4’), 71.95 (C-5’), 73.91 (C-1’), 115.09 (C-5), 141.19 (H-8), 155.28 (C-4), 
162.18 (C-2), 162.46 (C-6). EI MS= 254.13 (M+H). HPLC= H2O/MeOH 90/10 to 30/70 
in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min = retention time 7.15, 8.64 min. 
 Synthesis of 6-O-methyl acyclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate 
[4.4a] 
Chemical Formula: C25H29N6O7P 
Molecular Weight: 556.5075 
Prepared according to Standard Procedure D, from 4.1a 
(0.40 g, 1.68 mmol) in anhydrous THF (20 mL), 
tBuMgCl (1.0 M THF solution, 3.36 mL, 3.36 mmol), 
2.2a (1.78 g, 5.04 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred 
at room temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6. The product was purified 
by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 40/60 in 5 
min, 60/40 isocratic 10 min, then to 0/100 in 5 min) to give a white solid (733 mg, 
78%). 
31P NMR (MeOD, 202 MHz): ! 3.76, 3.47. 
1H NMR (MeOD, 500 MHz): ! 7.94-7.91 
(1H, m, H-8), 7.35-7.28 (7H, m, PhO, OCH2Ph), 7.18-7.12 (3H, m, PhO, OCH2Ph), 
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5.52-5.48 (2H, m, H-1’), 5.13-5.12 (2H, m, OCH2Ph), 4.18-4.11 (2H, m, H-5’), 4.06-
4.05 (3H, 2s, OCH3), 3.99-3.95 (1H, m, NHCH), 3.76-3.71 (2H, m, H-4’), 1.35-1.31 
(3H, m, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.30 (d, JC–P = 6.3 Hz, CHCH3), 
20.38 (d, JC–P = 6.3 Hz, CHCH3), 51.58, 51.70 (2s, NHCH), 54.24 54.26 (2s, OCH3), 
66.98 (d, JC–P = 5.04 Hz, C-5’), 67.08 (d, JC–P = 5.04 Hz, C-5’), 67.94 (OCH2Ph), 69.38 
(d, JC–P = 6.30, C-4’), 69.40 (d, JC–P = 6.30, C-4’), 73.71 (C-1’), 115.10, 121.39, 121.43, 
121.47, 121.50, 126.03, 126.06, 129.32, 129.34, 129.37, 129.57, 129.59, 129.88, 130.69 
(C-5, PhO, OCH2Ph), 137.28 (‘ipso’ OCH2Ph), 141.17, 141.20 (2s, C-8), 152.13 (d, JC–P 
= 5.04 Hz, ‘ipso’PhO), 152.24 (d, JC–P = 5.04 Hz, ‘ipso’PhO), 153.24 (C-4) 155.26 (C-
2), 162.20, 162.79 (2s, C-6), 174.73 (d, JC–P = 5.04 Hz, COOCH2Ph), 174.88 (d, JC–P = 
5.04 Hz, COOCH2Ph). EI MS= 579.17 (M+Na). HPLC = H2O/ACN from 100/0 to 
0/100 in 20 min = retention time 12.00 min; H2O/MeOH 90/10 to 40/60 in 5 min, 40/60 
isocratic 10 min, then to 0/100 in 5 min, 0/100 isocratic 5 min = retention time 14.35, 
15.39 min. 
Synthesis of 6-O-methyl acyclovir-[1-naphthyl(benzyloxy-L-alaninyl)] phosphate 
[4.4b] 
 Chemical Formula: C29H31N6O7P 
Molecular Weight: 606.5662 
Prepared according to Standard Procedure D, from 
4.1a (0.30 g, 1.26 mmol) in anhydrous THF (15 
mL), tBuMgCl (1.0 M THF solution, 2.52 mL, 2.52 
mmol), 2.2b (1.02 g, 2.52 mmol) in anhydrous THF (5 mL). The reaction mixture was 
stirred at room temperature overnight. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4. The product was 
purified by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 
30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min) to give a white solid 
(0.46 g, 60%). 
31P NMR (MeOD, 202 MHz): ! 4.11, 3.93. 
1H NMR (MeOD, 500 MHz): ! 8.10-8.08 
(1H, m, H-8 Naph), 7.88-7.86 (1H, 2s, H-6 Naph), 7.85-7.84 (1H, m, H-8), 7.67-7.66 
(1H, m, H-2 Naph), 7.52-7.47 (2H, m, H-5 Naph, H-7 Naph), 7.42-7.23 (7H, m, Naph, 
OCH2Ph), 5.45,5.41 (2H, 2s, H-1’), 5.10-5.00 (2H, m, OCH2Ph), 4.23-4.16 (2H, m, H-
5’), 4.09-4.04 (1H, m, NHCH), 4.02, 4.01 (3H, 2s, OCH3), 3.74-3.70 (2H, m, H-4’), 
1.33 (1.5H of one diasteroisomer, d, J= 7.08 Hz, CHCH3), 1.30 (1.5H of one 
N
NN
N
NH2O
O
P
O
O
NH
O
O
Bn CH3
O CH3
Chapter 9 
 239 
diasteroisomer, d, J= 7.08 Hz, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.35 (d, JC–P = 
6.3 Hz, CHCH3), 20.46 (d, JC–P = 6.3 Hz, CHCH3), 51.73, 51.79 (2s, NHCH), 54.26 
(OCH3), 67.21 (d, JC–P = 6.3 Hz, C-5’), 67.28 (d, JC–P = 6.3 Hz, C-5’), 67.93, 67.96 
(OCH2Ph), 69.35 (d, JC–P = 7.56 Hz, C-4’), 69.41 (d, JC–P = 7.56 Hz, C-4’), 73.70 (C-1’), 
115.12, 116.25, 116.27, 116.34, 116.36, 122.71, 122.82, 125.89, 125.91, 126.52, 
126.52, 127.42, 127.44, 127.73, 127.90, 127.95, 128.80, 128.82, 129.27, 129.32, 
129.52, 129.57 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, 
C-8 Naph, OCH2Ph), 136.23 (‘ipso’ OCH2Ph), 137.18, 137.22 (2s, C-8a Naph) 141.11, 
141.14 (2s, C-8), 147.96, 148.02 (2s, ‘ipso’ ONaph), 155.21 (C-4), 162.15 (s, C-2), 
162.75 (C-6), 174.74 (d, JC–P = 5.04 Hz, COOCH2Ph), 174.91 (d, JC–P = 5.04 Hz, 
COOCH2Ph). EI MS= 607.20 (M+H), 629.19 (M+Na). HPLC= H2O/ACN from 100/0 
to 0/100 in 20 min = retention time 16.55 min; H2O/MeOH 90/10 to 30/70 in 5 min, 
30/70 isocratic 10 min, then to 0/100 in 10 min, 0/100 isocratic 5 min = retention time 
12.31, 12.85 min. 
Synthesis of 6-O-ethyl acyclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate [4.4c] 
 Chemical Formula: C26H31N6O7P 
 Molecular Weight: 570.5341 
Prepared according to Standard Procedure D, from 4.1b 
(0.20 g, 0.79 mmol) in anhydrous THF (10 mL), 
tBuMgCl (1.0 M THF solution, 1.58 mL, 1.58 mmol), 
2.2a (0.56 g, 1.58 mmol) in anhydrous THF (5 mL) and the reaction mixture was stirred 
at room temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2, then, 96/4 then 94/6. The product was further 
purified by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 
30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min) to give a white solid 
(241 mg, 53%). 
31P NMR (MeOD, 202 MHz): ! 3.76, 3.47. 
1H NMR (MeOD, 500 MHz): ! 7.92-7.89 
(1H, 2s, H-8), 7.35-7.26 (7H, m, PhO, OCH2Ph), 7.15-7.12 (3H, m, PhO, OCH2Ph), 
5.49, 5.46 (2H, 2s, H-1’), 5.11 (2H, OCH2Ph), 4.54-4.49 (2H, m, OCH2CH3), 4.19-4.10 
(2H, m, H-5’), 4.00-3.93 (1H, m, NHCH), 3.74-3.70 (2H, m, H-4’), 1.42 (3H, t, J= 7.09 
Hz, OCH2CH3), 1.34 (1.5H of one diasteroisomer, d, J= 7.00 Hz, CHCH3), 1.31 (1.5H 
of one diasteroisomer, d, J= 7.00 Hz, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 14.82 
(OCH2CH3), 20.37 (d, JC–P = 6.3 Hz, CHCH3), 20.45 (d, JC–P = 6.3 Hz, CHCH3), 51.58, 
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51.71 (2s, NHCH), 63.63 (OCH2CH3), 66.99 (d, JC–P = 5.04 Hz, C-5’), 67.09 (d, JC–P = 
5.04 Hz, C-5’), 67.95 (OCH2Ph), 69.36 (d, JC–P = 7.56 Hz, C-4’), 69.39 (d, JC–P = 7.56 
Hz, C-4’), 73.71 (C-1’), 115.13, 121.41, 121.45, 121.49, 121.53, 126.05, 126.08, 
129.33, 129.37, 129.59, 129.61, 129.72, 130.71, 130.69 (C-5, PhO, OCH2Ph), 137.28 
(‘ipso’ OCH2Ph), 141.16 (C-8), 152.11, 152.17 (2s, ‘ipso’PhO),  153.41 (C-4), 155.27 
(C-2), 162.16, 162.43 (2s, C-6), 174.74 (d, JC–P = 5.04 Hz, COOCH2Ph), 174.88 (d, JC–P 
= 5.04 Hz, COOCH2Ph). EI MS= 571.29 (M+H), 593.27 (M+Na). HPLC = H2O/ACN 
90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min, 0/100 isocratic 5 
min = retention time 7.51 min; H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 isocratic 10 
min, then to 0/100 in 5 min, 0/100 isocratic 5 min = retention time 10.36 min. 
 Synthesis of 6-O-ethyl acyclovir-[1-naphthyl(benzyloxy-L-alaninyl)] phosphate 
[4.4d] and 6-O-ethyl acyclovir-[1-naphthyl(methoxy-L-alaninyl)] phosphate 
[4.4f] 
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Chemical Formula: C24H29N6O7P
Molecular Weight: 544.4968
Chemical Formula: C30H33N6O7P
Molecular Weight: 620.5928
4.4d 4.4f
 
Prepared according to Standard Procedure D, from 4.1b (0.20 g, 0.79 mmol) in 
anhydrous THF (10 mL), tBuMgCl (1.0 M THF solution, 1.58 mL, 1.58 mmol), 2.2b 
(0.64 g, 1.58 mmol) in anhydrous THF (2 mL). The reaction mixture was stirred at 
room temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6 to give two products: 4.4d 
and its transesterification product 4.4f. The products were further purified by 
preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 30/70 in 5 
min, 30/70 isocratic 10 min, then to 0/100 in 5 min) to give a white solid [(4.4d)  0.15 g, 
30%, (4.4f) 0.07 g, 16%].  
[4.4d] 
31P NMR (MeOD, 202 MHz): ! 4.11, 3.94. 
1H NMR (MeOD, 500 MHz): ! 8.10-8.09 
(1H, m, H-8 Naph), 7.88-7.85 (2H, m, H-8, H-6 Naph), 7.68-7.66 (1H, m, H-2 Naph), 
7.53-7.48 (2H, m, H-5 Naph, H-7 Naph), 7.41-7.23 (7H, m, Naph, OCH2Ph), 5.45, 5.42 
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(2H, 2s, H-1’), 5.05, 5.03 (2H, 2s, OCH2Ph), 4.52-4.47 (2H, m, OCH2CH3), 4.23-4.16 
(2H, m, H-5’), 4.09-4.02 (1H, m, NHCH), 3.75-3.70 (2H, m, H-4’), 1.42 (1.5 H, t, J= 
7.09 Hz, OCH2CH3), 1.41 (1.5 H, t, J= 7.09 Hz, OCH2CH3), 1.33 (1.5H of one 
diasteroisomer, d, J= 7.12 Hz, CHCH3), 1.30 (1.5H of one diasteroisomer, d, J= 7.12 
Hz, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 14.68  (OCH2CH3), 20.33 (d, JC–P = 7.56 
Hz, CHCH3), 20.45 (d, JC–P = 7.56 Hz, CHCH3) 51.73, 51.79 (2s, NHCH), 63.59 
(OCH2CH3), 67.23 (d, JC–P = 5.41 Hz, C-5’), 67.30 (d, JC–P = 5.41 Hz, C-5’), 67.95, 
67.93 (OCH2Ph), 69.34 (d, JC–P = 6.3 Hz, C-4’), 69.41 (d, JC–P = 6.3 Hz, C-4’), 73.69 (C-
1’), 115.14, 116.25, 116.28, 116.35, 116.37, 122.72, 122.82, 125.88, 125.91, 126.23, 
126.53, 127.42, 127.44, 127.72, 127.86, 127.91, 127.95, 128.80, 128.82, 129.27, 
129.33, 129.52, 129.57, 129.65, 129.73, 129.90 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, 
C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.24 (‘ipso’ OCH2Ph), 137.18, 
137.22 (2s, C-8a Naph) 141.06, 141.09 (2s, C-8), 147.96, 148.02 (2s, ‘ipso’ ONaph), 
155.23 (C-4), 162.15 (s, C-2), 162.42 (C-6), 174.74 (d, JC–P = 5.04 Hz, COOCH2Ph), 
174.91 (d, JC–P = 5.04 Hz, COOCH2Ph). EI MS= 621.02 (M+H), 642.99 (M+Na). HPLC 
= H2O/ACN 90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min, 
0/100 isocratic 5 min = retention time 8.56 min; H2O/MeOH 90/10 to 30/70 in 5 min, 
30/70 isocratic 10 min, then to 0/100 in 5 min, 0/100 isocratic 5 min = retention time 
15.56, 16.65 min. 
[4.4f] 
31P NMR (MeOD, 202 MHz): ! 4.05, 4.04. 
1H NMR (MeOD, 500 MHz): ! 8.11-8.09 
(1H, m, H-8 Naph), 7.91-7.90 (1H, 2s, H-8), 7.87-7.85 (1H, m, H-6 Naph), 7.68-7.67 
(1H, m, H-2 Naph), 7.54-7.50 (2H, m, H-5 Naph, H-7 Naph), 7.42-7.37 (2H, m, H-3 
Naph, H-4 Naph), 5.49, 5.47 (2H, 2s, H-1’), 4.53-4.48 (2H, m, OCH2CH3), 4.31-4.22 
(2H, m, H-5’), 4.04-3.96 (1H, m, NHCH), 3.75-3.70 (2H, m, H-4’), 3.61, 3.58 (3H, 2s, 
OCH3), 1.42 (1.5 H, t, J= 7.09 Hz, OCH2CH3), 1.41 (1.5 H, t, J= 7.09 Hz, OCH2CH3), 
1.32 (1.5H of one diasteroisomer, d, J= 7.14 Hz, CHCH3), 1.28 (1.5H of one 
diasteroisomer, d, J= 7.14 Hz, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 14.68  
(OCH2CH3), 20.40 (d, JC–P = 7.56 Hz, CHCH3), 20.51 (d, JC–P = 7.56 Hz, CHCH3) 51.78 
(NHCH), 52.70, 52.78 (2s, OCH3), 63.60 (OCH2CH3), 67.25 (d, JC–P = 6.30 Hz, C-5’), 
67.31 (d, JC–P = 6.30 Hz, C-5’), 69.41 (d, JC–P = 7.56 Hz, C-4’), 69.48 (d, JC–P = 7.56 Hz, 
C-4’), 73.73 (C-1’), 115.14, 116.22, 116.25, 116.27, 122.71, 122.75, 125.88, 126.53, 
127.43, 127.73, 127.87, 127.92, 128.81 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 
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Naph, C-6 Naph, C-7 Naph, C-8 Naph), 136.23 (C-8a Naph) 141.11 (C-8), 147.97, 
148.03 (2s, ‘ipso’ ONaph), 155.23 (C-4), 162.16 (s, C-2), 162.42 (C-6), 175.44 (d, JC–P 
= 5.04 Hz, COOCH2Ph), 174.61 (d, JC–P = 5.04 Hz, COOCH2Ph). EI MS= 545.26 
(M+H), 567.25 (M+Na). HPLC = H2O/ACN 90/10 to 30/70 in 5 min, 30/70 isocratic 10 
min, then to 0/100 in 5 min, 0/100 isocratic 5 min = retention time 9.36 min; 
H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min, 
0/100 isocratic 5 min = retention time 6.88 min. 
Synthesis of 6-O-methyl acyclovir-[phenyl(benzyloxy-L-leucinyl)] phosphate 
[4.4e] 
Chemical Formula: C28H35N6O7P 
Molecular Weight: 598.5873 
Prepared according to Standard Procedure D, from 4.1a 
(0.06 g, 0.25 mmol) in anhydrous THF (10 mL), 
tBuMgCl (1.0 M THF solution, 0.5 mL, 0.5 mmol), 2.2k 
(0.198 g, 0.5 mmol) in anhydrous THF (2 mL). The reaction mixture was stirred at 
room temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 96/4. The product was further purified by 
preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 30/70 in 5 
min, 30/70 isocratic 10 min, then to 0/100 in 5 min) to give a white solid (60 mg, 40%). 
31P NMR (MeOD, 202 MHz): ! 4.03, 3.58. 
1H NMR (MeOD, 500 MHz): ! 7.94-7.91 
(1H, 2s, H-8), 7.36-7.28 (7H, m, PhO, OCH2Ph), 7.19-7.14 (3H, m, PhO, OCH2Ph), 
5.51, 5.49 (2H, 2s, H-1’), 5.11(2H, OCH2Ph), 4.20-4.09 (2H, m, H-5’), 4.06 (3H, 
OCH3), 3.96-3.86 (1H, m, NHCH), 3.74-3.71 (2H, m, H-4’), 1.74-1.65 (1H, m, 
CH2CH(CH3)2), 1.60-1.48 (2H, m, CH2CH(CH3)2), 0.89 (3H, d, J= 6.64 Hz, 
CH2CH(CH3)2), 0.80 (3H, d, J= 6.64 Hz, CH2CH(CH3)2). 
13C NMR (MeOD, 126 MHz): 
! 21.74, 22.00, 23.11, 23.20 (4s, CH2CH(CH3)2), 25.39, 25.54 (2s, CH2CH(CH3)2), 
43.84 (d, JC–P = 7.84 Hz, CH2CH(CH3)2), 44.06 (d, JC–P = 7.84 Hz, CH2CH(CH3)2), 54.25 
(OCH3), 54.56, 54.69 (2s, NHCH), 67.05 (d, JC–P = 5.04 Hz, C-5’), 67.06 (d, JC–P = 5.04 
Hz, C-5’), 67.85, 67.88 (2s, OCH2Ph), 69.41 (d, JC–P = 7.29 Hz, C-4’), 69.42 (d, JC–P = 
7.29 Hz, C-4’), 73.71 (C-1’), 115.09, 121.25, 121.29, 121.51, 121.55, 125.96, 126.07, 
129.35, 129.37, 129.45, 129.48, 129.56, 130.67 (C-5, PhO, OCH2Ph), 137.28 (‘ipso’ 
OCH2Ph), 141.16, 141.20 (2s, C-8), 152.19, 152.24 (2s, ‘ipso’PhO), 153.42 (C-4), 
155.26 (C-2), 162.20, 162.78 (2s, C-6), 174.81 (d, JC–P = 2.76 Hz, COOCH2Ph), 175.14 
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(d, JC–P = 2.76 Hz, COOCH2Ph). EI MS= 599.05 (M+H), 621.03 (M+Na). HPLC = 
H2O/ACN 90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then  to 0/100 in 10 min, 
0/100 isocratic 5 min = retention time 8.50 min; H2O/MeOH 90/10 to 30/70 in 5 min, 
30/70 isocratic 10 min, then to 0/100 in 5 min, 0/100  isocratic 5 min = retention time 
15.12, 16.03 min. 
Synthesis of 6-O-methyl acyclovir-[1-naphthyl(neopentyloxy-L-alaninyl)] 
phosphate [4.4g] 
Chemical Formula: C23H33N6O7P 
Molecular Weight: 536.5179 
Neopentyl alcohol (0.05 g, 0.55mmol) was added to 
a solution of 4.4a (0.15 g, 0.27 mmol) and tBuMgCl 
(sol THF 1 M, 0.3 ml, 0.3mmol) in THF (3 mL). 
The mixture was stirred for 2h at room temperature. The solvent was removed and the 
the residue was purified by column chromatography gradient elution of DCM/MeOH = 
98/2, then 96/4, then 94/6 to give a solid which was further purified by preparative 
reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 40/60 in 5 min, 60/40 
isocratic 10 min, then to 0/100 in 5 min) to give a white solid (100 mg, 70%).  
31P NMR (MeOD, 202 MHz): ! 3.76, 3.47. 
1H NMR (MeOD, 500 MHz): ! ! 7.90, 7.88 
(1H, 2s, H-8), 7.36-7.33 (2H, m, PhO), 7.21-7.17 (3H, m, PhO), 5.56, 5.50 (2H, 2s, H-
1’), 4.18-4.11 (2H, m, H-5’), 4.06 (3H, OCH3), 3.99-3.95 (1H, m, NHCH), 3.86-3.76 
(4H, m, H-4’, COOCH2C (CH3)3), 1.39 (1.5H, d, J= 2.52 Hz, CHCH3 of one 
diasteroisomer), 1.35 (1.5H, d, J= 2.52 Hz, CHCH3 of one diasteroisomer) 0.96-0.95 
(9H, m, COOCH2C(CH3)3). 
13C NMR (MeOD, 126 MHz): ! 20.57 (d, JC–P = 6.97 Hz, 
CHCH3), 20.71 (d, JC–P = 6.97 Hz, CHCH3), 26.74 (C(CH3)3), 32.36 (C(CH3)3), 51.63, 
51.72 (2s, CHCH3), 54.25 (OCH3), 67.05 (d, JC–P = 5.51 Hz, C-5’), 67.14 (d, JC–P = 5.51 
Hz, C-5’), 69.42 (d, JC–P = 6.97 Hz, C-4’), 69.46 (d, JC–P = 6.97 Hz, C-4’), 73.75 (C-1’), 
75.40 (COOCH2C(CH3)3), 115.10, 121.41, 121.45, 121.48, 121.52, 126.04, 126.08, 
130.71 (C-5, PhO), 141.19, 141.22 (2s, C-8), 152.19 (‘ipso’PhO), 153.41 (C-4) 155.29 
(C-2), 162.22, 162.79 (2s, C-6), 174.99 (d, JC–P = 5.53 Hz, COOCH2C(CH3)3), 175.14 
(d, JC–P = 5.53 Hz, COOCH2C(CH3)3). EI MS= 559.20 (M+Na). HPLC = H2O/MeOH 
90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min, 0/100 isocratic 5 
min = retention time 13.25, 13.57 min. 
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9.5. Experimental procedures for chapter 5: synthesis of 8-bromo- and 
8-methylacyclovir ProTides  
Standard procedure E: tBuMgCl method 
To a stirring suspension of the appropriate nucleoside (1 eq.) in anhydrous THF was 
added dropwise under argon atmosphere tButMgCl (2 eq.). The reaction mixture was 
stirred at room temperature for 30 min. Then, a solution of the appropriate aryl amino 
acid ester phosphorochloridate 2.2 (2 to 4 eq.) in anhydrous THF was added dropwise 
and the reaction mixture was stirred at room temperature overnight. The solvent was 
removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH in different proportions.  
Standard procedure F: bromination of ACV PRoTides 
N-Bromosuccinimide (1 eq) was added to a solution of the appropriate ACV Protide 3.2 
(1 eq) in methanol. The mixture was stirred at room temperature overnight. The solvent 
was then removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH in different proportions. 
Synthesis of 8-bromoacyclovir: 9-[(2-hydroxyethoxy)methyl]-8-bromoguanine [5.1] 
 
Chemical Formula: C8H10BrN5O3 
    Molecular Weight: 304.1007 
Method 1 
N-Bromosuccinimide (0.45 g, 2.5 mmol) was added to a solution of ACV (0.54 g, 2.4 
mmol) in acetic acid (7 ml) and the mixture was stirred at room temperature for 20 h. 
The solution was diluted with water. The precipitated was filtered and washed with 
water to give a white solid (40%, 0.30 g). 
Method 2 
A saturated solution of bromine in water was added slowly to a stirring solution of ACV 
(0.45 g, 2 mmol) in 100 mL of H2O until the color of Br2 persisted in solution. This 
solution was allowed to stand at 0 °C for 2 h. The separated solid was filtered and 
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recrystallised from EtOH/H2O to give a white solid (80%, 0.50g). 
 
1H NMR (DMSO, 500 MHz): ! 10.74 (1H, s, NH), 6.63 (2H, s, NH2), 5.31 (2H, s, H-
1’), 4.66 (1H, bs, OH), 3.51-3.47 (4H, m, H-4’, H-5’). 13C NMR (MeOD, 126 MHz): ! 
59.82 (C-5’), 70.78 (C-4’), 72.36 (C-1’), 116.57 (C-5), 120.85 (C-8), 152.83 (C-4), 
154.15 (C-2), 155.50 (C-6). EI MS= 302.9965 (M+H). HPLC = H2O/AcCN from 90/10 
to 0/100 in 20 min = retention time 3.32 min; H2O/MeOH 90/10 to 20/80 in 5 min, 
20/80 isocratic 10 min, then to 0/100 in 5 min = retention time 5.36 min. 
Synthesis of 8-methylacyclovir: 9-[(2-hydroxyethoxy)methyl]-8-bromoguanine [5.2] 
Chemical Formula: C9H13N5O3 
Molecular Weight: 239.2312 
A stirred solution of ACV (0.5 g, 2.22 mmol) and 
FeSO4*7H2O (2 g, 7.25 mmol) in 125 mL of H2SO4/H2O (1 M) was deoxygenated 
thoroughly (O2-freeN2) and treated slowly with a mixture of tert-butyl hydroperoxide 
(2.5 g, 27.74 mmol) in 12.5 mL of H2O over 30 min. The resulting solution was stirred 
for an additional 30min and adjusted to neutral pH with 1M NaOH/H2O. A fine brown 
precipitate was removed by centrifugation and the supernatant solution was evaporated 
under reduced pressure. The residue was purified by reverse phase column 
chromatography. Gradient elution with H2O/ACN (10/0, then 7/3) gave an 
approximately equal mixture of starting material and product (TLC, i/PrOH/ H2O/conc. 
NH3 (aq), 7:2:1). These fractions were combined and evaporated and the residue was 
resubmitted to the above reaction conditions. TLC now indicated complete conversion 
of ACV to 5.2. Purification by reverse phase column chromatography gave a white 
solid (56%, 0.3 g).  
1H NMR (DMSO, 500 MHz): ! 10.60 (1H, bs, NH), 6.46 (2H, s, NH2), 5.32 (2H, s, H-
1’), 4.65 (1H, br s, OH), 3.47-3.42 (4H, m, H-4’, H-5’), 2.37 (3H, s, CH3). 
13C NMR 
(MeOD, 126 MHz): ! 13.34 (CH3), 59.87 (C-5’), 70.11 (C-4’), 70.93 (C-1’), 114.64 (C-
5), 144.64 (C-8), 152.34 (C-4), 153.52 (C-2), 156.34 (C-6). EI MS= 240.1052 (M+H). 
HPLC= H2O/AcCN from 100/0 to 90/10 in 5 min, 90/10 isocratic 5 min, then to 0/100 
in 5 min, 0/100 isocratic 5 min = retention time 7.87 min; H2O/MeOH 100/0 to 0/100 in 
20 min, 0/100 isocratic 5 min = retention time 7.13 min. 
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Synthesis of N2-DMF-8-methylacyclovir: N2-(N,N-dimethylformamidine)-(9-[(2-
hydroxyethoxy)methyl]-8-methylguanine [5.6] 
Chemical Formula: C12H18N6O3 
Molecular Weight: 294.3097 
To a suspension of 5.2 (0.3g, 1.25 mmol) in dry DMF 
(10 ml) was added N,N-dimethylformamide dimethyl 
acetale (0.83 mL, 6.25 mmol). The reaction mixture was stirred at room temperetature 
for 24 h. After this period the suspension was filtered, and the solid was washed with 
ET2O to give a white solid (68%, 0.25 g). 
1H NMR (MeOH, 500 MHz): ! 8.61 (1H, s, CHN(CH3)2),  5.58 (2H, s, H-1’), 3.67-3.60 
(4H, m, H-4’, H-5’), 3.24, 3.15 (6H, 2s, N(CH3)2), 2.55 (3H, s, CH3). 
Synthesis of 8-bromoacyclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate [5.4a] 
Chemical Formula: C24H26BrN6O7P 
Molecular Weight: 621.3770 
Prepared according to Standard Procedure E, from 5.1 
(0.40 g, 1.43 mmol) in anhydrous THF (15 mL), 
tBuMgCl (1.0 M THF solution, 2.86 mL, 2.86 mmol), 
2.2a (1.53 g, 4.32 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred 
at room temperature overnight. The residue was purified by column chromatography, 
gradient elution of DCM/MeOH = 98/2 then 96/4. The product was further purified by 
preparative reverse phase HPLC (gradient elution of H2O/AcCN from 90/10 to 0/100 in 
20 min) to give a white solid (18%, 0.15 g). 
31P-NMR (MeOD, 202 MHz): ! 3.72, 3.46. 1H-NMR (MeOD, 500 MHz): ! 7.36-7.29 
(7H, m, PhO, OCH2Ph), 7.19-7.14 (3H, m, PhO, OCH2Ph), 5.44, 5.40 (2H, 2s, H-1’), 
5.15-5.13 (2H, 2s, OCH2Ph), 4.18-4.14 (2H, m, H-5’), 4.02-3.99 (1H, m, CHCH3), 3.78-
3.76 (2H, m, H-4’), 1.37-1.31 (3H, m, CHCH3). 
13C-NMR (MeOD, 126 MHz): ! 20.35 
(d, JC–P = 7.02 Hz, CHCH3), 20.40 (d, JC–P = 7.02 Hz, CHCH3), 51.58, 51.71 (2s, 
CHCH3), 66.92 (d, JC–P = 6.30 Hz, C-5’), 66.98 (d, JC–P = 6.30 Hz, C-5’), 67.95, 67.97 
(2s, OCH2Ph), 69.61 (d, JC–P = 6.31 Hz, C-4’), 69.66 (d, JC–P = 6.31 Hz, C-4’), 73.75 (C-
1’), 117.93 (C-5), 121.41, 121.45, 121.48, 121.51, 123.61, 126.08, 127.04, 129.32, 
129.35, 129.57, 129.59, 130.22, 130.71 (C-8, PhO, OCH2Ph), 137.27 (‘ipso’ OCH2Ph), 
152.13, 152.19 (2s, ‘ipso’PhO), 154.88 (C-4), 155.84 (C-2), 158.30 (C-6), 174.71 (d,  
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JC–P = 5.04 Hz, COOCH2Ph), 174.87 (d, JC–P = 5.04 Hz, COOCH2Ph). EI MS= 643.0697 
(M+Na). HPLC= H2O/AcCN from 90/10 to 0/100 in 20 min = retention time 12.40 min. 
Synthesis of 8-bromoacyclovir-[1-naphthyl(benzyloxy-L-alaninyl)] phosphate 
[5.4b]. 
Chemical Formula: C28H28BrN6O7P 
Molecular Weight: 671.4357 
Prepared according to Standard Procedure E, from 
5.1 (0.30 g, 0.98 mmol) in anhydrous THF (10 mL), 
tBuMgCl (1.0 M THF solution, 1.96 mL, 1.96 
mmol), 2.2b (0.79 g, 1.96 mmol) in anhydrous THF (3 mL). The reaction mixture was 
stirred at room temperature overnight. The residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. The 
product was further purified by preparative reverse phase HPLC (gradient elution of 
H2O/AcCN from 90/10 to 0/100 in 20 min) to give a white solid (21%, 0.14 g).  
31P-NMR (MeOD, 202 MHz): ! 4.01, 3.92. 1H-NMR (MeOD, 500 MHz): ! 8.15-8.12 
(1H, m, H-8 Naph), 7.88-7.87 (1H, m, H-6 Naph), 7.70-7.68 (1H, m, H-2 Naph), 7.53-
7.51 (2H, m, H-5 Naph, H-7 Naph), 7.46-7.25 (7H, m, Naph, OCH2Ph), 5.36, 5.33 (2H, 
2s, H-1’), 5.11-5.05 (2H, m, OCH2Ph), 4.25-4.18 (2H, m, H-5’), 4.12-4.06 (1H, m, 
CHCH3), 3.78-3.74 (2H, m, H-4’), 1.36-1.33 (3H, m, CHCH3). 
13C-NMR (MeOD, 126 
MHz): ! 20.39 (d, JC–P = 7.84 Hz, CHCH3), 20.45 (d, JC–P = 7.84 Hz, CHCH3), 51.73, 
51.81 (2s, CHCH3), 67.17 (d, JC–P = 4.85 Hz, C-5’), 67.21 (d, JC–P = 4.85 Hz, C-5’), 
67.95, 67.99 (2s, OCH2Ph), 69.65 (d, JC–P = 7.79 Hz, C-4’), 69.70 (d, JC–P = 7.79 Hz, C-
4’), 73.74 (C-1’), 116.30, 116.32, 116.38, 116.41, 117.93, 122.74, 122.85, 123.55, 
123.57, 125.95, 126.54, 127.44, 127.48, 127.75, 128.81, 128.85, 129.28, 129.30, 
129.34, 129.53, 129.58, 130.22, 130 (C-5, C-8, C-2 Naph, C-3 Naph, C-4 Naph, C-5 
Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.26 (‘ipso’ OCH2Ph), 137.18 
137.24 (2s, C-8a Naph), 148.00 (d, JC–P = 7.38 Hz, ‘ipso’ ONaph), 154.81, 154.84 (2s, 
C-4), 155.83 (C-2), 158.30, 158.32 (C-6), 174.70 (d, JC–P = 4.39 Hz, COOCH2Ph), 
174.90 (d, JC–P = 4.39 Hz, COOCH2Ph). EI MS= 693.119 (M+Na). HPLC= H2O/AcCN 
from 90/10 to 0/100 in 20 min = retention time 12.40 min. 
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Synthesis of 8-bromoacyclovir-[1-naphthyl(benzyloxy-dimethylglycinyl)] 
phosphate [5.4c] 
Chemical Formula: C29H30BrN6O7P 
Molecular Weight: 685.4623 
Prepared according to Standard Procedure E, from 
5.1 (0.25 g, 0.83 mmol) in anhydrous THF (15 mL), 
tBuMgCl (1.0 M THF solution, 1.7 mL, 1.7 mmol), 
2.2h (0.67 g, 1.7 mmol) in anhydrous THF (5 mL). The reaction mixture was stirred at 
room temperature overnight. The residue was purified by column chromatography, 
gradient elution of DCM/MeOH = 98/2 then 96/4, to give a white solid (20%, 0.11 g). 
31P-NMR (MeOD, 202 MHz): !. 2.52. 1H-NMR (MeOD, 500 MHz): ! 8.18-8.16 (1H, 
m, H-8 Naph), 7.87-7.85 (1H, m,  H-6 Naph), 7.68-7.67 (1H, m,  H-2 Naph), 7.53-7.51 
(2H, m, H-7 Naph, H-5 Naph), 7.46-7.25 (7H, m, Naph, OCH2Ph), 5.33 (2H, s, H-1’), 
5.16-5.08 (2H, m, OCH2Ph), 4.20-4.17 (2H, m, H-5’), 3.74-3.71 (2H, m, H-4’), 1.53, 
1.51 (6H, 2s, NHC(CH3)2). 
13C-NMR (MeOD, 126 MHz): ! 27.46 (d, JC–P = 4.65 Hz, 
CH3), 27.76 (d, JC–P = 4.65 Hz, CH3), 58.09 (C(CH3)2), 67.16 (d, JC–P = 5.63 Hz, C-5’), 
68.25 (OCH2Ph), 69.81 (d, JC–P = 7.65 Hz, C-4’), 73.74 (C-1’), 116.35, 116.38, 117.93, 
122.99, 123.54, 125.76, 126.51, 127.31, 127.68, 127.90, 127.95, 128.78, 129.26, 129.54 
(C-5, C-8, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, 
C-8a Naph, OCH2Ph), 136.25, 137.31 (C-4a Naph, ‘ipso’ OCH2Ph), 148.11 (d, JC–P = 
7.61, ‘ipso’ Naph), 154.82 (C-4), 155.62 (C-2), 158.34 (C-6), 176.57 (d, JC–P = 3.55 Hz, 
COOCH2Ph). EI MS= 707.1128 (M+Na). HPLC = H2O/AcCN from 90/10 to 0/100 in 
20 min = retention time 14.80 min; H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 
10 min, then to 0/100 in 5 min = retention time 12.27 min. 
Synthesis of 8-bromoacyclovir-[1-naphthyl(benzyloxy-L-valinyl)] phosphate [5.4d]. 
Chemical Formula: C30H32BrN6O7P 
Molecular Weight: 699.4888 
Prepared according to standard procedure F, from 
N-Bromosuccinimide (7.7*10-3 g,  
0.43*10-1 mmol) and 3.2g (2.7*10-2 g,  
0.44*10-1 mmol) in MeOH (6 ml). The mixture was stirred at room temperature 
overnight. The solvent was then removed under reduced pressure and the residue was 
purified by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 
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to 20/80 in 5 min, 20/80 isocratic 10 min, then to 0/100 in 5 min) to give a white solid 
(36%, 0.11*10-1 g). 
31P-NMR (MeOD, 202MHz): ! 4.74, 4.82. 1H NMR (MeOD, 500 MHz): ! 8.17-8.14 
(1H, m, H-8 Naph), 7.89-7.87 (1H, s, H-6 Naph), 7.70-7.68 (1H, m, H-2 Naph), 7.55-
7.50 (2H, m, H-5 Naph, H-7 Naph), 7.46-7.37 (2H, m, H-3 Naph, H-4 Naph), 7.33-7.25 
(5H, m, OCH2Ph), 5.36 (2H, 1s, H-1’), 5.05 (2H, 1s, OCH2Ph), 4.28-4.18 (2H, m, H-
5’), 3.81-3.75 (3H, m, NHCH, H-4’), 2.06-1.99 (1H, m, CH(CH3)2), 0.89-0.86 (6H, m, 
CH(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 18.27, 18.32 (2s, CH(CH3)2), 19.48, 19.54 
(2s, CH(CH3)2), 33.09 (d, JC–P = 7.56 Hz, CH(CH3)2) 33.27 (d, JC–P = 7.56 Hz, 
CH(CH3)2), 62.03, 62.07 (2s, NHCH), 67.18 (d, JC–P = 5.55 Hz, C-5’), 67.34 (d, JC–P = 
5.55 Hz, C-5’), 67.82 (s, OCH2Ph), 69.69 (d, JC–P = 7.23 Hz, C-4’), 69.75 (d, JC–P = 7.23 
Hz, C-4’), 73.75, 73.78 (2s, C-1’), 116.20, 116.23, 116.38, 117.94, 122.79, 122.91, 
123.54, 125.88, 125.92, 126.54, 127.41, 127.44, 127.74, 127.88, 128.78, 128.83, 
129.32, 129.36, 129.49, 129.54, 129.56 (C-5, C-8 C-2 Naph, C-3 Naph, C-4 Naph, C-5 
Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.27 (‘ipso’ OCH2Ph), 137.13 (C-
8a Naph), 148.03 (d, JC–P = 3.78 Hz, ‘ipso’ ONaph), 148.08 (d, JC–P = 3.78 Hz, ‘ipso’ 
ONaph) 154.83 (C-4), 155.80 (C-2), 158.28 (C-6), 173.90 (d, JC–P = 2.52 Hz, 
COOCH2Ph), 174.09 (d, JC–P = 2.52 Hz, COOCH2Ph). EI MS= 699.1307 (M+H
+). 
HPLC = H2O/AcCN from 90/10 to 0/100 in 20 min = retention time 16.48 min; 
H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 10 min, then to 0/100 in 5 min = 
retention time 13.44 min., 14.09 min. 
Synthesis of N2-DMF-8-methylacyclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate 
[5.7] 
Chemical Formula: C28H34N7O7P 
Molecular Weight: 611.5860 
Prepared according to Standard procedure E, 
from 5.6 (0.25 g, 0.85 mmol) in anhydrous THF 
(8 mL), tBuMgCl (1.0 M THF solution, 1.7 mL, 
1.7 mmol), 2.2a (0.6 g, 1.7 mmol) in anhydrous THF (2 mL). The reaction mixture was 
stirred at room temperature overnight. After this period the solvent was removed under 
reduced pressure. The residue was purified by column chromatography gradient elution 
of DCM/MeOH = 98/2 then 96/4 to give a white solid (27%, 0.14 g). 
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31P-NMR (MeOD, 202 MHz): ! 3.87, 3.51. 1H-NMR (MeOD, 500 MHz): ! 8.69 (1H, 
bs, NCHN(CH3)2), 7.34-7.29 (7H, m, PhO), 7.19-7.14 (3H, m, PhO), 5.53 (2H, s, H-1’), 
5.13, 5.12 (2H, 2s, OCH2Ph), 4.20-4.12 (2H, m, H-5’), 3.99-3.94 (1H, m, CHCH3), 
3.74-3.69 (2H, m, H-4’), 3.17, 3.11 (6H, 2s, N(CH3)2), 2.51, 2.49 (3H, 2s, CH3-8), 1.36, 
1.34 (1.5H, d, J = 6.30, CHCH3 of one diasteroisomer), 1.33, 1.31 (1.5H, d, J = 6.30 
CHCH3, of one diasteroisomer). 
13C NMR (MeOD, 126 MHz): ! 13.60 (CH3-8), 20.35 
(d, JC–P = 7.30 Hz, CHCH3), 20.42 (d, JC–P = 7.30 Hz, CHCH3), 35.38, 41.51 (2s, 
N(CH3)2), 51.60, 51.75 (2s, CHCH3), 66.97 (d, JC–P = 5.5 Hz, C-5’), 67.04 (d, JC–P = 5.5 
Hz, C-5’), 67.95 (OCH2Ph), 69.04 (d, J = 6.4 Hz, C-4’), 69.09 (d, JC–P = 6.4, C-4’), 
72.46 (C-1’), 118.57, 121.38, 121.42, 121.46, 121.50, 126.10, 126.12, 129.33, 129.34, 
129.60, 130.75, 130.77 (C-5, PhO, OCH2Ph), 137.28 (‘ipso’ OCH2Ph), 149.57 (C-8), 
152.14, 152.19 (2s, ‘ipso’PhO), 153.21 (C-4), 154.33 (C-2), 156.91 (C-6), 159.77 
(NCHN(CH3)2), 174.65 (d, JC–P = 5.2 Hz, COOCH2Ph), 174.85 (d, JC–P = 5.2 Hz, 
COOCH2Ph). EI MS= 634.21 (M+Na).  
Synthesis of 8-methylacyclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate [5.5] 
Chemical Formula: C25H29N6O7P 
Molecular Weight: 556.5075 
A solution of 5.7 (0.14 g, 0.81 mmol) in isopropanol (10 
mL) was stirred under reflux for 62 h. The solvent was 
then removed under reduced pressure and the residue 
was purified by column chromatography, gradient elution of DCM/MeOH = 98/2 then 
96/4 then 94/6. The product was further purified by preparative TLC plate DCM/MeOH 
98/2 then 96/4 then 94/6) to give a white solid (21%, 0.027 g). 
31P NMR (MeOD, 202 MHz): ! 3.77, 3.48. 
1H NMR (MeOD, 500 MHz): ! 7.39-7.14 
(10H, m, OCH2Ph) 5.43-5.40 (2H, 2s, H-1’), 5.14-5.13 (2H, 2s, OCH2Ph), 4.18-4.11 
(2H, m, H-5’), 4.02-3.94 (1H, m, CHCH3), 3.71-3.66 (2H, m, H-4’), 2.47, 2.45 (3H, 2s, 
CH3-8), 1.37, 1.35 (1.5H, d, J = 6.30 Hz, CHCH3 of one diasteroisomer), 1.34, 1.32 
(1.5H, d, J = 6.30 Hz CHCH3, of one diasteroisomer).
13C NMR (MeOD, 126 MHz): ! 
13.45 (CH3-8), 20.31 (d, JC–P = 7.21 Hz, CHCH3), 20.39 (d, JC–P = 7.21 Hz, CHCH3), 
51.70, 51.85 (2s, CHCH3), 66.95 (d, JC–P = 5.55 Hz, C-5’), 67.03 (d, JC–P = 5.55 Hz, C-
5’), 67.97 (OCH2Ph), 69.05 (d, JC–P = 5.79 Hz, C-4’), 69.12 (d, JC–P = 5.79 Hz, C-4’), 
72.37 (C-1’), 115.68, 121.38, 121.42, 121.46, 121.49, 122.08, 124.11, 126.08, 126.10, 
128.90, 129.02, 129.36, 129.42, 129.58, 130.02, 130.72 (C-5, PhO, OCH2Ph), 137.27, 
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137.69 (2s, ‘ipso’ OCH2Ph), 148.60 (C-8), 152.14, 152.19 (2s, ‘ipso’PhO), 153.25 (C-
4), 154.42 (C-2), 155.31 (C-6), 174.70 (d, JC–P = 5.47 Hz, COOCH2Ph), 174.90 (d, JC–P 
= 5.47 Hz, COOCH2Ph). EI MS= 579.17 (M+Na). HPLC = H2O/ACN from 100/0 to 
0/100 in 15 min, then 0/100 isocratic 5 min = retention time 10.23 min; H2O/MeOH 
90/10 to 0/100 in 25 min, then 0/100 isocratic 5 min = retention time 18.03, 18.29 min. 
9.5. Experimental procedures for chapter 5: synthesis of penciclovir 
and ganciclovir ProTides 
Figure 9.2 reports the numbering assigned to the different position in PCV and GCV 
structures. 
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Figure 9.2. Numbering of GCV and PCV structures  
Standard procedure G  
To a stirring solution/suspension of the appropriate nucleoside (1 eq.) in anhydrous THF 
or pyridine was added dropwise under argon atmosphere tButMgCl (2 to 6 eq). The 
reaction mixture was stirred at room temperature for 30 min. Then, a solution of the 
appropriate aryl amino acid ester phosphorochloridate 2.2 (2 to 4 eq.) in anhydrous THF 
was added dropwise and the reaction mixture was stirred at room temperature overnight. 
The solvent was removed under reduced pressure and the residue was purified by 
column chromatography eluting with DCM/MeOH in different proportions.  
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9.5.1 Synthesis of 2,2-dimethylglycine benzyl ester derivatives of penciclovir 
ProTides 6.5a-b and 6.6a-b  
Synthesis of N2-DMF-penciclovir: 
N2-(N,N-dimethylformamidine)-9-[(4-dihydroxy-3-hydroxymethylbut-1-ylpropan-
2-yl]-guanine [6.8a]. 
Chemical Formula: C13H20N6O3 
Molecular Weight: 308.3363 
To a suspension of PCV (2.5 g, 9.8 mmol) in anhydrous 
DMF (35 ml) was added N,N-dimethylformamide 
dimethyl acetal (6.5 mL, 49 mmol) and the reaction mixture was stirred at room 
temperature overnight. After this period the suspension was filtered and the solid was 
washed with diethyl ether to give a white solid (90%, 2.7 g).  
1H-NMR (DMSO, 500 MHz): ! 11.20 (1H, bs, NH), 8.56 (1H, s, CHN(CH3)2), 7.81 
(1H, s, H-8), 4.09 (2H, t, J = 7.3 Hz, H-1’),  3.47-3.37 (4H, m, H-4’, H-5’), 3.16, 3.04 
(6H, 2s, N(CH3)2), 1.79-1.74 (2H, m, H-2’), 1.47 (1H, m, H-3’).  
Synthesis of N2-DMF-penciclovir-[phenyl(benzyloxy-dimethylglicinyl)] phosphate 
[6.9a] and  N2-DMF-penciclovir-[phenyl(benzyloxy-dimethylglicinyl)] diphosphate 
[6.10a] .  
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Chemical Formula: C30H38N7O7P
Molecular Weight: 639.6392
Chemical Formula: C47H56N8O11P2
Molecular Weight: 970.9421
6.9a 6.10a
 
Prepared according to standard procedure G from 6.8a (0.6 g, 1.95 mmol) in anhydrous 
THF (30 mL) tBuMgCl (1.0 M THF solution, 3.89 mL, 3.89 mmol), 2.2g (1.43 g, 3.9 
mmol) in anhydrous THF (5 mL). The reaction mixture was stirred at room temperature 
overnight. After this period tBuMgCl (1.0 M THF solution, 2.0 mL, 2.0 mmol), 2.2g  
(0.77 g, 2.1 mmol) in anhydrous THF (2 mL) were added and the reaction mixture was 
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stirred at room temperature for 6 h. The solvent was removed under reduced pressure.  
The residue was purified by column chromatography gradient elution of DCM/MeOH = 
98/2 then 96/4 then 94/6 then 92/8, to give two products: [6.9a] (30%, 0.38 g) and  
[6.10a] (33%, 0.61 g). 
[6.9a] 
31P-NMR (MeOD, 202 MHz): ! 2.07, 1.49. 1H-NMR (MeOD, 500 MHz): ! 8.72 (1H, s, 
NCHN(CH3)2), 7.75, 7.70 (1H, 2s, H-8), 7.39-7.28 (7H, m, PhO, OCH2Ph), 7.20-7.14 
(3H, m, PhO, OCH2Ph), 5.13-5.11 (2H, m, H-5’), 4.16-4.00 (4H, m, H-1’, H-5’), 3.08, 
2.99 (6H, 2s, N(CH3)2) 3.54-3.53 (2H, m, H-4’), 1.80-1.75 (3H, m, H-2’, H-3’), 1.50 
(6H, br s, C(CH3)2). 
[6.10a] 
31P-NMR (MeOD, 202 MHz): ! 2.28, 2.22 (br s). 1H-NMR (MeOD, 500 MHz): ! 8.65 
(1H, s, NCHN(CH3)2), 7.84 (1H, bs, H-8), 7.31-7.20 (20H, m, 2 x PhO,  2 x OCH2Ph), 
5.10-5.08 (4H, m, 2 x OCH2Ph), 4.17-4.09 (6H, m, H-1’, H-4’, H-5’), 3.01-3.00 (6H, m, 
N(CH3)2) 1.88-1.74 (3H, m, H-2’, H-3’), 1.52-1.47 (12H, m, 2 x C(CH3)2). 
Synthesis of penciclovir-[phenyl(benzyloxy-dimethylglicinyl)] phosphate [6.5a] 
Chemical Formula: C27H33N6O7P 
Molecular Weight: 584.5607 
A solution of 6.9a (0.15 g, 0.23 mmol) in isopropanol 
(10 mL) was stirred under reflux for 24 h. After this 
period the solvent was removed under reduced pressure 
and the residue was purified by column chromatography, gradient elution of 
DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8 then 90/10. The product was further 
purified by preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 
40/60 in 5 min, 40/60 isocratic 15 min, then to 0/100 in 5 min) to give a white solid 
(5.2%, 0.07*10-1 g). 
31P-NMR (MeOD, 202 MHz): ! 2.37, 2.35. 1H-NMR (MeOD, 500 MHz): ! 7.70, 7.69 
(1H, 2s, H-8), 7.38-7.27 (7H, m, PhO, OCH2Ph), 7.20-7.14 (3H, m, PhO, OCH2Ph), 
5.15, 5.14 (2H, 2s, H-5’), 4.19-4.07 (4H, m, H-1’, H-5’), 3.54-3.53 (2H, m, H-4’), 1.85-
1.72 (3H, m, H-2’, H-3’), 1.49 (6H, br s, C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 
27.43 (d, JC–P = 4.95 Hz, C(CH3)2), 27.49 (d, JC–P = 4.95 Hz, C(CH3)2), 27.66 (d, JC–P = 
7.06 Hz, C(CH3)2), 27.73 (d, JC–P = 7.06 Hz, C(CH3)2), 29.43, 29.52 (2s, C-2’), 40.19 (d, 
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JC–P = 7.56 Hz, C-3’), 40.28 (d, JC–P = 7.56 Hz, C-3’), 42.33, 42.25 (2s, C-1’), 62.25, 
62.29 (2s, C-4’), 67.74 (d, JC–P = 6.3 Hz, C-5’), 67.91 (d, JC–P = 6.3 Hz, C-5’), 68.19 (br 
s, OCH2Ph), 117.59, 121.54, 121.58, 121.59, 121.63, 126.01, 129.23, 129.27, 129.57, 
130.68 (C-5, PhO, OCH2Ph), 137.37 (‘ipso’ OCH2Ph), 139.54 (C-8), 152.37, 152.43 
(2s, ‘ipso’ OPh), 153.11 (C4), 155.24 (C-2), 159.45 (C-6), 176.62 (bs, COOCH2Ph). EI 
MS= 607.21 (M+Na). HPLC = H2O/ACN from 90/10 to 0/100 in 25 min = retention 
time 12.07 min; H2O/MeOH  90/10 to 40/60 in 5 min, 40/60 isocratic 15 min, then to 
0/100 in 5 min  = retention time 12.35 min. 
Synthesis of penciclovir-[phenyl(benzyloxy-dimethylglicinyl)] diphosphate [6.6a] 
Chemical Formula: C44H51N7O11P2 
Molecular Weight: 915.8636 
A solution of 6.10a (0.60 g, 0.62 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. After this 
period the solvent was removed under reduced pressure 
and the residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 
100/0, then 98/2, then 97/3. The product was further purified by preparative reverse 
phase HPLC (gradient elution of H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 
15 min, then to 0/100 in 5 min) to give a white solid (5%, 0.03g). 
31P-NMR (MeOD, 202 MHz): ! 2.23, 2.18, 2.17. 1H-NMR (MeOD, 500 MHz): ! 7.65, 
7.63 (1H, 2s, H-8), 7.34-7.26 (14H, m, PhO, OCH2Ph), 7.19-7.13 (6H, m, PhO, 
OCH2Ph), 5.15-5.09 (4H, m, 2 x OCH2Ph), 4.09-4.07 (4H, m, H-4’, H-5’), 4.02-3.98 
(2H, m, H-1’), 1.88-1.82 (1H, m, H-3’), 1.76-1.65 (2H, m, H-2’) 1.49 (12H, br s, 2x 
C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.47 (d, JC–P = 5.04 Hz, C(CH3)2), 27.56 (d, 
JC–P = 5.04 Hz, C(CH3)2), 27.71 (d, JC–P = 6.30 Hz, C(CH3)2), 27.81 (d, JC–P = 6.30 Hz, 
C(CH3)2), 29.01, 29.05 (2s, C-2’), 38.38 (d, JC–P = 7.56 Hz, C-3’), 38.50 (d, JC–P = 7.56 
Hz, C-3’), 41.81, 41.85 (2s, C-1’), 66.90, 66.94, 67.08, 67.13 (C-4’, C-5’), 68.19 (s, 
OCH2Ph), 117.56, 121.35, 121.52, 121.56, 121.58, 121.62, 121.66, 126.05, 129.19, 
129.21, 129.24, 129.28, 129.58, 130.74 (C-5, PhO, OCH2Ph), 137.36 (‘ipso’ OCH2Ph), 
139.49 (C-8), 152.29, 152.35 (2s, ‘ipso’ OPh), 153.16 (C4), 155.23 (C-2), 159.44 (C-6), 
176.56, 176.58, 176.59 (3s, COOCH2Ph), EI MS= 938.31 (M+Na);  
H2O/MeOH  90/10 to 20/80 in 5 min, 20/80 isocratic 15 min, then to 0/100 in 5 min  = 
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retention time 16.28 min. 
Synthesis of N2-DMF-penciclovir-[1-naphthyl(benzyloxy-dimethylglicinyl)] 
phosphate [6.9b] and N2-DMF-penciclovir-[1-naphthyl(benzyloxy-
dimethylglicinyl)] diphosphate [6.10b].  
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Chemical Formula: C55H60N8O11P2
Molecular Weight: 1071.0594
Chemical Formula: C34H40N7O7P
Molecular Weight: 689.6979
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Prepared according to standard procedure G from 6.8a (0.6 g, 1.95 mmol) in anhydrous 
THF (35 ml), tBuMgCl (1.0 M THF solution, 3.89 mL, 3.89 mmol), 2.2h (1.43 g, 3.9 
mmol) in anhydrous THF (10 ml) and the reaction mixture was stirred at room 
temperature overnight. After this period tBuMgCl (1.0 M THF solution, 2.0 mL, 2.0 
mmol), 2.2h (0.9 g, 2.1 mmol) in anhydrous THF (2 mL) were added and the reaction 
mixture was stirred at room temperature for 4 h. The solvent was removed under 
reduced pressure.  The residue was purified by column chromatography gradient elution 
of DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8, to give two products: [6.9b] 
(48%, 0.66 g) and [6.10b] (40%, 0.54 g,). 
 [6.9b] 
31P-NMR (MeOD, 202 MHz): ! 2.44  (br s). 1H-NMR (MeOD, 500 MHz): ! 8.65 (1H, 
s, NCHN(CH3)2), 8.15-8.09 (1H, m, H-8 Naph), 7.89-7.70 (2H, m, H-6-Naph, H-8), 
7.65-7.55 (1H, m, H-2 Naph), 7.50-7.40 (2H, m, H-5 Naph, H-7 Naph), 7.30-7.21 (7H, 
NaphO, OCH2Ph), 5.15-5.07 (2H, m, OCH2Ph), 4.06-3.98 (4H, m, H-1’, H-5’), 3.37-
3.25 (2H, m, H-4’), 2.80-2.75 (6H, 2s, N(CH3)2), 1.75-1.64 (1H, m, H-3’), 1.56-1.50 
(8H, m, H-2’, C(CH3)2). 
[6.10b] 
31P-NMR (MeOD, 202 MHz): ! 2.82, 2.74, 2.59. 1H-NMR (MeOD, 500 MHz): ! 8.34-
8.29 (1H, m, NCHN(CH3)2), 8.18-8.13 (2H, m, 2 x H-8 Naph), 7.77-7.70 (2H, m, 2 x H-
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6 Naph), 7.67-7.52 (3H, m, H-8, 2 x H-2 Naph), 7.47-7.16 (18H, m, Naph, 2 x 
OCH2Ph) 5.11-5.04 (4H, m, 2 x OCH2Ph), 4.15-4.00 (4H, m, H-4’, H-5’), 3.91-3.79 
(2H, m, H-1’), 2.89-2.81 (6H, m, N(CH3)2), 1.79-1.75 (1H, m, H-3’),  1.53-1.47 (14H, 
m, H-2’, 2 x C(CH3)2). 
Synthesis of penciclovir-[phenyl(benzyloxy-dimethylglicinyl)] phosphate [6.5b] 
Chemical Formula: C31H35N6O7P 
Molecular Weight: 634.6194 
A solution of 6.9b (0.66 g, 0.95 mmol) in 
isopropanol (20 mL) was stirred under reflux for 24 
h . After this period the solvent was removed under 
reduced pressure and the residue was purified by column chromatography, gradient 
elution of DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8 then 90/10. The product 
was further purified by preparative reverse phase HPLC (gradient elution of 
H2O/MeOH 90/10 to 80/20 in 5 min, 80/20 isocratic 15 min, then to 0/100 in 5 min) to 
give a white solid (5%, 0.3*10-1 g).  
31P-NMR (MeOD, 202 MHz): ! 2.89, 2.85. 1H-NMR (MeOD, 500 MHz): ! 8.18-8.13 
(1H, m, H-8 Naph), 7.84-7.79 (1H, m, H-6 Naph), 7.66,7.64 (1H, 2s, H-8), 7.62-7.59 
(1H, m, H-2 Naph), 7.49-7.40 (2H, m, H-5 Naph, H-7 Naph), 7.37-7.21 (7H, NaphO, 
OCH2Ph), 5.1-5.04 (2H, m, OCH2Ph), 4.06-4.00 (4H, m, H-1’, H-5’), 3.37-3.20 (2H, m, 
H-4’), 1.79-1.70 (1H, m, H-3’), 1.56-1.50 (8H, m, H-2’, C(CH3)2). 
13C NMR (MeOD, 
126 MHz): ! 27.50 (d, JC–P = 4.77 Hz, C(CH3)2), 27.57 (d, JC–P = 4.77 Hz, C(CH3)2), 
27.86 (d, JC–P = 7.28 Hz, C(CH3)2), 27.96 (d, JC–P = 7.28 Hz, C(CH3)2), 29.35, 29.53 (2s, 
C-2’), 40.21 (d, JC–P = 7.48 Hz, C-3’), 40.31 (d, JC–P = 7.48 Hz, C-3’), 42.16, 42.26 (2s, 
C-1’), 62.21, 62.25 (2s, C-4’), 67.85 (d, JC–P = 6.07 Hz, C-5’), 68.08 (d, JC–P = 6.07 Hz, 
C-5’), 68.25 (bs, OCH2Ph), 116.55, 116.58, 116.71, 116.73, 117.55, 123.02, 125.84, 
125.87, 126.48, 127.29, 127.68, 127.69, 127.97, 128.02, 128.06, 128.81, 129.23, 
129.25, 129.27, 129.55 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-
7 Naph, C-8 Naph, OCH2Ph), 136.25 (‘ipso’ OCH2Ph), 137.34 (C-8a Naph) 139.45 (C-
8), 148.20, 148.26 (2s, ‘ipso’ ONaph), 153.03 (C-4), 155.20 (C-2), 159.46 (C-6), 
176.69, 176.72 (2s, COOCH2Ph). EI MS= 635.28 (M+H). HPLC = H2O/ACN from 
90/10 to 0/100 in 25 min = retention time 13.87 min; H2O/MeOH 90/10 to 20/80 in 5 
min, 20/80 isocratic 5 min, then to 0/100 in 5 min= retention time 8.55 min. 
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Synthesis of penciclovir-[1-naphtyl-(benzyloxy-dimethylglicinyl)]diphosphate 
[6.6b] 
Chemical Formula: C52H55N7O11P2 
Molecular Weight: 1015.9809 
A solution of 6.10b (0.54 g, 0.50 mmol) in 
isopropanol (20 mL) was stirred under reflux for 62 
h. After this period the solvent was removed under 
reduced pressure and the residue was purified by 
column chromatography, gradient elution of 
DCM/MeOH = 100/0, 98/2, then 97/3. The product was further purified by preparative 
reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 
isocratic 25 min, then to 0/100 in 5 min) to give a white solid (5%, 0.25*10-1 g).  
31P-NMR (MeOD, 202 MHz): ! 2.76, 2.70, 2.64, 2.57. 1H-NMR (MeOD, 500 MHz): ! 
8.18-8.13 (2H, m, 2 x H-8 Naph), 7.84-7.79 (2H, m, 2 x H-6 Naph), 7.65,7.64 (1H, 2s, 
H-8), 7.62-7.59 (2H, m, 2 x H-2 Naph), 7.49-7.18 (18H, m, Naph, 2 x OCH2Ph), 5.12-
5.03 (4H, m, 2 x OCH2Ph), 4.09-4.07 (4H, m, H-4’, H-5’), 4.02-3.98 (2H, m, H-1’), 
1.78-1.72 (1H, m, H-3’), 1.52-1.47 (14H, m, H-2’, 2 x C(CH3)2). 
13C NMR (MeOD, 126 
MHz): ! 27.48 (d, JC–P = 7.48 Hz, C(CH3)2), 27.54 (d, JC–P = 7.48 Hz, Hz C(CH3)2), 
27.59 (d, JC–P = 7.56, C(CH3)2), 27.89 (d, JC–P = 7.56, C(CH3)2), 27.97 (d, JC–P = 7.56 Hz, 
C(CH3)2), 28.07 (d, JC–P = 7.56 Hz, C(CH3)2), 28.88, 28.72 (2s, C-2’), 38.32 (d, JC–P = 
7.56 Hz, C-3’), 38.48 (d, JC–P = 7.56 Hz, C-3’), 41.72, 41.67 (2s, C-1’), 66.88, 66.97, 
67.01, 67.28 (C-4’, C-5’), 68.21 (OCH2Ph), 116.46, 116.48, 116.66, 116.69, 116.77, 
116.80, 117.53, 122.96, 123.02, 123.07, 123.10, 125.83, 125.88, 125.92, 126.50, 
126.52, 126.54, 127.35, 127.37, 127.68, 127.70, 127.72, 128.84, 129.17, 129.19, 
129.22, 129.25 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, 
C-8 Naph, OCH2Ph), 136.22, 136.25 (‘ipso’ OCH2Ph), 137.28, 137.31 (2s, C-8a Naph) 
139.25, 139.31 (2s, C-8), 148.14, 148.18 (2s, ‘ipso’ ONaph), 153.00 (C-4), 155.15 (C-
2), 159.43 (C-6), 176.62, 176.64 (2s, COOCH2Ph). EI MS= 1038.34 (M+Na). 
HPLC=H2O/MeOH 90/10 to 20/80 in 5 min, 20/80 isocratic 5 min, then to 0/100 in 5 
min, then 0/100 for 5= retention time 30.76, 31.97 min. 
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9.5.2 Synthesis of 2,2-dimethylglycine benzyl ester derivatives of ganciclovir 
ProTides 6.5c-d and 6.5c-d  
Synthesis of N2-DMF-ganciclovir:  
 N2-(N,N-dimethylformamidine)-9-[(1,3-dihydroxypropan-2-yloxy)methyl]-guanine 
[6.8b]. 
 Chemical Formula: C12H18N6O3 
Molecular Weight: 310.3091 
To a suspension of GCV (2 g, 7.8 mmol) in anhydrous 
DMF (35 ml) was added N,N-dimethylformamide 
dimethyl acetal (5.2 mL, 39 mmol) and the reaction mixture was stirred at room 
temperature overnight. After this period the suspension was filtered and the solid was 
washed with diethyl ether to give a white solid (95% 2.3 g). 
1H-NMR (DMSO, 500 MHz): ! 11.33 (1H, bs, NH), 8.58 (1H, s, CHN(CH3)2), 7.96 
(1H, s, H-8), 5.54 (2H, s, H-1’),  4.64 (2H, bs, 2XOH), 3.66-3.60 (1H, m, H-3’), 3.49-
3.43 (4H, m, H-4’, H-5’), 3.17, 3.05 (6H, 2s, N(CH3)2). 
Synthesis of N2-DMF-ganciclovir-[1-phenyl(benzyloxydimethylglicinyl)] phosphate 
[6.9c] and N2-DMF ganciclovir-[1-phenyl(benzyloxydimethylglicinyl)] diphosphate 
[6.10c] 
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Chemical Formula: C29H36N7O8P
Molecular Weight: 641.612
Chemical Formula: C46H54N8O12P2
Molecular Weight: 972.9149
6.9c 6.10c
 
Prepared according to standard procedure G from 6.8b (0.4 g, 1.3 mmol) in anhydrous 
mixture of THF (30 mL) and pyridine (10 mL), tBuMgCl (1.0 M THF solution, 2.6 mL, 
2.6 mmol), and 2.2g (1.43 g, 3.9 mmol) in anhydrous THF (5 mL) and the reaction 
mixture was stirred at room temperature overnight. After this period tBuMgCl (1.0 M 
THF solution, 2.6 mL, 2.6 mmol) ws added and the reaction mixture was stirred at room 
temperature for 6 h. The solvent was removed under reduced pressure.  The residue was 
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purified by column chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 
then 94/6 then 92/8, to give two products: [6.9c] (40%, 0.33 g), [6.10c] (38%, 0.47 g).  
[6.9c] 
31P-NMR (MeOD, 202 MHz): ! 1.72 (br s). 1H-NMR (MeOD, 500 MHz): ! 8.70 (1H, s, 
NCHN(CH3)2), 7.82-7.81 (1H, m, H-8), 7.40-7.30 (7H, m, PhO, OCH2Ph), 7.20-7.15 
(3H, m, PhO, OCH2Ph), 5.55, 5.52 (2H, 2s, H-1’), 5.19-5.11 (2H, m, OCH2Ph), 4.45-
4.20 (1H, m, H-3’), 4.07-4.01 (1H, m, H-5’), 3.99-3.94 (1H, m, H-5’), 3.60-3.47 (2H, 
m, H-4’), 2.80-2.75 (6H, 2s, N(CH3)2), 1.49 (6H, br s, C(CH3)2). 
[6.10c] 
31P-NMR (MeOD, 202 MHz): ! 1.91 (br s). 1H-NMR (MeOD, 500 MHz): ! 8.70-8.64 
(1H, m, NCHN(CH3)2), 7.70 (1H, bs, H-8), 7.40-7.30 (14H, m, PhO, OCH2Ph), 7.19-
7.15 (6H, m, PhO, OCH2Ph), 5.45-5.42 (2H, m, H-1’), 5.20-5.15 (4H, m, OCH2Ph), 
4.18-4.01 (5H, m, H-3’, H-4’, H-5’), 2.90-2.82 (6H, 2s, N(CH3)2) 1.50 (12H, br s, 2 x 
C(CH3)2) 
Synthesis of ganciclovir-[phenyl(benzyloxydimethylglicinyl)] phosphate [6.5c] 
Chemical Formula: C26H31N6O8P 
Molecular Weight: 586.5335 
A solution of 6.9c (0.33 g, 0.52 mmol) in isopropanol (10 
mL) was stirred under reflux for 24 h. After this period the 
solvent was removed under reduced pressure and the 
residue was purified by column chromatography, gradient elution of DCM/MeOH = 
98/2 then 96/4 then 94/6 then 92/8. The product was further purified by preparative 
reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 30/70 in 5 min, 30/70 
isocratic 10 min, then to 0/100 in 5 min) to give a white solid (6.5%, 0.02 g). 
31P-NMR (MeOD, 202 MHz): ! 2.26, 2.24. 1H-NMR (MeOD, 500 MHz): ! 7.82, 7.81 
(1H, 2s, H-8), 7.37-7.31 (7H, m, PhO, OCH2Ph), 7.19-7.15 (3H, m, PhO, OCH2Ph), 
5.52, 5.51 (2H, 2s, H-1’), 5.16-5.12 (2H, m, OCH2Ph), 4.20-4.14 (1H, m, H-3’), 4.09-
4.04 (1H, m, H-5’), 3.94-3.90 (1H, m, H-5’), 3.60-3.47 (2H, m, H-4’), 1.49 (6H, br s, 
C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.39 (d, JC–P = 6.3 Hz, C(CH3)2), 27.61 (d, 
JC–P = 6.3 Hz, C(CH3)2), 27.63 (d, JC–P = 6.3 Hz, C(CH3)2), 61.95, 61.99 (2s, C -4’), 
67.15 (d, JC–P = 5.54 Hz, C -5’), 67.19 (d, JC–P = 5.54 Hz, C -5’), 68.21, 68.20 (2s, 
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OCH2Ph), 72.96, 73.07 (2s, C-1’) 79.23 (d, JC–P = 5.29 Hz, C-3’), 79.30 (d, JC–P = 5.29 
Hz, CH2CHCH2), 115.24, 115.85, 117.55, 121.51, 121.55, 122.00, 126.01, 128.00, 
129.25, 129.27, 129.57, 130.68, 130.70 (C-5, PhO, OCH2Ph), 137.38 (‘ipso’ OCH2Ph), 
139.76 (s, C-8), 152.25 (d, JC–P = 2.56 Hz, ‘ipso’ OPh), 152.31 (d, JC–P = 2.56 Hz, ‘ipso’ 
OPh), 153.32 (C4), 155.65 (C-2), 159.34 (C-6), 176.54 (d, JC–P = 3.78 Hz, COOCH2Ph), 
176.57 (d, JC–P = 3.78 Hz, COOCH2Ph). EI MS= 587.2022 (M+H
+). HPLC = 
H2O/AcCN from 90/10 to 0/100 in 20 min = retention time 10.96 min; H2O/MeOH 
90/10 to 30/70 in 5 min, 30/70 isocratic 10 min, then to 0/100 in 5 min = retention time 
9.67 min. 
Synthesis of ganciclovir-[phenyl(benzyloxydimethylglicinyl)] diphosphate [6.6c] 
Chemical Formula: C43H49N7O12P2 
Molecular Weight: 917.8364 
A solution of 6.10c (0.47 g, 0.49 mmol) in isopropanol 
(15 mL) was stirred under reflux for 62 h. After this 
period the solvent was removed under reduced pressure 
and the residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 
98/2 then 96/4. The product was further purified by preparative reverse phase HPLC 
(gradient elution of H2O/MeOH 90/10 to 30/70 in 5 min, 20/80 isocratic 15 min, then to 
0/100 in 5 min) to give a white solid (4.3%, 0.02 g). 
31P-NMR (MeOD, 202 MHz): ! 2.18, 2.16, 2.11. 1H-NMR (MeOD, 500 MHz): ! 7.76 
(1H, bs, H-8), 7.37-7.27 (14H, m, PhO, OCH2Ph), 7.18-7.14 (6H, m, PhO, OCH2Ph), 
5.43 (2H, br s, H-1’), 5.16-5.10 (4H, m, OCH2Ph), 4.17-4.04 (5H, m, H-3’, H-4’, H-5’), 
1.48 (12H, br s, 2 x C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.43 (d, JC–P = 3.64 Hz, 
C(CH3)2), 27.65 (d, JC–P = 3.64 Hz, C(CH3)2), 27.70 (d, JC–P = 3.64 Hz, C(CH3)2), 66.38, 
66.42, 66.47, 66.52 (C-4’, C-5’), 68.22 (bs, OCH2Ph), 72.66, 72.79 (2s, C-1’) 77.96, 
77.05 (2s, C-3’), 117.58, 121.50, 121.53, 121.57, 126.06, 129.23, 129.24, 129.29, 
129.59, 130.72, 130.75 (C-5, PhO, OCH2Ph), 137.36 (‘ipso’ OCH2Ph), 139.66, 139.68 
(s, C-8), 152.21 (d, JC–P = 7.56 Hz, ‘ipso’ OPh), 152.22 (d, JC–P = 7.56 Hz, ‘ipso’ OPh), 
153.32 (C4), 155.65 (C-2), 159.30 (C-6), 176.52 (s, JC–P = 3.78, COOCH2Ph), 176.54 (s, 
JC–P = 2.52 Hz, COOCH2Ph). EI MS= 918.3033 (M+H
+). HPLC = H2O/AcCN from 
90/10 to 0/100 in 20 min = retention time 16.88 min; H2O/MeOH 90/10 to 30/70 in 5 
NH
NN
N
NH2O
O
O
O
P
O
O
HN
O
O
Bn
CH3
CH3
PO O
HN
CH3
CH3
O
O
Bn
Chapter 9 
 261 
min, 20/80 isocratic 15 min, then to 0/100 in 5 min = retention time 14.65 min. 
Synthesis of N2-DMF-ganciclovir-[1-naphthyl(benzyloxydimethylglicinyl)] 
phosphate [6.9d] and N2-DMF-ganciclovir-[1-naphthyl(benzyloxy-
dimethylglicinyl)] diphosphate [6.10d] 
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Chemical Formula: C33H38N7O8P
Molecular Weight: 691.6707
Chemical Formula: C54H58N8O12P2
Molecular Weight: 1073.0322
6.9d
6.10d
 
Prepared according to standard procedure G from 6.8b (0.5 g, 1.6 mmol) in anhydrous 
THF (30 mL), tBuMgCl (1.0 M THF solution, 3.2 mL, 3.2 mmol), 2.2h (1.67 g, 4.14 
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. After this period the solvent was removed under reduced 
pressure.  The residue was purified by column chromatography gradient elution of 
DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8, to give two products: 6.9d (56%, 
0.62 g), 6.10d (35%, 0.6 g).  
[6.9d] 
31P-NMR (MeOD, 202 MHz): ! 2.31 (br s). 1H-NMR (MeOD, 500 MHz): ! 8.60 (1H, s, 
NCHN(CH3)2, 7.78-7.81 (1H, m, H-8), 7.40-7.35 (7H, m, PhO, OCH2Ph), 7.20-7.14 
(3H, m, PhO, OCH2Ph), 5.57-5.50 (2H, m, H-1’), 5.15-5.12 (2H, m, OCH2Ph), 4.20-
4.14 (1H, m, H-3’), 4.07-4.00 (1H, m, H-5’), 3.91-3.87 (1H, m, H-5’), 3.60-3.47 (2H, 
m, H-4’), 2.74-2.64 (6H, 2 s, N(CH3)2), 1.52 (6H, br s, C(CH3)2). 
[6.10d] 
31P-NMR (MeOD, 202 MHz): ! 2.70, 2.66, 2.62, 2.60. 1H-NMR (MeOD, 500 MHz): ! 
8.47, 8.46 (1H, 2s, NCHN(CH3)2, 8.13-8.10 (2H, m, 2x H-8 Naph), 7.85 (2H, bs, 2 x H-
6 Naph), 7.68-7.65 (3H, m, H-8, 2 x H-2 Naph), 7.51-7.24 (18H, m, Naph, 2 x 
OCH2Ph), 5.32-5.28 (2H, m, H-1’), 5.11-5.08 (4H, m, OCH2Ph), 4.25-4.07 (5H, m, H-
3’, H-4’, H-5’), 2.90-2.88 (6H, m, N(CH3)2), 1.48-1.43 (12H, m, 2 x C(CH3)2) 
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Synthesis of ganciclovir-[1-naphthyl(benzyloxydimethylglicinyl)] phosphate [6.5d] 
Chemical Formula: C30H33N6O8P 
Molecular Weight: 636.5922 
A solution of 6.9d (0.62 g, 0.9 mmol) in isopropanol 
(20 mL) was stirred under reflux for 62 h. After this 
period the solvent was removed under reduced 
pressure and the residue was purified by column chromatography, gradient elution of 
DCM/MeOH = 98/2 then 96/4 then 94/6 then 92/8. The product was further purified by 
preparative TLC (gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6) to give a 
white solid (2.7%, 0.15*10-1 g). 
31P-NMR (MeOD, 202 MHz): ! 2.65, 2.69. 1H-NMR (MeOD, 500 MHz): ! 8.19-8.14 
(1H, m, H-8 Naph), 7.89-7.87 (1H, 2s, H-6 Naph), 7.76 (1H, s, H-8), 7.71-7.68 (1H, m, 
H-2 Naph), 7.54-7.52 (2H, m, H-5 Naph, H-7 Naph), 7.47-7.27 (7H, m, Naph, 
OCH2Ph), 5.42, 5.43 (2H, 2s, H-1’), 5.17-5.10 (2H, m, OCH2Ph), 4.26-4.20 (1H, m, H-
5’), 4.15-4.10 (1H, m, H-5’), 3.93-3.88 (1H, m, H-3’), 3.57-3.45 (2H, m, H-4’), 1.53-
1.51 (6H, m, C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.47 (d, JC–P = 5.20 Hz, 
C(CH3)2), 27.75 (d, JC–P = 5.20 Hz, C(CH3)2), 27.80 (d, JC–P = 5.20 Hz, C(CH3)2), 61.93, 
61.96 (2s, C-4’), 67.34 (d, JC–P = 5.76 Hz, C-5’), 67.38 (d, JC–P = 5.76 Hz, C-5’), 68.24 
(OCH2Ph), 72.96, 73.06 (2s, C-1’) 79.23 (d, JC–P = 7.90 Hz, C-3’), 79.29 (d, JC–P = 7.90 
Hz, C-3’), 116.41, 116.44, 116.47, 117.54, 122.98, 125.82, 126.51, 127.36, 127.71, 
127.91, 127.91, 127.96, 128.80, 129.23,  129.25, 129.55 (C-5, C-2 Naph, C-3 Naph, C-
4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 136.26 (‘ipso’ 
OCH2Ph), 137.34 (C-8a Naph), 139.69 (C-8), 148.10 (d, JC–P = 7.56, ‘ipso’ ONaph), 
148.13 (d, JC–P = 7.56, ‘ipso’ ONaph), 153.25 (C4), 155.62 (C-2), 159.31 (C-6), 176.60 
(d, JC–P = 3.35 Hz, COOCH2Ph), 176.62 (d, JC–P = 3.35 Hz, COOCH2Ph).  EI MS= 
659.20 (M+Na). HPLC = H2O/AcCN from 90/10 to 0/100 in 20 min = retention time 
13.71 min; H2O/MeOH from 90/10 to 20/80 in 5 min, 20/80 isocratic 10 min, then to 
0/100 in 5 min = retention time 9.99 min. 
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Synthesis of ganciclovir-[1-naphthyl(benzyloxydimethylglicinyl)] diphosphate 
[6.6d] 
Chemical Formula: C51H53N7O12P2 
Molecular Weight: 1017.9537 
A solution of 6.10d (0.6 g, 0.56 mmol) in 
isopropanol (20 mL) was stirred under reflux for 
62 h. After this period the solvent was removed 
under reduced pressure and the residue was 
purified by column chromatography, gradient 
elution of DCM/MeOH = 98/2 then 96/4 then 94/6 to give a white solid (5.3%, 0.3*10-1 
g). 
31P-NMR (MeOD, 202 MHz): ! 2.63, 2.57, 2.53, 2.52. 1H-NMR (MeOD, 500 MHz): ! 
8.13-8.10 (2H, m, 2 x H-8 Naph), 7.85 (2H, bs, 2 x H-6 Naph), 7.68-7.65 (3H, m, H-8, 
2 x H-2 Naph), 7.51-7.24 (18H, m, Naph, 2 x OCH2Ph), 5.32-5.28 (2H, m, H-1’), 5.11-
5.08 (4H, m, OCH2Ph), 4.25-4.07 (5H, m, H-3’, H-4’, H-5’), 2.90-2.88 (6H, m, 
N(CH3)2), 1.48-1.43 (6H, m, C(CH3)2). 
13C NMR (MeOD, 126 MHz): ! 27.47 (br s, 
C(CH3)2), 27.79, 27.82, 27.85, 27.88, (C(CH3)2), 66.44, 66.49, 66.52, 66.57, 66.67, 
66.64 (C-4’, C-5’), 68.23 (br s, OCH2Ph), 72.66, 72.79 (2s, C-1’) 77.10, 77.03 (2s, C-
3’), 116.39, 116.42, 116.44, 116.51, 116.53, 117.56, 122.93, 122.98, 123.50, 125.87, 
126.53, 127.21, 127.42, 127.70, 127.73, 127.89, 127.94, 128.81, 129.19, 129.24, 
129.54, 129.76 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, 
C-8 Naph, OCH2Ph), 136.24, 136.26 (2s, ‘ipso’ OCH2Ph), 137.29, 137.31 (2s, C-8a 
Naph), 139.53 (C-8), 147.99, 148.05 (2s, ‘ipso’ONaph), 153.23 (C4), 155.59 (C-2), 
159.26 (C-6), 176.57, 176.59 (2s, COOCH2Ph). EI MS= 1018.34 (M+H
+). HPLC = 
H2O/ACN from 90/10 to 0/100 in 40 min = retention time 34.05 min; H2O/MeOH 90/10 
to 20/80 in 5 min, 20/80 isocratic 30 min, then to 0/100 in 5 min = retention time 35.52 
min. 
 
 
 
 
NH
NN
N
NH2O
O
O
O
P
O
O
HN
O
O
Bn
CH3
CH3
PO
NH
O
CH3
CH3
OO Bn
Chapter 9 
 264 
9.5.3 Synthesis of L-alanine benzyl ester derivatives of penciclovir ProTides  
[6.7a-b]  
Synthesis of penciclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate [6.7a] 
Chemical Formula: C51H53N7O12P2 
Molecular Weight: 1017.9537 
Prepared according to standard procedure G, from 
penciclovir (0.3 g, 1.18 mmol) in anhydrous 
pyridine (20 mL), tBuMgCl (1.0 M THF solution, 
2.36mL, 2.36 mmol), 2.2a (0.8 g, 2.36 mmol) in 
anhydrous THF (2.5 mL). The reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure.  The residue was purified 
by column chromatography gradient elution of DCM/MeOH = 98/2, then 96/4, then 
94/6, then 92/8. The product was further purified by preparative reverse phase HPLC 
(gradient elution of H2O/MeOH 90/10 to 40/60 in 5 min, 40/60 isocratic 15 min, then to 
0/100 in 5 min) to give a white solid (5%, 0.035 g) . 
31P-NMR (MeOD, 202 MHz): ! 4.12, 4.05, 3.61, 3.59. 1H-NMR (MeOD, 500 MHz): ! 
8.01-7.99 (1H, m, H-8), 7.37-7.27 (7H, m, PhO, OCH2Ph), 7.21-7.15 (3H, m, PhO, 
OCH2Ph), 5.15, 5.14 (2H, 2s, OCH2Ph), 4.20-4.11 (4H, m, H-1’, H-5’), 4.04-4.01 (1H, 
m, CHCH3), 3.57-3.51 (2H, m, H-4’), 1.89-1.75 (3H, m, H-2’, H-3’), 1.39-1.36 (3H, m, 
CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.39, 20.44 (CHCH3), 29.28, 29.32, 29.37, 
29.39, 29.46 (C-2’), 40.20 (C-3’), 42.77, 42.81 (C-1’), 51.67, 51.70 (NHCH), 62.21, 
62.25, 62.32 (C-4’), 67.70, 67.74, 67.79 (C-5’), 67.98, 68.00 (2S, OCH2Ph), 120.84, 
121.47, 121.52, 121.55, 121.59, 121.63, 126.17, 128.01, 128.28, 129.27, 129.33, 
129.37, 130.32, 130.78, 131.06, 131.10 (C-5, PhO, OCH2Ph), 137.26 (‘ipso’ OCH2Ph), 
141.05 (C-8), 152.21, 152.27 (‘ipso’ OPh), 153.11 (C4), 155.20, 152.24, 152.6 (C-2, C-
3), 155.68 (C-6), 174.82, 175.07 (2s, COOCH2Ph). EI MS = 571.24 (M+H). HPLC = 
H2O/ACN from 90/10 to 0/100 in 25 min, then 0/100 isocratic  
5 min = retention time 16.88 min; H2O/MeOH from 90/10 to 0/100 in 25 min, then 
0/100 isocratic 5 min = retention time 23.35 min. 
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Synthesis of N2-(N,N-dibenzylformamidine)-penciclovir:  
 N2-(N,N-dibenzylformamidine)-9-[(4-dihydroxy-3-hydroxymethylbut-1-ylpropan-
2-yl]-guanine [6.11] 
Chemical Formula: C25H28N6O3
 
Molecular Weight: 460.5282 
Freshly distilled dibenzylamine  (7.5 g, 38.1 mmol) and 
N,N-dimethylformamide dimethylacetale (1.7 mL, 12.8 
mmol) were refluxed in ACN (15 mL) for 24 h. Anhydrous toluene (15 mL)  was added 
and the solvent was removed under reduced pressure. The crude residue in anhydrous 
ACN (10 mL) was added to PCV (1.06 g, 4.2 mmol) in ACN (20 mL). The solution was 
stirred for 24 h at 45 °C and precipitated in ET2O (65 mL). The solid was filtrated and 
purified by column chromatography, gradient elution of DCM/MeOH = 98/2 to 80/20, 
to give a white solid (52%, 1 g). 
1H-NMR (DMSO, 500 MHz): ! 11.41 (1H, bs, NH), 8.99 (1H, s, CHN(Bn)2), 7.85 (1H, 
s, H-8), 7.42-7.31(10H, m, Bn), 4.62, 4.58 (2H, 2s, NCH2Ph), 4.43 (2H, t, J = 5.23 Hz,  
H-1’),  3.49-3.38 (4H, m, H-4’, H-5’), 1.81-1.76 (2H, m, H-2’), 1.51-1.46 (1H, m, H-
3’).  
Synthesis of N2-(N,N-dibenzylformamidine)-penciclovir-[1-naphthyl(benzyloxy-L-
alaninyl)] phosphate [6.12] 
Chemical Formula: C45H46N7O7P 
Molecular Weight: 827.8632 
Prepared according to standard procedure G 
from 6.11 (0.13 g, 0.28 mmol) in anhydrous 
mixture of THF (6 mL) and pyridine (2 mL), 
tBuMgCl (1.0 M THF solution, 0.56 mL, 0.56 mmol), and 2.2b (0.23 g, 0.56 mmol) in 
anhydrous THF (3 mL) and the reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure.  The residue was purified 
by column chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6 
then 92/8, to give a white solid (30%, 0.07 g).  
31P-NMR (MeOD, 202 MHz): ! 4.52, 4.64, 4.19, 4.09. 1H-NMR (MeOD, 500 MHz): ! 
9.05 (1H, s, NCHN(CH2Ph)2), 8.28-8.27 (1H, m, H-8 Naph), 8.14-8.13 (1H, m, H-6 
Naph), 7.78-7.13 (21H, m, H-8, Naph, OCH2Ph, N(CH2Ph)2), 5.04-5.02 (2H, m, 
OCH2Ph), 4.61-4.58 (2H, m, NCH2Ph), 4.42-4.37 (2H, m, NCH2Ph), 4.11-4.03 (6H, 
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m, H-1’, H-5’, CHCH3),  3.51-3.45 (2H, m, H-4’), 1.78-1.66 (2H, m, H-2’), 1.31-1.28 
(1H, m, H-3’), 1.19 (3H, d, J= 6.86 Hz, CHCH3). 
Synthesis of N2,O-bis(MTT)-penciclovir:  
(N2-(monomethoxytrity1)-9-[3-(hydroxymethyl)-4-[(monomethoxytrityl)oxy]but-l-
yl]guanine) [6.13a]  
and 
 N2-MTT-penciclovir: 
 (N2-(monomethoxytrity1)-9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine) 
[6.14a] 
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 6.13a  6.14a
Chemical Formula: C50H47N5O5
Molecular Weight: 797.9387
Chemical Formula: C30H31N5O4
Molecular Weight: 525.5982
 
 A solution of penciclovir (4.05 g, 16 mmol), monomethoxytrityl chloride (10.9 g, 35 
mmol), anhydrous triethylamine (6.7 mL) and 4-dimethylaminopyridine (40 mg) in 
anhydrous DMF (50 mL) was stirred at room temperature for 2 h. The reaction was 
quenched with MeOH and the solvent was removed. The residue was taken up in ethyl 
acetate and the solution washed with aqueous NaHCO3 and water. The solution was 
dried (MgSO4) and the solvent removed. The residue was purified by column 
chromatography on silica gel eluting with CHCL3/MeOH (gradient elution = 100/0, then 
98/2, then 96/4, then 94/6) The first product to elute was 6.13a (4.4 g, 34%). The 
second product to elute was 6.14a (1.4 g, 17%). 
[6.13a] 
1H-NMR (DMSO, 500 MHz): ! 10.50 (1H, bs, NH), 7.55 (1H, s, N-2), 7.44 (1H, s, H-
8), 7.4-6.7 (28H, m, Ph), 4.35 (1H, t, J = 4.8 Hz, OH), 3.74 (3H, s, CH3O), 3.66 (3H, s, 
CH3O), 3.42 (2H, t, J=6.7 Hz, H-1’), 3.40-3.10 (2H, m, H-5’), 2.90-2.70 (2H, m, H-4’), 
1.43 (1H, m, H-3’), 1.24 (2H, m, H-2’). 
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[6.13a] 
1H-NMR (DMSO, 500 MHz): ! 10.49 (1H, bs, NH), 7.56 (1H, s, N-2), 7.54 (1H, s, H-
8), 7.35-6.86 (14H, m, Ph), 4.28 (2H, t, J = 5.2 Hz, 2 X OH), 3.72 (3H, s, CH3O), 3.52 
(2H, t, J=6.6 Hz, H-1’), 3.3-3.1 (4H, m, 2 X CH2OH), 1.25 (3H, m, H-2’, H-3’). 
Synthesis of N2,O-bis(MTT)-penciclovir-[1-naphtyl(benzyloxy-L-alaninyl)] 
phosphate [6.15a] 
Chemical Formula: C70H65N6O9P 
Molecular Weight: 1165.2737 
Prepared according to standard procedure G 
from 6.13a  (0.6 g, 0.75 mmol) in anhydrous 
THF (15 mL) tBuMgCl (1.0 M THF solution, 
1.5 mL, 1.5 mmol), 2.2b (0.6 g, 1.5 mmol) in 
anhydrous THF (5 mL). The reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure. The residue was purified 
by column chromatography, gradient elution of DCM/MeOH = 100/0 then 98/2, to give 
a white solid (40%, 0.36 g,).  
31P-NMR (DMSO, 202 MHz): ! 3.99, 3.85, 3.81, 3.75. 1H-NMR (DMSO, 500 MHz): ! 
10.51 (1H, bs, NH-1), 8.09-8.03 (1H, m, H-8 Naph), 7.95-7.94 (1H, m, H-6 Naph), 
7.73-7.71 (1H, m, H-8), 7.56 (1H, bs, NH-2), 7.46-6.74 (38H, m, Naph, OCH2Ph, 2 x 
Tr), 5.13-4.95 (2H, m, OCH2Ph), 4.03-3.80 (5H, m, H-1’, CHCH3, H-5’), 3.72 (3H, s, 
OCH3), 3.65 (3H, s, OCH3), 2.73-2.71 (2H, m, H-4’), 1.52-1.47 (3H, m, H-2’, H-3’), 
1.28-1.24 (3H, m, CHCH3). EI MS = 1187.39 (M+Na).  
Synthesis of penciclovir-[1-naphtyl(benzyloxy-L-alaninyl)] phosphate [6.7b] 
Chemical Formula: C30H33N6O7P 
Molecular Weight: 620.5928 
A solution of 6.15a (0.164 g, 0.14 mmol) in 
CH2Cl2/MeOH mixture 7:3 (10 mL) was treated 
with p-toluensulfonic acid (0.133 g, 0.7 mmol). The 
mixture was stirred at room temperature for 2 h. After this period the solvent was 
removed under reduced pressure and the residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6 then, 
92/8, then 90/10). The product was further purified by preparative reverse phase HPLC 
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(gradient elution of H2O/MeOH 90/10 to 80/20 in 5 min, 80/20 isocratic 15 min, then to 
0/100 in 5 min) to give a white solid (30%, 0.027 g).  
31P-NMR (MeOD, 202 MHz): ! 4.46, 4.44, 4.16, 4.13. 1H-NMR (MeOD, 500 MHz): ! 
8.17-8.15 (1H, m, H-8 Naph), 7.87-7.86 (1H, m, H-6 Naph), 7.70-7.67 (1H, m, H-8), 
7.63-7.58 (1H, m, H-2 Naph), 7.52-7.50 (2H, m, H-5 Naph, H-7 Naph), 7.47-7.26 (7H, 
NaphO, PhO), 5.13, 5.09 (2H, m, OCH2Ph), 4.23-4.11 (3H, m, H-5’, CHCH3), 4.03-
3.94 (1H, m, H-1’), 3.49-3.43 (2H, m, H-4’), 1.76-1.62 (3H, m, H-2’, H-3’), 1.38 (3H, 
bs, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.39, 20.42, 20.44, 20.48, 20.50 
(CHCH3), 29.44, 29.54 (C-2’), 40.27, 40.31, 40.40 (C-3’), 42.25, 42.29 (C-1’), 51.83, 
51.87, 51.93 (NHCH), 62.24, 62.31 (H-4’), 67.82, 67.86, 67.94, 67.99, 68.07 (H-5’, 
OCH2Ph), 116.47, 116.50, 116.60, 116.69, 116.71, 117.56, 119.99, 122.73, 122.76, 
122.85, 122.88, 123.15, 125.46, 126.03, 126.51, 126.99, 127.42, 127.45, 127.75, 
128.02, 128.27, 128.43, 128.84, 128.87, 129.25, 129.30, 129.33, 129.54, 129.57 (C-5, 
C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, OCH2Ph), 
136.27 (‘ipso’ OCH2Ph), 137.20 (C-8a Naph) 139.48 (C-8), 148.05, 148.11 (2s, ‘ipso’ 
ONaph), 153.04 (C-4), 155.21 (C-2), 159.42 (C-6), 174.84, 175.04 (2s, COOCH2Ph).  
EI MS = 621.22 (M+H). HPLC: H2O/ACN from 90/0 to 0/100 in 30 min, then 0/100 
isocratic 5 min = retention time 12.93 min 
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9.5.4 Synthesis of L-alanine benzyl ester derivatives of ganciclovir ProTides  
6.7c-d 
Synthesis of N2,O-bis(MTT)-ganciclovir: 
 (N2-(monomethoxytrityl)-9-[(1-monomethoxytrityloxy-3-hydroxypropan-2-
yloxy)methyl]guanine) [6.13a] 
and 
N2-MTT-ganciclovir: 
(N2-Monomethoxytrityl-9-[(1,3-dihydroxypropan-2-yloxy)methyl]guanine) [6.14b] 
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 6.13b  6.14b
Chemical Formula: C49H45N5O6
Molecular Weight: 799.9115
Chemical Formula: C29H29N5O5
Molecular Weight: 527.5711
 
A solution of GCV (0.5 g, 1.96 mmol), monomethoxytrityl chloride (1.33 g, 4.32 
mmol), triethylamine (0.82 mL, 5.88 mmol) and 4-dimethylaminopyridine (5 mg) in 
DMF (5 mL) was stirred at room temperature for 2 h. The reaction was quenched with 
MeOH and the solvent was removed. The residue was taken up in ethyl acetate and the 
solution washed with aqueous NaHCO3 and water. The solution was dried (MgSO4) and 
the solvent removed. The residue was purified by column chromatography on silica gel 
using a gradient elution of DCM/MeOH (98/2, then 96/4, then 94/6). The first product 
to elute was 6.13b (53%, 0.84 g). The second product to elute was 6.14b (30% 0.3 g) 
[6.13b] 
1H-NMR (MeOH, 500 MHz): ! 7.79 (1H, s, H-8), 7.32-6.73 (28H, m, Ph), 5.06 (2H, s, 
H-1’), 3.82 (3H, s, CH3O), 3.66 (3H, s, CH3O), 3.57-3.54 (1H, m, H-3’), 3.28-3.18 (2H, 
m, H-5’), 2.87-2.79 (2H, m, H-4’) 
[6.14b] 
1H-NMR (MeOH, 500 MHz): ! 7.74 (1H, s, H-8), 7.38-6.87 (14H, m, Ph), 3.80 (3H, s, 
CH3O), 3.66-3.60 (1H, m, H-3’), 3.49-3.43 (4H, m, H-4’, H-5’). 
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Synthesis of N2,O-bis(MTT)-ganciclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate 
[6.15b] 
Chemical Formula: C66H63N6O10P 
Molecular Weight: 1131.2144 
Prepared according to standard 
procedure G from 6.13b (0.45 g, 0.58 
mmol) in anhydrous THF (10 mL) 
tBuMgCl (1.0 M THF solution, 1.12 
mL, 1.12 mmol), 2.2a (0.45 g, 1.27 
mmol) in anhydrous THF (2 mL) and the reaction mixture was stirred at room 
temperature overnight. The solvent was removed under reduced pressure. The residue 
was purified by column chromatography, gradient elution of DCM/MeOH = 100/0 then 
98/2, to give a white solid (38%, 0.247 g,). 
31P-NMR (MeOD, 202 MHz): ! 3.32, 3.30, 3.27, 3.16. 1H-NMR (MeOD, 500 MHz): ! 
7.74-7.73 (1H, m, H-8), 7.34-6.70 (38H, m, PhO, OCH2Ph, 2 x Tr), 5.17-4.99 (2H, m, 
OCH2Ph), 4.95-4.89 (2H, m, H-1’), 3.79-3.60 (8H, m, CHCH3, H-3’, 2X OCH3) 3.17-
3.07 (2H, m, H-5’), 2.81-2.78 (2H, m, H-4’), 1.85, 1.72 (3H, m, CHCH3).  
Synthesis of ganciclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate [6.7c] 
Chemical Formula: C25H29N6O8P 
Molecular Weight: 572.5069 
 
A solution of 6.15b (0.11 g, 0.1 mmol) in 
CH2Cl2/MeOH mixture 7:3 (5 mL) was treated with p-
toluensulfonic acid (0.09 g, 0.48 mmol). The mixture was stirred at room temperature 
for 2 h. After this period the solvent was removed under reduced pressure and the 
residue was purified by preparative TLC plate chromatography, gradient elution of 
DCM/MeOH = 98/2 then 96/4 then 94/6. The product was further purified by 
preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 80/20 in 5 
min, 80/20 isocratic 15 min, then to 0/100 in 5 min) to give a white solid (28%, 1.7*10-2 
g).  
31P-NMR (MeOD, 202 MHz): ! 3.92, 3.83, 3.63, 3.61. 1H-NMR (MeOD, 500 MHz): ! 
7.84-7.79 (1H, m, H-8), 7.40-7.30 (7H, m, PhO, OCH2Ph), 7.21-7.13 (3H, m, PhO, 
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OCH2Ph), 5.54-5.50 (2H, m, H-1’), 5.17-5.14 (2H, m, OCH2Ph), 4.23-3.91 (4H, m, H-
5’, H-3’, CHCH3), 3.61-3.47 (2H, m, H-4’), 1.38-1.31 (3H, m, CH3). 
13C NMR (MeOD, 
126 MHz): ! 20.50 (d, JC–P = 7.1 Hz, CHCH3), 20.40 (d, JC–P = 7.1 Hz, CHCH3), 20.37 
(d, JC–P = 7.1 Hz, CHCH3), 51.62, 51.75 (CHCH3), 61.91, 61.99, 62.02 (C-4’), 67.31 (d, 
JC–P = 5.9 Hz, C-5’), 67.25 (d, JC–P = 5.9 Hz, C-5’), 67.20 (d, JC–P = 5.9 Hz, C-5’), 67.97, 
68.00, 68.03 (OCH2Ph), 73.07, 73.11, 79.13 (C-1’) 79.24 (d, JC–P = 7.56, C-3’), 79.25 
(d, JC–P = 5.6 Hz, C-3’), 79.30 (d, JC–P = 5.6 Hz, C-3’), 117.55, 121.41, 121.44, 121.47, 
121.49, 121.51, 121.53, 121.54, 126.09, 126.12, 126.15,129.27, 129.32, 129.33, 129.35, 
129.58, 129.61, 129.63, 130.76 (C-5, PhO, OCH2Ph), 137.30 (‘ipso’ OCH2Ph), 139.8 
(s, C-8), 152.12, 152.17, 152.19, 152.23 (4s, ‘ipso’OPh), 153.30 (C-4), 155.68 (C-2), 
159.37 (C-6), 174.92 (d, JC–P = 5.4 Hz, 1C), 174.82 (d, JC–P = 5.4 Hz, COOCH2Ph), 
174.72 (d, JC–P = 5.4 Hz, COOCH2Ph). EI MS= 595.162 (M+Na). HPLC = H2O/ACN 
from 100/0 to 0/100 in 15 min, then 0/100 isocratic 5 min = retention time 9.29 min; 
H2O/MeOH from 100/0 to 0/100 in 15 min, then 0/100 isocratic 5 min = retention time 
13.18 min. 
Synthesis of N2-MTT-ganciclovir-[1-naphthyl(benzyloxy-L-alaninyl)] phosphate 
[6.16] 
Chemical Formula: C48H45N6O8P 
Molecular Weight: 864.8801 
Prepared according to standard 
procedure G, from 6.14b (0.24 g, 0.46 
mmol) in anhydrous THF (8 mL) 
tBuMgCl (1.0 M THF solution, 0.92 mL, 0.92 mmol), 2.2b (0.37 g, 0.92 mmol) in 
anhydrous THF (2.5 mL). The reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure. The residue was purified 
by column chromatography, gradient elution of DCM/MeOH = 100/0, 98/2, then 96/2, 
to give a white solid (35%, 0.146 g).  
31P-NMR (MeOD, 202 MHz): ! 3.58, 3.52, 3.48, 3.35. 1H-NMR (MeOD, 500 MHz): ! 
8.19-8.11 (1H, m, H-8 Naph), 7.91-7.89 (1H, m, H-6 Naph), 7.69-7.68 (1H, m, H-8), 
7.66-6.75 (m, 24H, Naph, OCH2Ph, Tr), 5.1-5.03 (m, 2H, OCH2Ph), 4.95-4.91 (2H, m, 
H-1’), 4.04-3.72 (3H, m, CHCH3, H-5’), 3.67 (3H, s, OCH3), 3.52-3.44 (1H, m, H-3’), 
3.29-3.08 (2H, m, H-4’), 1.34-1.30 (3H, m, CHCH3). 
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Synthesis of ganciclovir-[1-phenyl(benzyloxy-L-alaninyl)] phosphate. [6.7d] 
Chemical Formula: C29H31N6O8P 
Molecular Weight: 622.5656 
A solution of 6.16 (0.09 g, 0.1 mmol) in 
CH2Cl2/MeOH 7:3 (5 mL) was treated with p-
toluensulfonic acid (0.09 g, 0.48 mmol). The 
mixture was stirred at room temperature for 2 h. After this period the solvent was 
removed under reduced pressure and the residue was purified by preparative TLC plate 
chromatography, gradient elution of DCM/MeOH = 98/2 then 96/4 then 94/6, to give a 
white solid (25%, 1.5*10-2 g). 
31P-NMR (MeOD, 202 MHz): ! 4.29, 4.24, 4.18, 4.09. 1H-NMR (MeOD, 500 MHz): ! 
8.16-8.09 (m, 1H, H-8 Naph), 7.90, 7.80 (1H, 2s, H-6 Naph), 7.79-7.75 (1H, m, H-8), 
7.72-7.70 (1H, m, H-2 Naph), 7.54-7.24 (12H, m, Naph, OCH2Ph), 5.46-5.42 (2H, m, 
H-1’), 5.13-5.07 (2H, m, OCH2Ph), 4.29-4.06 (4H, m, H-5’, H-3’ CHCH3), 3.97-3.90 
(2H, m, H-4’), 1.38-1.31 (3H, m, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.38 (d, J 
= 6.7 Hz, CHCH3), 20.43 (d, J = 6.7 Hz, CHCH3), 20.53 (d, J = 6.7 Hz, CHCH3), 51.80, 
51.85 (CHCH3), 61.84, 61.94, 61.97 (C-4’), 67.43 (d, J = 5.6 Hz, C-5’), 67.49 (d, J = 
5.6 Hz, C-5’), 67.53 (d, J = 5.6 Hz, C-5’), 67.97, 68.01, 68.04 (OCH2Ph), 72.96, 73.00, 
73.08, 79.10 (4s, C-1’), 79.11 (d, JC–P = 7.8 Hz, C-3’), 79.25 (d, JC–P = 7.8 Hz, C-3’), 
79.31 (d, JC–P = 7.8 Hz, C-3’), 116.34, 116.36, 116.39, 116.42, 116.45, 116.47, 122.70, 
122.74, 122.47, 125.99, 126.01, 126.55, 127.50, 127.53, 127.79, 128.87, 129.22, 
129.27, 129.30, 129.32, 129.34, 129.54, 129.58, 129.60 (C-5, PhO, OCH2Ph), 136.30, 
137.23 (‘ipso’ OCH2Ph, C4aNaph), 139.73 (C-8), 147.98, 148.03 (2s, ‘ipso’OPh), 
153.27 (C-4), 155.65 (C-2), 159.34 (C-6), 174.74 (d, JC–P = 4.7 Hz, COOCH2Ph), 
174.86 (d, JC–P = 4.7 Hz, COOCH2Ph), 174.96 (d, JC–P = 4.7 Hz, COOCH2Ph). EI MS= 
645.187 (M+Na). HPLC = H2O/ACN from 100/0 to 0/100 in 15 min, then 0/100 
isocratic 5 min = retention time 10.49 min; H2O/MeOH from 100/0 to 0/100 in 15 min, 
then 0/100 isocratic 5 min = retention time 13.93 min. 
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9.5.5 Synthesis of ganciclovir ProTide 6.19c 
Synthesis of N2-DMF-O-monoacetyl-ganciclovir: 
N2-(N,N-dimethylformamidine)-9-[(1-acetoxy-3-hydroxypropan-2-yloxy)methyl]-
guanine) [6.17b]  
and 
N2-DMF-O,O-diacetyl-ganciclovir: 
N2-(N,N-dimethylformamidine)-9-[(1,3-diacetoxy-propan-2-yloxy)methyl]- 
guanine) [6.20] 
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Chemical Formula: C14H20N6O5
Molecular Weight: 352.3458
Chemical Formula: C16H22N6O6
Molecular Weight: 394.3825
6.17b 6.20
 
A suspension of 6.8b (0.3 g, 0.97 mmol) in a mixture of pyridine (50 mL) and benzene 
(25 mL) was treated with vinyl acetate (7.46 mL, 80.76 mmol) and porcine pancreatic 
lipase (1.46 g, 33’407 units). This suspension was allowed to stir at room temperature. 
After 24 h, TLC on silica of mixture reaction showed an incomplete acetylation of the 
starting material. An additional portion of porcine pancreatic lipase (0.48 g, 11’135 
units) was added and the suspension was allowed to stir for an additional 24 h. At this 
point TLC of mixture reaction showed monoacetylated product along with traces of 
diacetylated product. The crude of the reaction was filtered and the solvent was 
removed under vacuum. The residue was purified by flash column chromatography, 
gradient elution of CHCl3/MeOH = 98/2, then 95/5, then 92/8, to give 6.17b as a white 
solid (53%, 0.180 g) 6.20 as a white solid (0.03 g, 8%).  
6.17b 
1H-NMR (MeOH, 500 MHz): ! 8.67 (1H, s, CHN(CH3)2), 7.95 (1H, s, H-8), 5.63 (2H, 
s, H-1’), 4.22-4.01 (1H, dd, J = 11.22, 3.13, H-4’), 4.05-3.98 (2H, m, H-3’, H-4’), 3.64-
3.56 (2H, m, H-5’), 3.23, 3.11 (6H, 2s, N(CH3)2), 1.91 (3H, br s, COCH3). 
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6.20 
1H-NMR (MeOH, 500 MHz): ! 8.73 (1H, s, CHN(CH3)2), 7.98 (1H, bs, H-8), 5.62 (2H, 
s, H-1’), 4.30-4.05 (5H, m, H-3’, H-4’, H-5’), 3.27, 3.16 (6H, 2s, N(CH3)2), 1.95 (6H, br 
s, 2 x COCH3). 
Synthesis of N2-dimethylformamidine-O-monoacetyl-ganciclovir-
[phenyl(benzyloxy-L-alaninyl)] phosphate [6.18c] 
Chemical Formula: C30H36N7O9P 
Molecular Weight: 669,6221 
Prepared according to standard procedure G, 
from 6.17b (0.18 g, 0.51 mmol) in anhydrous 
THF (10 mL), tBuMgCl (1.0 M THF solution, 3 
mL, 3 mmol), 2.2a (0.36 g, 1.02 mmol) in anhydrous THF (2.5 mL). The reaction 
mixture was stirred at room temperature overnight. The solvent was removed under 
reduced pressure. The residue was purified by column chromatography, gradient elution 
of DCM/MeOH = 100/0, then 98/2, then 96/4, to give a white  solid (68%, 0.24 g,). 
31P-NMR (CDCl3, 202 MHz): ! 3.93, 3.88, 3.47, 3.42. 
1H-NMR (CDCl3, 500 MHz): ! 
8.68-8.62 (1H, m, NCHN(CH3)2), 7.76-7.75 (1H, m, H-8), 7.39-6.81 (10H, m, Ph, 
OCH2Ph), 5.53-5.37 (2H, m, H-1’), 4.95-4.84 (2H, m, OCH2Ph), 4.23-3.98 (6H, m, H-
3’, H-4’, H-5’, CHCH3), 3.14, 3.02 (6H, 2s, N(CH3)2), 1.92 (bs, 3H COCH3), 1.41-1.38 
(3H, m, CH3).  
Synthesis of O-monoacetyl-ganciclovir-[phenyl(benzyloxy-L-alaninyl)] phosphate 
[6.19c] 
Chemical Formula: C27H31N6O9P 
Molecular Weight: 614.5436 
A solution of 6.18c (0.24 g, 0.35 mmol) in 
isopropanol (15 mL) was stirred under reflux for 62 
h. The solvent was then removed under reduced 
pressure and the residue was purified by column chromatography gradient elution of  
DCM/MeOH = 98/2, then 96/4, then 94/6) to give  a white solid (31%, 0.07g). 
31P-NMR (MeOD, 202 MHz): ! 3.93, 3.83, 3.53, 3.47. 1H-NMR (MeOD, 500 MHz): ! 
7.84-7.80 (1H, m, H-8); 7.43-7.17 (10H, m, Ph, OCH2Ph), 5.51-5.49 (2H, m, H-1’), 
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5.18-5.14 (2H, m, OCH2Ph), 4.18-4.11 (5H, m, H-3’, H-4’, H-5’), 4.01-3.98 (1H, m, 
CHCH3), 1.94- 1.90 (3H, m, COCH3), 1.38-1.31 (3H, m, CHCH3).  
9.5.6 Synthesis of penciclovir ProTide 6.24 
Synthesis of N2-isobutyryl penciclovir:  
N2-isobutyryl-9-(4-hydroxy-3-hydroxymethylbut-1yl)-guanine [6.21] 
Chemical Formula: C14H21N5O4 
Molecular Weight: 323.3476 
Isobutyryl chloride (2.23 mL, 21.13 mmol) was added 
dropwise at 0 °C to a suspension of penciclovir (1 g, 3.95 
mmol) suspended in pyridine (50 mL). The mixture was stirred at room temperature for 
16 h. After this period, the reaction was quenched with methanol (5 mL) and the solvent 
was removed under reduced pressure. The residue was dissolved in pyridine/methanol 
mixture (2:1, 30 mL) and the pH was adjusted to 12.5 with 2M NaOH. The mixture was 
kept at room temperature for 10 min. The pH was adjusted to 7.0 with 2 M HCl and the 
solvent was removed under vacuum. The residue was purified by flash chromatography, 
gradient elution of DCM/MeOH  = 95/5, then 90/10, the 85/15), to give a white solid 
(78%, 1 g). 1H-NMR (MeOH, 500 MHz): ! 7.99 (1H, s, H-8), 4.28 (2H, t, J = 7.49 Hz, 
H-1’), 3.64 (2H, dd, J = 10.9 Hz, 5.9 Hz, H-5’), 3.59 (2H, dd, J = 10.9 Hz, 5.9 Hz, H-
4’), 2.74 (1H, septet, J = 6.86 Hz, CH(CH3)2), 1.95 (2H, m, H-2’), 1.64 (1H, m, H-3’), 
1.25 (6H, d, J =  6.86 Hz,  CH(CH3)2). 
Synthesis of N2-isobutyryl-O,O-diacetyl-penciclovir:  
N2-isobutyryl-9-(4-Acetoxy-3-Acetoxymethylbut-1yl)-guanine [6.22] 
Chemical Formula: C18H25N5O6 
Molecular Weight: 407.4210 
A mixture of 6.21 (1 g, 3.09 mmol), DMAP (0.05 g, 0.4 
mmol) and acetic anhydride (2.1 mL, 22.47 mmol) in 
DMF (80 mL) was stirred for 1 h at room temperature. 
Solvent was removed under vacuum and the crude was purified by flash 
chromatography, gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white 
solid (0.9 g, 71%). 
1H-NMR (MeOH, 500 MHz): ! 7.99 (1H, s, H-8), 4.29 (2H, t, J = 7.03 Hz, H-1’), 4.13 
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(4H, d, J = 5.35 Hz,  H-4’, H-5’), 2.74 (1H, septet, J = 6.87 Hz, CH(CH3)2), 2.06-1.98 
(9H, m, H-2’, H-3’, 2X COCH3), 1.25 (6H, d, J =  6.87 Hz,  CH(CH3)2). 
Synthesis of N2-isobutyryl-O-monoacetyl-penciclovir : 
N2-isobutyryl-9-(4-hydroxy-3-Acetoxymethylbut-1yl)-guanine [6.23] 
Chemical Formula: C16H23N5O5 
Molecular Weight: 365.3843 
A mixture of diacetate 6.22 (0.32 g, 0.79 mmol) in DMF 
(30 mL) and buffer phosphate (pH 7.00, 300 mL) was 
treated with and porcine liver esterase (1.44 g, 27’360 
units). The mixture was stirred for 2 h at room temperature, then lyophilized. The 
residue was sonicated with DCM/MeOH (3:1, 3X 100 mL) and the insoluble portion 
was filtered off. The solvent was removed under reduced pressure and the residue was 
purified by flash column chromatography using gradient elution of DCM/MeOH = 98/2, 
then 95/5, then 90/10 to give the monoacetate 6.23 (60%, 0.173 g) as a white solid and 
unreacted starting material 6.22 (0.15 g, 18%). 
1H-NMR (MeOH, 500 MHz): ! 7.98 (1H, s, H-8), 4.26 (2H, t, J = 7.25 Hz, H-1’), 4.16-
4.08 (2H, m, H-4’), 3.63-3.60 (2H, m, H-5’), 2.77-2.72 (1H, m, CH(CH3)2), 2.04 (3H, 
m, CH3CO), 2.01-1.87 (2H, m, H-2’), 1.84-1.79 (1H, m, H-3’), 1.24 (6H, d, J =  6.84 
Hz,  CH(CH3)2). 
Synthesis of N2-isobutyryl-O-monoacetyl-penciclovir-[phenyl(benzyloxy-L-
alaninyl)]-phosphate. [6.24]  
Chemical Formula: C32H39N6O9P 
Molecular Weight: 682.6606 
Prepared according to standard procedure G from 
6.24 (0.93 g, 0.25 mmol) in a mixture of anhydrous 
THF (6 mL) and anhydrous pyridine (2 mL), tBuMgCl (1.0 M THF solution, 1.5 mL, 
1.5 mmol), 2.2a (0.18 g, 0.5 mmol) in anhydrous THF (1.5 mL). The reaction mixture 
was stirred at room temperature overnight. The solvent was removed under reduced 
pressure. The residue was purified by column chromatography, gradient elution of 
DCM/MeOH = then 98/2, then 96/4, then 94/6, to give a white solid (40%, 0.07 g). 
31P-NMR (MeOH, 202 MHz): ! 3.95, 3.39.  1H-NMR (CDCl3, 500 MHz): ! 7.96-7.93 
(1H, m, H-8); 7.33-7.29 (7H, m, PhO, OCH2Ph), 7.19-7.16 (3H, m, PhO, OCH2Ph), 
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5.13-5.12 (2H, m, OCH2Ph), 4.28-3.97 (6H, m, H-1’, H-5’, H-4’, CHCH3), 2.77-2.68 
(1H, m, CH(CH3)2), 2.04-1.84 (6H, m, H-2’, H-3’, CH3CO), 1.38-1.35 (3H, m, CHCH3), 
1.25-1.20 (6H, m, CH(CH3)2). 
9.6. Experimental procedures for chapter 6: synthesis of 
phosphonoamidate derivatives of S-HPMPC 
9.6.1 Synthesis of the L-alanine benzyl ester phosphonodiamidate derivative of S-
HPMPC [7.19] 
Synthesis of (S)-1-{3-[(4-Methoxytrityl)oxy]-2-(phosphonomethoxy)propyl} 
cytosine [7.18] 
Chemical Formula: C28H30N3O7P 
Molecular Weight: 551.5275 
To a suspension of S-HPMPC dihydrate (free acid, 0.16 g, 0.5 mmol) 
in methanol (15 mL), tributylamine (1.6 g, 10 mmol) was added. The 
suspension of the free acid easily dissolved to a clear solution of 
tributyl-ammonium salt. The solvent was removed under reduced 
pressure. The residue, co-evaporated with acetonitrile, was dissolved 
in DMSO and 4-methoxytrityl chloride (0.46 g, 1.5 mmol) was added. The reaction 
mixture was stirred for 3 h. Proceeding of the reaction was monitored by TLC in 
propan-1-ol-ammonia-water (11:7:2). Tributylamine and DMSO were extracted down 
with Et2O; the product was collected by filtration, recrystallized from ethyl acetate and 
dried in vacuo (32%, 0.09 g).  
31P NMR (DMSO, 202 MHz): ! 15.40. 
1H NMR (DMSO, 500 MHz): ! 7.55 (1H, d, J = 
7.27 Hz, H-6), 7.43-6.90 (14 H, m, CPh3), 5.63 (1H, d, J = 7.27 Hz, H-5), 4.00 (1H, dd, 
J = 12.0 Hz, 7.5 Hz, H-1’); 3.83 (1H, m, H-2’), 3.71 (3H, s, MTr), 3.64 (1H, dd, J = 
12.4 Hz, 10.0 Hz, CH2P), 3.63 (1H, dd, J = 12.0 Hz, 7.5 H-1’), 3.40 (1H, dd, J = 12.4 
Hz, 10.0 Hz CH2P), 3.10 (1H, dd, J = 10.5 Hz, 4.0 H-3’), 2.95 (1H, dd, J = 10.5 Hz, 4.0 
Hz, H-3’). EI MS= 445.12 (M+Na+). 
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Synthesis of (S)-1-{[3-(4-methoxytrityl)-oxy]-2-{[bis(benzyloxy-L-Alaninyl)]- 
phosphonomethoxy}-propyl}-cytosine [7.19] 
Chemical Formula: C48H52N5O9P 
Molecular Weight: 873.9283 
Compound 7.18 (0.08 g, 0.15 mmol) and the para-toluene-
sulphate salt of L-alanine-O-benzyl ester (0.31 g, 0.89 mmol) 
were mixed in anhydrous pyridine (5 mL). Triethylamine 
(0.25 mL, 1.8 mmol) was added and the resultant mixture was 
stirred at 60 °C under nitrogen. In a separate flask, 2-
2’dithiodipyridine (0.27 g, 1.05 mmol) and PPH3 (0.23 g, 1.05 mmol) were dissolved in 
anhydrous pyridine (2 mL), and the resultant yellow solution was stirred for 20 minutes. 
The solution was then added to the 60 °C solution of 7.18 in one portion. The combined 
mixture was stirred at 60 °C under nitrogen for 16 h to give a clear yellow solution. The 
solvent was removed under reduced pressure. The resultant oil was dissolved in CH2Cl2 
and purified by flash column chromatography, gradient elution of DCM/MeOH = 98/2, 
then 96/4, then 94/6. The product was purified by preparative TLC (gradient elution of 
DCM/MeOH = 98/2, then 96/4, then 94/6) to give a white solid (20%, 0.25*10-1g). 
31P NMR (MeOD, 202 MHz): ! 23.36. 
1H NMR (MeOD, 500 MHz): ! 7.48-6.88 (25 H, 
m, H-6, OCH2Ph, CPh3), 5.74 (1H, d, J = 7.21 Hz, H-5), 5.16-5.05 (4H, m, 2 x 
OCH2Ph), 4.10 (1H, dd, J = 13.66 Hz, 4.06 Hz, H-1’), 4.02-3.97 (2H, m, 2X CHCH3), 
3.84-3.71 (7H, m, H-1’, H-2’, OCH2P, OCH3), 3.30-3.27 (1H, m, H-3’), 3.15-3.12 (1H, 
m, H-3’), 1.36 (6H, d, J = 7.17 Hz, 2 x CHCH3). EI MS= 896.34 (M+Na
+). HPLC = 
H2O/MeOH from 100/0 to 20/80 in 5 min, then 20/80 isocratic for 10 min, then from 
20/80 to 0/100 in 5 min, then 0/100 isocratic for 5 min = retention time 17.88 min. 
9.6.2 Synthesis of the diethyl ester derivative of S-HPMPC [7.23] 
Synthesis of (S)-Tritylglycidol [7.26] 
Chemical Formula: C22H20O2 
Molecular Weight: 316.3930 
Tritylchloride (18 g, 64.5 mmol) was dissolved in CH2Cl2 (50 mL)  under nitrogen, 
cooled down to around 0 °C and treated with TEA (13 mL, 94 mmol). After an hour of 
stirring at 0°C, a solution of (R)-Glycidol (5 g, 67.5 mmol) in CH2Cl2 (15 mL) was 
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added over 45 min. The resulting solution was allowed to warm to room temperature 
and was stirred for 3 h. It was then filtered and the filtrate was washed with water and 
brine. The organic phase was dried over Na2SO4. The solvent was removed under 
reduced pressure and the residue was crystallized to give the desired compound as an 
off-white powder (60%, 12 g). 
1H NMR (DMSO, 500 MHz): ! 7.42-7.40 (6H, m, Tr), 7.36-7.33 (6H, m, Tr), 7.29-7.26 
(3H, m, Tr), 3.28 (1H, dd, J = 10.89 Hz, 2.58 Hz, CH2OTr), 3.17-3.14 (1H, m, 
CHCH2OTr), 2.91 (1H, dd, J = 10.89, 2.58 Hz, CH2OTr), 2.71 (1H, dd, J = 4.65, 2.70 
Hz, CH
2
CHCH2OTr), 2.56 (1H, dd, J = 5.07 Hz, 2.67 Hz, CH2CHCH2OTr). 
Synthesis of (S)-N
1
-(3-triphenylmethoxy-2-hydroxy)-propyl)-cytosine [7.27] 
Chemical Formula: C26H25N3O3 
Molecular Weight: 427.4950 
Cytosine (1.68 g, 15.1 mmol) and K2CO3 (2.1 g, 15.3 mmol) in DMF 
(30 mL) were stirred for 1h at 105 °C under nitrogen. Compound 7.26 
(4.77 g, 15 mmol) was dissolved in DMF (30 mL) and added to the solution of cytosine. 
According to TLC of reaction mixture, the alkylation reaction was complete after 5 h at 
105 °C. Solvent was removed under reduced pressure and 7.27 was obtained by 
precipitation from ethyl ether (71%, 4.55 g). 
1H NMR (MeOH, 500 MHz): ! 7.38 (1H, d, J = 7.22 Hz, H-6), 7.49-7.48 (6H, m, Tr), 
7.30-7.27 (6H, m, Tr), 7.23-7.20 (3H, m, Tr), 5.75 (1H, m, H-5), 4.19-4.12 (2H, m, H-
1’, H-2’), 3.57 (1H, d, J = 13.16 Hz, 7.87 Hz, H-1’), 3.18-3.12 (2H, m, H-3’). 
Synthesis of (S)-N
1
-(3-triphenylmethoxy-2-hydroxy)-propyl)-N
4
-benzoyl-cytosine 
[7.28]. 
Chemical Formula: C33H29N3O4 
Molecular Weight: 531.6011 
Benzoic anhydride (2.91 g, 12.90 mmol) and 7.27 (4.59 g, 10.80 
mmol) were added to an anhydrous mixture of pyridine (46.50 mL) 
and DMF (24 mL). The reaction was carried out under nitrogen at 
100 °C for 3 h. Solvent was removed under reduced pressure and the 
residue was dissolved in 100 mL of CH2CL2, followed by aqueous work up using 35 
mL saturated solution NaHCO3 solution twice. The organic phase was dried over 
Na2SO4 and solvent removed under vacuum. The residue was further purified by flash 
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column chromatography, gradient elution DCM/MeOH = 100/0, then 98/2, to give a 
brown solid (82.5%, 4.74 g).  
1H NMR (CDCl3  500 MHz): ! 8.11 (1H, d, J = 7.10 Hz, H-6), 7.94-7.93 (2H, m, Bz), 
7.68-7.23 (19H, m, H-5, Bz, Tr), 4.52 (1H, dd, J = 13.81 Hz, 4.09 Hz H-1’), 4.41-4.24 
(1H, m, H-2’), 3.80 (1H, d, J = 13.81 Hz, 4.09 Hz, H-1’), 3.32-3.27 (1H, m, H-3’), 3.21-
3.18 (1H, m, H-3’). 
Synthesis of diethyl-[(tosyloxy)methyl]-phoshonate [7.30]. 
Chemical Formula: C12H19O6PS 
Molecular Weight: 322.3144 
A two-necked, 250 mL, round bottom flask was charged under 
argon with CH2Cl2 (20 mL), diethyl-(hydroxymethyl)-
phosphonate (5.04 g, 30 mmol) in CH2Cl2 (5 mL), DMAP (0.6 g), TEA (6.30 mL, 45.20 
mmol). P-toluensulfonyl-chloride (8.04, 42.17 mmol) was dissolved in CH2Cl2 (20 mL) 
and added at 5 °C via a dropping funnel to the diethyl-(hydroxymethyl)-phosphonate. 
The reaction mixture stirred at 5 °C for 3 h. The organic phase was washed with H2O 
and dried over Na2SO4. Solvent was removed under vacuum and the residue was 
purified by flash column chromatography, elution of chloroform:acetone (2:1), to give  
a clear yellow oil (61%, 5.90 g). 
31P NMR (CDCl3  500 MHz): ! 15.13. 
1H NMR (CDCl3  202 MHz): ! 7.76 (2H, d, J = 
8.33 Hz, TsH), 7.34 (2H, d, J = 8.33 Hz, TsH), 4.16, 4.14 (2H, 2s, CH2P), 4.13-4.07 
(4H, m, 2 x OCH2CH3), 2.42 (3H, s, CH3-Ts), 1.28 (6H, t, J= 7.32 Hz, 2 x OCH2CH3). 
(S)-N
1
-[(3-triphenylmethoxy-2-diethylphosphonylmethoxy)-propyl)]-N
4
-
benzoylcytosine [7.31]. 
Chemical Formula: C38H40N3O7P 
Molecular Weight: 681.7139 
Compound 7.28 (1g, 1.88 mmol) was dissolved in anhydrous DMF 
(2.7 mL) and transferred to a solution of 7.29 (0.91 g, 2.8 mmol) in 
anhydrous DMF (2.77 mL). The reaction mixture was cooled down 
to 5 °C before 3-fold excess of NaH (0.23 g, 60% dispersion in oil, 5.64 mmol) was 
added under argon. The reaction mixture was stirred under argon for 2 h at 5 °C. The 
residue was dissolved in ethyl acetate and the excess of NaH was eliminated by 
dropwise addition of ethyl acetate (H2O saturated) until no further evolvement of 
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hydrogen gas could be detected. An additional 100 mL of ethyl acetate was added to the 
reaction mixture followed by 5 mL of H2O-saturated ethyl acetate. The organic phase 
was washed with 10 mL H2O and 20 mL saturated NaHCO3 solution and the organic 
phase was dried over Na2SO4. Solvent was removed under reduced pressure. The 
residue was purified by flash column chromatography, eluting with DCM/MeOH = 
100:0 then 98:2, to give a white solid (62%, 0.80 g).  
31P NMR (MeOD, 202 MHz): ! 21.65. 
1H NMR (MeOD, 500 MHz): ! 8.00-7.98 (2H, m, 
Bz), 7.90 (1H, d, J = 7.28 Hz, H-6), 7.56-7.22 (19 H, m, H-5, Bz, CPh3), 4.36 (1H, dd, J 
= 13.31 Hz, 3.83 Hz, H-1’); 4.20-4.17 (1H, m, H-2’); 4.13-4.06 (1H, m, CH2P), 3.98-
3.93 (1H, m, CH2P), 3.79-3.72 (1H, m, H-1’); 3.49 (4H, q, J = 7.27 Hz, 2 x OCH2CH3), 
3.23-3.20 (1H, m, H-3’); 3.17-3.15 (1H, m, H-3’), 1.37 (6H, t, J = 7.27 Hz, 2 x 
OCH2CH3). EI MS= 720.22 (M+K
+).   
(S)-N
1
-[(3-triphenylmethoxy-2-diethylphosphonylmethoxy)-propyl)]-cytosine 
[7.23]. 
Chemical Formula: C31H36N3O6P 
Molecular Weight: 577.6078 
A stirring solution of 7.31 (0.22 g, 0.32 mmol) in MeOH (10 mL) 
was saturated with NH3 gas in a sealed tube at 0 °C. The solution 
was stirred for 3 h at room temperature. Solvent was removed under vacuum. The 
residue was purified by flash column chromatography, gradient elution of DCM/MeOH 
= 100:0, then 98:2, then 96/4), to give a white solid (95%, 0.175 g).  
 31P NMR (MeOD, 202 MHz): ! 21.57. 
1H NMR (MeOD, 500 MHz): ! 7.50-7.47 (5H, 
m, CPh3); 7.43 (1H, d, J = 7.25 Hz, H-6), 7.36-7.24 (10H, m, CPh3); 5.76 (1H, d, J = 
7.25 Hz, H-5); 4.20 (1H, dd, J = 13.53 Hz, 3.93 Hz, H-1’), 4.13-4.09 (2H, m, H-2’, 
CH2P); 3.81-3.75 (1H, m, CH2P); 3.63 (4H, q, J = 7.05 Hz, 2 x OCH2CH3); 3.61-3.57 
(1H, m, H-1’); 3.18-3.11 (2H, m, H-3’); 3.17-3.15 (1H, m, H-3’); 1.20 (6H, t, J = 7.05 
Hz, 2 x OCH2CH3).   
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9.6.2 Synthesis of the L-alanine benzyl ester phosphonoamidate derivative of S-
cHPMPC [7.4] 
Synthesis of the dicyclohexyl-morpholinocarboxamidine salt of 1-[((S-2-hydroxy-2-
oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine [S-cHPMPC]. 
Chemical Formula: C25H43N6O6P 
Molecular Weight: 554.6193 
To a stirred suspension of S-HPMPC*2H2O (0.3 g, 
1.07 mmol) in DMF (7.5 Ml) was added N,N-
dicyclohexyl-4-morpholinecarboxamidine (0.31 g, 
1.07 mmol). The reaction mixture was stirred for 12 h at room temperature, during 
which the S-HPMPC dissolved. This solution was then added slowly to a hot pyridine 
solution (7.5 Ml) of 1,3 dicyclohexyl carbodiimide (0.5 g, 2.42 mmol). The mixture was 
stirred at 100 °C for 16 h, cooled to room temperature and filtered, and the filtrate was 
concentrated under vacuum. The solvent was then removed under reduced pressure and 
the residue was purified by column chromatography, gradient elution of DCM/MeOH  
from 90/10 to 80/20, to give the dicyclohexyl-morpholinocarboxamidine (DCMC) salt 
of S-cHPMPC as a white solid (50%, 0.3 g).  
31P NMR (MeOD, 202 MHz): ! 7.30. 
1H NMR (MeOD, 500 MHz): ! 7.53 (1H, d, J = 
7.26 Hz, H-6), 5.86 (1H, d, J = 7.26 Hz, H-5), 4.25-4.21 (1H, m, OCH2P), 4.15-4.10 
(1H, m, OCH2P), 4.04-4.00 (2H, m, H-1’), 3.92-3.87 (1H, m, H-2’), 3.77-3.75 (4H, m, 
CH2OCH2 (DCMC)), 3.67-3.60 (2H, m, H-3’), 3.46-3.45 (4H, m, CH2NCH2 (DCMC), 
3.37-3.33 (2H, m, CHN of (DCMC), 1.96,-1.18 (20H, m, cHx (DCMC)). 13C NMR 
(MeOD, 126 MHz): ! 26.22 (cHx (DCMC)), 26.38 (cHx (DCMC)), 34.48 (cHx 
(DCMC)), 49.89 (CH2NCH2 (DCMC)), 50.68 (C-1’), 56.08 (CHN (DCMC)), 67.31 (d, 
Jc-p = 144.07 Hz, OCH2P), 67.38 (CH2OCH2 (DCMC)), 70.84 (d, Jc-p = 6.67 Hz, C-3’), 
75.85 (d, Jc-p = 3.71 Hz, C-2’), 95.49 (C-5), 148.61 (C-6), 159.03 (C-2), 159.37 
(NC(NH)N (DCMC)), 168.11 (C-4).  
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Benzyl-O-[(5S)-5-[(4-Amino-2-oxopyrimidin-1(2H)-yl)-methyl]-2-oxido-1,4,2-
dioxaphosphinan-2-yl]-(L)-alaninate [7.4] 
Chemical Formula: C18H23N4O6P 
Molecular Weight: 422.3722 
 
The dicyclohexyl-morpholinocarboxamidine salt of  
S-cHPMPC (0.113 g, 0.2 mmol) and para-toluenesulphate salt of 
L-alanine-O-benzyl ester (0.41 g, 1.2 mmol) were mixed in 
anhydrous pyridine (5 mL). Triethylamine (0.3 mL, 2.4 mmol) was 
added and the resultant mixture was stirred at 60 °C under 
nitrogen. In a separate flask, 2-2’dithiodipyridine (0.368 g, 1.40 mmol) and PPH3 (0.306 
g, 1.40 mmol) were dissolved in anhydrous pyridine (2 mL). The resultant yellow 
solution was stirred for 20 minutes. The solution was then added to the 60 °C solution 
of S-cHPMPC in one portion. The combined mixture was stirred at 60 °C under 
nitrogen for 16 h to give a clear yellow solution. The solvent was removed under 
reduced pressure. The resultant oil was dissolved in CH2Cl2 and purified by flash 
column chromatography, gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6. 
The product was further purified by preparative TLC (gradient elution of DCM/MeOH 
= 98/2, then 96/4, then 94/6) to give a white solid (30%,  0.25*10-1g). 
31P NMR (MeOD, 202 MHz): ! 17.76, 16.69. 
1H NMR (MeOD, 500 MHz): ! 7.50, 7.49 
(1H, 2d, J = 7.80 Hz H-6), 7.42-7.32 (5H, m, OCH2Ph), 5.86, 5.85 (1H, 2d, J = 7.80 Hz, 
H-5), 5.20-5.18 (2H, m, OCH2Ph), 4.43-3.20 (2H, m, H-3’), 4.11-3.97 (3H, m, CHCH3, 
H-2’, OCH2P), 3.86-3.73 (2H, m, OCH2P, H-1’), 3.66-3.62 (1H, m, H-1’), 1.46, 1.40 
(3H, 2d, J = 7.15 Hz, CHCH3). 
13C NMR (MeOD, 126 MHz): ! 20.43 (d, JC–P = 5.84 Hz 
CHCH3) 20.73 (d, JC–P = 5.84 Hz, CHCH3), 50.08, 50.40 (C-1’), 50.48, 50.70 (2s, 
CHCH3), 65.89 (d, Jc-p = 131.79 Hz, OCH2P), 67.11 (d, Jc-p = 131.79 Hz, OCH2P), 68.08 
(OCH2Ph), 71.13 (d, JC–P = 6.64 Hz, C-3’), 71.62 (d, JC–P = 6.64 Hz, C-3’), 75.00 (d, JC–P 
= 5.19 Hz, C-2’), 75.40 (d, JC–P = 5.19 Hz, C-2’), 95.48, 95.66 (2s, C-5), 129.37, 129.60 
(2s OCH2Ph), 137.28, 137.32 (‘ipso’ OCH2Ph), 148.27, 148.68 (2s, C-6), 158.68, 
158.71 (C-2), 167.87, 167.97 (C-4), 174.80 (d, JC–P = 3.30 Hz, COOCH2Ph), 175.10 (d, 
JC–P = 3.30 Hz, COOCH2Ph). EI MS= 445.12 (M+Na
+). HPLC = H2O/MeOH from 
90/10 to 0/100 in 20 min, then 0/100 isocratic for 5 min = retention time 13.11 min. 
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9.7 Enzymatic assays 
Carboxypeptidase Y assay: standard procedure 
The appropriate ProTide (5 mg) was dissolved in acetone-d6 (150 !L) and Trizma 
buffer (pH 7.6, 300 !L) was added. A 31P NMR spectrum was recorded at 25 ºC (64, 
128 or 264 scans). Carboxypeptidase Y (ca. 0.1 mg) in the Trizma buffer (150 !L) was 
added to the solution of the ProTide and 31P NMR spectra were recorded at regular 
intervals overnight (usually 128 or 264 scans, repeated every 6-15 min for 14 h, 25 ºC). 
Adenosine deaminase 
A stock solution of adenosine deaminase was prepared by dissolving 0.50 mg of 
adenosine deaminase in 1.0 mL of phosphate buffer (pH 7.5, 0.05 M). A solution of the 
appropriate nucleosides in phosphate buffer (pH 7.5, 44 µM) was similarly prepared. 
The assay was performed by transferring 1.0 mL of nucleoside stock solution and 
recording UV spectrum at 25 °C over the range 400 to 220 nm, then 5-30 µL of the 
enzyme solution was added and UV spectra were recorded at 10 min intervals over a 
period of 20 h. 
9.8 Molecular modeling 
The modeling studies presented in this work were performed on MacPro dual 2.66GHz 
Xeon running Ubuntu 9.10. The crystal structures were downloaded from PDB website 
(http://www.rcsb.org/). Hydrogen atoms were added to the protein, using Molecular 
Operating Enviroment (MOE) 2008.10 and minimized, keeping all the heavy atoms 
fixed until a rmsd gradient of 0.05 kcal mol-1 Å-1 was reached (MOE). Ligand 
structures were built with MOE and minimized using the MMFF94X force field until a 
rmsd gradient of 0.05 kcal mol-1 Å-1 was reached. The docking simulations were 
performed using PLANTS. Cathepsin Y binding site: center 47.758, -2.019, 35.82, 
radius 10 Å, cluster RMSD 2, cluster structures 10. Hint-1 binding site: center 10.8, 
12.4, 14.4, radius 12 Å, cluster RMSD 2, cluster structures 10. 
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Recently, it has been reported that phosphorylated acyclovir (ACV) inhibits human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase in a cell-free system. To deliver phosphorylated ACV inside
cells, we designed ACVmonophosphorylated derivatives using ProTide technology. We found that the
L-alanine derived ProTides show anti-HIV activity at noncytotoxic concentrations; ester and aryl
variation was tolerated. ACV ProTides with other amino acids, other than L-phenylalanine, showed no
detectable activity against HIV in cell culture. The inhibitory activity of the prodrugs against herpes
simplex virus (HSV) types -1 and -2 and thymidine kinase-deficient HSV-1 revealed different structure-
activity relationships but was again consistent with successful nucleoside kinase bypass. Enzymatic and
molecular modeling studies have been performed in order to better understand the antiviral behavior of
these compounds. ProTides showing diminished carboxypeptidase lability translated to poor anti-HIV
agents and vice versa, so the assay became predictive.
Introduction
Human immunodeficiency virus (HIVa) belongs to the
retroviradae family and causes the acquired immunodefi-
ciency syndrome (AIDS). A variety of different compounds
have been developed for the treatment of HIV, and currently
25 drugs have been approved for clinical use including nucleo-
side reverse transcriptase inhibitors (NRTIs), non-nucleoside
reverse transcriptase inhibitors (NNRTIs), protease inhibi-
tors (PI), a viral fusion inhibitor (FI), a CCR-5 coreceptor
inhibitor, and a viral integrase (IN) inhibitor.1
Because of the rapid development of drug resistance as well
as to the toxicity shown by these drugs,2 novel anti-HIV
agents are needed. Diverse structures are sought to address
the constant threat of viral resistance.
In this context, recently it has been reported how the
antiherpetic drug acyclovir (ACV, 1, Figure 2) inhibits HIV
upon human herpesvirus (HHV) coinfection in tissue cul-
tures.3 This activity was found to be correlated with the
phosphorylation of the parent drug to the monophosphate
form mediated by HHV-encoded kinase(s). HIV does not
encode an enzyme that recognizes ACV as a substrate for this
activation (phosphorylation) step, hence the need for the
HHV coinfection for activity. The subsequent phosphoryla-
tions to the di- and triphosphate derivatives may be mediated
by cellular guanosine monophosphate kinase and nucleoside
diphosphate kinase, respectively.4,5 In its triphosphate form,
ACV inhibits HIV RT acting as a chain terminator.3 Follow-
ing these results, it is evident that the anti-HIV activity can
only occur uponACVmonophosphate (ACV-MP) formation
which requires HHV coinfection. ACV-MP itself can not be
used as efficient anti-HIV chemotherapeutic agent to bypass
the first limitingphosphorylation stepbecauseof its instability
inbiologicalmedia and its poor efficiencyof diffusion through
intact cell membranes. A suitable strategy to overcome these
limitations would consist of masking the negative charges of
the monophosphate with lipophilic groups. In this regard, the
phosphoramidate ProTide technology has been developed
and successfully applied to a range of nucleosides of antiviral
and anticancer interest.6-9 The structural motif of this app-
roach consists of masking the nucleoside monophosphate
with an aryl moiety and an amino acid ester. Cell entry then
apparently occurs by passive diffusion. Once inside the cell,
the phosphoramidate prodrug is activated and converted to
the monophosphorylated ACV (Figure 1).10 The first step
involves an enzymatic hydrolysis of the amino acid ester
moiety mediated by an esterase- or carboxypeptidase-type
enzyme followed by spontaneous cyclization and subsequent
spontaneous displacement of the aryl group and opening of
the unstable ring mediated by water. The last step before
release of the ACV monophosphate involves a hydrolysis of
the P-Nbondmediated by a phosphoramidase-type enzyme.
The phosphoramidate ProTide approach has been already
successfully applied to ACV, demonstrating its ability to
bypass the thymidine kinase deficiency of HSV-1 and -2 and
varicella zoster virus strains resistant to ACV.11
In this paper, we present the synthesis and initial biolo-
gical evaluation of a novel series of ACV ProTides
(Figure 2). The ProTide moiety has three different change-
able parts: the aryl moiety, the amino acid, and the ester. In
the first part of this study, we have chosen L-alanine as the
*To whom correspondence should be addressed. Phone: þ44 29
20874537. Fax: þ44 29 20874537. E-mail: mcguigan@cardiff.ac.uk.
aAbbreviations: ACV, acyclovir; HIV, human immunodeficiency
virus; HSV, herpes simplex virus; NNRTIs, non-nucleoside reverse
transcriptase inhibitors; PI, protease inhibitor; FI, fusion inhibitor;
HHV, human herpes virus; ACVMP, acyclovir 50-monophosphate;
DMF, N,N-dimethylformamide.
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amino acid, as it has shown previously an optimal biologi-
cal profile,12 varying the other two components. For the
aryl moiety we considered phenol, naphthol, and p-fluoro-
phenol and as the ester moiety methyl, ethyl, n-propyl, iso-
propyl, tert-butyl, and benzyl and combinations thereof.
All of these combinations allowed us to extensively vary
the LogP for these compounds and to study how this
variation can influence the antiviral activity. Moreover, it
has been previously reported how the substitutions can
influence the bioactivation of the ProTide; for example,
naphthol has shown an enhancement of activity against a
panel of cancer cell lines for phosphoramidates6 and the
tert-butyl ester showed a lack of biological activity due to
the poor bioactivation of the bulky moiety. Following the
results for these derivatives, different amino acids have been
considered including L-valine, L-leucine, L-isoleucine, L-
proline, glycine, and the non-natural D-alanine, D-valine,
and dimethylglycine. Moreover, some intermediate-prote-
cted (N2-DMF)-ACV ProTides have been biologically
evaluated.
Chemistry
The compounds have been synthesized following the pro-
cedure reported by Uchiyama13 using tert-butylmagnesium
chloride (tBuMgCl) as a coupling reagent and using THF as a
solvent in most of the cases.
Aryl phosphorodichlorophosphates 26 and 27 have been
synthesized, coupling respectively 1-naphthol (24) or p-fluor-
ophenol (25) with POCl3 in the presence of Et3N (1equiv)
(Scheme 1), while phenyl dichlorophosphate (28) was com-
mercially available. The coupling with the appropriate amino
acid ester salt (29-44) has been performed in the presence of
Et3N (2 equiv) (Scheme 2), giving the final product (45-65) as
an oil which was, in most of the cases, purified by column
chromatography.
To improve the solubility of ACV in THF, used as ideal
solvent for the coupling reaction, the 2-amino was protected
using dimethylformamide dimethyl acetal (Scheme 3). How-
ever, compound 66 is not completely soluble in THF but the
solubility was improved sufficiently to carry out the reaction.
The final coupling of the nucleoside was performed using an
excess of the appropriate phosphorochloridate (1.50-4.00
equiv) in the presence of tBuMgCl (2 equiv). Because of the
reactivity problem, the use of N-methylimidazole (NMI),
following the Van Boom procedure,14 was used for the
synthesis of the L-proline (22) and glycine (23) derivatives.
Moreover, a mixture of THF/pyridine (3/2) was used as a
solvent to improve the solubility of N2-DMF-ACV.
The deprotection of the dimethylformyl DMF derivative
was initially carried out by refluxing the compound in
1-propanol (Scheme 3).However, because of a transesterifica-
tion during the synthesis of 2, obtaining compound 3, the
solvent was changed to 2-propanol, obtaining the desired
compounds (2, 4-23).
All the compounds were obtained as a mixture of
two diastereoisomers confirmed by the presence of two peaks
in the 31P NMR, with the exception of the glycine and
Figure 1. Proposed activation pathway of the acyclovir ProTides.
Figure 2. ACV and its ProTides.
Scheme 1a
aReagents and conditions: (i) POCl3, anhydrous TEA, anhydrous
Et2O, -78 !C, 1 h then rt, overnight.
Scheme 2a
aReagents and conditions: (i) anhydrous TEA, anhydrous DCM,
-78 !C, 30 min to 1 h, then rt, 30 min to 4 h.
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dimethylglycine derivatives, due to the absence of a chiral
center, and L-proline, for which we were able to isolate only
one diastereoisomer.
Biological Results
Anti-HSV Activity. The activity of the compounds were
evaluated against three different strains of HSV including
HSV-1 (KOS), HSV-2 (G), and thymidine kinase-deficient
HSV-1 (ACVR).
Native ACV showed submicromolar (EC50: 0.4 μM and
0.2 μM) activity against respectively HSV-1 and HSV-2
(Table 1) but was inactive against TK-deficient HSV-1
(EC50: 50 μM). The ACV ProTides did not show increased
activity against HSV-1 and HSV-2 compared to the parent
compound. Only two compounds (11 and 20), respectively
the p-fluorophenyl-L-Ala-OBn and the phenyl-L-Leu-OBn
derivatives, showed anti-HSV activity in the submicromolar
range, while the majority of the compounds showed an
activity in the range of ca. 1-30 μM. Compound 6 having
the bulky t-butyl group as ester moiety did not show any
marked activity (g50 μM) against theHSV strains. ACV has
been evaluated against thymidine kinase-deficient HSV-1
showing a dramatic loss of activity (>100-fold) (EC50:
50 μM). Interestingly, several of the ProTides showed sig-
nificant retention of activity, demonstrating a successful
bypass of the first phosphorylation step (i.e., compounds
11, 13, 20, 21). Notably, none of the ACV ProTides showed
appreciable cytostatic/cytotoxic activity despite the potential
loss of antiviral selectivity that could follow from viral
nucleoside kinase bypass.
Anti-HIV Aactivity. The ACV ProTides have also been
evaluated against HIV-1 and HIV-2 in CEM and against
Table 1. Anti-HSV Activity for ACV and Its Protides
antiviral activity EC50
a (μM) cytotoxic/cytostatic activity (μM)
compds aryl amino acid ester CLogP HSV-1 HSV-2 HSV-1 TK- MCCb (Hel) IC50
c (Hel)
2 Naph L-Ala Bn 2.06 2 ( 0 1.4 ( 0.8 10 ( 2.1 g20 20
3 Naph L-Ala nPr 1.41 5.5 ( 2.1 1.9 ( 1.6 16 ( 5.7 g50 68
4 Naph L-Ala Me 0.35 16 ( 5.7 10 ( 2.1 79 ( 29 >50 >100
5 Naph L-Ala Et 0.88 32 ( 25 9.5 ( 0.7 32 ( 18 >150 >100
6 Naph L-Ala tBu 1.59 >100 50 >100 >50 >100
7 Naph L-Ala iPr 1.19 15 ( 7.1 10 ( 0 g45 >50 >100
8 Ph L-Ala Me -0.82 20 ( 0 16 ( 5.7 79 ( 29 >100 ND
9 Ph L-Ala Bn 0.89 8 ( 5.7 4 ( 0 15 ( 7.1 >50 91
10 Ph L-Ala iPr 0.02 10 ( 0 8.5 ( 0.7 27 ( 25 >50 >100
11 p-F-Ph L-Ala Bn 1.11 0.9 ( 0.1 0.5 ( 0 1.5 ( 0.7 >100 ND
12 Ph D-Ala Bn 0.89 2 ( 0 1.4 ( 0.8 23 ( 16 >100 ND
13 Naph DMG Bn 2.37 2.4 ( 0 1.6 ( 1.1 3.2 ( 1.1 >50 >100
14 Ph DMG Bn 1.20 1.4 ( 0.85 0.8 ( 0.0 5.5 ( 2.1 >100 ND
15 Ph Phe Bn 2.31 17 ( 4.2 8 ( 5.7 g100 >50 87
16 Ph L-Val Bn 1.82 2 ( 0 0.85 ( 0.2 7.5 ( 6.4 >100 ND
17 Naph L-Val Me 1.28 >100 >100 >100 >100 ND
18 Naph L-Val Et 1.81 51 ( 9.2 32 ( 18 42 ( 3.5 >100 ND
19 Naph D-Val Me 1.28 >100 >100 >100 >100 ND
20 Ph L-Leu Bn 2.35 0.8 ( 0.07 0.7 ( 0 1.4 ( 0.8 >100 ND
21 Ph L-Ile Bn 2.35 1.1 ( 0.4 1.1 ( 0.4 1.4 ( 0.8 >100 ND
22 Ph L-Pro Bn 2.82 >100 >100 >100 >100 >100
23 Ph Gly Bn 0.58 3 0.8 9 >100 ND
ACV (1) -2.42 0.4 0.2 50 >100 ND
a 50% Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity by 50%. bMinimal cytotoxic concentra-
tion, or compound concentration required to cause a microscopically visible alteration of cell morphology. c 50% Inhibitory concentration, or
compound concentration required to inhibit cell proliferation by 50%. ND=not determined
Scheme 3a
aReagents and conditions: (i) dimethylformamide dimethyl acetal, anhydrous DMF, rt, 1 day; (ii) tBuMgCl, THF, rt, overnight or NMI, THF/
pyridine=3/2, rt, overnight; (iii) 1-propanol, reflux, for 18 h or 2-propanol, reflux, 24-96 h.
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HIV-1 in MT-4 cell cultures and in HIV-infected tonsillar
tissues ex vivo (Table 2).
While parent ACV was inactive, in most of the L-alanine
derivatives (2-11), with the exception of 6, 10, and 11,
showed activity (EC50) in a range of 6.2-17 μM against
HIV-1 (CEM) and in a range of 8.9-42 μM against HIV-2
(CEM) (Table 2). Similar results were obtained when these
compounds were applied to the HIV-1-infected MT-4 cell
cultures. In these cells, parental ACV was inactive whereas
HIVwas suppressed by all the tested compoundswith EC50’s
in the range of 0.8-30 μM, with the exception of 6, 10, 78,
and 81 (Table 2). The antiviral activity of the ACV ProTides
was confirmed in HIV-infected tonsillar tissue ex vivo. The
compounds 4, 5, and 9 suppressed HIV replication with
EC50’s in a range of 0.1-0.6 μM (data not shown). These
findings indicate that theACVProTide approach can also be
successfully applied to HIV-infected tissue.
No clear-cut structure-activity relationship could be ob-
served with regard to the nature of the aryl moiety nor the
alaninyl ester moiety in terms of eventual antiviral activity of
the ProTide derivatives. The lack of activity obtained for the
t-butyl analogue (6) is in agreement with the previous report
and with the enzymatic experiment to be discussed later. All
of these compounds showed an antiproliferative effect (on
CEM or MT-4 cell cultures) in a range between 17 and
76 μM.
With regard to the amino acid modifications, we found
that, besides the L-alanine ProTides, only the phenylalanine
derivative (15) had activity against HIV-1 (26 μM) andHIV-
2 (34 μM). All other derivatives, including D-alanine (12),
dimethylglycine (13 and 14), L-valine (16-18), D-valine (19),
L-leucine (20), L-isoleucine (21), L-proline (22), and glycine
(23), did not show appreciable activity inCEM.These results
are in agreement with previous reports for other nucleosides,
in which the substitution of the L-alanine with different
natural L-amino acids gave loss (∼10- to 100-fold) of anti-
viral activity.15 However, in the case of dimethylglycine, this
result is quite surprising as this variation led usually to a
retention of anti-HIV activity compared to the L-alanine
derivatives.16
Interestingly, in MT-4 cell cultures, the amino acid mod-
ification seems to be tolerated, in fact compounds 14 (DMG)
and 20 (L-Leu), showed respectively an anti-HIV-1 activity of
7 and 0.8 μM.
Moreover, in MT-4, the N2-DMF-protected ACV Pro-
Tides (77, 78, and 86) showed activity againstHIV-1 (EC50’s:
15, 70, and 30, respectively), indicating that this kind of
substitutionmay be tolerated. However, in the case of CEM,
these compounds did not show any inhibitory activity.
From these results, it is possible to conclude that the
amino acid L-alanine is optimal for the anti-HIV activity of
the ACV ProTides. Neither D-alanine nor glycine can effi-
ciently substitute for L-alanine nor can bulkier amino acids.
In contrast to the structural requirement for anti-HIV
activities, the anti-HSV activity tolerates liberal amino acid
variation. This may reflect different substrate specificities
and/or different intracellular levels of the necessary activat-
ing enzymes. It should indeed be noticed that the HIV
assays are performed in rapid proliferating lymphocyte cell
cultures (generation time ∼ 24 h), whereas the antiherpetic
assays are carried out in confluent fibroblast monolayer
(nonproliferating) cell cultures. Thus, the different cell-type
and cell-cycle conditions between both assay models can
result in different prodrug activation modalities that may
Table 2. Anti-HIV Activity of the ACV ProTides and ACV
antiviral activity EC50
a (μM) cytostatic activity (μM)
compds aryl amino acid ester HIV-1 CEM HIV-2 CEM HIV-1 MT-4 IC50
bCEM CC50
c (MT-4) IC50
b (MT-4)
2 Naph L-Ala Bn 15 ( 14 8.9 ( 6.3 0.8 17 ND >150
3 Naph L-Ala nPr 6.6 ( 5.6 24 ( 30 10 22 ND ND
4 Naph L-Ala Me 10 ( 7.9 13 ( 6.4 4.7 ( 2.1 57 >150 18.7 ( 3.2
5 Naph L-Ala Et 12 ( 9.8 42 ( 13 1.7 ( 0.8 32 ( 7.8 >150 12 ( 5.3
6 Naph L-Ala tBu >100 >100 >150 >100 >150 >150
7 Naph L-Ala iPr 6.2 ( 5.4 12 ( 0.71 5.4 36 ( 15 >150 72.5
8 Ph L-Ala Me 17 ( 4.6 26 ( 8.5 15 67 ( 7.8 ND ND
9 Ph L-Ala Bn 16 ( 14 11 ( 4.9 5.7 ( 1.6 42 ( 11 >150 33.8 ( 10.6
10 Ph L-Ala iPr >100 >100 >150 >100 >150 >150
11 p-F-Ph L-Ala Bn >20 >20 ND 76 ( 13 ND ND
12 Ph D-Ala Bn >250 >250 ND g250 ND ND
13 Naph DMG Bn g100 79 ( 30 ND >100 ND ND
14 Ph DMG Bn >100 >100 7 >100 >150 >150
15 Ph Phe Bn 26 ( 11 34 ( 24 16 42 ND ND
16 Ph L-Val Bn >50 >50 ND g100 ND ND
17 Naph L-Val Me >100 >100 ND >100 ND ND
18 Naph L-Val Et >100 >100 ND >100 ND ND
19 Naph D-Val Me >100 >100 ND >100 ND ND
20 Ph L-Leu Bn >20 >20 0.8 >20 17 >150
21 Ph L-Ile Bn >20 >20 ND ND ND ND
22 Ph L-Pro Bn >20 >20 ND >100 ND ND
23 Ph Gly Bn >100 >100 ND >100 ND ND
77d Naph DMG Bn >20 >20 15 40 ( 2.8 45 140
78d Ph DMG Bn >100 >100 70 >100 >150 >150
81d Naph L-Val Me >100 >100 >150 >100 >150 >150
86d Ph L-Pro Bn >20 >20 30 45 ( 0.0 90 >150
ACV (1) >250 >250 >250 >250 >250 >250
a 50%Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity by 50%. b 50%Cytotoxic concentration,
or compound concentration required to decrease the viability of the cell cultures by 50%. c 50% Inhibitory concentration, or compound concentration
required to inhibit cell proliferation by 50%. ND= not determined. dN2-DMF-ACV.
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explain the differential antiviral activities of the ACV Pro-
Tides.
Enzymatic Studies. The mechanism of activation of the
ProTides involves a first enzymatic activation step mediated
by carboxypeptidase-type enzyme(s), which hydrolyze the
ester of the amino acid moiety (Figure 1).
To probe the activation of the ACV ProTides to the
monophosphorylated form inside cells, we performed an
enzymatic study using carboxypeptidase Y following the
conversion by 31P NMR. Of three different L-alanine deri-
vatives (9, 6, and 10), the first one is active vs HIV and the
second and third compounds are inactive against HIV, as
well as the inactive L-valine 17 and D-valine derivatives 19
that have been considered for these experiments. The assay
has been carried out by dissolving the compounds in acetone-
d6 and trizma buffer (pH=7.6), incubating with the enzyme
Figure 3. Carboxypeptidase-mediated cleavage of compound 9, monitored by 31P NMR.
Figure 4. Carboxypeptidase-mediated cleavage of compound 10, monitored by 31P NMR.
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and recording a blank for each sample before the addition of
the enzyme.
In the case of the phenyl benzylalanine compound 9
(Figure 3), the experiment showed a fast hydrolysis of the
starting material (δP=3.65 and 3.60) to the intermediate type
88 (Figure 1) (δP=4.85 and 4.70), noting the presence of the two
diastereoisomers. This intermediate is then processed to a
compound of type 90 (δP=7.10) through the putative inter-
mediate89,which is notdetectedby31PNMR.Thehalf-life for9
is 17 min. In the case of the isopropyl ester analogue 10
(Figure 4), the experiment showed a slow conversion of the
startingmaterial to90withahalf-lifeof 46h.This is ca. 150 times
slower than 9. This result is in accordance with the inactivity of
10 against HIV (Table 2). Notably one of the two diastereo-
isomers seems to be faster converted compared to the other one.
Compound 6, the naphthyl t-butyl alanine analogue
(Figure 5), showed no conversion at all presumably due to
the presence of the tert-butyl ester, which is too bulky to be
processed by the enzyme. This observation is in agreement
with the lack of antiviral activity for this compound.
In the case of the L-valine derivative 17 (Figure 6), the
experiment showed, as already demonstrated for compound
10, a slow conversion to the compound of type 90, with a
half-life of 72 h. The D-valine derivative 19 (Figure 7) was not
processed due to the presence of the non-natural amino acid,
which seems not to be recognized by the enzyme.
Also, CEM cell extracts have been prepared to examine
the rate of hydrolysis of the antivirally active 9 and 4 and the
inactive 6 derivatives. Whereas 9 and 4 were efficiently
hydrolyzed within a short time period (>95% conversion
of 9 and 65% conversion of 4 within 1 h of incubation), 6
proved entirely stable after a 120 min incubation period
(Figure 8). These observations are in agreement with the
antiviral data and demonstrate that CEM cell-associated
enzymes can efficiently convert methyl and benzyl esters of
the ACV ProTides but not tert-butyl esters. Tonsil extracts
were also found to efficiently hydrolyze 9 and 4, with the
same preference profile of 9 over 4 as found for the CEM cell
extracts (data not shown).
These experiments support the need of activation of ACV
ProTide in order to deliver the ACV monophosphate meta-
bolite. The enzymatic data correlate well with the in vitro
anti-HIV data andmay support the role of carboxypeptidase
Y in the ProTide activation in the lymphocyte cell cultures.
Stability Studies of ACV ProTide. Two different stability
studies of compound 9 using human serum and pH1.0 buffer
have been conducted. In the case of human serum, 9 was
dissolved in DMSO and D2O and human serum was added.
The experiment was conducted at 37 !C and monitored by
31PNMR. In Figure 9 are reported 31P NMR spectra 10 min
after the addition of the serum and after 12 h. For a better
resolution, both original spectra and deconvoluted ones have
Figure 6. Carboxypeptidase-mediated cleavage of compound 17, monitored by 31P NMR.
Figure 5. Carboxypeptidase-mediated cleavage of compound 6, monitored by 31P NMR.
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been reported. The spectra show that the ACV ProTide is
stable under these conditions. In fact, after 12 h, 56% of the
compound is still present. The spectra also show the forma-
tion of the compound type 90 and the formation of a peak at
δP= 1.90, which may correspond to the monophosphate
form. The peak at δP=2.25 corresponds to the human serum
that in the first experiment is overlapping with the peak at at
δP=1.90.
In the case of the stability in acid, a pH of 1.0 was used.
Compound 9 was dissolved in MeOD, and the buffer was
added. The experiment was conducted at 37 !C and moni-
tored by 31P NMR. The experiment showed a good stability
of the compound (see Figure 12 in the Supporting In-
formation) having an half-life of 11 h. Notably, the forma-
tion after 5 h of a peak at δP = -0.25, which should
correspond to the monophosphate form was observed.
Molecular Modeling-1: Carboxypeptidase Y Enzyme.
To better understand the enzymatic results obtained using
carboxypeptidase Y, molecular modeling studies using a
crystal structure of the enzyme have been performed.17 The
Figure 8. Stability of ACV ProTides in crude CEM cell extracts as a function of incubation time.
Figure 7. Carboxypeptidase-mediated cleavage of compound 19, monitored by 31P NMR.
Figure 9. Stability of compound 9 in human serum, monitored by 31P NMR.
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putative mechanism of action involves an attack from the
Ser146 to the carbonyl of the ester, which is coordinatedwith
the NH from Gly52 and Gly53.18
The processed compound 9 showed a positive interaction
with the active site of the enzyme for both phosphate
diastereoisomers (shown only the RP diastereoisomer)
(Figure 10a). In particular, the carbonyl moiety is in a
suitable position for the nucleophilic attack from the cata-
lytic Ser146, with the NH from Gly52 and Gly53 correctly
placed to stabilize the tetrahedral intermediate. This result is
in accordance with the enzymatic result for this compound.
In the case of the inactive compound 6, the carbonyl is not
in a favorable position, pointing away from Gly52 and
Gly53, probably due to the presence of the bulky tert-butyl,
whichmay influence the interaction with enzyme resulting in
a poor activation (reported only the SP-diastereoisomer,
Figure 10b). The docking of compound 10, which showed
a faster hydrolysis of one diastereoisomer compared to the
other one, showed interesting results. In fact, the two dia-
stereoisomers docked in a different way. The R-diastereo-
isomer showed a preferable position for the carbonylmoiety,
while in the case of the S-diastereoisomer the position of
carbonyl group is different and it is not able to coordinate
with the Gly52 and Gly53. This result supports the fact that
one of them is faster metabolized, presumably the RP, than
the other one, and this is due to a different binding in the
catalytic site of the enzyme. In the case of the valine
derivatives, none of them showed a suitable pose in the active
site of the enzyme.
Molecular Modeling-2: Human Hint Enzyme.As shown in
the enzymatic experiment on 9, the first step of activation
proceeds well and leads to compound 90, which needs to be
further converted in order to release the monophosphate
form 91. The last step of the activation of the ProTide
involving the cleavage of the P-N bond is not well-known,
and it is considered to be mediated by a phosphoramidase-
type enzyme called Hint, belonging to the HIT superfam-
ily.19 A molecular modeling study using human hint enzyme
1, cocrystallized with adenosine monophosphate, has been
performed in order to investigate this last step of activation.
The catalytic activity of this enzyme is due to the presence of
three histidines, which interact with the substrate, and to the
presence of a serine, which binds the nitrogen of the amino
acid, protonating the nitrogen, and favoring P-N bond
cleavage (Figure 11a). From Figure 11b, it is clear to see
how the compound binds correctly in the active site of the
Figure 10. (a) Docking of compound 9 within the catalytic site of
carboxypeptidase Y enzyme. (b) Docking of compound 6within the
catalytic site of carboxypeptidase Y enzyme.
Figure 11. (a) Interactions of 90 (L-Ala) with the active site of
human Hint-1. (b) Docking of compound 90 (L-Ala) ACV-MP
phosphoramidate within the catalytic site of human HINT (I)
enzyme.
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enzyme positioning the phosphatemoiety (pink) in a suitable
position for the cleavage of the P-N bond. This experiment
suggests that the last step of the activation to release ACV-
MPmay proceed well in the case of ACV alaninyl phosphate
in vivo, supporting the biological data.
Conclusion
A series of 22 acyclovir ProTides has been reported. These
compounds as well as the parent ACV have been biologically
evaluated against HSV-1 and -2 and against HIV-1 and -2.
In the case of HSV-1 and -2, the compounds did not show
any improvement of activity compared to the parent. How-
ever, these compounds retained activity against the TK-
deficient HSV-1 strain while ACV showed a loss on activity.
These results showed a successful thymidine-kinase bypass.
In the case of HIV-1 and -2, ACV did not show any acti-
vity, while the ProTides show a good activity in a range of
6.2-17 μM (HIV-1, CEM), 8.9-42 μM (HIV-2, CEM), and
0.8-30 μM (HIV-1, MT-4).
The variation of the amino acid moiety seems to be
tolerated in the case ofHSV. In the case ofHIV, this variation
is less tolerated, showing good results only in the case of the L-
alanine derivatives and phenylalanine derivative. In theMT-4
cell cultures, dimethylglycine, and L-leucine are tolerated.
These differences on activity may be due to different substrate
specificities and/or different intracellular levels of enzyme
necessary for the activation of these compounds.
Experimental Section
General. Anhydrous solvents were bought from Aldrich and
used without further purification. All reactions were carried out
under an argon atmosphere. Reactions were monitored with
analytical TLC on silica gel 60-F254 precoated aluminum plates
and visualized under UV (254 nm) and/or with 31P NMR
spectra. Column chromatography was performed on silica gel
(35-70 μM). Proton (1H), carbon (13C), and phosphorus (31P)
NMR spectra were recorded on a Bruker Avance 500 spectro-
meter at 25 !C. Spectra were autocalibrated to the deuterated
solvent peak and all 13C NMR and 31P NMR were proton-
decoupled. High resolution mass spectra was performed as a
service by Birmingham University using electrospray (ES).
CHN microanalysis were performed as a service by the School
of Pharmacy at the University of London. Purity (g95%) of all
final products was assured by a combination of microanalysis,
andHPLC, with additional characterization in every case by: H,
C, and P NMR, and HRMS.
Standard Procedure A: Synthesis of Dichlorophosphates (26,
27). To a solution of phosphorus oxychloride (1.00 mol/equiv)
and the appropriate substituted phenol or naphthol (1.00mol/eq)
in anhydrous diethyl ether, stirred under an argon atmosphere,
and added dropwise at -78 !C under an argon atmosphere
anhydrous TEA (1.00 mol/equiv). Following the addition, the
reaction mixture was stirred at -78 !C for 30 min and then at
room temperature overnight. Formation of the desired com-
pound was monitored by 31P NMR. The mixture was filtered
under nitrogen and the corresponding filtrate reduced to dryness
to give the crude product as an oil.
Standard Procedure B: Synthesis of Phosphorochloridates
(45-65). To a stirred solution of the appropriate aryl dichlor-
ophosphate 26-28 (1.00 mol/equiv) and the appropriate amino
acid ester salt 29-44 (1.00 mol/equiv) in anhydrous DCM was
added dropwise at -78 !C under an argon atmosphere, anhy-
drous TEA (2.00 mol/equiv). Following the addition the reac-
tion mixture was stirred at-78 !C for 30 min to 1 h and then at
room temperature for 30 min to 3.5 h. Formation of the desired
compound was monitored by 31P NMR. After this period, the
solvent was removed under reduced pressure and the residue
triturated with anhydrous diethyl ether. The precipitate was
filtered under nitrogen and the solutionwas concentrated to give
an oil. Most of the aryl phosphorochloridates synthesized were
purified by flash column chromatography (eluting with ethyl
acetate/petroleum ether in different proportions).
Standard Procedure C: Synthesis of Phosphoramidates (67-
85).To a stirring suspension of N2-DMF-ACV (1.00mol/equiv)
in anhydrous THF was added dropwise under an argon atmo-
sphere tBuMgCl (2.00 mol/equiv), and the reaction mixture was
stirred at room temperature for 30 min. Then was added
dropwise a solution of the appropriate phosphorochloridate
(1.50 to 4.00 mol/equiv) in anhydrous THF. The reaction
mixture was stirred at room temperature overnight. The solvent
was removed under reduced pressure, and the residue was
purified by column chromatography eluting with DCM/MeOH
in different proportions.
Standard Procedure D: Deprotection of N2-DMF-Phosphor-
amidates (2-23). A solution of 67-87 in 1-propanol or
2-propanol was stirred under reflux for 24-96 h. The solvent
was then removed under reduced pressure, and the residue was
purified by column chromatography eluting with DCM/MeOH
in different proportions. The product was usually further pur-
ified by preparative TLC or semipreparative HPLC to give a
white solid.
Synthesis of N2-DMF Acyclovir (N0-(9-((2-Hydroxyethoxy)-
methyl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,N-dimethylformi-
midamide) (66). To a suspension of 1 (1.00 g, 4.44 mmol) in dry
DMF (20 mL) was added N,N-dimethylformamide dimethyl
acetal (2.96 mL, 22.20 mmol) and the reaction mixture was
stirred at room temperature for 1 day. After this period, the
solvent was removed and the residue triturated with diethyl
ether and filtered. The solid was washed with diethyl ether to
give a white solid (97%, 1.20 g). 1HNMR (DMSO, 500MHz): δ
11.30 (1H, s, NH), 8.58 (1H, s, CHN(CH3)2), 7.94 (1H, s, H-8),
5.45 (2H, s, H-10), 4.65 (1H, t, OH), 3.52-3.49 (4H, m, H-40, H-
50), 3.17, 3.04 (6H, 2s, N(CH3)2).
Synthesis of 1-Naphthyl Dichlorophosphate (26). Prepared
according to standard procedure A, using 24 (4.00 g, 27.74
mmol) in anhydrous diethyl ether (60 mL), POCl3 (2.59 mL,
27.74mmol), and anhydrous TEA (3.87mL, 27.74mmol). After
31P NMR, the solvent was removed under reduced pressure and
the residue was triturated with anhydrous diethyl ether. The
precipitate was filtered, and the organic phase was removed
under reduced pressure to give an oil (95%, 6.91 g). 31P NMR
(CDCl3, 202 MHz): δ 3.72.
1H NMR (CDCl3, 500 MHz): δ
8.02-8.00 (1H, m, H-8), 7.81-7.80 (1H, m, H-5), 7.72-7.70
(1H, m, H-4), 7.54-7.45 (4H, m, H-2, H-3, H-6, H-7).
Synthesis of 1-Naphthyl(benzoxy-L-alaninyl)-phosphorochlor-
idate (45). Prepared according to standard procedure B, 26
(6.91 g, 26.48 mmol), L-alanine benzyl ester tosylate 29 (9.30 g,
26.48 mmol), and anhydrous TEA (7.40 mL, 52.96 mmol) in
anhydrous DCM (100 mL). The reaction mixture was stirred at
-78 !C for 1 h, then at room temperature for 2 h. The crude was
purified by column chromatography eluting with ethyl acetate/
hexane=5/5 to give an oil (72%, 7.68 g). 31P NMR (CDCl3, 202
MHz): δ 8.14, 7.88. 1H NMR (CDCl3, 500 MHz): δ 7.99-7.25
(12H, m, Naph, OCH2Ph), 5.15-5.07 (2H, m, CH2Ph), 4.30-
4.23 (1H, m, CHCH3), 1.49-1.46 (3H, m, CHCH3).
Synthesis of N2-DMF-acyclovir-[1-naphthyl(benzoxy-L-alani-
nyl)] Phosphate (67). Prepared according to standard procedure
C, from 66 (0.30 g, 1.07 mmol) in anhydrous THF (10 mL),
tBuMgCl (1.0MTHF solution, 2.14mL, 2.14mmol), 45 (1.31 g,
3.25 mmol) in anhydrous THF (10 mL), and the reaction
mixture was stirred at room temperature overnight. The residue
was purified by column chromatography, eluting with DCM/
MeOH=95/5, to give a white solid (17%, 0.12 g). 31P NMR
(MeOD, 202 MHz): δ 4.18, 3.92. 1H NMR (MeOD, 500 MHz):
δ 8.47, 8.46 (1H, 2s, NCHN(CH3)2), 8.01-7.98 (1H, m, H-8
Naph), 7.78-7.74 (2H, m, H-8, H-6 Naph), 7.56, 7.55 (1H, m,
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H-2 Naph), 7.41-7.12 (9H, m, Naph, OCH2Ph), 5.37-5.36
(2H, 2s, H-10), 5.00-4.93 (2H, m, OCH2Ph), 4.14-4.06 (2H, m,
H-50), 3.96-3.88 (1H, m, CHCH3), 3.88-3.59 (2H, m, H-40),
2.95-2.93 (6H, m, N(CH3)2), 1.20-1.17 (3H, m, CHCH3).
Synthesis of Acyclovir-[1-naphthyl(benzoxy-L-alaninyl)] Phos-
phate (2). A solution of 67 (0.10 g, 0.16 mmol) in 2-propanol
(5 mL) was stirred under reflux for 2 days. The solvent was then
removed under reduced pressure, and the residue was purified
by column chromatography eluting with DCM/MeOH=96/4.
The product was purified by preparative TLC (gradient elution
of DCM/MeOH=99/1, then 98/2, then 96/4) to give a white
solid (35%, 0.032 g). 31PNMR (MeOD, 202MHz): δ 4.13, 3.96.
1H NMR (MeOD, 500 MHz): δ 8.01-7.99 (1H, m, H-8 Naph),
7.77-7.75 (1H, m, H-6 Naph), 7.67, 7.64 (1H, 2s, H-8), 7.58-
7.13 (10H, m, Naph, OCH2Ph), 5.28, 5.25 (2H, 2s, H-1
0), 4.99-
4.94 (2H, m, OCH2Ph), 4.12-4.06 (2H, m, H-50), 3.97-3.93
(1H, m, CHCH3), 3.64-3.59 (2H, m, H-40), 1.24-1.20 (3H, m,
CHCH3).
13CNMR (MeOD, 125MHz): δ 20.32 (d, JC-P=7.63,
CHCH3), 20.43 (d, JC-P = 6.61, CHCH3), 51.76, 51.81 (2s,
CHCH3), 67.20 (d, JC-P=5.58, C-5
0), 67.28 (d, JC-P=4.91, C-
50), 67.95, 67.98 (2s,OCH2Ph), 69.34 (d, JC-P=7.72,C-40), 69.40
(d, JC-P = 8.14, C-4
0), 73.65 (C-10), 116.26, 116.29, 116.35,
122.69, 122.80, 125.92, 126.51, 127.20, 127.42, 127.46, 127.74,
128.81, 128.83, 129.27, 129.33, 129.52, 129.57 (C-5, C-2 Naph,
C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8
Naph, C-8a Naph, OCH2Ph), 136.26, 137.23 (C-4a Naph,
“ipso” OCH2Ph), 139.69 (C-8), 147.98, 148.04 (“ipso” Naph,
C-4), 152.44 (C-2), 159.39 (C-6), 174.61, 174.88 (2s,
COOCH2Ph). EI MS=615.1735 (M þ Na). Anal. Calcd for
C28H29N6O7P 3 0.5H2O: C, 55.91; H, 5.03; N, 13.97. Found: C,
55.81; H, 4.91; N, 13.78.
Antiviral Activity Assays. The compounds were evaluated
against the following viruses: HSV-1 strain KOS, thymidine
kinase-deficient (TK-) HSV-1 KOS strain resistant to ACV
(ACVr), HSV-2 strain G, HIV-1 strain IIIB/Lai, and HIV-2
strain ROD. The antiviral, other than anti-HIV, assays were
based on inhibition of virus-induced cytopathicity or plaque
formation in human embryonic lung (HEL) fibroblasts. Con-
fluent cell cultures in microtiter 96-well plates were inoculated
with 100 CCID50 of virus (1CCID50 being the virus dose
required to infect 50% of the cell cultures). After a 1-2 h
adsorption period, residual virus was removed and the cell
cultures were incubated in the presence of varying concentra-
tions of the test compounds. Viral cytopathicity was recorded as
soon as it reached completion in the control virus-infected cell
cultures that were not treated with the test compounds. Anti-
viral activity was expressed as the EC50 or effective compound
concentration required to reduce virus-induced cytopathicity by
50%.
Human CEM cell cultures (∼3"105 cells mL-1) were infected
with 100 CCID50 HIV-1(IIIB) or HIV-2(ROD) per mL and
seeded in 200 μL well microtiter plates, containing appropriate
dilutions of the test compounds. After 4 days of incubation at
37 !C, CEMgiant cell formationwas examinedmicroscopically.
MT-4 cells (1" 104 cells per mL) were suspended in fresh
culture medium and infected with 10 μL (0.7 ng of p24) of
X4LAI.04 viral stock per mL of cell suspension. Infected cell
suspensions were then transferred to microplate wells, mixed
with 1 mL of medium containing the test compound at an
appropriate dilution and further incubated at 37 !C. After 3
days, p24 production was measured in the MT-4 cell culture
supernatants. The EC50 corresponded to the compound con-
centration required to suppress the production of p24 in the
virus-infectedMT-4 cell cultures by 50%. Viability inMT-4 cell
cultures were evaluated using a nucleocounter automated cell
counting system (Chemometec, Denmark). Total number of
cells and number of dead cells in the cultures untreated and
treated with ACVProTides were enumerated using a propidium
iodide-based assay according to the manufacturers’ protocol.
Data were collected and analyzed using Nucleoview software
(Chemometec, Denmark).
Human tonsils obtained under an IRB-approved protocol
were dissected into∼2mmblocks and cultured on collagen rafts
at the medium-air interface. Tissues were inoculated ex vivo
with X4LAI.04 (∼0.5 μg of p24gag per block) and treated with
ACV ProTides at concentrations ranging from 0.1 to 10 μM.
The culture medium was changed every 3 days, and ACV
ProTides were replenished. For each compounds’ concentration
HIV-1 release was quantified by measurements of p24gag accu-
mulated over 3-day periods in the culture media bathing 18
tissue blocks. The EC50 corresponded to the compound con-
centration required to suppress by 50% the production of p24.
Preparation of CEM and Tonsil Cell Extracts and Analysis of
ProTide Conversion. Exponentially growing CEM cells or tonsil
tissues were washed twice with PBS. Then, cells and tissues were
suspended in PBS, and extracts were made in a Precellys-24
homogenizator (Berlin Technologies, Montigny-en-Breton-
neux, France) (tonsils) or by a Hielscher-Ultrasound Technol-
ogy (CEM cells) (Germany). The extracts were cleared by
centrifugation (10 min, 15000 rpm) and frozen at-20 !C before
use. Ten micromolar solutions of 9, 4, and 6 were added to the
crude cell and tissue extracts (100 μL) and incubated for 30, 60,
and 120min at 37 !C.At each time point, 20μLof the incubation
mixtures were withdrawn and added to 30 μL cold methanol to
precipitate the proteins. After centrifugation, the supernatants
were subjected toHPLC analysis on a reverse phaseC18 column
(Merck) to separate the parent ACV ProTides from their
hydrolysis products that may be formed during the incubation
process. Data were plotted as percent of disappearance of the
intact parent ACV ProTide from the incubation mixture.
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